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ABSTRACT
Background. Chronic diseases, such as lung cancer, require a provider-patient
relationship developed over time. This relationship fosters shared decision-making
(SDM), a collaborative, dynamic information exchange and analysis between provider
and patient regarding treatment and desired outcomes. Established benefits to SDM
include an improved quality of life and decreased anxiety and depression. Despite
established benefits, recent research suggests radiation oncologists are not engaging in
SDM. A decision-aid tool utilizing patient reported outcome measures may increase
SDM between radiation oncologists and patients with lung cancer. Patient-reported
outcome measures, wherein the patient provides direct assessment of their health and
quality of life, can inform and initiate SDM. This study investigated the design and
implementation of a collaborative decision-aid tool for patients with lung cancer at a
Midwestern cancer center as informed by stakeholders, practice considerations, and the
evidence base.
Objectives. The primary objective was to develop a collaborative decision-aid tool, using
patient-reported outcome measures, that can be implemented in an academic radiation
oncology clinic. Secondary objectives then assessed the tool’s impact through surrogates of
shared decision making (add-on oncology visits, concomitant medication prescriptions),
medical management (adverse events, radiation therapy compliance, chemotherapy
compliance) and emergent care and its costs (emergency room visits and estimated costs,
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inpatient admissions and estimated costs). The hypothesized result was a decision aid
designed to increase collaborative communication between radiation oncologists and
patients will result in improved shared decision making, yielding better medical
management and patient outcomes and reducing emergent care costs. Lastly, an
implementation roadmap provided information on experienced barriers, facilitators, and
considerations for performance objectives.
Materials and Methods. A sequential exploratory mixed methods design was employed.
The qualitative strand explored how stakeholders, practice considerations, and the
evidence base informed the design and installation of an ideal collaborative decision-aid
tool. Semi-structured interviews were completed with both patients who completed
radiation therapy for lung cancer and their radiation oncologist. Interviews were coded
and evaluated for themes. Interviews were transcribed verbatim, coded using Atlas.ti
software, and analyzed thematically and visually. The results of this analysis, combined
with information from the literature base and implementation stakeholders, was used to
inform design of the collaborative decision-aid tool that was installed employing the
principles of clinical implementation using the plan-do-study-act (PDSA) implementation
cycle model. Simple descriptive analysis was performed on objective measures. Mixed
analysis included data display, comparison, and integration.
Results. Six patients and six radiation oncologists participated in the semi-structured
interviews. Interviews provided insights that patients did not know what to ask of their
radiation oncologists, prioritized survival over reduced side effects, and minimized
complaints to their radiation oncologists, often to their detriment. Interviews yielded
feedback on commonly used patient reported outcome instruments, identifying context as
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important and the recall timeframe as difficult. Commonly patient-identified adverse
events of concern were fatigue, dyspnea, vomiting, and dysphagia. Radiation oncologists
identified a patient’s personality as critical to care and translating responses and
symptoms to adverse events of treatment. For this reason, numeric scales were not
endorsed as they were seen as ambiguous and lacking context. With this feedback, a
collaborative decision-aid tool was designed that focused on adverse events of interest
(nausea, vomiting, fatigue, dyspnea, chest pain, weight loss). Rather than numeric scales,
responses provided granular context that clued physicians to medical needs (i.e., “I
cannot walk to my appointment,” “It hurts when I eat,” “I am not vomiting but I’m not
hungry”). This tool was implemented as a quality initiative project for pragmatic impact.
Four patients were assigned the tool during the first PDSA implementation cycle. The
first follow-up evaluation meeting identified four critical outcomes for the next
implementation cycle: how to identify which consults require the decision-aid, how the
need for the decision-aid on doctor visits is consistently provided to scheduling, how
unplanned visits/special complaints are addressed with regard to the decision-aid, and
what actions are necessary if the patient leaves prior to the decision-aid being reviewed.
Mixed analysis provided direction for next steps in implementation, tool design, and
quantitative data measures. The primary concern, increase in time expended per clinic
visit, was not supported by the limited data available from the first implementation cycle.
Conclusion. Implementation of collaborative decision-aid within the radiation oncology
clinic is feasible without disruption of the on-treatment visit time. Radiation oncologists
can use the tool as a guide for routine on-treatment visit review, so that it is harmonized
with their routine practice. Care should be taken during implementation to ensure all
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stakeholders are included in the tool’s implementation and that desired outcomes are
appropriately identified to truly capture what impact the tool has, if any, on clinical
outcomes. Focusing on the patient with the goal of improving their experience will guide
collaborative decision-aid tool adaptation, implementation, and uptake.
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“It is not the critic who counts; not the man who points out how the strong man stumbles
or where the doer of deeds could have done better. The credit belongs to the man who is
actually in the arena, whose face is marred by dust and sweat and blood, who strives
valiantly, who errs and comes up short and short again and again, because there is no
effort without error or shortcoming, but who knows the great enthusiasms, the great
devotions, who spends himself for a worthy cause; who, at best, knows, in the end, the
triumph of achievement, and who, at the worst, if he fails, at least he fails while daring
greatly, so that his place shall never be with those cold and timid souls who knew neither
victory nor defeat.”
President Theodore Roosevelt

“I am only one, but still I am one.
I cannot do everything, but still I can do something.
And because I cannot do everything, I will not refuse to do the something that I can do.”

~ Edward Everett Hale
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CHAPTER 1

1
1.1

INTRODUCTION
Overview
Shared decision-making (SDM) is described conceptually as a collaborative,

dynamic information exchange and analytic process between the healthcare provider and
the patient (Charles et al., 1999). Essential elements of SDM include openly discussing
the risks and benefits of possible therapies as well as the patient’s preferences and their
understanding of the healthcare problem (Hughes et al., 2018). Incorporating the patient’s
desires and values into the treatment decision is a hallmark of successful SDM (Noonan
et al., 2017). For patients with chronic disease, such as those with cancer, SDM should
not be a singular event but should occur often throughout the course of their illness (Peek
et al., 2014). Chronic diseases require a provider-patient relationship developed over time
and, for this reason, educating patients about cancer and its treatment options can be
time-consuming but yields rewards through an enhanced relationship developed through
the process (Morrow, 2016).
Potential benefits to SDM include improved quality of life, decreased anxiety and
depression, reduced psychological distress, and increased satisfaction (Shabason et al.,
2014). Patients with cancer who perceive concordance between preferred and actual
treatment decision roles have higher vitality, less fatigue, less confusion, less anger, and
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better overall mood (Atherton et al., 2013). The most significant benefit to SDM is one
that is not easily measured: respecting the patient’s autonomy (Beers et al., 2017).
Respecting a patient’s independence and individual values and preferences adds a layer
of complexity because not all want to engage in SDM. While the majority of patients
prefer to be asked regarding their choice; some prefer to rely on their doctors’
professional opinion (Beers et al., 2017).
Patients with lung cancer are often referred to radiation oncology from an outside
clinic or after a primary treatment recommendation from a multi-disciplinary oncology
board (Golden et al., 2017). As one of the three primary therapeutic modalities, radiation
is administered curatively, alone or in combination with other therapies, or as a palliative
treatment to provide a better quality of life for patients. Radiation treatment requires a
weekly on-treatment visit (OTV), comprised of a personal discussion visit and an
examination by the radiation oncologist to monitor for treatment-emergent side effects
and symptoms of the cancer. Toxicities from radiation therapy not only include skin
erythema (i.e., radiation burn) but subjective symptoms of fatigue, nausea, diarrhea, and
anorexia. Patients with lung cancer have the highest rate of medical comorbidities and as
such have additional concerning treatment toxicities including dyspnea, sore throat, and
dysphagia (Sogaard et al., 2013). Each of these symptoms requires management to
continue radiation treatment as well as reduce morbidity. Radiation oncologists rely on
the patient’s exchange of information during the OTV to identify and manage these
symptoms and gauge response to radiation. Thus, SDM for radiation oncologists includes
not only the initial decision to undergo radiation treatment but a continued process to
adjust concomitant medications for symptom management, potentially modify the
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radiation therapy plan, consider instituting a break from the daily radiation treatment, or
even discontinue radiation therapy if necessary.
A disparity has been identified between a patient’s reported side effects and the
oncologist’s determination of adverse events. In general, oncologists report adverse events
to be less severe than as described by patients–even subjective symptoms such as fatigue
and nausea (Atherton & Sloan, 2006; Basch, Deal, et al., 2016; Cirillo et al., 2009;
Falchook et al., 2016). This, coupled with other recent research, suggests radiation
oncologists are not optimally participating in SDM during their OTVs (Fromme et al.,
2016; Golden et al., 2016; Golden et al., 2017). Identified barriers to SDM include timeconstraints, the education gap between provider and patient, and the patient’s concern of
being labeled ‘difficult’ (Frosch et al., 2012; Legare et al., 2008; Woodhouse et al., 2017).
Additionally, and more specifically, research from Fromme and colleagues (2016)
identifies poor communication between patient and radiation oncologist regarding
treatment side-effects and symptoms of disease. While communication has been identified
as a key facilitator to SDM and to patient-centered medicine, interventions to improve
communication are typically time intensive, require intervention away from clinic, and
have a short-effect window (Beers et al., 2017; Golden et al., 2017; Pollak, Alexander, et
al., 2010; Pollak, Arnold, et al., 2010; Pollak et al., 2007; Tulsky et al., 2011).
In their 2017 review of the current research literature, Noonan et al. stated patientreported outcome measures (PROMs) can increase communication between providers
and patients and utilizing PROMs positively impacted SDM and overall patient
outcomes. The United States Food and Drug Administration (FDA) define PROM as:
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Any report of the status of a patient’s health condition that comes directly from
the patient, without interpretation of the patient’s response by a clinician or
anyone else. The outcome can be measured in absolute terms (e.g., severity of a
symptom, sign, or state of a disease) or as a change from a previous measure.
(2009, p. 2)
Patient-reported outcome measures should be validated for sensitivity to change over
time, focused on the outcomes or concepts being measured, and for those outcomes to be
impactful toward the intended use for the medical condition (FDA, 2009). The FDA
requires the PROM be evidence-based to document it is measuring the right thing in the
right way in the specified patient population so that the score accurately and reliably
provides information to be interpreted clinically (i.e., provides benefit to the providers
and patients) (FDA, 2018). When a new drug or device is approved utilizing a PROMbased endpoint, FDA also reviews the recall period, response burden, and number of
items for the patient to complete (FDA, 2009). Current criticisms from FDA include a
significant burden of questions and time-points as well as a misalignment between known
drug toxicities, PROM questions and instruments, and the lack of investigation as to the
impact of a side-effect or symptom on a patient’s life (FDA, 2018). In 2016, the 21st
Century Cures Act mandated patient-focused drug development (PFDD) and oncology
excellence, requiring the patient’s voice to be incorporated into drug design as early as
the pre-clinical development phase (FDA, 2020a). This federal requirement provides a
new opportunity to investigate the impact of PROMs in the radiation oncology clinic as
well as strategize methods to make PROMs easy, fast, and meaningful for both provider
and patient.
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A logical application of the electronic health record (EHR) would be to utilize it
as a central repository for PROMs. Initial research suggests this alone does not prompt
patient-provider communication or resolve the disconnect between provider and patient
regarding adverse events (Fromme et al., 2016). Thus, the next step is to create a tool that
stimulates effective information transfer for radiation oncologists and patients without
increasing burden to either. Information from the tool would be stored in the EHR,
providing a foundation for radiation oncologists to identify trends between their
assessments and the patient's assessments, thereby increasing SDM.
1.2

Statement of the Problem
Patient-reported outcome measures can facilitate communication and SDM

(Noonan et al., 2017). To date, there is a lack of research evaluating the use of PROMs in
clinical radiation oncology practice, including which PROMs should be used, when they
should be used, and how they impact clinical measures (Fromme et al., 2016; Gracie &
Ford, 2016; Hawley & Jagsi, 2015). Additionally, a disparity exists between the
oncologists’ and patients’ assessments of adverse events and, as a result, a knowledge gap
translating the two perspectives has emerged (Atherton & Sloan, 2006; Basch, Deal, et al.,
2016; Cirillo et al., 2009; Falchook et al., 2016; Sneeuw et al., 1998; Sneeuw et al., 2002).
With required weekly OTVs, radiation oncology has both unique potential and
unique demands for SDM. Radiation oncology presents the opportunity to investigate the
relationship between PROM, SDM, and clinical outcomes. Prior work investigating
PROM and radiation oncology did not incorporate PROM into the medical record, did
not evaluate time expenditure, and had a limited review of clinical outcome measures
(Fromme et al., 2016; Golden et al., 2016). Without consistent and clear clinical benefit,
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it is difficult to gain buy-in from stakeholders for SDM implementation. Extending prior
work to include objective measures–such as time spent in weekly examinations, number
of add-on visits, or healthcare expenditures during radiation therapy–would provide
foundational evidence to support SDM implementation.
A collaborative decision-aid using PROMs as an intervention could align the
importance of specific adverse events between provider and patient, harmonizing
evaluation. This collaborative decision-aid would be used at each radiation oncology
OTV to review side effects common to the patient and adverse events that are important
to the physician. An ideal decision-aid would not only enhance communication but focus
it on those side effects most concerning to the radiation oncologist or patient. This
discussion should then spur a dynamic discussion about provider and patient treatment
goals, increasing SDM.
This would enable trends to be measured over time, empowering the provider to
implement interventions earlier and avoid inpatient hospitalizations or breaks in radiation
therapy. Most importantly, the decision aid tool could help enforce the importance of
treatment and medication compliance, resulting in reduced side effects and thereby
reduce the potential for emergency room visits, admissions, or breaks in therapy.
To be useful, the decision-aid would need to be clear, simple, and easy to
understand. A decision-aid adding time to a hectic clinical schedule will challenge
implementation. The decision-aid should create collaboration between the provider and
patient toward the patient’s ultimate goals, whether it is palliative or definitive.
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1.3

Purpose and Research Questions
This study will develop a decision-aid using PROMs as an intervention tool to

promote collaborative communication between radiation oncologists and their patients.
First, the study will employ an interpretivist paradigm to determine key factors and
considerations from stakeholders to create the decision-aid. Next, a pragmatic paradigm
will be used to evaluate the implementation and impact of the decision-aid in a radiation
oncology clinic. The overarching hypothesis is a decision-aid designed to increase
collaborative communication between radiation oncologists and patients will result in
improved SDM, yielding better medical management and patient outcomes and reducing
emergent care costs. The primary objective is to develop a collaborative decision-aid tool,
using patient-reported outcome measures, that can be implemented in an academic
radiation oncology clinic. Secondary objectives then assess the tool’s impact through
surrogates of SDM (add-on oncology visits, concomitant medication prescriptions),
medical management (adverse events, radiation therapy compliance, chemotherapy
compliance), and emergent care and its costs (emergency room visits and estimated costs,
inpatient admissions and estimated costs). To examine this hypothesis, the following
research questions will be addressed:
How do the stakeholders, practice considerations, and evidence base inform the
ideal design and implementation of a collaborative decision-aid tool?
What is the impact of the collaborative decision-aid on the medical management of
patients actively undergoing radiation treatment for lung cancer?
How does the impact of the collaborative decision-aid tool inform
recommendations for future designs and implementation ?
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1.4

Translational Nature of the Study
Patient reported outcome measures have been established in clinical research but

have not been routinely translated to practice (T3 chasm) or implemented in the
oncologic population (T4 chasm) (Drolet & Lorenzi, 2011; Khoury et al., 2007).
Additionally, the lack of PROM in routine assessments and medical care impact bench
science and discoveries by diminishing the effectiveness of the overarching T4 to T1
feedback loop. Bench science is starved of key feedback about how treatments affect
patients, robbing investigators of potential discoveries only evident through the important
lens of patient tolerance and preference rather than solely focusing on tumor cell killing.
A core facet of translational medicine in oncology is not being robustly addressed,
resulting in a translational knowledge deficit in patient-focused drug development,
patient-centered medicine, and individualized cancer care.
1.5

Statement of Potential Impact
Rather than a single-point treatment decision, patients with lung cancer

undergoing radiation treatment make continual collaborative decisions with their
oncologist. Treatment options for these patients include different radiation delivery
strategies (i.e., daily for 6-7 weeks, every other day for 1-2 weeks, or even a single
treatment alone), concurrent chemotherapy and/or immunotherapy options, or declining
aggressive care and transitioning to palliative radiation or medical therapy to reduce
symptoms. Additional decisions are made regarding supportive care to get through
therapy, for example when a gastrostomy tube should be placed (e.g., prophylactically or
only if weight loss is greater than a certain percent). Many patients with lung cancer
undergo multiple courses of radiation: first to treat the primary disease and then
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additional rounds to treat metastases. Despite weekly OTV for up to nine weeks per
course, recent research suggests shared decision making with radiation oncologists
diminishes longitudinally (Ernstmann et al., 2012).
Currently, there is a lack of a systematic approach to evaluate radiation oncology
patients’ symptoms or quality of life. Researchers have not identified what patient
reported outcomes to measure in which patient base, how to measure them, nor how to
analyze them (FDA, 2018). Without foundational research, oncologists do not understand
benefits from PROMs and how to implement them in their clinic. Ultimately, this impacts
the oncology patients, whose voice and perspective are reduced or removed entirely in
their treatment plan. A lack of real-world evidence limits a patient’s ability to understand
a treatment’s effects in the context of their priorities and treatment goals.
The collaborative decision-aid tool has the potential to not only improve patients’
medical management but also provide foundational information about how patients
prioritize treatment goals and symptomatic adverse events and how these change over
time. This would provide real world evidence to propel patient-centered medicine and
patient-focused drug development in oncology. If successful, this research will provide
key information on PROM implementation into a radiation oncology clinic as well as for
patient-focused cancer research, enabling a new clinical outcome and scientific strategy
for subsequent oncology research (FDA, 2018).
1.6

Theoretical Foundation or Conceptual Framework
Perpetual research into antineoplastic therapy has shifted cancer away from a fatal

disease toward a chronic healthcare condition. While these treatments prolong life they
also present different risk profiles. Shared decision-making becomes a logical process
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between oncologist and patient to determine which treatment matches a patient’s lifestyle
and value system.
Shared decision-making describes a knowledge-transfer between the provider and
patient at critical timepoints in medical care (Charles et al., 1999). The SDM model
identifies three key phases to the model: choice talk, option talk, and decision talk (Elwyn
et al., 2012). Choice talk reminds the provider to offer choices, justify the patient’s choice
by emphasizing the consideration of their personal preferences, and gauge the reaction of
the patient before continuing forward. Opinion talk focuses on assessing the patient’s
foundational knowledge, providing a list of options and their descriptions, and then
providing support. Choice talk combined with opinion talk guides patients to informed
preferences through deliberation of pros and cons. Patients can then make their decisions

Figure 1
Model of Shared Decision Making Process as Designed by Elwyn et al. (2012)

Note: This figure is contained within an open access article distributed under the terms of
the Creative Commons CC BY license, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. Copyright
information provided by Springer Nature, publisher of Journal of General Internal
Medicine. Shared decision making: A model for clinical practice by Elwyn et al. ©2013.
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and review them with their provider; the provider may or may not agree with the patient’s
decision (i.e., decision talk).
This idealized model will be adapted to address the radiation oncology OTV
because of the varied levels of decision making (Figure 1). Radiation treatment does not
represent a singular treatment decision but a continued processes between the radiation
oncologist and the patient. Together, patients and their radiation oncologist decide to
continue radiation therapy, determine which side effects are problematic and need
intervention, and if further tests or evaluations are required. In early therapy no
intervention may be needed. In contrast, in the final weeks of radiation therapy a
physician may need to adjust medications several times a week to counter the side
effects. Thus, choice talk translates to prioritizing goals and symptoms of therapy while
option discussion is the radiation oncologist reviewing and confirming the patient’s
preferences for treatment and medical management. The decision is then collaborative
management, with PROMs providing the critical information for deliberation by both
patient and radiation oncologist.
Research shows SDM is not occurring consistently in radiation oncology
(Fromme et al., 2016; Golden et al., 2016; Golden et al., 2017). A collaborative decisionaid will need to be developed and implemented in a radiation oncology clinic in hopes of
initiating SDM. The Ottawa Model of Research Use (OMRU) provides a framework for
implementation of evidence-based innovations by assessing barriers and supports,
monitoring the intervention, and evaluating the outcomes (Graham & Logan, 2004). The
OMRU documents the interactions between the evidence-based innovation, potential
adopters, and the practice environment when assessing the barriers, facilitators, and
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Figure 2
Graphical Depiction of the Guiding Conceptual Frameworks.

Note. The Ottawa Model for Research Use provides granularity for the NIRN stages
Exploration and Installation, which flow directly into the PLAN segment of the PlanStudy-Do-Act implementation model (Bertram et al., 2015; Graham & Logan, 2004;
Langley et al, 2009). The NIRN stage Initial Implementation includes improvement cycles
and managing change; this aligns with the DO and STUDY segments of the PDSA cycle.
The dotted arrow represents a return to the OMRU and NIRN stages Exploration and
Installation to broaden the implementation, assess for newly identified facilitators or
barriers, or to adopt an amended workflow due to an unforeseen event.
environment. It also highlights a feedback loop from implementation, adoption, and
outcomes to enable adaptation and fit as required (Graham & Logan, 2004).
The Plan-Do-Study-Act (PDSA) cycle begins by addressing the considerations for
implementation (i.e., PLAN segment) (Langley et al., 2009). Although the elegance and
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flexibility of use for the PDSA cycle lies within its simplicity, greater detail is needed to
guide implementation planning within the healthcare setting–thus the OMRU framework
and the National Implementation Research Network’s (NIRN) framework are relied upon
to provide further details for the PLAN segment (Figure 2). The OMRU describes the initial
decision-aid tool design, from assessing the stakeholders and practice considerations to
identifying key barriers and workflow concerns (Figure 2). The key domains of the OMRU
(assess, monitor, evaluate) interleaf with the stages of the NIRN Framework, which in turn
provides needed detail for the PDSA PLAN segment (Figure 2) (Bertram et al., 2015). The
NIRN framework has three stages of interest: exploration, installation, and initial
implementation (Bertram et al., 2015). Exploration describes needs assessment, reviewing
intervention components and implementation drivers, and assessing fit. Exploration aligns
with the PDSA’s PLAN segment and also the OMRU’s Establish Evidence Base and
Practice Considerations, providing more granularity for these concepts. Installation aligns
with the OMRU Stakeholders except for one key aspect: the NIRN framework describes
acquiring the resources which is not addressed in the OMRU (Bertram et al., 2015). The
NIRN stage of Initial Implementation outlines managing change, deploying data systems,
and adjusting implementation drivers, aligning with the PDSA segments DO and STUDY
(Bertram et al., 2015; Langley et al., 2009). The PDSA cycle continues from an initial
implementation to subsequent cycles, for improvement, expansion, or adaptation
(Langley et al., 2009). In contrast the NIRN implementation framework is linear and the
OMRU, although having a feedback loop, is not designed for purposeful iteration of
implementation and ramp-up of the intervention.
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Although other SDM research has suggested using the Theoretical Domains
Framework, this framework is most useful for creating theory-informed behavior change
(French et al., 2012). The purpose of this collaborative decision-aid will not involve
behavior change as measured by PROM but clinical behavior change as the radiation
oncologist and patient form a partnership by using PROM as a tool to achieve identified
treatment goals. This nested framework incorporating implementation of evidence-based
practice with shared decision making will provide strong conceptual guidance.
1.7

Summary of the Methodology
A sequential exploratory mixed methods study will be employed because

resolving the disconnect between research, practice, and population requires a pragmatic
ontology (i.e. constructing real-world solutions) with an overall pragmatic epistemology
(i.e., objective and subjective knowledge) (Creswell & Plano Clark, 2011). Mixed
methods research synergizes the strengths of the single method strategies (i.e. qualitative
or quantitative), thereby addressing an individual method’s weaknesses and providing
additional credibility, completeness, and context to the study (p.12, Creswell & Plano
Clark, 2011).
The qualitative strand of the study will provide insight to the design and
implementation of the collaborative decision-aid tool. Briefly, a literature search and a
review of existing decision-aid tools will provide the initial insight for tool design as well
as identifying known barriers and facilitators to SDM and PROM. Once reviewed, semistructured interviews with patients will inform on communication, the radiation oncology
experience, how a collaborative decision-aid tool could be designed, and how it could
work. After the patient interviews are initiated, radiation oncologists will also be
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Figure 3
Examples of Items for Fatigue from PRO-CTCAE™, PROMIS®, and EORTC

Note: PROMIS® is ©2006-2017 PROMIS Health Organization; EORTC ©1995 EORTC
Quality of Life Group.
interviewed to regarding the collaborative decision-aid tool design and implementation.
This is an iterative process: information and knowledge obtained from interviews with
patient participants and treating radiation oncologists informs future interviews.
Similarly, radiation oncologists will be contacted for clarifications about OTV
workflows, patient’s treatments, or their clinic workflow. Upon completing the
interviews, the tool will be designed to contain PROMs of interest to the patient and
radiation oncologist. Items measuring the side-effects/symptoms of interest will be drawn
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from validated item banks: the Patient Reported Outcomes–Common Terminology
Criteria for Adverse Events item library (PRO-CTCAE™, National Cancer Institute), the
Patient-Reported Outcomes Measurement Information System (PROMIS®, Department
of Health & Human Services, U.S.), and the QLQ-C30 quality of life questionnaire
(European Organization for Research and Treatment of Cancer (EORTC, Brussels)
(Figure 3). These three item banks were selected based on the work presented at the 2018
FDA Public workshop Clinical Outcome Assessments in Cancer Trials. During this
webinar, experts demonstrated how to utilize the validated items from the EORTC,
PROMIS®, and PRO-CTCAE™ in a mix-and-match strategy to achieve fit-for-purpose
(FDA, 2018). Additionally, the EORTC, PROMIS® and PRO-CTCAE are item banks that
contain common cancer symptoms recommended by the Center for Medical Technology
Policy as important for comparative effectiveness research in oncology (Basch et al., 2012).
Planning the implementation of the collaborative decision-aid tool will extend the
qualitative research from the patient/physician dyad to encompass Epic® EHR
information technology specialists as well as key stakeholders within the radiation
oncology clinic. After their feedback is provided and a strategy for implementation
determined, the study transitions from the qualitative strand to the quantitative strand.
The quantitative stand is rooted in the principles of quality improvement yet is not
a formal quality improvement project. Within the U.S., research focusing on improving
the quality of patient care or collecting patient or provider data for clinical, practical, or
administrative purposes is termed ‘quality improvement,’ and is generally exempted from
Institutional Review Board oversight (U.S. Department of Health and Human Services
(DHHS) Office for Human Research Protections, 2021). Although the term quality
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Figure 4
Concept Schema of the Clinical Implementation

improvement project may be misleading in the context of a formalized quality
improvement plan, for the purposes of this work’s IRB exemption it was used. This work
is designed to pragmatically evaluate the impact of the collaborative decision-aid outside
of a formalized clinical trial structure (Figure 4). Data obtained from the tool’s clinical
implementation will be compared to a historical baseline of patients treated in the same
facility for lung cancer. Patients recommended for long course radiation therapy for nonsmall cell lung cancer will have the collaborative decision-aid tool assigned to their OTVs.
Both the radiation oncologist and patient will be provided the opportunity to review the
questions prior to the collaborative decision-aid being implemented.
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The initial concept is that a set of six to eight patient-reported outcome items could
be provided to a patient at their OTV (Figure 4). The workflow exploits two EHR: Epic®
and MOSAIQ®. Whereas Epic® is a systems-wide EHR used in the UIHC care system,
MOSAIQ® is a record-and-verify EHR unique to radiation oncology, enabling radiation
oncology-specific notations in designated areas regarding a patient’s care plan.
MOSAIQ® could be utilized to communicate the need for the decision aid for each
patient. Because MOSAIQ® is not house-wide, Epic® was targeted for collection and
dissemination of patient reported outcome measures. Thus, the PROM responses are
entered into Epic® EHR through a direct data input function utilizing a computer tablet.
The PROMs would then be transferred into a collaborative decision-aid tool, printed, and
provided to the radiation oncologist. The radiation oncologist would take the
collaborative decision-aid tool to the OTV for review with the patient. The collaborative
aid-design tool informed from the qualitative strand should be easy to understand, free
from medical jargon, and provide trends over time. The tool should be flexible in design
to accommodate changes in patient or radiation oncology priorities. Outcome measures
include number of emergent visits, costs of emergent care, treatment compliance, changes
to medical management, and time expenditure for the OTV.
This research will be conducted as a single-site study at the University of Iowa
Hospitals and Clinics. Ethics approval will be obtained from the institutional review
board (IRB) of record (University of Iowa IRB-01, biomedical) as well as an IRB
Authorization Agreement (IAA reliance) executed with George Washington University
IRB prior to the initiation of any human subjects research. The study did not require
registration on www.ClinicalTrials.gov per federal regulations (42CFR§11).
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1.8

Limitations and Delimitations
This study is designed as a single-site study recruiting only English-speaking

individuals who have already decided to undergo radiation therapy for the treatment of
their lung cancer. This delimitation of the study population then impacts generalizability,
limiting the findings. By approaching this established patient base, a significant treatment
decision has already been undertaken: the patients have opted to seek treatment rather
than comfort care or watchful waiting. Therefore, the results of this study will most likely
not be meaningful to those patients. Additionally, the lung cancer patient base at
University of Iowa currently has only two primary radiation oncologists for that clinic,
limiting the richness and depth of understanding a radiation oncologist’s perspective as to
the ideal decision-aid tool and its ideal workflow. Another limiting factor is the use of a
‘covering’ radiation oncologist if the treating radiation oncologist is out of office. This
can cause disruption and affect internal validity of this pilot study. Lastly, the University
of Iowa serves a rural, midwestern region of the nation. While the coverage area includes
the state of Iowa as well as the neighboring bordering communities, the socioeconomic
status, agrarian economy, and shared culture of the patient population are markedly
different compared to other geographic regions of the United States (e.g., higher
socioeconomic status, metropolitan areas).
1.9

Definition of Key Terms
Adverse event (AE). Any untoward medical occurrence whether or not considered

related to the treatment or study, often colloquially termed side-effect or symptom.
Clinical outcomes assessment (COA). As defined by the FDA-NIH Biomarker
Working Group (2021) this is an assessment of a clinical outcome made through report
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by a clinician, a patient, a non-clinician observer or through a performance-based
assessment. There are four types of COAs: (a) clinician-reported outcome (ClinRO), (b)
observer-reported outcome (ObsRO), (c) patient-reported outcome (PRO), and (d)
performance outcome (PerfO). It should be noted that all COAs are considered measures
but do not contain the “M” within their acronym denoting “measure.”
Clinician-reported outcome (ClinRO). A type of clinical outcome assessment that
is a measurement based on a trained health-care professional’s report after observation of
a patient’s health condition and involve objective measures or observable manifestations
of the condition or treatment. ClinRO do not include symptoms that can only be known
by the patient (FDA-NIH Biomarker Working Group, 2021).
Common Terminology for Adverse Events (CTCAE). A matrix categorizing
adverse events by a harmonized naming structure (term) and the associated severity
(grade). The CTCAE is used to standardize adverse events for reporting to the Food and
Drug Administration for drug and device approval.
Covering radiation oncologist. Herein, a covering radiation oncologist is
considered to be a faculty radiation oncologist who is not the treating radiation oncologist
but sees the patient for an on-treatment visit because the treating radiation oncologist is
not available.
Epic® Electronic Health Record (EHR). Epic® is a commercial medical record
system utilized by roughly one-third of the medical institutions within the United States
and throughout the University of Iowa Healthcare system. Epic® contains clinic and
hospitalization notes, vital signs, medication administration records, procedure and
imaging results, and pathology results (e.g., blood counts, metabolic panels, cultures).
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Epic® also serves as a filing repository for scanned paper records that are received from
outside medical facilities. Epic® is sold by Epic Systems Corporation, Verona,
Wisconsin, USA.
Functional Assessment of Chronic Illness Therapy (FACIT). A collection of
quality-of-life questionnaires that are validated as a measurement system for patient
reported outcome measures.
Functional Assessment of Cancer Therapy (FACT). A subset of FACIT, these
quality-of-life questionnaires were designed to focus on cancer and its therapies.
Health-related quality-of-life (HRQL). Defined by the International Society for
Quality of Life Research (ISOQOL) (Mayo & McGill, 2015) as:
A term referring to the health aspects of quality of life, generally considered to
reflect the impact of disease and treatment on disability and daily functioning; it
has also been considered to reflect the impact of perceived health on an
individual’s ability to live a fulfilling life. However, most specifically HRQL is a
measure of the value assigned to duration of life as modified by impairments,
functional states, perceptions and opportunities, as influenced by disease, injury,
treatment and policy.
Industry. A jargon term referring to for-profit companies who design, create, or
study drugs, biologics or devices for profit. This term also include PhRMA, the
Pharmaceutical Research and Manufacturers of America.
MOSAIQ®. A commercial electronic health record for radiation treatments that
contains the radiation prescription, the treatment plan, contours, radiation to target, and
elapsed treatment time by field and completion time by field. Unlike Epic®, MOSAIQ®
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access is limited to only authorized radiation oncology staff due to radiation compliances.
MOSAIQ® is sold by Elekta Solutions AB, Stockholm, Sweden.
National Institutes of Health (NIH). Comprised of 27 institutes and centers, with
each focusing on research within a specific organ class or a healthcare condition. The NIH
is funded by the U.S. government with an annual budget of over 40 billion U.S. dollars,
serving as a key source of funding for academic medical research. The NIH is based in
Bethesda, MD, USA.
National Cancer Institute (NCI). One of the largest NIH centers, the NCI was first
established in 1937 and currently has a budget of over 6.5 billion U.S. dollars. The NCI is
the primary funding source for academic oncologic research and is a significant influence
on research priorities and strategies in oncologic treatments and preventions. Like NIH, the
NCI is based in Bethesda, MD, USA.
New drug application (NDA). The application package submitted to a regulatory
oversight agency for consideration and ultimately legal approval to market and sell a new
drug or biologic. Within the United States, the NDA is submitted to the Food and Drug
Administration.
Observer Reported Outcome (ObsRO). A type of clinical outcome assessment
measuring observable signs or behaviors related to a patient’s health condition by
someone who observes the patient in daily life (other than the patient or a health
professional). This measure does not include medical judgment or interpretation (FDANIH Biomarker Working Group, 2021).
On-call radiation oncologist (on-call). An on-call radiation oncologist is a
radiation oncologist who is assigned to consult and plan emergent or add-on patients who

41
cannot be scheduled through routine workflows. When on-call, the radiation oncologist
accepts patients outside their standard clinical focus and, unless care is transitioned,
typically is considered their treating radiation oncologist.
On-treatment visit (OTV). A weekly exam required within the United States for
patients undergoing radiation therapy.
Patient reported outcomes (PRO). Defined as “aspects of a patient’s health status
directly reported by the patient” (p.2, van der Wees et al., 2019).
Patient-Reported Outcomes version of the Common Terminology Criteria for
Adverse Events (PRO-CTCAE™). A measurement system developed by the National
Cancer Institute to capture patient’s assessments of symptomatic adverse events.
Patient-Reported Outcomes Measurement Information System (PROMIS®). An
NIH-funded measurement system that evaluates and monitors physical, mental, and
social health.
Patient reported outcome measure (PROM). A type of clinical outcome
assessment that is a measurement of a PRO based on the patient’s direct report without
amendment or interpretation of the response by a third party. The PROM can be
measured by self-report or by interview only the patient’s response is recorded without
interpretation. Symptoms or other unobservable concepts known only to the patient can
be measured only by PROM (FDA-NIH Biomarker Working Group, 2021).
Performance Outcomes (PerfO). A clinical outcome assessment measuring task(s)
performed by the patient following standardized instructions. The assessment may be
administered by trained personnel or directly by the patient (FDA-NIH Biomarker
Working Group, 2021).
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Quality-of-life (QoL). Defined by the International Society for Quality of Life
Research as:
A term often used erroneously to refer to health-related quality-of-life or health
status, but is broader than just health and includes components of material
comforts, health and personal safety, relationships, learning, creative expression,
opportunity to help and encourage others, participation in public affairs,
socializing in leisure. (Mayo & McGill, 2015)
Quality-of-life questionnaire, cancer-30 questions (QLQ C-30). A validated
questionnaire developed and maintained by the European Organization for Research and
Treatment of Cancer (EORTC) to measure the quality-of-life for cancer patients. It is not
disease-site specific and is comprised of 30 questions covering five functional scales
(physical, role, emotional, social and cognitive), three symptom scales (fatigue, nausea &
vomiting and pain) and a global health status/QOL scale and six single items (dyspnea,
insomnia, appetite loss, constipation, diarrhea and financial difficulties).
Radiation oncology. The medical discipline encompassing all aspects of cancer
treatment using radiation.
Radiation oncologist. A physician who has completed post-graduate training in
using radiation to treat disease, including cancer. Radiation oncologists are board
certified to treat all cancers using a variety of methods (e.g., external beam,
brachytherapy, or nuclear medicine).
Shared decision making (SDM). A collaborative information exchange between
the healthcare provider and the patient (Charles et al., 1999).
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Treating radiation oncologist. The board-certified physician specializing in
therapeutic radiation who prescribes, creates, and approves the radiation plan for a
patient. While the treating radiation oncologist is typically the physician that sees the
patient for an on-treatment visit a covering radiation oncologist can also cover the visit.
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CHAPTER 2

2
2.1

LITERATURE REVIEW
Introduction
The Agency for Healthcare Research and Quality (AHRQ) states SDM can

improve health outcomes, including decreasing anxiety, reduced recovery times, and
increasing compliance with treatment regimens (AHRQ, 2020). Despite these potential
benefits, research suggests radiation oncologists do not participate in SDM (Fromme et
al., 2016; Golden et al., 2016; Golden et al., 2017). Radiation oncology is a unique
discipline which mandates a minimum of weekly visits (i.e., OTV) for patients
undergoing active treatment (American College of Radiology (ACR), 2018); radiation
oncologists routinely see patients more frequently to address treatment emergent health
issues. It is possible SDM may not be employed during these visits due to the absence
of a significant medical choice (e.g., radiation versus surgery). Shared decision making
as described by Elwyn et al. (2012) employs three steps (i.e., choice talk, option talk,
decision talk) but does not address identifying the antecedent need. Patient reported
outcome measures can identify this need, detecting unrecognized issues and initiating
SDM (Greenhalgh et al., 2018; Greenhalgh et al., 2005). To further investigate SDM
and PROM for patients actively receiving radiation therapy, they must be explored
through the lens of a treatment requiring frequent healthcare decisions. A literature
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review was undertaken to understand and elucidate the path forward to understand the
interrelationships between SDM and PROM for application within radiation therapy.
This chapter summarizes literature from this search with focus on SDM, PROM, and
considerations for implementation within a radiation facility.
2.2

Shared Decision-Making
Shared decision making between physician and patients was initially introduced

to provide an ethical balance, reduce risk of medical malpractice, preserve individual
dignity, and restore justice (Brody, 1980; Veatch, 1972). It is described as the middle
ground between a paternalistic approach, where the physician makes all therapeutic
decisions for the patient, and the informed decision model, where the physician is simply
a source of information and the patient solely makes the decision (Charles et al., 1997;
Gafni et al., 1998).
Identified benefits to SDM include improved quality-of-life, decreased anxiety,
reduced psychological distress, increased satisfaction (Atherton et al., 2013; Joosten et
al., 2008; Shabason et al., 2014; Sondergaard et al., 2019), and improved treatment
adherence (Coulter & Collins, 2011). Research has revealed patients engaging in SDM
were more likely to report higher quality of care, even if their preference aligned with
the paternalistic model (Kehl et al., 2015).
Hughes et al. (2018) analyzed two databases created and maintained by the
AHRQ to explore the fiscal impact of SDM. Data were mined from the Consumer
Assessment of Healthcare Providers and Systems (CAHPS) survey and the Medical
Expenditure Panel Survey (MEPS) and then analyzed to determine how patient-perceived
SDM impacted not only patient-reported outcomes and healthcare quality but also
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healthcare utilization (Hughes et al., 2018). Shared decision making was described as
‘patient-perceived’ and derived from the CAHPS survey results by assigning Likert
values to answers. The composite scores ranged from four (worst) to twelve (best); poor
SDM was considered a score between four to eight points where optimal was a score of
twelve (Hughes et al., 2018). Results suggest optimal SDM decreased the incidence of
two or more emergency room visits but was not associated with a change in inpatient
hospital stays (Hughes et al., 2018). While not statistically significant, there was a trend
in the mean annual healthcare expenditure between optimal SDM ($6,238) and poor
SDM ($5,862) (p=0.60) (Hughes et al., 2018). The trend in healthcare expenditures
against SDM and inpatient hospital stays in days invites further exploration. The findings
of this research are limited in generalizability to the oncologic SDM due to its
retrospective nature as well as poor context (e.g., provider, service, established rapport).
The crux of SDM is individuality, not generality.
In 2012, Elwyn and colleagues were the first to fashion a model for SDM
(Chapter 1, Figure 1), based upon prior published work that described the concept of
SDM but did not describe its process. The model provided a simplified path for SDM,
beginning with choice talk which transitions to option talk and then ends with decision
talk. Choice talk is the conversation stating options are available, that a decision will need
to be made, the patient will have an active role in that decision making process. Elwyn et
al. (2012) discourage paternalism and suggest if the patient defers to the physician that
the physician agrees to provide perspective but also to review options in more detail so a
decision can be made. Option talk is then the transition to identifying all available options
and then describing the pros and cons of those options (Elwyn et al., 2012). Options
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should be provided as a clear list, preferably in a format conducive to discussion between
the patient and provider. After deliberation, the final step is decision talk, which
encourages the patient to make a decision but also can provide the iterative process of
reviewing the options in brief and then identifying the selected option (Elwyn et al.,
2012). Within choice talk, the first step of the model, Elwyn et al. (2012) suggest a
guiding opening statement of “Now that we have identified the problem, it’s time to think
what to do next” (p. 1363). This reveals a key assumption: a problem has been identified.
Thus, a barrier to SDM may be lack of acknowledgement that a problem exists.
A qualitative synthesis of 40 articles describing SDM models identified 24 SDM
components relevant to healthcare (Bomhof-Roordink et al., 2019). The incidence of
these components was identified according to disciplines of care (e.g., oncology, chronic
care, emergency medicine) and expressed as a percentage of the total SDM models for
that discipline (p. 8, Bomhof-Roordink et al., 2019). Components with highest incidence
(76% to 100%) in oncologic care overlapped somewhat with the chronic care discipline,
sharing describe treatment options and deliberate in high incidence (Table 1). The SDM
components of make the decision, patient preferences, determine the next step, and
provide information are more commonly associated with the discipline of chronic care
(Figure 8) but provide neutral information, offer time, support decision making process,
advocate patient views, and learn about the patient have a high incidence in oncologic
care but are absent from SDM models in chronic care (Table 1). This is interesting as
many malignancies are transitioning from terminal illnesses to chronic healthcare
conditions, transitioning the SDM model from oncologic care to chronic healthcare. Not
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Table 1
SDM Comparison between Chronic Healthcare and Oncologic Care
Component

Chronic Healthcare

Oncologic Care

Describe treatment options

≥ 76%

≥ 76%

Deliberate

≥ 76%

≥ 76%

Make the decision

≥ 76%

50 – 75%

Patient preferences

≥ 76%

50 – 75%

Determine next step

≥ 76%

50 – 75%

Provide information

≥ 76%

50 – 75%

50 – 75%

≥ 76%

Learn about the patient

—

≥ 76%

Advocate patient views

—

≥ 76%

Support decision making process

—

≥ 76%

Offer time

—

≥ 76%

Provide neutral information

—

≥ 76%

Tailor information

Note: This table is adapted from a figure within an open access article distributed under
the terms of the Creative Commons CC BY license, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly
cited. Copyright information provided by BMJ Publishing Group Ltd., publisher of BMJ
Open. Key components of shared decision making models: A systematic review by
Bomhof-Roordink et al. ©2019
listed as an identified SDM component is identification of the problem/issue requiring a
decision (Bomhof-Roordink et al., 2019). Without it, SDM cannot occur.
A solution to identifying the problem can be found in work by Greenhalgh et al.
in 2005, which explored through a thought exercise why there were differences in
treatment and healthcare outcomes when utilizing HRQL in the clinic. In the review,
points and paths critical to impact of HRQL within the clinic were identified and
discussed (Figure 5). Prior work was deemed simplistic in its approach for a complex
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phenomenon with a multitude of confounding factors influencing the path of HRQL
instruments changing care within a clinic. Greenhalgh et al. (2005) identified concerns
within the information flow such as identifying the appropriate clinical provider to
receive the HRQL (e.g. nurse versus physician), if a single collection is adequate or if
Figure 5
Outcomes and hypotheses in the trials evaluating the impact of health status measures on
clinical decision making (Greenhalgh et al., 2005)

Note. Reprinted from Social Science & Medicine ©2005 with permission from Elsevier.
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trends over time should be provided, and if the information is provided in a format to
maximize its value and interpretation. The model from Greenhalgh (Figure 5) visually
depicts a significant portion of proposed work, especially panels D (detecting
unrecognized problems) and F (changes to clinician management of patient). The authors
concluded further research needed to be conducted.
In 2018, Greenhalgh and others reviewed the published peer-reviewed literature
on HRQL and impact on the healthcare clinics, including oncology clinics, to create a
realist synthesis. The synthesis yielded two theories: (a) completing HRQL supported
patient to clinician communication regarding issues, and (b) the reported HRQL scores
brought the patient’s problems to the clinician’s attention (Greenhalgh et al., 2018). Some
physicians raised concerns that HRQL questions could be upsetting or distressing to
patients, but this was minor compared to the opinion HRQL instruments gave patients
permission to discuss concerns, including issues they may have felt awkward raising
independent of the instrument (Greenhalgh et al., 2018). Similar to prior work,
communication became key to HRQL and its impact on the patient-physician treatment
dyad. In general, utilization of an HRQL instrument increased a patient’s awareness of
their health as well as of their care by their physician. The authors acknowledged not all
patients want to discuss these issues with their physicians or that it may be contextually
dependent (Greenhalgh et al., 2018). In their oncology literature review, Greenhalgh et al.
(2018) noted the physicians commonly treated HRQL answers consistent with another
lab result or test, focusing on the specific symptom rather than its impact on the patient’s
functioning and/or quality-of-life. Greenhalgh et al. (2018) concluded, “Exploring how
and why patients answer PROMs in the ways that they do, in addition to understanding
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how clinicians and patients interpret the score itself, can expand our knowledge of how
patients understand their condition and its impact” (p. 24).
Golden et al. (2016) explored the patient’s perception of SDM when deciding
between surgery or stereotactic radiation therapy (SBRT) for definitive treatment for
early stage non-small cell lung cancer. Both treatments are accepted as best practice for
this patient population and meet the definition of equipoise. The authors used a patientcentered communication model to guide the study questions (Golden et al., 2016).
Enrollment continued until thematic saturation was reached. Thirteen patients were
enrolled, with six deciding to receive SBRT. Roughly 25% described a complete absence
of SDM, describing their experience as being “…completely uninformed about other
possible treatment options” (p. 1364, Golden et al., 2016). The authors identified trust,
and not simply information exchange, as a significant factor in SDM and that it served as
both a facilitator and a barrier. As a facilitator, trust enabled patients to be comfortable
with their provider and rely upon clinicians’ information. Conversely, trust became a
barrier if it created such a security as to instill acquiescence and cause the patients to take
a passive role (Golden et al., 2016). This is echoed in a qualitative study by Smith et al,
which identified that patients perceived the decision making process as agreeing with the
treatment team and, when the team did not align or contradicted itself, trust was
negatively impacted (Smith et al., 2017). Recommendations from the patient participants
included to use numbers, written materials, and tailored information. Patient participants
recommended providers reinforce important points about the treatment at each encounter
(Golden et al., 2016).
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Poor understanding of decision points was reflected in work examining SDM and
maintenance chemotherapy for patients diagnosed with lung cancer (Sztankay et al.,
2017). Maintenance therapy is a cytotoxic chemotherapy regimen designed to keep the
disease and its symptoms stable, shifting the cancer to a chronic healthcare condition.
Patients were interviewed when initiating maintenance chemotherapy as well as at its end
(Sztankay et al., 2017). In review, there was a discrepancy between the physician and the
patients (n=84) as to why therapy was initiated and why it was ended. Sztankay et al.
(2017) posited the inclusion of PROM would strengthen identification of treatment
emergent side effects and toxicities. This is consistent with other research identifying
differences between anticipated side effects of therapy as well as their severity (Pilote et
al., 2019; Shaverdian et al., 2019).
From 2018 forward, work in shared decision making in oncology, including
radiation oncology, has included patient decision aids and their impact on shared
decision making (Agin et al., 2018; Leech et al., 2020; Raphael et al., 2020; Treffers &
Putora, 2020). Decision aids can be videos, graphical/cartoon, paper, or electronic
(Agin et al., 2018; Berman et al., 2016) but should provide steps 1 and 2 in the SDM
model as described by Beers et al. (2017): informing the patient there is a decision to be
made and providing information in a medium that is useful to the patient. What remains
critical, and are most likely tied to the success of a decision aid and its outcomes, are
steps 3 and 4 of the work by Beers et al. (2017): identify the patient’s preferences for
treatment and goals for therapy and then make the decision by summarizing
preferences, points, and potential problems.
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Steps 3 and 4 of Beers et al. (2017) were echoed in findings from Rocque and
colleagues (2019). This work explored what was considered important by patients when
making treatment decisions for metastatic breast cancer (Rocque et al., 2019), using a
qualitative design with the Ottawa Framework as the guiding model (Graham & Logan,
2004). Researchers interviewed patients (n=20), community oncologists (n=6), and
academic oncologists (n=5). Thematic findings identified physicians considered the
treatment efficacy and side effects at the expense of patient preference (Rocque et al.,
2019). Patient participants expressed trust in their doctor but also expressed frustrations
with communication and listening. Rocque et al. (2019) provided the following poignant
quotes which clearly illustrate the chasm in shared decision making within oncology:
Patients wanted oncologists to ask them about their preferences and wanted to be
heard. One woman stated “I know doctors have a busy schedule, but making time
to ask questions and listen is the main thing” (patient 12). One woman expressed
frustration that her concerns were dismissed. “I do think that the doctor should
take out a little more time to kind of, ask you questions…my doctor be ‘oh, you
gonna be all right.’ That ain’t what I want to hear” (patient 17) (p. 1318).
For example, when asked about intolerable side effects, one participant identified
‘not being able to focus and think’ (patient 4) as unacceptable. In contrast, another
patient commented ‘I would rather accept the chemo brain than not have an
aggressive treatment’ (patient 8) (pp. 1317-1318).
The authors present rich quotes from patients in a point/counter-point fashion regarding
side effects (physical, emotional, cognitive), personal responsibilities such as work,
logistics and convenience, financial, and impact on activities of daily life (Rocque et al.,
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2019, Table 2). The quotes provide clear imagery of diametric opposition, highlighting
the spectrum of opinions and preferences within this patient population. When reviewing
the marked differences in patient preferences, the scope of work for SDM in the field of
oncology is highlighted by a quote from an oncologist in Rocque et al. (2019):
I feel like their goals are my goals, which is to live as long as possible with least
toxicity. I feel like they all have the same goal, pretty much...which would be to
have as long a life with as good a quality-of-life. (p. 1318)
When an oncologist believes their goals are the same as the patient’s information transfer
is foundationally flawed and SDM fails (Beers et al., 2017; Herrmann et al., 2018). Other
discussed contributing factors to problems in SDM implementation include trust in
provider, lack of treatment consensus, time constraints, and poor communication (Agin et
al., 2018; Ankolekar et al., 2019; Covvey et al., 2019; Legare & Thompson-Leduc, 2014).
It is reasonable to extend these findings to patients diagnosed with lung cancer as well as
their treating radiation oncologist.
2.2.1

Communication
Communication serves as a foundation to shared decision making, a co-factor in

each step of the SDM model as posited by Beers et al. (2017): informing, explaining
identifying, and summarizing. Not only is communication key for SDM, it is critical for
accurate diagnosis and proper medical care; unfortunately, communication between the
physician and patient is not only complex but problematic (Palmieri & Stern, 2009). In
addition to health literacy, medical jargon, and tight clinical schedules, known problems in
patient-provider communication also include provider-pleasing behavior, so-called “white
lies,” (a falsehood to spare pain, discomfort, or emotional distress), and ‘nudging,’ (a
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strategy for changing a patient’s behavior or decision without impinging on autonomy)
(Avitzour et al., 2019; Palmieri & Stern, 2009). Standards for communication typically
include readability, ease of interpretation, and the patient’s comprehension; regardless,
simply discussing a diagnosis, prognosis, or treatment options with a patient does not align
with the quality of communication necessary for SDM. In addition to this rote exchange of
information, the National Cancer Institute (NCI) identifies quality communication in
oncology as one that has a dynamic to promotes healing, that engages in emotional
discussion and displays empathy, and asks patients for their preferences to aid them in
being proactive in their care (Epstein & Street, 2007). Factors influencing the
communication dynamic include information preferences and emotional state/climate of
the visit whereas the patient-provider dyad is commonly impacted by pre-existing factors
(e.g., socioeconomic, communication style, personality) (Siminoff & Step, 2005).
In 2017, Golden and colleagues examined the provider’s perspective on the quality
of patient-provider communication. This qualitative study extended prior work (Slatore et
al., 2015) by exploring the experiences of 20 clinicians (eight radiation oncologists, seven
thoracic surgeons, four pulmonologists, and an oncology nurse) using a patient-centered
communication model (Figure 6) to guide qualitative questions and analysis (Golden et al.,
2017). The model has five domains to help explain communication strategies: information
exchange, sharing power & responsibility, therapeutic alliance, provider as person, patient
as person. Golden and colleagues (2017) focused on information exchange, patient as
person, and sharing power & responsibility to guide their work. The clinicians expressed
uncertainty as to how to frame treatment goals for each individual patient. While all
clinicians described the importance of information sharing, only thirteen (80%) believed all
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Figure 6
Patient-Centered Communication Model as Adapted by Golden et al. (2017).

Note. Reprinted from Patient Education and Counseling with permission from Elsevier
©2017.

treatment options should be discussed with the patient. The clinicians concurred the patient
made the final decision regarding their treatment but noted a treatment recommendation or
decision was made prior to the consult with radiation oncology. This treatment
recommendation could be made by the multi-disciplinary oncology board, the
pulmonologist, or the referring surgeon (Golden et al., 2017). When patients are distressed,
the clinicians responded by providing more information rather than exploring the reasons
for the distress. Similarly, the clinicians did not query patients for their preferences or
values – thus limiting SDM engagement and instead simply providing a rote information
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exchange (Golden et al., 2017). The authors concluded that oncologists should continue to
provide clear and accurate information, but this should be framed by patient values and
preferences (Golden et al., 2017).
The differences in recall over what has been communicated between oncologist
and patient (‘recall disparities’) have been documented regarding treatment goals and
purpose (Chen et al., 2021; Gabrijel et al., 2008; Lee et al., 2018; Linford et al., 2020;
Temel et al., 2011). To address this, Linford et al. (2020) recommended a caregiver be
present for discussions and that this should be prioritized by the provider. This is
consistent with the findings of Smith et al. (2017) in their research on SDM.
Exploratory work done in India identified that not only was the family/caregiver
instrumental in support, but key to communication (Datta et al., 2017). This work reflects
cultural norms – such as the family providing diagnosis rather than the provider as well
as making treatment decisions independent of the patient (Datta et al., 2017; Kim et al.,
2007; Lee et al., 2018). These findings further emphasize the first step of healthcare
communication should be to ascertain the patient’s and caregivers’ preferences (Beers et
al., 2017; Datta et al., 2017; Herrmann et al., 2018; Siminoff & Step, 2005).
Another factor for communication in oncology is creating a dynamic to encourage
conversations about diagnosis and prognosis as well as the psychological and emotional
strain accompanying the disease (Epstein & Street, 2007; Siminoff & Step, 2005). Creating
this dynamic and providing appropriate support requires empathy, which can be provided
by the provider providing support by sitting silently or leaving the room to allow the patient
and caregivers to collect their thoughts prior to further discussion (Back et al., 2005; Martin
et al., 2019; Tulsky et al., 2011). Difficult conversations in oncology, such as diagnosis,
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prognosis, or relapse, are often guided by the N.U.R.S.E. mnemonic: Name the emotion,
Understand the emotion, Respect the patient/family, Support the patient/family, Explore
(i.e., tell me more) (Martin et al., 2019; Tulsky et al., 2011). Historically, communication
strategies have not been included as a formal educational program within medical school
and residency in radiation oncology (Martin et al., 2019). Education for communication
strategies can be viewed as costly as well as time intensive (Tulsky et al., 2011) and results
of interventions have been mixed (Paladino et al., 2019).
2.2.2

Documentation
A source of clear communication should be the written record, including the

patient’s electronic medical record. The medical record serves as the reference
document, the prime information source for the patient’s general healthcare as well as
for the condition under treatment. Inadequate documentation as well as erroneous
information negatively impact SDM by providing a false foundation for choice (Elwyn
et al., 2012). Practice parameters for the field of radiation oncology recommend
documents are prepared contemporaneously and in a useful format, reviewed to
minimize errors, and that it documents appropriate medical decision making (Schechter
et al., 2020). Revised approximately 9 times since its initial release in 1990, the ACRASTRO practice principles outline the need to clearly state the treatment options, the
intent of treatment, the risks / benefits that were discussed with the patient as well as
anticipated toxicities, and the anticipated treatment region (American College of
Radiology (ACR), 2018; Schechter et al., 2020). Despite a curated national guideline,
documentation errors are consistent within radiation oncology (Blakaj et al., 2017). A
review of the incident reporting system sponsored by the national radiation oncology
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group ASTRO identified 4617 safety-related events over 5 years; of these, 1002
directly involved communication (Blakaj et al., 2017). Based on a random sample, 20%
of the events were considered potentially serious and 39% of the events were related to
poor documentation from radiation oncologists (Blakaj et al., 2017).
In 2019, Dana Farber Cancer Institute published findings from a cluster randomized
controlled trial targeting improved documentation for patients with lung cancer (Paladino et
al., 2019). The goal of the research was to improve documentation such that covering
physicians or outside medical facilities could quickly and completely understand critical
information, rather than the often fragmented and scattered information within the
electronic health record (Paladino et al., 2019; Walker et al., 2018). The intervention was a
2 ½ hour training for clinicians on serious illness conversations as well as a template for the
electronic medical record notes (Paladino et al., 2019). Results demonstrated
documentation regarding goals/values increased significantly (<0.001) as well as goals of
care (<0.001) and life-sustaining procedures (p=0.004) (Paladino et al., 2019). A
subsequent study by the same research team confirmed the findings, this time by adding
audio recordings of the clinician’s visit to serve as the gold standard for the documentation
(Geerse et al., 2021). Unlike the 2019 study, documentation that did not use the EMR
template, but written by trained clinicians, was also reviewed (Geerse et al., 2021). When
utilizing the EMR template verbal information was 62% concordant with documentation
with 10% not documented whereas when not using the template, documentation was 13%
concordant and not documented 77% (Geerse et al., 2021). These findings suggest an EMR
template, and not necessarily the communication training, are responsible for better
documentation practices.
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2.3

Patient Reported Outcome Measures
Definitions of patient reported outcomes (PRO), patient reported outcome

measures (PROM), quality-of-life (QOL), health-related quality-of-life (HRQL), and
patient reported experience measures (PREM) vary based upon the researcher, the
organization, and the regulatory agency (Bottomley et al., 2016; Bottomley et al., 2019;
Gensheimer et al., 2018; Haraldstad et al., 2019; Karimi & Brazier, 2016; Mayo &
McGill, 2015; Snyder et al., 2012; U.S. Food and Drug Administration (FDA), 2020d;
van der Wees et al., 2019). All agree that a patient providing information directly,
without edit by a third-party, is a patient reported outcome; from there, opinions vary
based on inclusion of distal domains (e.g., emotional constructs, social impact), global
health vs. discrete symptoms, statistical planning and analysis as well as prime category
vs subset (e.g., HRQL as an umbrella for QOL and PROM; PROM as an umbrella for
QOL and PROM) (Fiero et al., 2019; Kluetz, O'Connor, et al., 2018; U.S. Food and Drug
Administration (FDA), 2007). Valderas and Alonso (2008) suggested the FDA relies
heavily on the source of the information rather than the information’s content. A model
differentiating concepts of patient reported outcomes (i.e., symptom status, functional
status, general health perceptions, and health-related quality-of-life) was synthesized
from work-to-date to help classify PROM (Valderas & Alonso, 2008). The model is
positing a linear, unidirectional pathway from symptom status to functional status to
general health perception and ending in health-related quality-of-life (Figure 1, Valderas
& Alonso, 2008). Despite this model, inconsistency in terminology continued. As
Bottomley et al. (2016) stated succinctly:
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The terms ‘patient -reported outcome’ and ‘HRQOL’ have, at times, been used
interchangeably, leading to confusion in terminology. However, patient-reported
outcome and HRQOL are two distinct terms that complement each other…This
distinction between patient-reported outcomes and HRQOL implies that, on the
one hand, patient-reported outcomes can be used to measure constructs other than
HRQOL (e.g., adherence and experiences of care), and that, on the other hand,
HRQOL can be measured by means other than a patient-reported outcome (e.g.,
observer or proxy reports). (p. e510)
This inconsistency, as well as the interchangeable use of PRO, PROM, QOL, and HRQL,
limits the application of the research (Bottomley et al., 2016; Burke et al., 2008; Fiero et
al., 2019; Haraldstad et al., 2019; Karimi & Brazier, 2016; Kluetz, Kanapuru, et al., 2018;
Valderas et al., 2008). As an example, in their 2019 review of quality-of-life literature,
Haraldstad et al. identified that of the papers reviewed (n=163), only 13% provided a
definition of QOL and only 25% provided the rationale for the choice of instrument. The
reasons for the lack of inclusion could include poor manuscript standardization strategy
as well as word count limitations, the findings could also suggest a lack of realization that
QOL should be defined and the instrument should be fit for purpose.
Due to the variability, for the purposes of this discussion, default definitions are
those provided previously (Introduction: Definition of key terms). If the reviewed
literature utilizes a different definition the difference and context will be highlighted
within the text as appropriate.
Regardless of the term selected, patient reported outcome measures (including the
patient-assessed health-related quality-of-life measures) address a concept of health that
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includes the social, somatic, semiotic, and psychological (Sturmberg, 2013). Patients
provide direct measures regarding an amalgamation of a complex system, the interactions
between the disease, the treatment, comorbidities, demographics, activities of daily life,
and many others. Direct report and measure from the patient based on their experience is
markedly different than the standard within the United States. Current medical practice
within the United States is rooted in a didactic and apprenticeship educational structure
passed down through generations of physicians, resulting in an alignment of assessments
and knowledge. To maintain their license, physicians must meet continuing medical
education requirements, further harmonizing the knowledge base across regions within
the U.S. It is this paradigm and knowledge base on which current medical care is based.
Incorporated patient experience data creates a spectrum of information: the rote
physician’s assessment to a patient’s reported outcome of an objective symptom (e.g.,
emesis or stooling frequency, weight loss) to health-related quality-of-life, a fully
subjective patient reported outcome. Translation of this information currently follows the
Cynefin model (Figure 7), transitioning from the Known (structured, categorize and
respond) to the Knowable (sense and respond, disease specific care) to the Complex
(probe, sense and respond; holistic care) (Sturmberg & Miles, 2013). When in the
Complex realm, the brain is overwhelmed in sense-making, attempting to predict and
organize in the current moment; however, knowledge is only gained in retrospect as the
pattern and experience is viewed in its entirety. This phenomenon, in which the mind
attempts to create predictive models based on past experiences and prior knowledge, is
termed ‘predictive coding’ (Clark, 2013; Sturmberg & Miles, 2013). The brain’s
sensemaking through this predictive modeling can cause misinterpretation and blind spots
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Figure 7
Medical Knowledge and Healthcare Intertwined in the Cynefin Framework

Note. Predictable knowledge, such as a physician’s routine assessments, lies in the known
whereas in the complex realm, patterns can only be identified in retrospect. Health related
quality of life falls within this realm as an integrated compilation of multiple confounding
factors. Reprinted/adapted by permission from Springer Science+Business Media, LLC,
part of Springer Nature: The Complex Nature of Knowledge by Joachim P. Sturmberg and
Andrew Miles ©2013.
by viewing the world through a singular lens with linear logic (Sturmberg & Miles,
2013). Upon realizing this phenomenon, the threads of predictive modeling become
identifiable in the peer-reviewed literature, is from seeking to align physician and patient
reported outcomes (Atkinson, Reeve, et al., 2018; Atkinson et al., 2017; Atkinson et al.,
2016) to cost-justification of patient reported outcome measures rather than
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acknowledging them as key medical information (Grewal & Berman, 2019; Hsiao et al.,
2019; Kotronoulas et al., 2014). Adapting to, and learning from, a complex adaptive
system such as HRQL requires dynamic assessment and adaptation; all available
knowledge should be used to adapt care to the patient (Sturmberg & Miles, 2013). With
that framing the question then becomes how to translate the experience and patterns
identified from the Complex realm of HRQL into the Knowable, contributing to a
knowledge base that is generalizable to other patients. Around 2005, research into patient
reported outcome measures beyond HRQL gained momentum in oncology; in 2016, the
U.S. FDA passed legislation patient reported outcome measures must be included in the
new drug application package or 510k application for new devices (U.S. Food and Drug
Administration (FDA), 2020a). This shifted PROM from the realm of research and use
within the clinic to also include drug and device development. With FDA’s current
emphasis on pragmatic and real world trials, as well as the 505(b)(2) application
mechanism allowing approval of drug indications based upon peer-reviewed literature,
PROM performed for academic research as well as for clinical use became a focus for
industry and, with it, regulatory oversight including FDA and EMA.
2.3.1

Research Use
Initial work in oncology clinical trials utilized instruments such as the EORTC

QLQ-C30 and the FACT-L (Haraldstad et al., 2019; Minasian et al., 2007). The National
Cancer Institute (NCI) funded initial work to create the PRO-CTCAE™ as well as
compare PROMs against ClinRO of treatment emergent adverse events (Basch et al.,
2005; Basch et al., 2006). The trial randomized participants to complete the PROCTCAE™ prior to or after a physician visit. Physicians did not review the completed
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PRO-CTCAE™ but did complete a matched CTCAE assessment sheet. Disparity was
noted with as much as a 59% discordance (Basch et al., 2006). This finding is consistent
with other studies utilizing other PROM, with other research teams reporting a disparity
between oncologists grading adverse events to be less severe than how the patients
perceive them to be (Atherton & Sloan, 2006; Basch, Deal, et al., 2016; Cirillo et al.,
2009; Falchook et al., 2016; Sneeuw et al., 1998; Sneeuw et al., 2002).
In 2007, the NCI held a clinical trials planning meeting to set priorities for the
upcoming calendar year (NCI, 2016a). It was decided PROs were a priority for cancer
research and should be adopted in future clinical trials. This position was further
strengthened by FDA’s draft (2006) and then final (2009) guidance documents (Burke et
al., 2006; U.S. Food and Drug Administration (FDA), 2009). In 2010, the NCI endorsed
PRO-CTCAE™ as a validated instrument for cancer research and released it for use free of
charge (National Cancer Institute (NCI), 2010, 2016d). A website was created for the
instrument download, with instructions provided as well as citations (NCI 2010, 2016a).
Factors promoting translation of this NCI-endorsed instrument to clinic include the NCI’s
extramural 2010 budget of just under 4 billion US dollars, NCI-directed intramural research
with a budget of 1.1 billion US dollars, control of the national cancer-therapy cooperative
group programs (e.g., Alliance, NRG, ECOG-ACRIN), and the NCI-designated Cancer
Center program (National Cancer Institute (NCI), 2015, 2016b, 2016c). Through these
mechanisms, NCI has a monopoly on research use of PROM instruments on several levels:
unfunded investigator-initiated research, extramural funded research, pivotal phase III
studies, and even pharmaceutical-sponsored research through academic-industrial funding
(through the SBIR/STTR mechanism). NCI’s endorsement PRO-CTCAE™ should have
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initiated a seamless transition to implementation and adoption. To date, this has not
occurred and implementation of PRO-CTCAE™ remains spotty, as evidenced by a lack of
presence in the peer-reviewed literature (<30 articles yearly for the past 3 years), poor
uptake of the instrument in NCI’s national protocols (Howell et al., 2021), and an absence
of requirement for its use in clinical trials to obtain extramural funding from the NCI.
The Center for Medical Technology Policy (CMTP) developed an effectiveness
guidance document (EGD) regarding the PROs in comparative effectiveness research
(Basch et al., 2012). The CMTP solicited input and feedback from multiple stakeholders,
including Patient Advocates in Research and PatientsLikeMe (Basch et al., 2012b). This
guidance evaluated various PRO-assessment instruments, including the QOL-C30,
PROMIS, FACT, and PRO-CTCAE™. Of those evaluated, PRO-CTCAE™ was one of
three evaluation instruments that captured 12 key cancer symptoms (Basch et al., 2012b,
Table 2). Fifteen recommendations were made for incorporating PROs to clinical
research; of note, electronic capture was preferred, and the questionnaire should be
limited to only taking 15 minutes of time (Basch et al., 2012). Other recommendations
included statistical considerations for missing data, power calculations, and to include an
assessment of health-related quality-of-life (Basch et al., 2012). This article served as a
summary of a longer EGD available online and sought to improve and promote PROs in
clinical effectiveness research.
In a study by Wood et al., patients undergoing a bone marrow transplant
completed a customized PROM (PRO-CTCAE™) at 24 hours post-procedure as well as
seven days post-procedure (Wood et al., 2015). The purpose of this study was to
determine concordance between these two timepoints; the authors concluded the data
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suggested a weekly assessment was preferred but that further research was needed (Wood
et al., 2015). This small feasibility study investigated frequency of assessment for a
specific cancer population but was not powered (n=32) for validation. Although the study
investigated use of PRO-CTCAE™, it did not use the questionnaire as an instrument to
assess patient outcomes in therapy.
Falchook and others investigated disparity between healthcare provider CTCAE
assessment and PROs (2016). For this study, participants enrolled in a phase II
therapeutic clinical trial for oropharyngeal cancer (NCT01530997) were invited to
complete PRO-CTCAE™ customized questionnaires weekly during therapy and then at
study-designated follow-up (Falchook et al., 2016). Unlike similar studies (Basch et al.,
2006), PRO-CTCAE™ evaluated a combined treatment modality (radiation therapy,
chemotherapy, surgical excision) compared to a chemotherapy-only regimen
(NCT01530997, Falchook et al., 2016). The authors found a substantial disagreement
between PROM and ClinRO during treatment (Falchook et al., 2016). Disagreement also
occurred at initial presentation, such as participants reporting dry mouth or hoarseness as
a baseline symptom whereas providers reported no symptomology (Falchook et al.,
2016). The implications for this disagreement are significant: in general, adverse events
occurring during therapy are defined only if they increase above baseline or if the
etiology is known to change. If a patient has baseline moderate dry mouth, reporting this
as a drug-related adverse event could be considered over-reporting as the event may not
be a valid drug-related side effect. More concerning was the provider’s inaccurate
assessment of fatigue during the six weeks of therapy (mean agreement 28%, range 12 to
49%) (Falchook et al., 2016). Fatigue is a check-point assessment for many
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chemotherapy regimens, with required dose reductions (or treatment interruptions) for
grades 2 or 3 fatigue. Despite being a subjective assessment, the three fatigue categories
have been parsed out as objectively as possible: relieved by rest (grade 1), interfering
with instrumental activities of daily life (grade 2), and limiting self-care (grade 3)
(Cancer Therapy Evaluation Program (CTEP), 2010). Instrumental activities of daily life
and limiting self-care are clearly defined and provide specific examples (CTEP, 2010).
Despite this, providers rated ~83% of participants as having mild to no fatigue at week
six of therapy whereas all participants reported some fatigue, with only 14% reporting
mild fatigue (Falchook et al., 2016).
Work from Fromme and colleagues (2016) suggests poor communication between
patient and radiation oncologist to be a factor regarding reporting disparity of treatment
side-effects and symptoms of disease: of 211 patient-identified adverse events (e.g., sideeffects, symptoms) only 19 were discussed with the radiation oncologist. In clinical trials,
the often-used model to treatment emergent adverse events as well as symptoms of disease
are for physicians to examine the patient, document their findings in a clinical note, and
have that information mined and abstracted by a research coordinator (Trotti et al., 2007).
Oncology often utilizes the Common Terminology Criteria of Adverse Events (CTCAE),
which categorizes the event (e.g., fatigue, nausea, pain) and then grades its severity. In
general, a grade of 0 equates to the symptom not being present whereas a grade 5 means
the patient died from that event. Grade 1 is mild (no treatment indicated or over the counter
only), grade 2 is moderate (prescription indicated, non-urgent medical intervention
required), grade 3 is severe (urgent medical intervention required, two or more
prescriptions, inpatient admission) and grade 4 is life-threatening or emergent care needed.
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This standardized system enables physicians to communicate to other physicians what they
diagnosed and what level of care or intervention was necessary in its management. Dose
reductions and delays of antineoplastic therapy are triggered by these events; for example,
grade 2 nausea may trigger a dose reduction and grade 3 fatigue may cause a dose delay.
The accuracy of assessing adverse events for severity becomes paramount for consistent
and safe oncologic treatment between cancer clinics and amongst providers.
As mentioned, Basch and colleagues published work documenting a disparity
between physicians’ documented adverse events and the patients’ reported events (Basch
et al., 2006). Patients diagnosed with lung cancer (n=200) were provided questionnaires
prior to examination with their oncologist; the oncologist then completed an assessment
using CTCAE version 3 for the same symptoms immediately after the exam (Basch et al.,
2006; Trotti et al., 2003). Resultant data demonstrated poor alignment between the
patient/provider dyad, including discrepancies in pain assessment (40%), fatigue (59%),
dyspnea (48%), and anorexia (34%) (Basch et al., 2006). Of the symptoms assessed, the
only assessment found to be significantly different was fatigue (p<0.01), yet pain grading
was different by at least two grades from the clinical assessment 7% of the time. This
discrepancy translates to a moderate pain being present (i.e. pain or analgesics interfering
with functioning but not interfering with activities of daily life) where the oncologist did
not identify it or severe pain was present (i.e. pain or analgesics severely interfering with
activities of daily life) but the oncologist considered it to be mild (Basch et al., 2006;
Trotti et al., 2003). Similarly, there was a 17% incidence of the patient judging the nausea
to be more severe by at least one grade and vomiting 9%. As graded by CTCAE, severity
of vomiting is graded by the episodes of emesis per 24 hours: grade 1 vomiting is defined
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by 1 episode only, grade 2 vomiting has 2 to 5 or a need for outpatient intravenous fluids,
and grade 3 vomiting lists an incidence of 6 or more emesis episodes or a requirement for
hospitalization or a requirement for total parenteral nutrition (TPN) (Rao & Faso, 2012;
Trotti et al., 2003). Grading the severity of nausea is more subjective as mild nausea
described as lack of appetite but without a change in eating habits (Trotti et al., 2003).
However, as severity grading increases, the criteria become more objective and align to
vomiting: grade 2 lists qualifying criteria as non-significant weight loss or outpatient
intravenous fluids and grade 3 the requirement for tube feedings or TPN (Trotti et al.,
2003). Given the objective data used to grade nausea and vomiting severity, it is unclear
why the discrepancy exists. Chemotherapy-induced nausea and vomiting (CINV) often
spurs dose modifications or treatment delays, ultimately impacting treatment compliance
and outcomes (Rao & Faso, 2012). Independent of cytotoxic regimens, radiation
therapy to the thorax and/or gastrointestinal tract also causes vomiting and resultant
treatment-associated comorbidities such as odynophagia, esophagitis, and
gastrointestinal pain causing inpatient admission for pain control (Abdelsayed, 2007;
Feyer et al., 2015; Ganesh et al., 2018; McKenzie et al., 2019; Rowbottom et al., 2016;
Salvo et al., 2012). It is reasonable differences in grading, and the exchange of
information these differences represent, could impact prescribed therapy as well as
adjust concomitant care to prevent admissions.
To further explore adverse event discrepancies, DiMaio et al. (2015) compared
physician grading of adverse events compared to PROMs collected utilizing the
EORTC’s QLQ-C30 in two randomized clinical trials managed by the National Cancer
Institute (Gridelli et al., 2012; Gridelli et al., 2007). Three trials representing 1459
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participants were reviewed; two of the trials focused lung cancer treatment and
contributed 1160 participants (79.5%) (Di Maio et al., 2015). The authors compared
patient and physician reported adverse events across 2482 cycles of treatment (Di Maio et
al., 2015). The authors translated the PROM survey responses to a binary response: the
symptom was reported by the patient (yes/no) and the symptom was reported by the
oncologist (yes/no) (Di Maio et al., 2015). The design is elegant in its simplicity by
focusing on data trustworthiness: (a) if a patient is reporting an adverse event, did the
physician capture it, and (b) if a physician captures an adverse event, is it real or a copy /
paste error (Di Maio et al., 2015; Gridelli et al., 2012; Gridelli et al., 2007). Although
nausea was not reviewed, six other core adverse events were reviewed and the interrater
reliability revealed poor reliability of data (McHugh, 2012). The symptoms with the
highest Cohen’s kappa were diarrhea (κ = 0.45) and vomiting (κ = 0.41); this translates
roughly to an estimated 15 to 35% of data that are reliable (McHugh, 2012). Nausea and
constipation were considered to have a minimal level of agreement resulting in an
estimated data reliability of 4 to 15% and with a Cohen’s kappa of 0.15, anorexia was
considered to have a reliability of ≤ 4% (Di Maio et al., 2015; McHugh, 2012).
According to DiMaio et al. (2015) “When examining only patients who reported ‘very
much’ toxicity in any cycle, the proportion of under-reporting by physicians was 50.0%
for anorexia, 25.8% for nausea, 13.0% for vomiting, 44.2% for constipation, 24.1% for
diarrhea” (p. 912). The authors’ conclusions suggest that physician discrepancy may, in
part, be explained by their focus on toxicities that would necessitate a treatment
modification as well as that patient self-reporting has a relatively minimal role in clinical
care as well as clinical trials. DiMaio et al. (2015) believed the findings to be
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generalizable to the larger cancer population and suggested:
[F]indings emphasize the need for modifying the current system of toxicity
assessment in clinical trials. Specifically, a collaborative reporting approach,
where the patients directly report symptomatic toxicity information, which is then
provided to clinicians to inform their CTCAE reporting, could improve the
efficiency of reporting, and modern technologic supports (e.g., tablets) could be
used to facilitate patient reporting. (p.914)
Although dated, the clinical trials’ data reflect a problem with currently conducted
clinical trials: there is not an integration between patients’ assessments and clinicians’
assessments. Data from PROMs (e.g., PROMIS, QLQ-C30) are frequently not considered
for adverse event reporting; this has resulted in the 21st Century Cures Act mandating
COAs, including PROMs, in drug development (FDA, 2020a).
2.3.2

Regulatory Use
The U.S. FDA finalized a guidance in 2009 regarding the use of PROM for the

labelling of medical products. Patient reported outcome measures (PROM) were brought
to the forefront of drug and device development within the United States by the passing
of the 21st Century Cures Act in 2016 under U.S. Public Law 116-255 (U.S. Food and
Drug Administration (FDA), 2020a). This law prioritized the patients’ perspectives
(creating the acronym PFDD for patient focused drug development) as well as
modernizing trial design to incorporate real-world evidence (FDA, 2020a). The FDA has
held a series of workshops for study designs (e.g., mixed methods, qualitative studies) as
well as how to incorporate those results into new drug applications (U.S. Food and Drug
Administration (FDA), 2020c).
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Of note, the FDA considers PFDD to utilize Clinical Outcome Assessments
(COAs), of which only one is PROM – the remaining are observer-reported outcome
(ObsRO) measures, clinician-reported outcome (ClinRO) measures, and performance
outcome (PerfO) measures (FDA-NIH Biomarker Working Group, 2021; SchultzKnudsen et al., 2021; U.S. Food and Drug Administration (FDA), 2020b). Thus, to
comply with the 21st Century Cures Act, the supplied data may be obtained from
observers or objective measures rather than PROM (U.S. Food and Drug Administration
(FDA), 2020a). Of the new drug applications approved between 2011 through 2015
(n=182), 18 were for malignancies but none had patient reported outcome data submitted
to support the filed indications (Gnanasakthy et al., 2017). Similarly, of the 2019 new
drug approvals, 11 were for anti-neoplastic indications but none had COA listed as a
primary objective but two utilized PROM: darolutamide (NUBEQA®, Bayer HealthCare
Pharmaceuticals Inc., Whippany, NJ, USA) and fedratinib (INREBIC®, Impact
Biomedicines, Inc., Celgene Corporation, Summit, NJ, USA) (Schultz-Knudsen et al.,
2021). Both provide case studies in the use of PROM in drug development and highlight
the necessity of proactively selecting the instrument and the rationale for its use.
Darolutamide was a new molecular entity approved in 2019 as a treatment for
patients diagnosed with non-metastatic castration resistant prostate cancer (Bayer
HealthCare Pharmaceuticals Inc., 2021). Of the tested secondary endpoints, one tested
time to pain progression, which was measured by question 3 of the Brief Pain Index –
Short Form (BPI-SF) (Cleeland & Ryan, 1994; U.S. FDA Center for Drug Evaluation and
Research, 2018). It should be noted that this question was the only one deemed fit-forpurpose by the FDA out of the 4 questionnaires which utilized a total of 95 questions that

74
were administered every 16 weeks (U.S. FDA Center for Drug Evaluation and Research,
2018). Time to pain progression was deemed both clinically relevant and statistically
significant and thus was listed as a benefit to the new drug. The FDA reviewer had this
comment regarding the PROM choices used for the pivotal study:
Interpreting the impact of the various composite scores analyzed on the safety and
tolerability of darolutamide is difficult due to methods of assessment that include
reports of emotional state and functionality that can be influenced by non-drug
factors. Therefore, these measures may not be truly reflective of the effects of the
drug being evaluated. Although the prostate cancer subscale of the FACT-P was
used in this trial the items are more relevant in assessing symptoms associated
with disease and treatment in the early prostate cancer setting as opposed to
patients with castration-resistant disease. (p. 142)
The pivotal JAKARTA trial evaluating fedratinib utilized only a single patient reported
outcome questionnaire – the Myelofibrosis Symptom Assessment Form – as did the
phase 2 open label trial JAKARTA2 (ClinicalTrials.gov, 2016a, 2016b). The
questionnaire had only six assessments (night sweats, pruritus, abdominal discomfort,
early satiety, pain under the ribs on left side, and bone/muscle pain) which mirrored
symptoms common to the disease under study (U.S. FDA Center for Drug Evaluation and
Research, 2019). The pre-specified test for the secondary outcome was the number of
participants who responded to treatment (i.e., investigational medical product or placebo),
where a responder was a participant who had a reduction of ≤ 50% of symptoms burden
by end of cycle 6 (U.S. FDA Center for Drug Evaluation and Research, 2019). Data
demonstrated a significant statistical difference, with 34 – 40% (dose dependent)
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achieving the pre-defined response compared to 8% in the placebo control (U.S. FDA
Center for Drug Evaluation and Research, 2019), p.16. These data were accepted by the
FDA to support the outcome of symptom reduction on the prescribing information
(Impact Biomedicines Inc. a subsidiary of Celgene Corporation, 2019). The FDA’s
multidisciplinary review of fedratinib noted:
[S]ponsors should carefully consider the study design and its effect on PRO data
interpretation. FDA recommends that if a claim of treatment benefit is sought,
there is a clear endpoint definition and formal statistical testing with adjustment
for multiplicity, as well as an appropriate pre‐specified statistical analysis plan
(SAP) with a plan to control the type 1 error rate. In the SAP, there should be
details on the statistical analysis methods, procedures for handling missing values,
justification for the endpoint definition and procedures for what constitutes
meaningful within‐patient change. (p.148).
These comments from the FDA’s Center for Drug Evaluation and Research regarding the
new drug approvals using patient reported outcomes highlight a current chasm in patient
focused drug development: a lack of fit to purpose when implementing PROM and a lack
of a statistical analysis plan when using PROM as a primary or secondary endpoint to
support labelling for a drug or device, representing one use for PROM.
The FDA considers five elements when evaluating patient reported outcome
measures: (a) identification of claim(s); (b) utilization of an appropriate conceptual
framework; (c) appropriately document content validity; (d) establish the definition of a
response; and (e) reassessment after modification to a PRO instrument (Burke et al.,
2008). The elements follow a typical strategy but include qualitative techniques,
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including focus groups with cognitive interviewing until saturation (Burke et al., 2008).
FDA encourages the PROM to focus on the symptom or side effect that is experienced by
the patient and not objectively quantifiable by the physician, as a difference in opinion is
expected between the two (Kim et al., 2018). The measurement should be fit-for-purpose,
sensitive to change over time, and be able to capture the toxicity over time through
longitudinal assessments (Burke et al., 2008; Kim et al., 2018; Kluetz, Kanapuru, et al.,
2018; Kluetz, O'Connor, et al., 2018). For example, FDA defines ‘tolerability’ as a
patient-generated concept, that the symptom or toxicity burden is tolerable and does not
interfere in day to day activities (Kluetz, Kanapuru, et al., 2018). FDA encourages trials
to focus on the symptom that could be used to inform tolerability. This becomes
exceedingly important as maintenance treatments are extending the lives of patients with
cancer but at the cost of continuing side effects (Addario et al., 2020).
Despite the FDA’s stance on tolerability as a PROM, integration of PROM to
assess tolerability within the U.S. drug approval process remains unclear – as it does for
most instruments deemed to be HRQL or QOL (DeMuro et al., 2013; Kluetz, O'Connor,
et al., 2018; Rock et al., 2007). For example, the FDA stresses that reviewing responses
to HRQL is incumbent upon investigators to protect the safety of clinical trials
participants (Kim et al., 2018). This elevates HRQL to a safety endpoint (Kim et al.,
2018; Kluetz, O'Connor, et al., 2018). Yet HRQL responses are often not reviewed as a
part of the safety assessment during a clinical trial nor are they used to define the adverse
event profile for the prescribing information. This is only one example of the confusion
created by nebulous direction from U.S. regulatory oversight for new drug and device
development (DeMuro et al., 2013; Kluetz, O'Connor, et al., 2018).
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In a 2013 review article comparing the types of PRO approvals between FDA and
the EMA, DeMuro et al. used Soliris™ (eculizumab, Alexion Pharmaceuticals, Inc.,
Cheshire, CT, USA) as an example of the discordance between the U.S. FDA and the
EMA. Soliris™ received approval for paroxysmal nocturnal hemoglobinuria (Alexion
Pharmaceuticals Inc.; U.S. Food and Drug Administration (FDA), 2007). Supporting
pivotal trials utilized both the EORTC QLQ-C30 and the FACIT-F instruments (U.S. Food
and Drug Administration (FDA), 2007). During its medical review, FDA stated that
although statistically robust, the “…FACIT-F QOL tool has not been validated for patients
in the hematology oncology setting. Therefore, the results…should not be included in
labeling…” (p. 72). Data from the EORTC QLQ-C30 were filed as exploratory and, as
such, were not considered by FDA for efficacy or labeling. In contrast and based upon the
same data, the EMA approved Soliris™ for claims based on data from both the FACIT-F
and QLQ-C30 instruments. The EMA-approved labelling states “74% of the patients
without a history of transfusion and treated with Soliris™ experienced clinically
meaningful improvements in FACIT-Fatigue score (i.e., increase by 4 points or more)
and 84% in EORTC fatigue score (i.e., decrease by 10 points or more)” (European
Medicines Agency (EMA), 2009).
Approval reviews suggest the U.S. FDA grants the majority of new drug
approvals based upon symptoms; whereas, EMA is more likely to approve based on
‘higher order constructs’–ostensibly HRQL (DeMuro et al., 2013). In 2018, selected
representatives from the FDA, the EMA, and Health Canada’s Therapeutic Products
Directorate authored an article identifying differences in PROM guidelines and policies
for drug approval (Kluetz, O'Connor, et al., 2018). In it, EMA deems HRQL an important
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primary outcome measure for oncology clinical trials, citing their reflection paper
providing instructions for claims of improving HRQL, such as the use of a validated
instrument and that all domains must be robustly impacted (EMA, 2005; Kluetz, O'Connor,
et al., 2018). In comparing PROM guidelines, FDA’s Paul Kleutz writes “discordance is
particularly notable with regards to the acceptability of the more global domains of healthrelated quality-of-life (HRQL), which can be viewed as being affected by non-drug
contributors (i.e., external influences not directly related to the study medication)” (p.e267,
Kleutz et al., 2018). The article further clarifies that FDA’s perspective is HRQL should
focus on core symptoms of disease under study, treatment emergent adverse events, and
quantifiable physical function assessments. Because emotional and/or social interactions
impact HRQL in the absence of the drug or therapy being examined, FDA requests
HRQL measures be supplemented with functional and well defined symptom data
(Kluetz, O'Connor, et al., 2018). Reviewing lung cancer clinical trials from 2007 through
2017 supporting new U.S. drug approvals underscores FDA’s stance (Fiero et al., 2019).
Common PROM instruments within the trials included the EORTC QLQ-C30, FACT-L,
and the LCSS, yet individual symptomatic domains (e.g. dyspnea, pain, fatigue) were the
FDA’s outcomes of interest rather than the composite HRQL score (Fiero et al., 2019).
The statistical analysis for the PROM utilized in the lung cancer trials was not systematic
nor justified, especially when determining clinical relevance for the composite scores
(Fiero et al., 2019). Fiero et al. conclude the impact of HRQL as an instrument to inform
both clinicians and patients is hampered due to poor planning and implementation and,
for this reason, FDA should be contacted early and often to effectively utilize PROM in
trial design with the end-goal of including the results in marketing applications.
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2.3.3

Clinical Use
Oncologic practice within the United States is significantly influenced by the U.S.

FDA through the drug approval cycle: oncologists treat based upon newly approved
indications but are influenced as well as by Industry with its perpetual clinical trials
regime to obtain those new marketing approvals. Secondary influences include research
based upon prior trials, so that if an earlier trial utilized a specific PROM instrument,
subsequent trials may incorporate that instrument. Similarly, investigator initiated trials
may copy instrument use from Industry clinical trials they have participated in. Academic
physicians may incorporate PROM instruments to provide data for chart review research
or quality improvement projects at later dates. Regardless of the cause, PROM
instruments have become part of the oncology clinic, with some clinics implementing and
adapting better than others.
Incorporating patient-reported outcome measures (PROMs) into the electronic
health record (EHR) seems the logical strategy to create patient-centered care as well as
harmonize communication between patient and provider and patient but initial work has
met with varied success (Basch et al., 2005; Basch, Rogak, et al., 2016; Boyce &
Browne, 2013; Chen et al., 2013; Gensheimer et al., 2018; Hsiao et al., 2019;
Kotronoulas et al., 2014; Kozlov & Benzon, 2020; Kyte, Ives, et al., 2013; Lavallee et al.,
2016; Nestle et al., 2020; Olde Rikkert et al., 2018; Snyder et al., 2012; Snyder et al.,
2017). A randomized controlled trial of the Patient Reported Outcomes Measurement
Information System (PROMIS) evaluated adding this PROM as an electronic survey in
an adult gastrointestinal clinic (Almario et al., 2016). The PROMIS-GI questionnaire was
completed by patients using an electronic portal one-week prior to their visit. Results
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showed no statistical difference between measures of patient satisfaction, assessments of
the providers’ interpersonal skills, and shared decision making (Almario et al., 2016).
Limitations include the single-visit structure of the study as well as the general GI-patient
population, rather than a GI-cancer population. Fromme et al. (2016) created an
electronic questionnaire based upon the Memorial Symptom Assessment Scale (MSAS)
Short Form and the EORTC’s QLQ-C30 quality-of-life questionnaire. Participants
completed this questionnaire on a Windows-based PC with results provided to the
radiation oncologist as a color-coded printed report showing change over time (Fromme
et al., 2016). Results suggest a continued inconsistency between patient-reported adverse
events and adverse events discussed with the radiation oncologist despite the
intervention. The study did not investigate shared decision making, patient
communication preferences, or measures of communication between provider and
patient. Limitations include not including the PROMs in the EHR, not evaluating
consultations (e.g., occupational, physical, nutritional), and not stratifying by tumor or
treatment type (e.g., chemoradiation, radiation only) (Fromme et al., 2016).
In contrast to much of the literature, the results of a multi-center, pragmatic
clinical trial funded by the National Institutes of Health (NIH) did not identify positive
results from incorporating the NIH’s own Patient Reported Outcomes Measurement
Information System (PROMIS) gastrointestinal (GI) instrument into clinic workflow
(Almario et al., 2016; Gracie & Ford, 2016). The trial employed the PROMIS GI
instrument approximately one week before the clinic visit through an electronic portal
(Almario et al., 2016). The primary study endpoint was patient satisfaction with
secondary endpoints including provider interpersonal skills and shared decision making
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(the 9-item shared decision making questionnaire, SDM-Q-9) (Almario et al., 2016). The
trial used alternating deployment of the PROMIS GI instrument, with one week on and
one week off for the clinic; this created the concurrent control group for comparison.
With over 200 patients in the GI PROMIS arm and 150 in the control arm, neither
statistically significant differences – or even trends – were detected between the groups
(Almario et al., 2016). A significant limitation to the work is the intervention occurred for
only one clinic visit compared to consecutive uses over the duration of the patient’s care.
Additionally, despite the authors discussion about the ‘extraordinary burden of
gastrointestinal illnesses,’ the exact diseases being cared for are not described (Almario et
al., 2016). Inclusivity is key to pragmatism but, in this instance, impacts internal validity
given the wide range of symptoms triggering gastrointestinal consults. Other recent
studies also report a lack of improvement in patient experience measures when using
patient reported outcome measure instruments, including PROMIS (Keulen et al., 2018;
Kroenke et al., 2018).
A key reason for the heterogeneity of findings could be the context of PROM use.
A 2008 systematic review of the literature explored the impact of use of PROMs in
clinical care (Valderas et al., 2008). In their review of 28 applicable studies, Valderas and
colleagues (2008) found the most significant impact occurred on the process of care
(e.g., education, diagnosis, referrals). The authors described consistent methodologic
concerns with PROM investigation and attributed these issues to the varied results.
However, this review had a broad scope, ranging from primary care (n=19) to dental
offices (n=1) to cancer clinics (n=2). It could be that the context of the medical discipline,
as well as context of use, impacts PROM functionality within the clinic. The authors
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concluded upon their review that methodologically stronger trials were required to
provide direction, context, and insight for clinicians regarding how to incorporate PROM
into clinical use.
Five years later, a systematic review found PROMs were often used in outpatient
specialized healthcare settings (Boyce & Browne, 2013). Inclusion criteria for this review
were restrictive, requiring an eligible study to utilize a randomized control with clinical
use of PROM being the sole intervention. Of the final cohort of 17 studies, only one was
an oncology study investigating the impact of PROM on pain management in patients
with cancer (Boyce & Browne, 2013). In conclusion, Boyce and Browne (2013)
identified consistent methodologic issues with the work to date, suggesting future
research focus not only on hypothesis driven quantitative research but also qualitative
work to provide a richer understanding of problems implementing PROM as well as
understand if PROM affect the decision-making process and, if so, how.
That same year, a systematic review by Chen and colleagues (2013) identified 27
publications evaluating the routine use of PROM in the oncologic setting. Outcomes
evaluated from PROM implementation included patient-provider communication,
monitoring treatment response, and changes to patient management (Chen et al., 2013).
Of the publications reviewed, 16 were randomized controlled trials (RCTs), two were
before/after studies, and 11 were observational studies. Identified limitations to the work
included simple-randomization strategies, which do not address contamination of the
system, failure to utilize a comprehensive model and/or framework, and all studies
occurring at a single site (Chen et al., 2013). Of the 27 studies reviewed, 23 reported on
the impact on patient-provider communication; 21 reported a positive effect. All of the 11
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studies reporting on monitoring treatment response found a positive impact, typically on
monitoring chemotherapeutic toxicity. Of the 16 studies describing the problem of
unrecognized problems, 15 reported a strong or moderately positive impact on detection.
The authors concluded the evidence base was weakest for PROM impact on changes to
patient management as well as improved health outcomes. None of the studies examined
changes to patient health behavior, quality improvement, or better health care system
performance (Chen et al., 2013). In their conclusions, the authors state that simple
feedback alone provided by adding PROM to the clinic may not improve patient
management or health outcomes. Additional resources, such as an implementation and
assessment plan, may be required to obtain benefit from incorporating PROM into the
oncology clinic (Chen et al., 2013).
A review by Kotronoulas and colleagues (2014) investigated the value of
routinely incorporating PROM into oncology clinics. Whereas Chen et al. evaluated the
impact of PROM on patients, providers, and healthcare organizations, Kotronoulas et al.
focused on if any improvement occurred in discrete patient outcomes, processes of care,
or health service outcomes (Chen et al., 2013; Kotronoulas et al., 2014). Seventeen of the
24 articles reviewed were also reviewed by Chen et al. (2013); perhaps for this reason,
the results were similar. Overall, a positive effect was observed on physical symptoms,
including psychological distress and greater satisfaction with emotional support and
communication with the healthcare team were observed with PROM use (Kotronoulas et
al., 2014). Despite these findings, Kotronoulas and colleagues (2014) stated evidence was
weak regarding the effectiveness of PROM in improving quality of care for patients
undergoing antineoplastic therapy. Like the previous reviews, the authors conclude with a
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need for rigorous research that would provide the context and guidelines for PROM
implementation to result in not only an effective use but a fiscally efficient use as well
(Kotronoulas et al., 2014).
To perhaps help with identified weaknesses, systematic guidance on how to
incorporate PROMs into clinical practice was drafted and provided by The International
Society for Quality of Life Research (ISOQOL) as well as others (International Society for
Quality of Life Research et al., 2015; Kyte, Draper, et al., 2013; Lavallee et al., 2016; Olde
Rikkert et al., 2018; Snyder et al., 2012; Snyder et al., 2017). Basch and colleagues
guidelines propose core symptom assessments for oncology clinics and trials using PROM
(Basch et al., 2012; Basch, Rogak, et al., 2016). Other guidelines include setting goals for
PROM use, identifying the method for capture (patients, setting, timing), and deciding how
to report and address results (ISOQOL et al., 2015; Snyder et al. 2012). The guidelines
omit the patient perspective, not including them in goal setting, instrument design, or how
they would like the results presented (ISOQOL et al., 2015; Snyder et al. 2012). This is in
contrast to recent publications that recommend including patients in the care-planning
process as well as regulations requiring goal setting for patient-centered care (Addario et
al., 2020; Baker et al., 2001; Olde Rikkert et al., 2018; van Dulmen et al., 2015). This
becomes key, as inviting patients to participate in setting goals of treatment bridges a gap,
identifying PROMs as an instrument in SDM.
2.4

Frameworks and Implementation
As mentioned previously, capturing PRO as well as initiating PROM

instruments have met with mixed success for both implementation and outcomes.
Recently, key opinion leaders have proposed standardized strategies. The majority of
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the leaders agree on the need to prospectively identify the PRO to measure, select the
instrument to measure the PRO, ensure the measurement is fit for purpose, confirm the
instrument is sensitive to change, define how often PROM are collected, how the
PROM are collected, and that analysis is well-defined prior to implementation (Basch,
Rogak, et al., 2016; Burke et al., 2008; Gensheimer et al., 2018; Kluetz, O'Connor, et
al., 2018; Snyder et al., 2012; U.S. Food and Drug Administration (FDA), 2009, 2018).
In addition to these considerations, there are others that may have not yet been
identified or may be identifiable only in context. When introducing a new instrument or
communication strategy into a complex adaptive system (such as multidisciplinary
oncologic care), frameworks should be reviewed if not utilized.
2.4.1

Frameworks
Theories, models, and frameworks become key when considering creation of an

instrument, its implementation, or its uptake. The FDA has listed identifying and utilizing
a conceptual framework as one of the five key criteria for successful PROM use and
evaluation (Burke et al., 2008). A framework provides a visual depiction of factors,
influences, and their interactions and may outline key steps that should be considered for
concept or phenomenon of interest (Nilsen, 2015). Frameworks for implementation,
termed determinant frameworks, can serve as a mediator for change by proactively
identifying barriers and facilitators (Nilsen, 2015). A framework does not specify
causality, but simply provides the implementation concepts or foundational constructs.
When used appropriately, frameworks provide structure to implementation, can decrease
poor fit, and increase uptake. Frameworks that were incidentally identified through the
search of the peer-reviewed literature PROM and SDM were reviewed; of these, three
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Figure 8
Conceptual Framework Identifying Potential Downstream Effects of PROM for Patients
with Chronic Health Issues

Note. Reprinted by permission from Springer Science+Business Media, LLC, part of
Springer Nature: Rapid Communications of Oxford, Ltd. Quality of Life Research.
Framework to assess the effects of using patient-reported outcome measures in chronic
care management by M. J. Santana and D. Feeny. ©2014
were identified as relevant to a shared decision making / communication instrument in
radiation oncology utilizing patient reported outcome measures.
Santana and Feeny (2014) proposed a framework for patient reported outcomes
and communication for clinical use for patients with chronic healthcare problems (Figure
8). The framework elegantly conveys the cascading effect of the PROM and downstream
communication between patient, caregiver, and physician (Santana & Feeny, 2014).
When considering implementation of the PROM, the first downstream effect is patient
engagement followed by decision making and outcomes (Figure 8). Increased patient
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engagement could stem from the PROM instrument establishing a foundation of items for
discussion, deeming them to be ‘acceptable’ for discussion with physicians (Greenhalgh
et al., 2018).
In 2019, van der Wees et al. developed a framework (Figure 9) which was then
evaluated in its preliminary format at an ISOQOL workshop. The framework provides a
stepwise strategy for thoughtful implementation and use of a PROM instrument (Figure
9). The framework aligns with the requirements underscored by FDA: define the
objective, select the PRO, select the PROM to ensure appropriate measure, identify the
metric to be used as an indicator of quality, and then maintain the PROM implementation

Figure 9
The Goal-Selection-Indicator-Use Framework

Note. Open access article which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. Van der Wees et al.
©2014.
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(van der Wees et al., 2019). The framework reminds that a patient reported outcome is
not a patient reported outcome measures, that quality strategy must be applied to PROM
instruments as another clinical assessment, and that the use of the PROM instrument must
be assessed for uptake and fit (van der Wees et al., 2019).
2.4.2

Implementation of SDM and PROMs
The proposed work relies heavily on three implementation frameworks and

models: the National Implementation Research Network as described by Bertram and
colleagues in 2015, the Ottawa Model of Research Use (OMRU) as written by Graham
and Logan in 2004, and the Plan-Do-Study-Act implementation cycle model originally
described by W. E. Deming in the 1920s (The W. Edwards Deming Institute, 2021). As
discussed in Chapter 1, the framework and models create an needed granularity when
integrated, providing details and considerations for implementing a decision-aid.
Despite known benefits, research demonstrates oncologists, including radiation
oncologists, do not participate in SDM (Amundsen et al., 2018; Glatzer et al., 2020;
Hopmans et al., 2015; Jabbour et al., 2018; Mokhles et al., 2018; Smith et al., 2017;
Sztankay et al., 2017). Research by Shabason et al. (2014) suggests only one-third of
patients at an academic center in the U.S. endorsed shared decision making with their
radiation oncologist. This is consistent with research from Australia, which suggests
incidence of SDM ranging from 33 to 37% in general oncology practice (Herrmann et al.,
2018; Jabbour et al., 2018).
Within generalized oncology practice (i.e. the radiation, surgical, or medical
specialties), barriers to SDM have been identified as time-constraints, a generalized
feeling of being rushed, lack of applicability of SDM to the current situation, an
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education gap between provider and patient, and the patient’s concern of being labeled
‘difficult,’ a lack of a treatment consensus between oncology disciplines (e.g., medical,
surgical, radiologic), patient concern over adverse effects, poor physician communication,
and the oncologist’s understanding of the patient’s preferred decision making preference
(Agin et al., 2018; Ankolekar et al., 2019; Covvey et al., 2019; Frosch et al., 2012;
Legare et al., 2008; Legare & Thompson-Leduc, 2014; Woodhouse et al., 2017).
A common concern is that SDM increases time per clinic visit and time
commitment for quality communication then becomes a significant barrier (Martin et
al., 2019; Paladino et al., 2019). A qualitative study from Australia explored patients’
first consultations with their oncologist (radiation or medical). The consults were audiorecorded were transcribed, coded, and compared between the two specialties. Results
revealed radiation oncologists spent less time with their patients (23.1 minutes vs. 36.7
minutes) and allowed less time for the patient to speak (6.2 minutes vs. 10.6 minutes)
(Dimoska et al., 2008). Although a partial explanation for this could be radiation
oncology is a referral service, with medical oncology providing initial diagnosis,
prognosis, and indications for therapy, in this work the visits were independent
(Dimoska et al., 2008). Radiation oncologists invested an average of 9 seconds during
the consult to confirm patient understanding and engaged only 25 seconds in
communication that was considered rapport building (Dimoska et al., 2008). The same
study demonstrated patients took a total of 62 seconds to reveal the problem/intention;
this is less than other studies which have found patients average 90 to 120 seconds to
provide their rationale for their visit and/or concerns (Langewitz et al., 2002;
Rabinowitz et al., 2004; Singh Ospina et al., 2019). Prior work has identified the
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majority of general practice physicians interrupt during their patient’s initial
monologue, with time-to-interruption ranging from 11 to 23 seconds (Singh Ospina et
al., 2019). It is reasonable to extrapolate this to radiation oncologists, as Martin et al.
(2019) describe the radiation oncologists’ communication style as, “…less patientcentered, more hurried, and less clear” (p. 294).
Beers et al. (2017) state that approximately 75% of oncology patients seek an active
or collaborative role with their oncologist(s) in decisions about their. Similarly, Zeng et al.
(2017) evaluated decision-making preference (active versus passive) of patients with
metastatic cancer to the brain and all participants requested an active SDM role. Patients
who seek a passive role tend to have poorer coping skills and are more fatalistic (Beers et
al., 2017). Hermann et al. (2018) identified five categories of decision making within
oncology: patient only, predominantly patient, collaborative, predominantly doctor,
doctor only. A cross-sectional survey querying the patient’s preferred involvement the
patient’s perceived involvement was sent to adult cancer patients treated at medical or
radiation oncology units. Of the 423 respondents, a third reported a discordance between
their preference and their perception and roughly 55% reported being asked about their
preference for decision making (Herrmann et al., 2018). Reasons cited for not asking
patients their preference for involvement in decision making include additional time
constraints or burden in an already hectic clinic and also the perception that patients
prefer not to be responsible for their treatment decisions (Herrmann et al., 2018).
With this research, Herrmann et al. (2018) adds a significant first step to the SDM
in oncology framework that was described by Beers et al. (2017). Whereas Beers outlined 4
steps: (1) informing patients, (2) explaining the treatment options, (3) identifying patients’
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values and goals, and (4) making the decision, Hermann et al. (2018), define the critical
first step as asking the patient to identify their preferred decision making method, rather
than assuming the patient’s preference. Failing to identify a patient’s preference has been
coined, “preference misdiagnosis,” and can result in anxiety, stress, depression, and patient
dissatisfaction with care (Mulley et al., 2012) as well as create a crack in the foundation of
patient-centered care, which is defined by the AHRQ and the National Academy of
Medicine as “Providing care that is respectful of and responsive to individual patient
preferences, needs, and values” (Agency for Healthcare Research and Quality, 2018, 2020;
Institute of Medicine, 2001).
This is noteworthy, as radiation oncology is–perhaps–the most patient-centered
oncologic discipline. Rather than a simple, binary treatment decision (i.e., radiation yes,
radiation no), radiation therapy techniques demand an individualized plan designed to the
sub-millimeter, customized to the patient’s unique anatomy, tumor type, treatment strategy
(e.g., palliative, definitive, adjuvant) and even medical comorbidities (Berman et al., 2016).
However, a metric to determine the success of SDM within radiation oncology has not yet
been identified much less agreed upon (Berman et al., 2016; Leech et al., 2020).
Radiation treatments vary in dose, schedule, technique, and modality; some may
not have a clear superiority and can be recommended based on provider preference or
technological capability of the radiation oncology facility (Woodhouse et al., 2017).
When such clinical treatments meet equipoise, or if patients express uncertainty or
confusion over treatment options, clinical decision-aids can serve as instruments to help
identify the best treatment path for the patient (Woodhouse et al., 2017). A decision-aid
instrument can promote shared decision making in situations where patient preference is
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influential, creating a collaborative dynamic where factors including treatment burden,
financial stressors, and therapy goals are incorporated into the treatment decision.
Decision-aids should be tailored for the patient (to the extent feasible) and provided to the
patient for retention. This not only encourages the patient to share information with
family and caregivers, but also to review the information provided after the initial
consultation, when patients report poor information retention (Charles et al., 1997).
Unfortunately, tailored patient information in radiation oncology, and thus a
decision aid instrument, includes discussion about a technically complex medical
discipline. Radiation oncology requires high-resolution imaging, assessment of tumor
motion, hundreds of contours of normal tissues as well as target tissues (i.e., tumor tissue or
tissue at risk), constraining doses to organs to reduce radiation damage, peer-review, a
medical physics plan check, and daily quality assurance. The American College of
Radiology-American Society for Radiation Oncology (ACR-ASTRO) Practice Parameter
for Communication: Radiation Oncology explicitly outlines information to be communicated
to the patient as well as information to be documented in the medical record (Schechter et
al., 2020). Direct communication between the radiation oncologist and patient should be
bidirectional, collaborative, supportive, and should include treatment options (Schechter et
al., 2020). The recommendations do not include discussing the technical aspects of the
radiation plan or documenting them in the patient’s notes (Schechter et al., 2020).
A study in 2017 explored a radiation decision aid for patients diagnosed with lung
cancer metastases who could have either of two radiation therapy strategies: whole brain
radiation with stereotactic radiosurgery (WBRT + SRS) or SRS alone (Zeng et al., 2017).
The decision-aid outlined differences in potential neurocognitive toxicities, treatment
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duration, and risk of recurrence for both treatments but did not provide differences in
survival, side effects, or quality-of-life – simply stating that they were ‘equal’ (Zeng et al.,
2017). After evaluating the decision aid, twenty-one of participants (91%) selected SRS
alone as their therapy. Participant responses to surveys suggested maintaining QOL and
functional independence was of greater importance to patients than disease recurrence,
development of new metastases, or the number of trips to the treatment center (Zeng et al.,
2017). Of concern, the peer-reviewed literature Zeng et al. cited in their work did not
support the information on the decision aid instrument. One of the two studies cited was
halted by its data and safety monitoring committee due to the severe neurocognitive
adverse effects of SRS+WBRT (Chang et al., 2009). Chang et al. state that QOL was not
the same for the SRS and SRS+WBRT cohorts as measured by the FACT-BR instrument.
Quality-of-life was not defined within the article or within the decision aid instrument
Figure 10
Decision Aid for SRS Alone or SRS Combined with WBRT

Note. SRS: stereotactic radiosurgery, WBRT: whole brain radiotherapy. This figure is
adapted from a figure within an open access article distributed under the terms of the
Creative Commons CC BY license, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. Copyright
information provided by AME Publishing Company, publisher of Annals of Palliative
Medicine. Patient preference for stereotactic radiosurgery plus or minus whole brain
radiotherapy for the treatment of brain metastases by Zheng et al. ©2011.
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(Zeng et al., 2017). Zeng et al. (2017) wrote, “but also the quality-of-life during that period
(in this case, possible worsening neurocognitive function)” (p. 159). This quote highlights
the discrepancy within the article: how does experiencing significant neurocognitive
decline not influence QOL? It seems illogical to suggest otherwise, but this is what is stated
within the decision aid drafted by Zeng et al. (2017) (Figure 10). This study further
highlights how the ambiguous use of the term HRQL can stifle research trustworthiness
and usability, as it is unclear how QOL is not impacted and side effects are the same but
deficits in neurocognition (which are a side effect of radiation) are significantly different
(Zeng et al., 2017).
Dyer and colleagues explored sharing technical details of an RT plan in a
randomized clinical trial (2019). Patients diagnosed with breast cancer requiring adjuvant
radiation were randomized prospectively to standard review vs. a detailed review which
included the radiation treatment plan, tissue doses, organ constraints, and the radiation
beam arrangement (Figure 11) (Dyer et al., 2019). As shown, the information provided for
the detailed review is technical with poor readability, with X-ray imaging for target
alignment (Figure 11, panel E) and dose volume histograms, which provide the normalized
volume to receive a specified radiation absorbed dose measured in centigray (cGy) (Figure
11, panel F). Despite the heavy technical details, overall satisfaction scores were increased
at baseline for patients increased for patients undergoing the detailed review; however,
these equalized to the control arm by week 1 of radiation and remained consistent with the
control by completion of radiation treatment (Dyer et al., 2019). With an average increase
of 4 minutes for the plan review, the work by Dyer does not support implementing a
detailed technical review to increase overall satisfaction, including the FACIT subdomains
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Figure 11
Sample Radiation Therapy Plan Shared with Patient for SDM

Note. Sample radiation therapy plan to treat a lumpectomy for a patient with breast
cancer. This figure is an example of the plan shared with patients for a detailed review
of their treatment (Dyer et al., 2019). A, B, C. Images from the radiation therapy
planning system showing contours for organs as well as the target (solid red area). D.
Three-dimensional representation of patient’s breast and where the radiation enters
(e.g., pink overlay). E. Positional imaging to ensure the radiation aligns with the target.
F. Dose volume histogram showing the volume of tissue receiving specified radiation
doses. Reprinted from Practical Radiation Oncology, volume 9, Dyer et al. Prospective,
randomized control trial investigating the impact of a physician-communicated
radiation therapy plan review on breast cancer patient-reported satisfaction, pages e487e496, ©2019, with permission from Elsevier.
of confidence & trust, physician communication, and technical competency (Dyer et al.,
2019) . It could be study utilized the wrong endpoint, as FACIT scale has a 1 to 3 numeric
scale and not designed for radiation therapy. The normalization could reflect a patient’s
passing interest in the technical information regarding the radiation plan. It could also
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reflect a patient’s lack of recall due to information overload or simply the stress of their
diagnosis. This would be consistent with earlier findings that found over half of patients
with lung cancer could not recall information about goals of therapy and treatment options
provided to them (Gabrijel et al., 2008) and 15% of patients believed they were receiving
radiation therapy to cure their cancer when it was palliative (Mackenzie et al., 2018).
2.5

Summary
Peer reviewed literature to date supports the use of SDM and identifies multiple

benefits. Despite the potential benefits, research suggests radiation oncologists are not
participating in SDM. Patient reported outcome measures prompt both quality
communication as well as SDM. Implementation of PROM, including HRQL, has met
with difficulty due to overlapping definitions, poor fit for purpose between the instrument
and the patient reported outcome, and a lack of planned statistical analysis. Clinical
outcome assessments include both PROM and ClinRO which often demonstrate a
disparity. Inclusion of COA, including PROM, is legally required for new drug and
device approvals within the U.S.; this creates additional pressure for oncology clinics to
proactively implement PROM. Frameworks should be used when implementing PROMs
and SDM within the radiation oncology clinic, as the literature suggests work to date has
been contradictory and inconsistent. Within radiation oncology, knowledge gaps remain
regarding design of decision aids, how to measure SDM effectiveness, and best practice
to increase incidence of quality communication.
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CHAPTER 3

3
3.1

RESEARCH METHODOLOGY
Overview
The aim of this study was to explore the impact of a collaborative decision-aid tool,

informed by stakeholders, the evidence base, and the practice considerations, when used for
weekly on-treatment visits for patients with lung cancer undergoing radiation therapy. This
is addressed through the following research questions:
1. How do the stakeholders, practice considerations, and evidence base inform the ideal
design and implementation of a collaborative decision-aid tool?
2. What is the impact of the collaborative decision-aid on the medical management of
patients actively undergoing radiation treatment for lung cancer?
3. How does the impact of the collaborative decision-aid tool inform recommendations
for future designs and implementation ?
The primary objective was to develop a collaborative decision-aid tool, using
patient-reported outcome measures, that could be easily implemented in an academic
radiation oncology clinic for patients undergoing radiation therapy for lung cancer.
Secondary objectives were indicators of impact: surrogate measures for SDM (unscheduled
oncology visits, concomitant medication prescriptions), indicators of medical management
(assessed adverse events, radiation treatment compliance, chemotherapy compliance), and
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emergent care visits and fiscal costs (emergency room visits and estimated cost, inpatient
admission frequency, length of stay, and estimated cost). The hypothesized result was
improved shared decision making, yielding better medical management and patient
outcomes and reducing emergent care costs.
A dualistic epistemology was employed, with both pragmatic and interpretivist
points of view utilized to obtain knowledge. The interpretivist paradigm was woven
throughout the study with the key stakeholder insights (i.e., patients, radiation
oncologists) contributing to the design and implementation of the collaborative decisionaid, its potential use, and their experiences with shared decision making. The pragmatic
Figure 12
Sequential Exploratory Mixed Methods Design

Note. Adapted from Creswell & Plano Clark (2011).
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approach was highlighted within the mixed methods by examining how the evidence base
and the practice inform the design and implementation of the decision aid, employing the
Plan-Do-Study-Act to iteratively adapt it for use within an academic radiation oncology
clinic, and provide mapping and guidelines for future design and implementation within
the real-world setting.
This design approach (i.e., sequential exploratory mixed methods case study)
was utilized to create and evaluate a decision tool yet enable flexibility through an
iterative research process (Figure 12). Challenges to this multiphase design included both
a significant time requirement and a high resource investment as well as practical focus
on implementation strategy and context (Creswell & Plano Clark, 2011). Although time
intensive, the design exploits the qualitative research strategy through interviews with
patients and radiation oncologists to inform the tool’s design and implementation and
then employ a clinical implementation initiative to implement the collaborative
decision-aid tool in a pragmatic, real-world fashion and then evaluate the tool’s initial
impact (Creswell & Plano Clark, 2011).
3.2

Research Setting
The study took place in Iowa City, Iowa within the University of Iowa Health Care

system (UIHC) which is a combination of the University of Iowa Hospitals and Clinics, the
University of Iowa Children’s Hospital, and the Roy J. and Lucille A. Carver College of
Medicine, serving as both the state’s only academic medical center and as the only NCIdesignated comprehensive cancer center, the Holden Comprehensive Cancer Center. For its
electronic health record, the UIHC utilizes Epic® as well as Care Everywhere® and
MyChart® (Epic Systems Corporation, Verona, Wisconsin, USA).
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3.2.1

University of Iowa Health Care System
This academic center has over 1,000 beds (190 pediatric, 860 adult) in a geographic

footprint of 17 acres. In fiscal year 2020, UIHC had 50,468 emergency room visits,
received just under 1100 patients by air transport, and had 32,872 acute inpatient
admissions. UIHC has more than 200 outpatient clinics which coordinated over one-million
outpatient clinic visits, 550 organ transplants, 32,000 major surgeries, and 150,000
minor/routine surgical procedures. UIHC employs over 1800 physicians and dentists, 3200
nurses, 3200 allied health staff, and 3100 non-patient care professionals. The UIHC is also
supported by a tremendous volunteer staff, which provides more than 82,000 hours –
roughly 225 volunteer hours daily.
3.2.2

The Department of Radiation Oncology
Located in the Center of Excellence in Image Guided Radiation Therapy, a facility

of over 40,000 ft2, the department has cutting edge technology including three Versa linear
accelerators, a Gamma-Knife, and one of only three MRI-guided linear accelerators within
the United States. The department has multiple national accreditations and is known for
treating difficult cases that other radiation oncology centers cannot. Staffing includes nine
radiation oncologists, four outreach radiation oncologists, one nurse practitioner, seven
radiation oncology residents, 14 licensed medical physicists, three medical physics
residents, eight clinical nurses, four research nurses, fifteen radiation therapists, six
dosimetrists, and five front desk staff responsible for scheduling and check-in. Radiation
Oncology utilizes Epic® EHR but the radiation planning, prescription, and delivery systems
utilizes a second EHR system, MOSAIQ® (Elekta Solutions AB, Stockholm, Sweden). The
system enables notes to be placed by staff about the patient or their radiation treatment.
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On average, the department treats approximately 20 new patients per month for
lung cancer. The department has two radiation oncologists who specialize in lung cancer;
each radiation oncologist has a unique day of the week designated for their OTVs. The
clinic treats an average of 90 to 100 patients per day with a radiation oncologist seeing 15
to 20 patients during their scheduled on-treatment clinic day.
3.2.3

Workflow for Patients with Lung Cancer Prescribed Long Course Radiation
Patients with lung cancer typically undergo a scheduled consultation with their

treating radiation oncologist. At this consult, acute and chronic side effects of radiation
therapy are discussed as is the expected treatment outcome (e.g., cure, prolongation of
life, palliation). The patient then returns for a scheduled simulation visit, in which the
patient is positioned on a computed tomography (CT) scanner as they will be for their daily
radiation treatment. The treatment plan is then created from this CT scan, taking
approximately 5 to 7 business days to complete dependent upon the plan’s complexity.
The patient then returns for verification, a practice run of their radiation treatment.
Typically, radiation begins the next business day. For patients with lung cancer
undergoing definitive treatment, a typical fractionated radiation regimen is 30 to 34
fractions with one fraction administered per business day. This long course of radiation
for patients being treated for lung cancer will involve approximately 7 OTVs and one
end-of-treatment visit (i.e., fini).
Standard of care for these patients requires concomitant or consecutive cytotoxic
chemotherapy. Chemotherapy is prescribed and managed by the Division of Medical
Oncology, located directly above the radiation oncology center. Chemotherapy is
administered in the infusion center, located two floors directly above the radiation
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oncology center. Of note, at UIHC radiation oncologists do not have hospital privileges
to admit patients. Thus, patients requiring inpatient medical management must be
referred to the medical oncology clinic or directly to the emergency room for
consideration of hospital admission.
3.2.4

The State of Iowa’s COVID-19 Center
Unfortunately, in 2020 the workflow at the academic center shifted dramatically, as

the UIHC and the UICH were designated as the State of Iowa’s COVID-19 center. As
such, protocols were put into place in early March to accept the first case of SARS-CoV-2
(COVID-19) and develop an in-house diagnostic test to address the shortage. The academic
center housed more than 1860 adult inpatients and 116 pediatric; 575 of these patients were
transferred in from other hospitals. As the designated center, UIHC provided 87,195
telehealth screenings and over 112,000 respiratory illness clinic visits. To prevent
community spread, as well as accommodate the increasing demand for beds and medically
licensed personnel, everything within the University of Iowa Health Care system was
dramatically altered.
3.3

Research Adaptation due to the SARS-CoV-2 Pandemic
The pandemic irrevocably altered the study as designed by making it impossible

to obtain three key sources of information to address the research questions:
audio recordings of on-treatment visits between the radiation oncologist and the patient,
non-participant observation of the clinic’s workroom, and SDM-Q-9/SDM-Q-DOC
questionnaires. Brief information is provided to acknowledge they were considered and
had to be omitted from the study. Further details regarding the impact of the pandemic on
this study is provided in Appendix A.
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3.3.1

Audio Recordings
The study sought and obtained permission from the UIHC’s legal department to

allow on-treatment visits to be recorded in secret. Ethics approval from the IRB was also
obtained and patients provided written consent to have a recording completed during the
fourth, fifth, sixth, or seventh OTV. The treating radiation oncologists provided verbal
consent to have the OTV recorded and were the individuals who obtained consent from
the patients. Neither the patient nor the radiation oncologist were aware of when the
recording was completed as the recorder was hidden in the examination room or by
attending staff. Recordings were to be obtained prior to the collaborative decision-aid
tool was implemented and then post-implementation. These recordings could serve as a
golden truth to evaluate shared decision making, if the collaborative decision-aid
instrument was being used as intended (i.e. fidelity), and how it could be improved. The
audio recordings were to be transcribed verbatim, coded inductively, and compared (preimplementation vs. post-implementation). The rich detail the recordings were anticipated
to have provided was significant. Due to the concern for fomite transmission of the
SARS-CoV-2 virus, no extraneous items were allowed within the examination room
(including the recorder) and this potential source data was terminated.
3.3.2

Non-Participant Observation
Academic training of radiation oncology residents employs an apprenticeship

model with milestone requirements for each of the four years of their specialized training.
A critical portion of the training is ‘giving report,’ wherein the resident provides the
information obtained from their interview with the patient as well as their findings of a
preliminary exam before the attending physician examines the patient. The attending
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radiation oncologist and their clinic nurse will correct, query, and address oversights in
the communal workroom before all three go into the exam room and then finish the
training post-exam in the same workroom. This process was identified as a possibly
causing communication confusion but most significantly identifying how experienced
radiation oncologists train new physicians in observations and communications with
patients. To capture this information, four sessions of 4-hour non-participant observation
of the communal workroom was planned prior to implementation and after
implementation. Non-clinical personnel were banned from clinic through June 2020 and
remain discouraged from remaining in clinical areas for prolonged periods of time.
Residents gave reports by phone or by using computer conferencing (e.g., Zoom, Skype).
The communal workroom was identified as a problem for SARS-CoV-2 transmission
and, for this reason, its use has changed and continues to change as the pandemic waxes
and wanes. For this reason, the non-participant observation of the communal workroom
has been removed from the research strategy.
3.3.3

SDM-Q-9 and SDMC-Q-DOC
The key data to be captured were from questionnaires completed by the patient-

participant (SDM-Q-9) and by the radiation oncologist (SDM-Q-DOC) were to be
obtained prior to implementation (as the baseline data) and post-implementation
(investigational data). Comparing the answers in a pre/post fashion would provide
information about the communication aid’s impact within the radiation oncology clinic.
Both questionnaires are five-point Likert-styled scales requiring a balance of
nonparametric and parametric review. Nonparametric procedures (e.g. median, range,
frequency) were to be used to describe the scores of the pilot study participants, the
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historical controls, and the treating radiation oncologists (both historical and pilot
phases). An independent t-test was to be used to evaluate significance. It was recognized
there was debate regarding use of a parametric test for Likert-scaled data, but
publications indicated this testing was the most robust to assess these data (Norman,
2010; Sullivan & Artino, 2013). These data would be assessed using a student’s t-test to
determine the statistical difference (if any). The questionnaire results would also be
compared to the qualitative data obtained from the OTV recordings. In attempts to reduce
community spread of SARS-CoV-2 and reduce risk to UIHC staff, paper and writing
implements were removed from the clinic and it was emphasized passing of documents
between patient/provider should not occur with the exception of obtaining written
consent. These prohibitions remain in place and the questionnaires discontinued.
3.3.4

Communication Patterns
An incidental impact was the shift in communication patterns. Prior to SARS-CoV-

2, numerous caregivers, family, and friends were allowed to be in attendance during the ontreatment visit. Given large farm families, it was not uncommon to have 4 or more
individuals in a small exam room to discuss the current therapy. These third parties
provided additional information as well as an additional lens the radiation oncologists had
utilized as an information source for their practice. To date, caregivers have not been
allowed to return to the radiation oncology clinic unless there is clear medical need. The
radiation oncologists have noted this has changed their communication strategy, causing
them to query further to try to obtain the information necessary at the visit. The difference
between the baseline communication recordings (caregivers, family) and the peri/post-
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pandemic recordings (no third parties in attendance) causes an irrevocable shift for
comparison purposes to assess shared decision making.
3.3.5

Amended Design
The overarching hypothesis (i.e., a decision aid designed to increase collaborative

communication between radiation oncologists and patients will result in improved shared
decision making, yielding better medical management and patient outcomes and reducing
emergent care costs) and aims (i.e., create a collaborative decision-aid tool, implement it,
and assess its impact) remain unchanged. Triangulation was only minimally impacted,
as the original research design did not rely on the audio recordings of the OTV as
assessments of SDM because it was a legal issue with the UIHC. Based on prior
requests, it was suspected the UIHC legal department would decline and one of the
treating thoracic radiation oncologists also objected. Data for triangulation were the
comprehensive literature review, contemporaneous review of new recommendations
regarding PROMs (e.g., new peer-reviewed literature, guidance from FDA regarding
PROM, webinars from oversight / regulatory authorities regarding PROM), patient
interviews, radiation oncologist interviews, and review of medical record notes to
compared to the interview and provide additional detail. Thus, the quantitative strand–
although altered–was still considered to have appropriate design to obtain the patients’
and providers’ insights regarding the collaborative decision-aid tool and its
implementation as well as providing data for triangulation for the qualitative strand.
Because the SDM-Q-9/SDM-Q-DOC could not be obtained, the quantitative
strand had to be amended slightly. These data were to address, in part, the quantitative
research question What is the impact of the collaborative decision-aid on the medical
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management of patients actively undergoing radiation treatment for lung cancer?
Although quantitative measures of SDM had been selected for this strand, it was only one
measure of many that could be used to address the question. In addition to improved
quality-of-life (Absolom et al., 2021; Grewal & Berman, 2019), research indicates
improved healthcare resource utilization – particularly emergency room visits (Barbera et
al., 2015; Basch, Deal, et al., 2017; Geerse et al., 2018; Howell et al., 2020). Although a
systematic review suggests variability in results of PROM-based interventions
(Kotronoulas et al., 2014), work by Howell et al. (2020) suggests this is due to
implementation and not the intervention. This is supported by the findings of a scoping
review, which identified the most efficacious PROM and SDM interventions as those
which involved active communication and not passive interpretation (Kirkland et al.,
2020; Kotronoulas et al., 2014) In 2016, Basch and colleagues published the results of a
randomized clinical trial which demonstrated the use of PROM decreased emergency
room visits and hospitalizations and improved both chemotherapy compliance and
survival (Basch, Deal, et al., 2016). Data as cited by Basch et al. (2016) (i.e., ER visits,
inpatient admission, and chemotherapy compliance) are easily obtained from Epic® EHR
and can be compared to the pre-implementation metrics. Estimated healthcare
expenditures for these visits can also be evaluated as can unplanned visits to oncologic
outpatient clinics.
The final issue was the unpredictable impact of the pandemic on the approval and
continuance of non-essential human subjects research studies. With research procedures
in continual flux based on the spread of the virus and the need for personnel, there was
significant concern the quantitative strand would not be approved, enrollment would be
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halted, or study procedures limited. It was during this time it was noted the literature
reported implementation of PROMs within oncology utilizing a clinical trial / research
study strategy. This increases internal validity but diminishes external validity and the
likelihood of fidelity during implementation. In contrast, if implemented through the
clinic using the PDSA cycle, a research team would not manage the workflow, thereby
not pre-emptively solving problems or omitting clinical pathways for research-only
pathways. Clinical-only implementation would be pragmatic and provide insights into
implementation within a clinic separate from research management. This would, in part,
address a knowledge gap in the literature regarding PROM implementation in an
academic radiation oncology clinic. Additional advantages of a clinical implementation
include all patients within the designated clinic would have the decision-aid applied, and
it would be clinical and–as such–not subject to research shutdowns. The departmental
chair agreed to implement the collaborative decision-aid tool clinically. The project was
then submitted to the University of Iowa IRB for human subjects research determination,
which concluded the clinical implementation, did not meet the definition of human
subjects research (Appendix B). The model selected for the clinical implementation
project was Plan-Do-Study-Act (PDSA) as it has been used with prior success with the
OMRU when examining SDM interventions (Graham et al., 2006; Gravel et al., 2006;
Langley et al., 2009; Legare et al., 2006; Legare et al., 2008; Legare & Thompson-Leduc,
2014; Reed & Card, 2016; Straus et al., 2013). The qualitative strand addressed PLAN, and
the quantitative strand addressed DO and STUDY.
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3.4

Qualitative Strand
The objective of the qualitative research strand was to understand how patients and

radiation oncologists described the design and implementation of a collaborative decisionaid tool regarding symptoms of lung cancer and side effects of the treatment. A case-study
strategy was utilized to explore the phenomenon of side-effects, symptoms, treatment
goals, and communication between provider and patients who had either undergone
radiation therapy for lung cancer or were finishing their treatment course (Creswell, 2013).
The end-products (e.g., key design principles, tool presentation, understanding workflow
concerns, barriers and facilitators) were then used to design the collaborative decision-aid
tool that was evaluated in the quantitative strand.
The Ottawa Model for Research Use (OMRU) framework provided essential
elements to translate research into meaningful clinical use, key for PROM that have
failed to cross the T3 chasm (Drolet & Lorenzi, 2011; Graham & Logan, 2004).
Contextual elements to be considered in the qualitative strand include attitudes,
knowledge, skill, culture, clinic workflow, and facility resources (i.e., documents and
storage in the electronic health record). These should be evaluated as both barriers and
facilitators to future adoption. The Shared Decision Making Model (Chapter 1, Figure 4
& Chapter 3, Figure 12) also informed this qualitative inquiry. Specifically, the SDM
framework graphically depicts the flow of information between provider and patient,
transitioning the decision-making process from initial preferences to informed
management (Chapter 1, Figure 4 & Chapter 3, Figure 12). It provided insight for
communication, discussion, and decision strategies for management of radiation
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oncology treatment. Participant interviews and the OTV notes within the medical record
were identified as key sources to identify SDM elements.
In addition to insights regarding communication and SDM, the qualitative strand
also informed implementation. The first stage of implementation science as described by
Bertram et al. (2015) NIRN framework Stages of Implementation is Exploration. This
focused on assessing the community, resources, and needs, evaluating and aligning to
desired outcomes and identifying potential barriers to fidelity and sustainability. The
PLAN

portion of the PDSA cycle was addressed by the NIRN Exploration stage by

establishing an evidence-base, identifying stakeholder’s goals and concerns, and
identifying practice considerations (Langley et al., 2009; Reed & Card, 2016; Snyder et
al., 2012). The qualitative strand assessed readiness for change at the individual and
provider level, identified potential adjustments to support fidelity and sustainability of the
program, and provided insight to the appropriateness and potential benefits of the
collaborative decision-aid tool (Graham & Logan, 2004). A key consideration for
readiness for change also included the adaptability of Epic® EHR, the culture surrounding
its use, and the clinic’s workflow.
The original rationale for targeting Epic®, the center’s EHR, was three-fold: enable
radiation oncologists to import the responses into their notes without issue, provide the
measures in an easy-to-find format for all healthcare providers, and to create a bank of
PROM to further inform the patient experience during clinical research or chart reviews.
With the advent of the pandemic, the choice of utilizing the EHR was of even more
significance as providing paper was removed from the clinic.
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Assessing multiple sources of information (i.e., interviews, EHR, literature)
aligned with the case study approach for qualitative inquiry (Creswell, 2013). This
approach examines “…a real-life, contemporary bounded system…through detailed, indepth data collection involving multiple sources of information…” (p. 97, Creswell,
2013). For this study, the unit of analysis was the provider-patient relationship of those
patients who have undergone radiation therapy for lung cancer.
3.4.1

Research Question
The central question How do the stakeholders, practice considerations, and

evidence base inform the ideal design and implementation of a collaborative decision-aid
tool? guided the interview, analysis, and tool development. This question served as the
anchor to guide and focus the research for the qualitative strand.
3.4.2

Sample Size
Sample size for data collection in qualitative research is dependent upon the

richness of the data, the depth and breadth of information sought, and the available time
and resources (Patton, 2015). This qualitative strand focused on depth of the interactions
between patients with lung cancer and their treating radiation oncologist. The case study
was tightly bounded to the interactions in the radiation oncology clinic regarding
treatment. The study explored communication patterns, side effects and symptoms, and
goals of therapy as well as facets of SDM (e.g., perceptions, barriers, facilitators), so the
openness of the inquiry was slightly constrained. Thus, the design is a middle-ground
between depth and breadth, reserving time and resources to explore design possibilities
for the collaborative aid tool (Patton, 2015). Based on this, the anticipated sample size for
the patients treated for lung cancer was between 6 and 30 participants with final sample
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size determined by data saturation. The provider sample size was constrained by the
number of radiation oncologists at the academic site (n=7).
3.4.3

Participant Selection, Recruitment, and Sampling Strategy
This case study focused on the communication relationship between the radiation

oncologist (i.e., provider) and the patient who is receiving, or has received, radiation and
chemotherapy for the treatment of lung cancer. The goal was to obtain new knowledge
about SDM to create a collaborative decision-aid for patients with lung cancer. Thus,
there were two participant pools to consider in study design.
3.4.3.1 Patients
The potential participant pool consisted of adult patients who were in their last
few weeks, or had recently completed, chemotherapy in combination with fractionated
radiation therapy at UIHC for a diagnosis of lung cancer. A purposeful sampling
technique was employed, focusing on typical cases representing patients referred for
standard chemotherapy and radiation (Patton, 2015). Selection criteria excluded atypical
presentations not representing the general lung cancer population. Medical oncologists
were consulted to create eligibility criteria to identify patients representing real-world
patients with lung cancer. Utilizing medical oncologists for the selection process
minimized the risk of a confounding bias from querying the treating radiation oncologists
regarding the patients to approach. The treating radiation oncologists required they
review the appropriateness of each potential participant. If the radiation oncologist agreed
with enrolling the patient on the study, they approached the patient and, if the patient
agreed, obtained consent. A signed copy of the informed consent document was provided
to the patient. Patients who appeared to meet eligibility in chart review, but were not
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deemed appropriate by the treating radiation oncologist, were either too ill/infirm or
unable to provide consent.
3.4.3.2 Providers
During the time of the study, UIHC employed seven radiation oncologists as
faculty at the Iowa City clinic. Of these, two had dedicated lung cancer clinics and the
remaining radiation oncologists provided coverage for patients with lung cancer. This
creates a nested hierarchy of informants based on not only how many patients they
treated for lung cancer but if the radiation oncologist had to provide clinic or on call
coverage for an unfamiliar patient base. The radiation oncologists with dedicated lung
cancer clinics were key informants; it was anticipated these providers were the richest
source of information and experience. Both of these radiation oncologists were
interviewed. Radiation oncologists who provided only coverage services to patients
undergoing radiation for lung cancer were considered tertiary. Of the remaining five
radiation oncologists, four agreed to participate in the interviews. They were interviewed
in two groups of two group and represented radiation oncologists who could be, or had
been, scheduled ad hoc to see patients with lung cancer. These radiation oncologists were
considered to have important information about managing communication and SDM
when covering for a treating radiation oncologist who was out of the office.
Collaborating oncologic specialists, such as surgical oncologists, medical
oncologists, and nurse practitioners, were not included in this study. The study’s primary
focus was on the shared decision-making of the treating radiation oncologist, the
covering radiation oncologist, and the patient undergoing radiation therapy for treatment
of lung cancer. Nurse clinicians are currently not authorized to independently staff the
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OTV at the University of Iowa. Medical and surgical oncologists are separate disciplines
and do not contribute to the discrete shared decision-making during the radiation
oncology OTV. The influence of these disciplines will be explored in later studies.
3.4.4

Interviewing Protocols
Within the United States, a radiation oncologist’s board certification is the

foundation for all therapeutic radiation interventions (e.g., cancer, nerve pain,
heterotopic ossification). A radiation oncologist may further subspecialize for specific
cancers (i.e. lung cancer). Those subspecializing are more familiar with current
techniques, concurrent therapies, and common sequelae. Those subspecializing in other
malignancies (e.g., brain, head & neck, prostate) do not have the same recall as those
specializing in lung cancer. Given the potential for varied knowledge bases, four
separate interviewing protocols were developed: one for patient participants (Appendix
C), a second for radiation oncologists specializing in lung cancer (Appendix D), and the
third for the covering radiation oncologists (Appendix E). A fourth interviewing
protocol was developed for radiation oncologists who did not specialize in lung cancer
but who served as the treating radiation oncologist for a patient with lung cancer
(Appendix F). This situation was not identified by the study (i.e., all patients with lung
cancer were treated by radiation oncologists specializing in lung cancer) and thus the
interview protocol was not used. An interviewer’s journal was maintained for
reflection, comments, and considerations during the interviewing phase to provide
context and clarity to the interviews.
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3.4.4.1 Patient participants
Interviews were scheduled in one-hour time slots at the participant’s preference
and conducted in a private examination room within the radiation oncologic clinic during
routine business hours for the clinic (Monday–Friday, 7 a.m. through 5 p.m.). All
interviews were audio-recorded.
A social constructionist interview strategy was employed with semi-structured
questions to prompt for previously-identified key topics (Patton, 2015). The social
constructionist inquiry method was selected to enable the dexterity and flexibility needed
to shift from what a participant knew about a particular topic but to create knowledge
through active dialogue (Patton, 2015). Using a constructionist strategy, it was expected
the interview questions would evolve over time, to further investigate knowledge created
by previous patient participants.
Questions were open-ended and probative to discuss the patient’s initial goals for
treatment, if the goals changed over time, explore the patient’s initial concerns regarding
therapy and if those concerns changed over time. Sample questions pulled from PROM
validated item banks (e.g., PRO-CTCAE, PROMIS) were reviewed with patients during
the interviews to explore not only how easily the items are understood but also how well
they fit the side-effect, symptom, or therapeutic goal. Patient were also queried regarding
communication with their treating radiation oncologist and–if appropriate–a covering
oncologist who covered an OTV. Communication preferences, barriers to
communication, and hindsight considerations (i.e., what they wish they would have
known) were also examined. Questions also investigated the participant’s perception of
SDM per their recollection. Patient interviews were extended or shortened depending
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upon the dynamic between the researcher and participant; similarly, if clarification was
sought, patient participants were asked if they could be contacted again. The reason for a
second interview would be documented in the participant’s casebook. Sample questions
for patient participants are provided (Appendix C).
3.4.4.2 Radiation Oncologists Specializing in Lung Cancer
Interviews with radiation oncologists who specialized in lung cancer (i.e. treating
radiation oncologists) were scheduled as their calendars allowed. Interviews were held in
a small conference room or in a physician’s office to respect privacy and confidentiality
for the provider. Interviews were scheduled for between 30 to 60 minutes and were
audio-recorded. Unlike patient participant interviews, the interview strategy employed
with the treating radiation oncologist was pragmatic, with straightforward questions
about issues identified from literature, patient participants, or observation (Patton, 2015).
This was considered a best-fit approach to focus on solutions for radiation oncologists,
address problems, and be considerate of time and resources while still yielding practical
insight. Inquiry focused on the provider’s identified toxicity management and treatment
goals as well as barriers and concerns to tool design, implementation, and use. Semistructured interview questions evolved from the patient-participant interview data. In
addition, the treating radiation oncologists clarified questions about the patient
participants’ treatment, adverse events, or workflow/clinical questions arising from the
interviews. It was anticipated interviews with treating radiation oncologists would be
iterative, with multiple interviews per physician. Lines of inquiry differed between
radiation oncologists focusing on lung cancer from the other treating radiation
oncologists. This was to obtain knowledge regarding how other radiation oncologists
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identified with patients who have lung cancer, if there was a difference between treating
patients with lung cancer compared to their standard clinic, and if they perceived barriers
or facilitators unique to patients undergoing treatment for lung cancer. This was a
perspective radiation oncologists dedicated to lung cancer treatment may not provide.
Sample questions are provided for radiation oncologists specializing in lung cancer
(Appendix D).
3.4.4.3 Radiation Oncologists Providing Ad Hoc Coverage
Covering radiation oncologists are those who do not specialize in lung cancer but
who could provide intermittent care for patients with lung cancer by covering absences of
the treating radiation oncologist. These radiation oncologists provide on-demand services
for patients not directly under their care or within their routine clinical focus. As such,
their perspective provided a different lens regarding prioritization of treatment goals, time
spent in clinic for each OTV, and interaction with the patient. Here, it is not only
interesting to understand the dynamic processes between providers when providing
coverage but to provide the opportunity to provide feedback to each other to create
additional buy-in to tool design. This interview thus served two purposes: (1) to obtain
information and (2) to reduce barriers from a stakeholder that has a reduced likelihood of
investment. Four radiation oncologists consented to participate in this portion; interviews
were completed as two groups of two. Sample questions unique to this group are
provided in Appendix E.
3.4.4.4 Radiation Oncologists (All)
Interview questions common for all radiation oncologists (i.e., regardless of
treatment specialty) focused on what information was important regarding patients
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undergoing radiation for lung cancer, how that information should be presented, and the
common workflow for routine on-treatment visits as well as when addressing coverage.
Radiation oncologists were provided sample questions to review regarding
symptoms of fatigue and dyspnea. These two subjective symptoms were selected because
they are two of the most common during radiation therapy for lung cancer (Defraene et
al., 2019; Vokes et al., 2007). Questions were pulled from the PRO-CTCAE™,
PROMIS®, and the QLQ-C30 (Chapter 1, Figure 3; Chapter 4, Figure 15). These sources
were selected as they are commonly used in healthcare research and utilized during
FDA’s conference on patient reported outcome measures in oncology (FDA, 2018).
Radiation oncologists were asked to review the questions, provide feedback, and mark
their preferred question format.
3.4.5

Implementation: the PDSA’s PLAN Segment
The tool was to be introduced to the clinic utilizing a real-world approach, with

minimal intervention from the researcher. The PDSA model was selected to guide
implementation as it has been used with prior success with the OMRU (Graham et al.,
2006; Gravel et al., 2006; Langley et al., 2009; Legare et al., 2006; Legare et al., 2008;
Legare & Thompson-Leduc, 2014; Reed & Card, 2016; Straus et al., 2013). An additional
benefit to the iterative nature of the PDSA model was it enabled implementation slowly
in parts, expanding over time to address long-term goals. This enabled the first
implementation cycle to focus on key areas identified by the stakeholders.
The initial key stakeholders were identified as the radiation oncology clinical
administrator (overseeing the entirety of the clinic, compliance, and front desk/scheduling)
and the two treating thoracic radiation oncologists. After the first meeting, an additional
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stakeholder was identified: the chief radiation therapist, who controlled the lynchpin
communication of the radiation therapists informing the front desk how to schedule a
patient—including assigning the questionnaire for each OTV. A focal point in the meetings
with stakeholders was the patients’ request for a paper collaborative decision-aid and the
radiation oncologists’ request for electronic entry into the EHR. Due to the pandemic,
collection of PROM using a pen and paper task was not considered as the transfer of paper
through multiple hands increased risk of fomite transmission as did pends. Meetings with
the stakeholders identified on four points for implementation cycle 1: who would distribute
the tablet, how would that staff know to distribute the tablet, how would the responses be
reviewed by the treating radiation oncologist, and how would the responses be printed for
the radiation oncologist to share with the patient. With an initial workflow designed, the
second check in was scheduled after the first patients completed the tool questionnaire from
baseline through the last day of radiation.
Implementation facilitators and barriers were documented through email
communication with the key stakeholders as well as through journaling in field notes.
Simplistic implementation mapping was completed employing a program theory logic
model (if/then) to identify the next steps as well as who was responsible, when it needed
to occur, how it would occur, and where (Funnell & Rogers, 2011). The purposeful
outcome chain would identify at what steps in the workflow the barriers and facilitators
were occurring while the taxonomy of barriers and facilitators as provided by Legare et
al. (2006, 2008) provided harmonized terminology and definitions. Attention was paid to
the work from Reed and Card (2016) who outlined pitfalls when using the PDSA for
implementation, with attention to utilizing program theory, adhering to the original data
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collection and analysis plan but also adapting to newly identified data of interest,
planning for the ‘who, what, where, when, and how,’ for the implementation, and
considering what will happen if there is failure in the logic chain steps (p. 149).
3.4.5.1 Data Collection and Analysis
In addition to interviews, additional data sources included the existing literature,
newly published contemporaneous literature, regulatory/oversight guidance documents
and webinars regarding PROM and SDM, and the electronic health record (Epic® EHR,
Verona, Wisconsin).
The first strategy employed for the qualitative strand was a brief literature review
to identify known barriers and facilitators and considerations for current PROM
instruments. After this literature was reviewed, a set of sample questions were developed
for fatigue and dyspnea as was a mock-up of treatments vs. outcomes (i.e., side-effects
and disease response). Patient-participant interviews began and then, after those
interviews started, the radiation oncologist interviews were started to help inform the
patient interviews. Upon conclusion of the interviews, the next step was to meet with the
Epic® EHR specialists for installing the questionnaire into Epic®. Once the translation of
the collaborative decision-aid tool into Epic® EHR was agreed upon, stakeholders again
extended to members of the Department of Radiation Oncology to finalize the
implementation plan as well as format of the printed tool. A summary of each step
undertaken in the qualitative strand is provided (Table 1, p.48) as well as the products of
each step and how they were used in both planning the collaborative decision aid and the
PLAN

segment of the PDSA implementation cycle.
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Table 2
Order of Procedure in the Qualitative Strand, the Source Data Obtained from that
Procedure, and Its Utilization in the Design of the Collaborative Decision Aid and
Implementation PLAN Segment of the PDSA
Step: Data Source1

Utilization2

First: Literature review

Secondary data

Literature review provided foundation of current PROM instruments and medium
(design) as well as barriers, facilitators, and implementation outcomes (planning).
The source is the iterative synthesis over time, archived in MS Word documents as
well as the sample PROM questionnaire.
Next: Patient interviews2

Primary data

Patient interviews yielded transcripts that were then coded and mapped
analytically for information on both design and implementation. Source data are
archived audio recordings, transcripts, codes, and analytic maps.
Next & concurrent: Physician interviews

Primary data

Physician interviews yielded transcripts that reviewed for key concepts and mined
for illustrative quotes. Source data are archived audio recordings and transcripts.
Last: Stakeholder meetings

Secondary data

Stakeholder meetings provided information on installing the tool in Epic® format,
identified key areas of focus/concern for the first implementation cycle, and created
a walkthrough. Source data are artifact electronic communication.
1

Source data will be archived in compliance with HIPAA and retained for a minimum
of six years after closure of the IRB application.

2

Utilization refers to the data use for both the decision aid tool design and PLAN
segment of PDSA
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3.4.5.2 Interviews and the Analysis
Interviews were performed by the student researcher to minimize interview-tointerview variation. This was feasible due to the convenience scheduling of the patient
participants and immediate access to the provider participants. Provider interviews began
after the first few patient participant interviews were completed. Interviews with a
radiation oncologist specializing in lung cancer were completed first (Appendix D). The
remaining four radiation oncologists, who provided coverage services for the thoracic
radiation oncologists, were interviewed after patient participants (Appendix E). The
paired interview setting was selected for the radiation oncologists who provided only
covering services for OTV so that their viewpoints were discussed as a group, providing
a consensus as to their thoughts, opinions, and considerations for a collaborative
decision-aid tool use in a clinic they only cover and do not routinely staff. All interviews
were audio recorded and transcribed verbatim.
All interview transcripts were analyzed using a qualitative inductive approach to
generate new concepts regarding communication of goals, priorities, and treatment
burden (Creswell, 2012; Patton, 2015; Thomas, 2006). An inductive analytic approach
identifies patterns, themes, and categories in the data using an open coding strategy. The
first step is to prepare the files in a common format for visual consistency and then
review the transcripts in their entirety to obtain a generalized understanding of the
content (Creswell, 2012; Creswell & Plano Clark, 2011; Thomas, 2006). At the end of the
review, the evaluator should be familiar with the text and context, already gaining insight
into themes and their descriptions present in the transcript (Thomas, 2006).
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Figure 13
Example of the First Level Open Coding Strategy Used

Note. An inductive open-coding strategy was applied to patient interview transcripts. These
first-level codes were designed to be granular and directly based on subject information
(i.e., burden, no normal) or used as an index to sort easily through the rich detail provided
in the text (i.e., patient reported outcome, anticipated events).
After this initial review, an open-coding process was used to create labels and
call-out patterns (Figure 13) (Creswell & Plano Clark, 2011; Saldaña, 2016; Thomas,
2006). Consistent with inductive coding, a pre-defined codebook was not employed,
instead codes and categories emerged from the transcripts (Creswell, 2012; Saldaña,
2016; Thomas, 2006). The data coding process divided the text into smaller granular
details (i.e., first level codes) but also enabled tagging sentences or sections for
quotations and/or future review (indexing) (Creswell & Plano Clark, 2011). The
ATLAS.ti qualitative data analysis software (Scientific Software Development GmbH,
Berlin, Germany) was be used to facilitate this process by enabling code organization as
well as maintaining a coding framework (Saldaña, 2016). The resultant codes were then
grouped together to further identify patterns or commonality across interviews (Figure
14). The number of times the code was used across the study’s documents (i.e.,
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Figure 14
Group View with Detail in ATLAS.ti

Note. Screenshot of the qualitative analysis depicting organization capabilities and
framework within ATLAS.ti. (A) user created second-level groups (red box: code groups),
(B) the frequency of the code’s use (orange box: grounded) and (C) the number of linkages
to codes, memos, and quotations (green box: density), and (D) an area for defining the code
and making notations (purple box: comment)
grounding) and the number of times the code was linked to another code, memo, or
quotation (i.e., density) is displayed within the group view, enabling an easy assessment
of the code’s frequency of use (Figure 14). Despite this framework, the interrelationships
remained elusive and not apparent to this researcher. For this reason, ATLAS.ti’s
network analysis (i.e. concept mapping) was utilized to explore the relationships between
the codes graphically (Daley, 2004; Pokorny et al., 2018). Similar to mind-mapping,
concept-mapping can be used for sense-making of complex systems by placing codes and
assigning relationships between them (Conceição et al., 2017; Daley, 2004; Friese, 2020;
Kinchin et al., 2010; Pokorny et al., 2018). The ATLAS.ti software serves as a
whiteboard, enabling codes to be moved, grouped, and colored to explore how the codes
and their quotations are interrelated–similar to piecing together a jigsaw puzzle. This
enables the researcher to reflect on the reduced data (i.e. codes), review memos and
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interview transcripts for relationships, and explore interconnectedness across subjects. It
is this deep dive and its journey that reveal the story (i.e. themes) the data are telling.
An initial concept mapping was performed consistent with prior literature as an
explorative technique (Conceição et al., 2017; Kinchin et al., 2010; Pokorny et al., 2018).
Concept mapping has multiple forms, including link, chain, network, weighted, and
directional (Daley, 2004; Friese, 2020; Kinchin et al., 2010; Pokorny et al., 2018). The
initial concept map used the network strategy, identified by Kinchin et al. (2010) as
scholarly maps which have linkages that are “often rich and complex showing deep
understanding” (p.55). A relational analysis was selected in lieu of software-based cluster
or weighted analysis (Conceição et al., 2017; Pokorny et al., 2018). The rationale for
relational analysis included the small sample size (n=6), the exploratory nature of the
research, and the study design, as cluster and weighted analysis are often utilized with
grounded theory approaches (Conceição et al., 2017; Kinchin et al., 2010; Pokorny et al.,
2018).
This initial ‘test’ analysis resulted in the Communication upper level category , a
central, downstream concept category created through the relationships of four direct
codes and eight categories (Appendix G). This upper level category graphically
represented the keystone of the overarching theme, “The shared decision-making tool
could address the patient-identified communication barriers of having to repeat
information across multiple providers as well as reduce the feeling of isolation while
undergoing radiation therapy.”
This graphical method of analysis proved to be a breakthrough and provided the
key insights needed for the qualitative string; thus, this method was utilized. The
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hierarchy and levels of analysis began with the first level coding (i.e., data reduction),
followed by a downstream grouping into categories by concept mapping and ultimately
ending in a concept category (i.e. node). These categories are the upper level, centralized
concept categories that represent foundation within the ATLAS.ti software for thematic
consideration (Conceição et al., 2017; Pokorny et al., 2018).
Relationships between the codes were defined by the patient participants (by
reviewing the transcripts) rather than presumptions from the researchers. These
relationships were important in identifying categories, both first level categories and
second level categories (i.e., conceptual categories, termed ‘nodes’ by ATLAS.ti). After
creating these analytic maps, relationships were further described through analytic
memos with example quotations as well as the defined codebooks. The analysis was done
in a stepwise fashion, with a single conceptual category being identified through
mapping, drafting the supporting information and rationale, and submission to senior
researchers. Further analysis was not performed until review and discussion between the
research team members. The research team was careful to identify participant defined
relationships between emergent data and logically / assumptively driven relationships from
the team. Resultant codes, categories, and themes were reviewed by an independent
committee to provide guidance as well as confirm codes and themes.
Transcripts were analyzed contemporaneously to inform subsequent patient
participant interviews as well as provider interviews. Data were collected from patient
participants until saturation was reached. Transcripts from the radiation oncologists
underwent the same inductive analysis and compared to patient participant themes.
Resultant themes were used to inform the design of the collaborative decision-aid tool.
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3.4.5.3 Data Collection via Electronic Health Record.
The OTV notes of the patient participants were downloaded, stripped of all
identifiers (i.e., de-identified), and loaded into the ATLAS.ti program for thematic
analysis. Dates of visit were retained. Information of interest was the length of the note, if
a resident was involved, the signature date of the note (if it is contemporaneous with the
visit), the number of adverse events, and any prescribed interventions. This provided
insight into the provider-patient dynamic during the OTV as well as serve as baseline
information for the quantitative phase of the study.
3.4.6

Anticipated Outcomes
The format of the collaborative decision-aid tool was informed on the themes

identified from the radiation oncologists’ and patients’ interviews. Based on the literature
review, it was anticipated the tool would be a hybrid presentation of both numeric data
and graphical trends over time, most likely a line graph. Similarly, the patients’
interviews would provide insight as to what areas to query for prioritization and how
many questions are preferred. For example, patients with lung cancer could choose to
focus on symptoms of their cancer (e.g., pain, dyspnea), acute side effects of their therapy
(e.g., esophagitis, dysphagia), or chronic side effects of therapy (e.g., numbness, dyspnea,
fibrosis) and balance these choices against the aggressiveness of therapy. Qualitative data
provided insight to prioritization and patients’ considerations of symptoms, side effects,
and treatment outcomes.
It was anticipated that two templates would be created for the collaborative
decision-aid tool. The first would be a prioritization questionnaire. This questionnaire
would be distributed to the patient and their treating radiation oncologist, empowering
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the patient to prioritize a disease symptom, treatment side-effect, or other outcome. The
radiation oncologist would also complete a prioritization questionnaire; however, based
on the literature review it was anticipated the prioritization would not routinely vary
between patients.
This prioritization would then determine the individual patient-reported outcome
elements to populate the collaborative decision-aid tool for the weekly OTV. Individual
queries measuring the goal or concern would be drawn from validated, standardized item
banks (Chapter 1, Figure 3). Items from the validated banks would be selected based on a
symptom (e.g., nausea, pain, appetite), a physical function (e.g., walking, gardening) or a
role function (e.g., cooking, grocery shopping, math). By utilizing the available item
banks across multiple tools, questions can be identified that focus on the patient’s
primary concern, fully informing on their experience. If a question was not available
from prior evaluation or use, sample questions could be reviewed with the patient
participant. In total, there would be seven to ten questions to capture the targeted goals
and concerns. The radiation oncologist would then review the tool to verify the
information queried reflects the information to be captured. Similarly, on the radiation
oncology verification visit, the patient would be asked to review the questions and
confirm they are understandable. If the patient did not believe the question adequately
captures their prioritized concern, or they did not understand the question, the validated
item banks would be reviewed for the patient’s preference. If a question was changed, the
radiation oncologist would again be consulted to confirm it is acceptable.
Although the PROMs would be queried to, answered by, the patient through
Epic® EHR, it was anticipated that the collaborative decision-aid tool would be printed in
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paper, distributed to the radiation oncologist for review before the OTV, and then carried
in to the OTV to discuss with the patient. The paper document would serve as a
communication prompt for the radiation oncologist as well as a visual summary for both
the provider and the patient. Prompt reminder questions for the patient and provider could
also be included to queue for additional symptoms or concerns. Prompt questions should
be simple and based on established healthcare improvement strategies, such as Ask-Me-3
(Institute for Healthcare Improvement (IHI), 2018). The originating digital data,
including the trends, would be maintained as source data in the EHR. The data should be
viewable, but not alterable, within Epic® EHR. Additionally, the data should be able to be
mined for future studies as well as be able to be imported into clinician notes or printing
groups as desired.
3.4.7

Trustworthiness and Rigor
Several strategies were undertaken to increase trustworthiness of the study results.

Triangulation of data sources (i.e., literature review, regulatory/oversight review, review
of electronic health record, interviews with patients, and interviews with radiation
oncologists) was employed to demonstrate alignment or consistency between sources.
Member-checking was employed with summaries of key findings from radiation
oncologist interviews (Creswell & Plano Clark, 2011). This reduced risk of investigator
bias and enabled clarification of interpretation. A committee of established researchers
independently reviewed the codes, themes, and outcomes to provide added
trustworthiness. Committee members included a senior researcher trained in both
qualitative methodology and patient reported outcome measures as well as a senior
physician researcher in oncology who served as a chief medical information officer at a
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large academic medical center (Creswell & Plano Clark, 2011; Thomas, 2006). Themes
identified from the interviews were cross-verified against themes in the published
literature as an available evidence base. Interviews with covering oncologists provided
additional cross-checking for interview data with radiation oncologists (Creswell & Plano
Clark, 2011). Lastly, disconfirming or contradictory information obtained from the
interviews or observations was evaluated and included in the analysis as a divergent
perspective (Creswell & Plano Clark, 2011).
3.4.8

Ethical Considerations
The qualitative strand met the definition of human subjects research. Institutional

review board (IRB) approval was obtained prior to study initiation with the University of
Iowa as the IRB of record (IRB00000099, IRB-01-Biomedical) and under the
Federalwide Assurance Number FWA00003007. No elements of consent were waived.
Legally authorized representative consent was not allowed, patients had to provide
independent consent. Written informed consent was obtained from patient participants
and included details regarding audio recording and storage of data for future use. Patients
were also asked to allow access to their medical record and mining of data from their
radiation therapy visits. A waiver of documentation of consent was obtained the radiation
oncologists, as they served as both as participants and as co-investigators in this study.
3.5

Quantitative Strand
The objective of the quantitative strand was to assess the impact of the

collaborative decision-aid tool when implemented in a midwestern radiation oncology
clinic within an academic medical center (Creswell, 2015). The tool was implemented
utilizing a practice initiative to assess clinical, and not research, use. Like the qualitative
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strand, this work was informed by the NIRN framework (Bertram et al., 2015), the
OMRU (Graham & Logan, 2004), and the Shared Decision-Making (SDM) model as
described by Elwyn (2008 and 2012), but also the Plan-Do-Study-Act (PDSA) cycle for
implementation (Langley et al., 2009; Reed & Card, 2016; Snyder et al., 2012). The
quantitative phase addressed the Do and Study segments of the PDSA cycle, including
barrier identification, adaptation of workflow, and assessing attitudes of providers. The
PDSA model provided guidance for the initial implementation cycle at the clinical level
where as the SDM model provided guidance for the initial implementation at the
patient/provider level, addressing decision support and use of the tool.
3.5.1

Research Question
The quantitative strand addresses the question What is the impact of the

collaborative decision-aid on the medical management of patients actively undergoing
radiation treatment for lung cancer? through the primary objective endpoints of time
expended per OTV and compliance with SDMCQ completion. Secondary objectives
provide insight into the tool’s impact on medical management: surrogates of shared
decision making (add-on oncology visits, concomitant medication prescriptions), medical
management (adverse events, radiation therapy compliance, chemotherapy compliance)
and emergent care and its costs (emergency room visits and estimated costs, inpatient
admissions and estimated costs).
It is anticipated utilizing a collaborative decision-aid tool employing PROM will
reduce the number of unplanned outpatient oncology visits as well as the number of ER
visits. This is based not only on prior findings (Barbera et al., 2015; Basch, Deal, et al.,
2016; Howell et al., 2020; Kirkland et al., 2020) as well as literature indicating common
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causes for emergency room visits for cancer patients, including those that can be
addressed in outpatient clinic settings (Caterino et al., 2019; Centers for Medicare &
Medicaid Services, 2021; Gallaway et al., 2021; Scholer et al., 2017). The most common
reasons for ER visits include pain and nausea; lung cancer patients are the most common
patients to seek ER services (Caterino et al., 2019; Panattoni et al., 2018; Scholer et al.,
2017). Perhaps most importantly, this expectation is based on the determination by
Centers for Medicare and Medicaid Services that nausea, emesis, anemia, neutropenic
fever, diarrhea, dehydration, and/or pain are adverse events for which an ER visit is
potentially avoidable (CMS, 2021). Potentially preventable ER visits are estimated to
account for 20% to 63.5% of cancer-associated visits (Panattoni et al., 2018; Shah &
Neal, 2021).
3.5.2

Sample Size
Sample size of patients using the collaborative decision-aid tool was determined

by the PDSA cycle length, which was determined by the length of time it took from
introduction of the collaborative decision-aid tool into clinic until the first patient’s
completion of intervention from initial treatment through last day of radiation. This was 8
calendar weeks; during this time, 15 patients had the collaborative decision aid applied to
at least one clinical visit.
3.5.3

Participant Selection
Patients referred for radiation therapy for treatment of their primary lung cancer,

with/without concomitant cytotoxic chemotherapy had the collaborative decision-aid tool
assigned to their clinical visit with their treating radiation oncologist. This provided an
inclusive and pragmatic sample. A request for human subjects determination was filed
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with the University of Iowa IRB-01. It was determined by the IRB the project did not
meet the definition of human subjects research and, as such, informed consent was
waived.
3.5.4

Research Procedures
Quantitative procedures focused on obtaining objective measures to assess the

implementation of the collaborative decision-aid tool in a radiation oncology clinic and
initial outcomes from its use. The tool was informed from the qualitative strand,
customized for both the patient population and the radiation oncology clinic’s workflow.
3.5.4.1 Historical Control
Patient participants from the qualitative strand and from a research registry served
as the historical control. The control provided historical information regarding emergent
treatment (i.e. ER visits, inpatient admissions), cost of emergent treatment, time
expended per OTV, patterns of adverse events, concomitant medication prescriptions
(including opioids), and the number of add-on oncologist visits. These data were
compared descriptively to the data obtained during the first implementation cycle.
3.5.4.2 Visit One
The collaborative decision-aid tool (Shared Decision Making-Communication
Questionnaire, SDMCQ) was to be assigned to patient with lung cancer prior to their
initial consult. If the patient was to receive long course radiation therapy, the student
researcher placed a notation in MOSAIQ® EHR to have the SDMCQ assigned to each
OTV and a tablet distributed at that visit’s check-in.
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3.5.4.3 On-treatment visits
After receiving the day’s radiation, but prior to being taken to an exam room, the
patient completed the SDMCQ using the tablet. The data were manually mined from
Epic® EHR and entered into the collaborative decision-aid tool. This tool was printed to
the communal workroom, where the treating radiation oncologist picked it up for their
OTV with the patient. The radiation oncologist reviewed the printed document with the
participant, discussing concerns or new issues that have developed.
3.5.4.4 Endpoints and Analysis
Data mining. Emergent add-on visits within radiation oncology, referrals to other
clinics (e.g., medical oncology, emergency room, pulmonology), and inpatient
admissions were mined from the EHR (Table 3). Mining was limited to the active
radiation treatment timeframe (i.e., consult through last day of RT) but include outside
facility records within that timeframe if available. Prescribed concomitant medications
were mined and reconciled with the patient’s use, if available (i.e., compliance). Time
expended for the OTV total (i.e., check in to check out) was mined and, if available, the
length of time for the discrete OTV. Use of a physician resident for an OTV, or
assignment of a covering radiation oncologist, was also noted for review.
Table 3
Source Data for Quantitative Strand
Data Source
Epic® Department Appointment Report

Impact

Implementation

Primary data

Primary data

®

The Epic EHR provided source data for OTV (e.g., check in time, rooming time,
check out time) as well as the time required for SDMCQ completion and time it was
completed. The DAR provided the assignment of the SDMCQ and the tablet.
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Data Source
On-treatment Visit Notes (OTV)

Impact

Implementation

Primary data

Primary data

OTV notes are a source of adverse events, use of the SDMCQ (when assigned), and
the time the note was signed (pre- or post-discharge). The OTV are source for
errors or ambiguous information that could negatively impact communication.
Epic® EHR, including Care Everywhere®

Primary data

—

Epic® provided incidence of unplanned outpatient visits as well as emergency room
visits and inpatient admissions. Also served as source for cost analysis,
chemotherapy compliance, and prescribed concomitant medications.
MOSAIQ® EHR

Primary data

Primary data

MOSAIQ® provided source for radiation treatment compliance (i.e., the number
treatments given, elapsed days, and breaks) and also source for requesting the
SDMCQ when assigned.
Note. Source data will be archived in compliance with HIPAA and retained for a
minimum of six years after closure of the IRB application.
Demographics. Self-reported race, ethnicity, gender, and insurer (as a surrogate
for socioeconomic status) were collected as demographic variables, as well as also the
clinical stage (i.e., T N M), the prognostic stage, pathology, prescribed chemotherapy,
and radiation prescription. These data were mined from Epic® EHR and MOSAIQ® EHR.
Primary objective. The primary objective is to develop the collaborative
decision-aid tool and implement it within the radiation oncology clinic. Quantitative
measures addressing this objective are time expended per OTV and compliance with
SDMCQ completion.
To estimate time expended per OTV, Epic® EHR was mined for the following
timepoints at each OTV: check-in time, time when patient was roomed, time the patient
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was queued as “waiting for MD,” time the resident physician entered the room, time the
resident physician exited the room, time the staff physician entered the room, time the
staff physician exited the room, time the Epic® note was signed, and time the patient was
discharged. For patients completing the SDMCQ, the time for completion was also mined
from Epic®. Times were analyzed using descriptive statistics and presented in tables.
SDMCQ compliance was measured using the number of patients who should have
had an SDMCQ assigned, the number who had it assigned, the number of patients who had
the tablet distributed to them, and the number of SDMCQ completed prior to physician
entry into the examination room. This information was mined from Epic® EHR.
Secondary objectives. Shared decision making is explored through surrogate
markers of unplanned oncology visits (i.e., same day add-on radiation or medical
oncology clinic visit) and concomitant medication prescribing patterns. These are both
mined from Epic EHR.
Unplanned outpatient clinic visits were defined as an office visit scheduled during
routine working hours outside the routine weekly oncology visits. Additionally, referrals to
other outpatient services (e.g., neurology, otolaryngology, ophthalmology) were included if
they were made at the request of the oncology service and not performed concurrently with
an emergency room visit or an inpatient admission. Nurse only visits were also included, as
the nurse clinician was often in contact with the oncologist and providing secondary
services. Phone call notes and MyChart® messages were not included.
Patients undergoing concurrent chemotherapy and radiation therapy for their lung
cancer have medications managed by a multitude of providers. Routine medications such
as anti-hypertensives may be managed by the patient’s primary care physician or treating
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oncologist. Medications to combat side effects (e.g., nausea, dry mouth, esophagitis) are
primarily managed by oncologists but also by emergency room physicians and
hospitalists. Most importantly, cancer associated pain and treatment emergent pain are
often managed by all divisions (i.e., medical, radiation, surgical, emergency room,
hospitalists), which coupled with the current opioid crisis, requires attention to active
prescriptions and harmonizing use to the patient’s complaints.
Concomitant medications were captured as medications prescribed during the
course of the radiation treatment course by any UIHC medical provider as well as those
concomitant medications prescribed only by radiation oncologists. Prescribing patterns
for concomitant medication were presented in tables with graphical descriptions as
appropriate. Medications not included in the review were those prescribed as part of an
infusion order set for infusion reactions (i.e., Benadryl, dexamethasone) or administered
as part of an emergency room visit or inpatient admission. Lastly, these values represent
only what prescriptions were written, not medication use or the number of doses and
refills provided.
Medical management was assessed through treatment compliance (radiation and
chemotherapy) as well as by review of adverse events. Treatment compliance was
evaluated for both radiation therapy and chemotherapy. Radiation therapy was evaluated
using three standard metrics for the field:
•

[total dose delivered]/[total dose prescribed]

•

number of breaks applied (i.e. times radiation was held)

•

number of break days required (i.e., calendar days radiation was held)
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It is standard practice for radiation clinics within the United States to follow the U.S.
banking holiday schedule; thus, prescribed elapsed days also include any weekends or
holidays from radiation treatment 1 to the final radiation treatment. Treatment breaks are
measured in calendar days and, if they abut weekends or holidays, these days are also
included in the treatment break as it is assumed those days contributed to the resolution
of the adverse event requiring the break.
Chemotherapy compliance was evaluated using the Relative Dose Intensity (RDI)
ratio (Crawford et al., 2020; Lyman, 2009). Briefly, this value was calculated by
determining the standard dose intensity (SDI–the intended dose of chemotherapeutic
agents over the original prescribed calendar days) and the actual delivered dose intensity
(DDI–the actual dose the patient received from treatment day 1 to the last day of
treatment). An RDI of < 85% has been associated with poorer outcomes in patients
treated for lung cancer (Crawford et al., 2020).
Adverse events were mined from the radiation oncologists’ notes, special
complaint notes (i.e., telephone notes, nursing notes, unscheduled radiation oncologist or
medical oncologist notes) the emergency room notes, and inpatient admission notes.
Adverse event terminology and severity was harmonized to CTCAE version 5 (National
Cancer Institute (NCI), 2016a). The sources of information were purposefully selected to
evaluate the alignment between the radiation oncologists’ notes, unplanned visit notes,
and the emergent notes. If the patient was assigned the collaborative decision-aid tool,
these answers would also be used to inform the adverse events. Adverse events were
presented in summary statistics in tabular format.
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Emergent care and associated costs were mined from Epic® but also utilized the
UIHC research chargemaster to estimate associated fiscal costs. The number of emergent
visits (i.e., ER, inpatient admission) were mined from Epic® EHR as well as from any
available secondary sources (i.e., Care Everywhere®, scanned outside medical facility
records). Visits were included if they occurred any time between initial consult through
the last day of radiation. If the patient was in an active admission during the last radiation
treatment, this hospital stay was included until the patient’s discharge.
Gross total costs of the emergent visits were estimated based on the UIHC utilized
two sources of costs based on the Current Procedural Terminology (CPT®) or Healthcare
Common Procedure Coding System (HCPCS) (American Medical Association (AMA),
2021; Centers for Medicare & Medicaid Services, 2020). For emergent visits that
occurred at UIHC, the CPT® technical charges and HCPCS charges are summarized in
the encounter; these were mined directly. CPT® professional charges required accessing
the UIHC professional services fee tool, utilizing the following parameters: 2021, State of
Iowa, Facility fee and, if appropriate, the 26 modifier (i.e. physician interpretation only).
The resultant value was then multiplied by 1.5 to estimate the professional fee charged to
a third-party payor, as outlined in the UIHC professional services fee tool instructions. If
the emergent visits occurred at an outside medical facility, the notes were mined for
procedures and the appropriate UIHC charges applied.
Generalizability. This clinical implementation project provides information on the
first PDSA implementation cycle as well as impact on emergent visits and their
associated cost, changes in visit metrics (time spent with patient, overall time from
check-in to note provider completion). The implementation mapping should inform
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future projects similar in nature to the collaborative decision-aid tool at the UIHC as well
as other sites with similar workflows and infrastructure. This work addresses the
knowledge gap of implementing a PROM through Epic® EHR through a clinical
implementation strategy, utilizing only clinical staff, rather than addressing barriers and
facilitators through a human subjects study utilizing an established clinical research
infrastructure.
3.5.4.5 Ethical Considerations
Institutional review board (IRB) approval was sought and obtained prior to
initiating this study. The University of Iowa IRB-01 served as the IRB of record
(IRB00000099, FWA00003007). After initial approval was granted through the
University of Iowa, an application was filed with The George Washington University
IRB for an IRB Authorization Agreement (IAA). After these steps IAA and GWU IRB
were completed, the study moved forward. At the request of the University of Iowa IRB01, a data usage agreement was also filed between the universities.
Informed consent was obtained from patient participants to participate in the
qualitative strand (i.e., describing the collaborative decision-aid tool, the SDMCQ),
including these data in the EHR, and the interview, its audio-recording, transcription, and
storage. A waiver of documentation of consent was obtained for the radiation oncologists
and associated clinical staff. Upon review, the University of Iowa IRB-01 determined the
project, designed to implement the SDMCQ as part of the clinical pathway, was not
human subjects research and did not require further IRB review. The application for
review, and the IRB’s determination, is provided in Appendix B.
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3.6

Mixed Methods Exploratory Sequential Interpretation
The mixed methods research question How does the impact of the collaborative

decision-aid tool inform recommendations for future designs and implementation? was
addressed utilizing a sequential exploratory design, so that the qualitative strand informs
the quantitative strand. However, the qualitative strand and quantitative strand were
analyzed in parallel, in which the data sets are independent and analyzed separately
(Onwuegbuzie & Leech, 2006; Onwuegbuzie et al., 2007; Teddlie & Tashakkori, 2009)
but then a cross-over analysis strategy was applied to identify links or integrate the data
to lead to synthesized results (Onwuegbuzie & Combs, 2015; Onwuegbuzie & Leech,
2006). With the quantitative question being descriptive, the cross-over analytic
techniques selected were data reduction, data display, data comparison, and integration
(Figure 4, Onwuegbuzie & Leech, 2006). The first step for analysis was data reduction
(i.e. coding qualitative data, assessing quantitative data through descriptive statistics).
The data was then analyzed as listed in Table 4. Sources of data included the qualitative
transcripts and resultant codes, the electronic health record (i.e., medications, visits, time
expended, notes), commonly used PROM (e.g., PROMIS®, PRO-CTCAE™, QLQ-C30),
the peer-reviewed literature providing work known to date about implementation and
format, FDA guidelines regarding PROM integration in oncology, and recommendations
from the implementation committee for the collaborative decision-aid tool. The NIRN
framework, the OMRU, and the PDSA implementation cycle informed the mixed
analysis (Onwuegbuzie & Leech, 2006).
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Table 4
Data Analysis : Mixed Analysis Matrix
Quantitative Data

Qualitative
Data

Time

Unscheduled

Medications

INTEGRATION

Format

—

format codes

—

C: barriers & facilitators

T: communication codes
Implementation

Adverse
events (AE)

Appt: times

C: workflow review

L: Frameworks

Q: AEs
COMPARISON

L: AEs to be captured

DISPLAY

INTEGRATION

T & OTV: AE codes

T & OTV: AE codes

T & OTV: AE codes

Q: completion time

EHR: diagnosis

Med: number & type L: Frameworks

Appt: times

EHR: length of stay
L: Literature

P: PROM tools (PROMIS, PRO-CTCAE, EORTC QLQ-C30)
CRT: chemo-radiation therapy C: Implementation committee

—

P: current format

T & OTV: AE codes

OTV: on-treatment visit notes;

—

T: AEs to be listed
—

format codes

L: preventable AEs
T: Transcript;

L: Common AEs

COMPARISON

T: communication &

DISPLAY

T & OTV: AE codes
Q: responses

INTEGRATION

C: barriers & facilitators

Compliance

COMPARISON

T: communication &

DISPLAY

Adverse events (AE)

prescribed

CORRELATION

OTV: AE codes
(quantified)

Q: AEs

EHR: chemotherapy

C: Committee

CRT: RDI

Q: collaborative decision-aid tool questionnaire
EHR: Electronic health record / Epic® Med: concomitant medications
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3.7

Human Participant Considerations
The University of Iowa Institutional Review Board (IRB-01, biomedical) served as

the IRB of record for this study. The IRB Authorization Agreement ceded oversight to the
University of Iowa consistent with The George Washington University IRB’s standard
operating procedures (The George Washington University Institutional Review Board,
2018). Thus, the human studies were submitted for oversight review to The University of
Iowa’s Biomedical Institutional Review Board (IRB-01, biomedical), the Protocol Review
and Monitoring Committee of the Holden Comprehensive Cancer Center (an NCI-required
oversight committee for PI-initiated studies utilizing patients with cancer), and the Data
and Safety Monitoring Committee of the HCCC. This human subjects study did not meet
the National Institutes of Health definition of a clinical trial and, as such, was not required
to be registered on clinicaltrials.gov. Research procedures did not begin until IRB approval
has been obtained from the University of Iowa and the IRB authorization agreement had
been signed and executed by both institutional IRBs. The GWU IRB was required to be
notified if there was a change in risk level for the study, there was a subject complaint,
there was an unanticipated problem, the research was suspended, there as a change in
principal investigator, a change in funding, a change in the GW staff roles or
responsibilities or when the study was closed (The George Washington University
Institutional Review Board, 2018).
3.7.1

Potential Risks
Breach of confidentiality: Privacy and confidentiality are always at risk when

participating in a human subjects study. Additional records were created as a result of the
research study and Epic® EHR was reviewed by non-clinical personnel to mine
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information from the medical chart. This can put a participant at psychological harm due
to breach of confidentiality.
Financial: Participants did not incur additional costs for participating in this
research study. However, some insurance companies deny coverage for any patient
participating in a clinical research study. This risk was minimized by not linking the
medical record to study participants for those consenting to the qualitative study.
3.7.2

Protection Against Risks
Breach of confidentiality: All investigators are required to take classes on human

subject research. To minimize risk, only the IRB-approved research team had access to
the study’s subjects and identifiable data. Once scrubbed of identifiers, data were
provided to study team members as described in the Methods section and the approved
IRB application.
Privacy. Only the information needed for the study was reviewed. Other medical
documentation was ignored. Only those study team members who needed to review the
medical data did so.
Confidentiality: The federal code identifies 18 pieces of information deemed to
be PHI that result in loss of confidentiality. These patient identifiers were removed from
all documentation saved or printed for the purposes of these studies. De-identified data
was stored in a research chart in locked offices as described in the IRB application. A
password protected tracking log was maintained to link the patient to the research ID.
Upon successful completion of the study, the study application will be closed with the
IRB of records and documents stored for 5 years. All documents are then to be shredded.
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Violations. Research violations, including breach of confidentiality or privacy,
are taken very seriously. Upon complaint by a research team member, staff member,
participant, or patient, the complaint is forwarded to the Human Subjects Office of the
University of Iowa for investigation.
Vulnerable populations: Vulnerable populations, including prisoners, pregnant
women, fetuses, and children, were not utilized. Children, due to their unique pediatric
status, would be better served by a study designed for their needs. A larger study may opt
to include prisoners at a later time.
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CHAPTER 4

4
4.1

RESULTS
Introduction
The qualitative strand, with interviews with patients and radiation oncologists,

was conducted from March 2019 through June 2020, with a four month shut-down due to
the SARS-CoV-2 pandemic. The interim phase for qualitative analysis, tool development,
Epic® EHR integration and build, and the plan segment of PDSA occurred from June
2020 through June 2021. The collaborative decision-aid tool was implemented starting
June 2021 and the end of the first PDSA cycle was completed the first week of August
2021, defining the PDSA cycle as roughly eight weeks. Thirteen patients consented to be
interviewed for the qualitative strand; of these, six completed the interviews. Six of the
seven radiation oncologists agreed to be interviewed and all completed the interviews as
agreed.
This chapter will provide the qualitative strand and quantitative strand results as
well as the Do and Study segments of the first PDSA implementation cycle.
4.2

Qualitative Results
The research question guiding the qualitative strand of this research was How do

the stakeholders, practice considerations, and evidence base inform the ideal design and
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implementation of a collaborative decision-aid tool? This question provided the lens to
guide the interviews as well as when exploring participants’ responses.
4.2.1

Patient Participants

4.2.1.1 Demographics
Although 13 patients consented to be interviewed at the conclusion of their
therapy, only 6 returned for interview. Reasons for withdrawal included death (n=1) as
well as SARS-CoV-2 diagnosis (n=1), but the most cited reason was a desire to reduce
time at the clinic (n=5). For this reason, the design was modified to allow the interview to
occur during the last week of therapy, this reduced participant withdrawal from the study.
Demographics of the subjects who participate in the interviews are provided in Table 5.
Table 5
Characteristics of Patients Consented for Qualitative Strand Interview
Characteristic

n=6

T category

Characteristic

n=6

Female

3

T1

2

White

6

T2

0

Non-Hispanic

6

T3

1

Age (years)

T4

3

50 – 59

3
3

N1

1

60 – 69
†
KPS

N2

0

80

2

N3

4

70

3

N4

1

60

1

N category

Prognostic Stage

Insurer

IIIA

2

Medicaid

1

IIIB

2

Medicare

3

limited stage

2

Private

1

VAMC

1
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Characteristic

n=6

Characteristic

n=6

Histology
adenocarcinoma

1

small cell lung cancer

2

squamous cell carcinoma

3

†
Karnofsky Performance Status is a subjective assessment in units of 10, with 100

having no signs/symptoms of disease, 50 being house-bound, and 0 denoting death.
4.2.1.2 Interviews
Overall, the interviews with patient participants lasted between ten to thirty
minutes due to the symptomatic fatigue and dyspnea. Audio recordings were transcribed
verbatim and analyzed as previously described. To obtain insight about the information
an individualized collaborative decision-aid tool required, the first question asked to the
patient participants was, “Thinking about your radiation treatment, what do you think
was important for your radiation doctor to know about how you were feeling?”
Surprisingly, none of the participants were able to answer this question. Participant 6
stated, “[I]t was really the other way around. Because I didn’t know. I didn’t … I knew I
had lung cancer and that was established before I showed up here… I’m not sure I would
of known what to ask at that point;” whereas, subject 34 stated, “It’s…more the other
way around and what I needed to hear.” The other interviewed participants noted it was
important to let the radiation oncologist know what was occurring during therapy and
monitor for side effects described to them. None of the participants prioritized their
lifestyles or activity needs when considering therapy. Additional questions then explored
the patient’s experience while undergoing radiation therapy, the side effects experienced,
and patterns of communication during treatment. Due to the patient participants’ inability
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to describe what was important for a radiation oncologist to know regarding their
preferences and concerns regarding treatment as well as the SARS-CoV-2 pandemic, the
interviews were concluded.
4.2.1.3 Coding, Analysis, and Synthesis
The coding process resulted in six keystones (i.e., conceptual categories); each
was then explored with its own analytic map and supportive memos: communication,
health literacy, patient reported symptoms, oncologic treatment, format of the SDM tool,
and implementation of the SDM tool. Each are described in further detail herein.
Communication. When reviewing the analytic map and relationships between
codes, barriers and facilitators are easily evident. Patients identified barriers included the
repeated efforts to contact/not knowing who to contact, the emotional responses shared
with their radiation oncologist, and the need for a safety net or gatekeeper. Safety net was
linked to caregiver and new information but also isolation, COVID-19, and fear. SDM
Implementation is linked to Communication through Symptoms but also safety net and
choice. This suggests the shared decision-making tool could address the patient-identified
communication barriers of having to repeat information across multiple providers as well
as reduce the feeling of isolation while undergoing radiation therapy. An interesting
finding was patients often referred to their physicians as they when they were unhappy
with a decision or a memory; conversely, the physicians were referred to as we for a
pleasant memory or outcome.
These findings pooled into Communication, which upon review, represents the
overarching theme, “The shared decision-making tool could address the patient-identified
communication barriers of having to repeat information across multiple providers as well
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as reduce the feeling of isolation while undergoing radiation therapy.” Quotations
highlighting communication between patient and radiation oncologist are:
•

“I don’t have an idea of who to call because I don’t recognize the physician on the
pill bottle.” [participant 26]

•

“That’s a lot of things they asked me. Not in a form like this. They did it verbal.
This would be helpful for me because they could have referenced this stuff. Some
doctors take good notes and other doctors don’t. This could have been a reference
for all the other doctors this would be helpful. I did a lot of that repeat, repeat.
And by the end, I’m tired.” [participant 26]

•

“[Y]ou can just hand it to them and they could go over it with you. You could just
answer it without going through everything over again.” [participant 27]

•

“If there was anything frustrating it didn’t have anything to do with them, you
know, it was a matter that no one can be with you and you know, so, you’re sort
of responsible to remember all the stuff to take home and to talk about it.”
[participant 06]

Analytic maps, links, supporting quotations and code definitions are provided in Appendix G.
Health literacy. The Health Resources & Services Administration, an agency of
the Department for Health and Human Services, defines health literacy as “…the degree to
which individuals have the capacity to obtain, process, and understand basic health
information and services needed to make appropriate health decisions” (n.p., Health
Resources & Services Administration, 2019). This concept directly impacts
Communication, SDM Format, and SDM Implementation but also has a secondary
relationship to Treatment and Symptoms through Communication. Thus, the collaborative
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decision-aid tool is dependent upon Health Literacy and may impact the tool’s
implementation and/or usefulness. Health Literacy is associated with codes such as
proactive, patient-to-provider communication, slow reader, choice, medical experience,
foreknowledge, and TV commercials. Two patients stated openly they were slow readers; of
which one painstakingly read the sample questions during the interview. During the
interview, it took the patient 52 seconds to read a PRO-CTCAE™ question for nausea, an
average of 30 seconds for each PROMIS® prompt, and an average of 25 seconds for each
QLQ-C30 prompt. The same patient participant commented on the questions, providing
key insight that the questions could be interpreted in a way that was not intended. The
alternate interpretation was not a reflection on poor health literacy but in the context of the
question (e.g., things you wanted to do, normal activities). The italicized words are those
the patient participants found difficult, as under treatment, they no longer had the desire to
do anything and they had no normal.
Patient participants were judicious in their source of medical information and its
application, restricting themselves to known academic internet sites (e.g., Mayo clinic,
National Cancer Institute) or directly asking their providers or allied health care staff for
further information. All patients endorsed wanting information provided to them directly,
without the need for ‘sugar coating,’ or hesitancy. The theme represented by Health
Literacy is, “The shared decision-making tool is dependent upon health literacy and may
impact the tool’s implementation and/or usefulness.” Representative quotations for this
note are:
•

“And the doctor would know, but I wouldn’t know.” [participant 22]

152
•

“You know, I mean, just… you know I’m…I’m never had cancer before.”
[participant 32]

•

“I didn’t ask a lot of questions because I didn’t know what to ask.” [participant 06]

•

“Well, you know, over the years you always hear when you’re unhealthy that…
well the white blood cells that are fighting off infection and stuff and that goes
low during chemo and radiation and I figured I would ask.” [participant 34]

Analytic maps, links, supporting quotations and code definitions are provided in Appendix H.
Patient-reported symptoms. Participants were asked to identify and describe
symptoms they experienced during treatment. Symptoms could be related to a treatment
(e.g., surgery, chemotherapy, radiation), to the underlying malignancy, or to an existing
health condition. The most commonly patient-identified symptoms were fatigue, nausea,
vomiting, dyspnea, and malaise, all of which are subjective, variable by patient, and
negatively impacted activities of daily life and all of which can be more consistently
quantified utilizing a collaborative decision-aid tool. Sample quotations include:
•

“It’s awful. You’re more tired then...this normal tired you’re supposed to be
experiencing. And…you can’t eat, and you know, you don’t want to do anything
but lay on the couch or your bed.” [participant 06]

•

“Well, I…. I wake up most of the time and I’m still tired.” [participant 34]

•

“So, when you poke 7 pills one day, 7 the next day. So that was 14 pills dumped
down in me and then try to drink enough water to dilute them…and I just couldn’t
do it and then I got sick and I couldn’t take my regular pills. I would put ‘em in
my mouth. I’d drink water. They would come right back up…I’d just … I’d give
up at a point. “ [participant 27]
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•

“Since I don’t have any usual or daily activities …or anything to do… it really
doesn’t interfere with anything. All I do is watch TV.” [participant 34]

•

“The burn on my back… it didn’t show up until I went home. And the nausea too.
Everything was delayed until I was done with it.” [participant 26]

Analytic maps, links, supporting quotations and code definitions are provided in Appendix I.
Oncologic treatment. This is linked to the patient experience, and thus shared
decision making, through symptoms and patient reported outcomes. This suggests the
impact of shared decision making on treatment is secondary and dependent not only on
symptoms but is influenced by the lens of patient reported outcome measures (symptoms,
treatment outcomes). This aligns with the research question, which seeks to identify the
collaborative decision-aid tool regarding side effects and symptoms (not treatment).
•

“So, they immediately jumped on you know, ‘We need the medicine for this and
that. You need to do this and that.’ It’s not like they ignore you when you say
there’s something wrong. They check it out.” [participant 27]

•

They suggested Lubriderm, which is what I put on it. And that took care of …
they’re like, ‘We’re gonna dry your skin out.’” [participant 22]

•

“They had me on 3 different pills of medication to help with the nausea so I never
noticed it.” [participant 22]

•

“They were gonna get me in right away to find out what the infection was. So,
they were gonna schedule me for some procedure the next day…Okay, fine. And
then they called back: ‘We can’t do that procedure because you have to have a
COVID test.’” [participant 06]

Analytic maps, links, supporting quotations and code definitions are provided in Appendix J.
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Format of the tool. Patient participants described a useful collaborative decisionaid tool as one that is paper-based, providing detail regarding side-effects and symptoms,
with a timeframe that addresses weekends and holidays as well as provides information
for providers across multiple clinics. Patient interviews identified a need for the tool to be
simple to address slow reading skills, modifiable to address poor health literacy, and
provide direct instructions to address concerning symptoms.
•

“You don’t want to ask too many questions.” [participant 06]

•

“[The PRO-CTCAE] is too general!” [participant 34]

•

“I don’t have any usual or daily activities…so… it really doesn’t interfere with
anything. All I do is watch TV.” [participant 34]

•

“This would be helpful for me because they could have referenced this stuff.
Some doctors take good notes and other doctors don’t. This could have been a
reference for all the other doctors this would be helpful. [participant 26]

•

“[I]f I’m home, and I had a piece of paper, and all of a sudden I hit that side effect
I could say, ‘Oh, this and…. Hmmm, call in!’” [participant 22]

•

“[The PRO-CTCAE] are pretty wide open…I mean, [the questions] could go back
to prior to you being ill. While you were being sick. So, if you were a patient and
you really wouldn’t know what you were answering. I know in the last 7 days…
but what about prior, right now I’m not, but back then I did.” [participant 27]
In total, fifty-one codes and categories are linked to SDM Format. There is little

interpretation and more directness regarding what should be present, per the patient, to
make this functional. Further details are provided in Appendix K.
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Implementation of the tool. Patient participants described implementation of a
collaborative decision-aid tool as multi-disciplinary, enabling consistent sharing
regarding of patient-reported side-effects and symptoms. If effectively implemented, the
tool could support the gatekeeper function, serving as a single source of information to
the multidisciplinary committee as well as a resource for the patient to know when to
escalate situations and who to contact during holidays and weekends.
•

“This would be helpful for me because they could have referenced this stuff.
Some doctors take good notes and other doctors don’t. This could have been a
reference for all the other doctors this would be helpful.” [participant 26]

•

“Then you can just hand it to them and they could go over it with you…without
going through everything over again.” [participant 27]

•

“Maybe you just want to know from week to week whether it’s getting better. It
was REALLY BAD and oh, now it’s not quite so bad, and you know so you can
see the trend that it’s getting better and better.” [participant 06]

•

“We need somebody that has direct input into the committee who knows what’s
going on. Like a gatekeeper. One person I talk to and they direct me.” [participant 26]

•

“You’re coming every day for radiation, and that was also sort of a safety net.
Because if you didn’t feel good from one day to the next, you knew you were
coming back and you could ask somebody the question.” [participant 06]

Analytic maps, links, supporting quotations and code definitions are provided in Appendix L.
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4.2.2

Radiation Oncologist Participants

4.2.2.1 Demographics
At the time of the qualitative study, there were seven radiation oncologists on
staff at UIHC. Per the IRB of record, written informed consent was not required but an
informed consent sheet was to be distributed. All seven radiation oncologists were
approached and six scheduled interviews. The seventh did not schedule an interview and
this was considered declining to participate. All of the interviewed physicians are board
certified in radiation oncology and have practiced in locations other than Iowa.
Demographics are provided in Table 6.
Table 6
Characteristics of Radiation Oncologists Consented for Qualitative Strand Interview
Characteristic
Female

n=6
2

Race

Characteristic

n=6

Academic status
Assistant professor

2

White

5

Associate professor

3

Asian

1

Professor

1

6

Tenure track

3

Non-Hispanic
Years in practice
Average

Terminal degree
11

Minimum

3

Maximum

28

M.D.

2

M.D., Ph.D.

4

4.2.2.2 Interviews
Interviews varied drastically across appointments (average 39 minutes; range 18
to 60 minutes). The longest interviews occurred with radiation oncologists 1, 2, and 5.
Despite the shorter length, key insights were provided from radiation oncologists 3, 4,
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and 6. For example, physicians 3 and 4 were able to clarify and specify what they would
prefer to see in the shared decision making tool (e.g., no scales, granular real-world
descriptions of activities of daily life) whereas physicians 1 and 2 had focused on
ambiguous terms and how they vary between patients. Similarly, physician 5 described a
potential process by which answers change between providers, but physician 6 provided
additional detail that answers could change because the event resolved or because the
patient was seeking to be admitted and knew the answers that would trigger an inpatient
stay. Interviews were often concluded due to clinical or patient interruptions with followup clarification as needed.
4.2.2.3 Coding, Analysis, and Synthesis
Due to the focused nature of the interviews with the radiation oncologists, coding
and thematic analysis were not performed. Transcripts were reviewed for exemplar points
as well as supportive concepts that further informed patient participant interviews and
provided triangulation to the analytic maps and memos .
Communication. Radiation oncologists described two themes in communication
problems: physician vs. patient and the prescribing radiation oncologist vs. other
physicians. Illustrative quotes highlighting these issues are provided within the following
sub-sections.
Communication between radiation oncologist vs. patient. Radiation oncologists
described inconsistencies in verbal communication and documentation with patients. This
was noted to happen directly to them during their training as well as in a faculty position.
The radiation oncologists used the term ‘flip-flopping,’ to describe the shift in patientreported information from provider to provider. Differences in patient reporting to
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physicians was expected based upon the literature review. The physicians had different
explanations as to why this might occur, from the initial query by a nurse or resident
physician prompting the patient to recall the symptom during reflection to the symptom
resolving between provider appointments. It was also discussed that gender bias did
occur in the predominantly male field, with female physicians being assumed to be
assistants or patients seeking male input even though the men are students. A radiation
oncologist believed this could be minimized by a presence of confidence and leadership;
the need for confidence and leadership was also mentioned by other radiation
oncologists.
Surprisingly, all radiation oncologists’ stated the personality of the patient was the
key to understanding communication was unexpected and notable. The personality
contributed to a shared history between patient and radiation oncologist, which enabled
interpretation of actions and non-verbal communication.
•

As a resident, patients would flip-flop all the time. They would say one thing and
then tell the staff a different thing. And you’re standing in the room with the staff
and you’re like, “Oh great!” Because you’re trying to make a good impression in
the staff. But now, as staff, I’m expecting the patient to flip-flop. Change their
mind. Think about things in between our visits where the resident goes in and five
minutes later, I come in. And “Oh, yeah, maybe I do have that symptom!” [MD 5]

•

I have not had the experience but [redacted] was on service at VAMC. She had a
male resident, a male fellow, and a male student. She goes in to deliver the
patient’s news. She tells him what the result is. The patient turns to the male
student and goes, “What’s your opinion about this?” the student is like, “I agree
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with Dr. [redacted].” It’s like, yeah, yeah. She’s looking at the student, “Please,
please enlighten us about this!” It’s not the student’s fault – clearly ….So, I feel
that patients probably respond differently to male and female physicians. [MD 6]
•

There was one patient…I used to love this lady. Every single time she would
come and she would be so unreasonable regarding her spouse’s symptoms to the
point that I would have to almost yell at her to stop. I mean, basically I would
have to yell at her to stop being so unreasonable and nearly abusive in her
frustration. And then she would cry. And then she’d be so happy and apologize
and she’d hug me and thank me for explaining what was occurring. And she did
this every single visit. And she came in over multiple years…She was a very nice
lady [but] she would have to replay this sequence each time. [MD1]
Communication between the treating radiation oncologist vs. other physicians.

Perhaps the most stunning was the revelation from the radiation oncologists that errors in
notes were not called out to peers, so they could be corrected. The radiation oncologists
described identifying frank errors, omissions, or information inconsistent with known
history of the patient. While some would feel comfortable addressing an issue if they
were friends with the physicians outside the office, in general the radiation oncologist
would resolve the issue by contacting the patient directly or scheduling a follow-up exam.
The radiation oncologists could also name specific physicians whose notes could always
be trusted and those whose should be discounted. This provides triangulation to the
patients’ insights that not all providers were consistent with their notes and also did not
share information about the patient consistently.
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•

[The problems] could have resolved, they could have actually not answered the
questions, or asked the questions and had a templated note. It can happen. [MD 6]

•

[E]ven if [the notes] are not detailed enough, unless there’s an in-between [and]
they see other providers, what else can you do? [MD 4]

•

Calling a note out with a colleague is not done…Would I talk to the other
physician? No. [MD5]

•

[O]ften times the inpatient unit notes are way behind and when they are admitted
they’re supposed to be coordinating care with Heme Onc, but they don’t. It’s a
game of telephone. They are hard to get a hold of. You page them and sometimes
they don’t respond for 3 or 4 hours. It’s just frustrating. [MD5]

•

[W]hen they are on the unit they are under the care of the hospitalist or of the
inpatient physician So if their inpatient physician says no treatment even if I think
they should have treatment, they make the call. When they are outpatient it’s
more of an egalitarian I’m equal you’re equal. [MD5]
Patient reported outcome measures and tools. Radiation oncologists were asked

about patient reported outcome measures and their opinion about related surveys.
Perspectives from the radiation oncologist identified two concerns: a patient’s poor
understanding of the scale of events/outcomes and the relevance of the outcome measures
in the oncology clinic.
Severity scales. The National Cancer Institute has employed a tool known as the
Common Terminology Criteria for Adverse Events (CTCAE). The CTCAE harmonizes
adverse event / symptom terms but also provides a severity grading from non-existent
(grade 0) to mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening (grade
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4), and causing death (grade 5). Patient reported outcome measures, such as the PROCTCAE™, use similar terms if not the same exact. Clinical interpretation compared to
patient reported measures can cause confusion and frustration.
Oncologists, including radiation oncologists, observe a spectrum of treatment
emergent events from none (at initial diagnosis) to acute and serious requiring routine
admission or intensive care, to overseeing a rapid response to an antineoplastic therapy.
In contrast, the patient’s only sphere of reference is their own experience and what
knowledge they can glean from third-party sources. This aligned with the patient
participants, who stated although they knew they would have the side effects of fatigue
and esophagitis, they had no understanding of what they would truly experience. This
also provided foreshadowing for clinical relevance.
•

Iowans are stoic. Very different than [State A] or [State B]. In [State A] they let
you know. In [State B] they expect you to know based on the labs and everything
else. In Iowa, “I’m fine. Everything’s great!” but I see they’ve lost 10 pounds.
[MD 5]

•

[I]f I, with my years of experience now looking at (side effects) say, “This looks
amazing. I‘ve never seen anybody get through it so well,” but for the patient this
is the worst thing they’ve ever been through in their whole life. It’s still like a
level 5 severity or whatever, you know, and it’s really hard because the patient
doesn’t know any better what they could have gone through. [MD 02]

•

The whole problem is the written word is very differently interpreted and different
written down than the person in front of you when you ask a question.…there is
something organic in seeing the person’s face when they do it. If they have a
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score sheet with this ECOG thing and they hand it to me, and they are sitting
there, do I know they knew what that meant? Did they internalize that and they
justify it? Or are they very stoic? [MD 01]
Clinical applicability. As an NCI-designated Comprehensive Cancer Center, the
radiation oncologists are familiar with patient reported outcome measures and the
standard instruments utilized by NCI: PROMIS, FACT/FACIT, EORTC, and the newer
PRO-CTCAE. Additionally, patient reported outcome measures were often confused by
physicians for patient satisfaction scores (e.g., Press-Gainey). This invites concern over
the patient’s evaluation of subjective outcomes being influenced by the physical
appearance of the treatment center or of the physician’s bedside manner rather than
focusing on the treatment emergent adverse events and outcomes of the treatment.
•

PCORI and all these federal agencies wanted to rate health care based on patient
reported outcomes. So there were places that had flowers on the desk…they could
have completely mistreated you but they were extraordinarily satisfied…there’s
this lack of recognition from one end of the spectrum to the other end. [MD 1]

•

I struggle with the idea of a patient having a piece of paper in their hands with
standardized questions, too, because those questions may not actually fit the
patient’s priorities. Even if you hand me the piece of paper and it has their scores
from today if don’t have the scores from last week in front of me, I’m not gonna
know how this compares. And I’m not necessarily going to be immediately aware
of the trend. And I’m not going to take the time to go look up last week’s scores.
[MD 2]
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•

The thing I don’t like about some of these is when they are simply numerical. And
then, as a covering person, you don’t necessarily even have a sense of what it
means. I mean, to have a useful tool would be one that...you know, very clearly
…almost be like a table with the ranking system but not score 1 2 3 4 5 but like
dyspnea, ‘none,’ ‘little,’ you know...Something that I can look at say, “Well, that’s
what’s happening.” You know? Eating. “hmmm, I really can’t eat any solids.” “Oh,
I can eat something.” If I can actually look at it and see what it means and track it
over time — that is potentially helpful. But I do agree something that’s potentially
overly granular or numerical based that isn’t intuitively obvious to anybody just
walking in the room is not worth anything. [MD 3]
The radiation oncologists identified trends as the critical information in an

assessment of a patient reported outcome measure as well as using the patient as their
own control. The doctors described three key timepoints in their assessment of a patient
undergoing radiation therapy: what were they like before they received any radiation,
what were they like the last time a radiation oncologist saw them, and what are they like
the day of the visit. The radiation oncologists were careful to note the assessment window
needed to be since the last visit, rather than the typical 7 day window for PROM
instruments, because they need to assess the efficacy of a prescribed intervention.
4.2.3

Collaborative Decision-Aid Tool Design
The first consideration for the tool was what the patients wanted the radiation

oncologists to know. None of the patient participants could voice that. This was the crux of
the tool design, as this information would be used to then select questions and prompts
from the validated item banks. This was key to tailoring the tool to each individual patient’s
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needs or concerns. In absence of these data, the decision was made to target the symptoms
commonly described by the patient participants as troublesome: dyspnea, nausea, vomiting,
esophagitis, and fatigue. The radiation oncologists had also been asked for the symptoms
they were most concerned about in the lung cancer patient population. Symptoms outlined
by the radiation oncologists also included in-field skin condition (i.e., was the skin breaking
down due to the radiation therapy), weight, swallowing, eating, changes in breathing (i.e.
concerning for a pulmonary embolism), and chest pain.
The radiation oncologist interviews also informed how the question should be
designed, as these physicians were not in favor of numeric or ambiguous scales (Figure
15 & Chapter 1, Figure 3). The numeric format as well as nebulous concepts as “mild,”
“somewhat,” and “severe” were considered difficult to interpret due to a patient’s
personality, the patient’s interpretation of symptoms, and the patient’s likelihood of
seeking intervention. Granular details capturing the activities of daily life were better
appreciated by radiation oncologists and patients alike, providing context and examples
of how they could be feeling. As such, all participants (including patient participants)
ranked the PRO-CTCAE™ lowest (i.e., unfavorably), with comments that it was too
general, failing to provide necessary framing. For this reason, PRO-CTCAE™ was no
longer considered for the tool.
Review of the PROMIS and EORTC questions regarding nausea and dyspnea by
patient participants provided crucial insight for tool design: framing and immediate
context was paramount. For example, when reviewing the example PROMIS fatigue
prompt ‘I was frustrated by being too tired to do the things I wanted to do,’ (Figure 15)
participant 34 provided the following feedback:
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Since I don’t have any usual or daily activities…Can’t say I was frustrated doing
things that I wanted to do, cause there really wasn’t to do. I don’t have a gal or
anything here with me, so…that would have made a difference!
Participant 34 strictly focused on the 7 -day window prompt as the frame of reference,
not the activities of daily life he had engaged in prior to therapy (Figure 15). At UIHC,
like many U.S. academic medical centers, cancer patients are housed locally in often
dormitory-like living arrangements. Thus, there are no normal activities and no
Figure 15
Examples of Items for Dyspnea from PRO-CTCAE™, PROMIS®, and EORTC

Note: PROMIS® is ©2006-2017 PROMIS Health Organization; EORTC ©1995 EORTC
Quality of Life Group.
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household chores. For this reason, Participant 34 marked answered these questions as
‘never’: fatigue never interrupted household chores (as there were no household chores)
and fatigue never interrupted the things he wanted to do (he had none as he was away
from family, friends, and work). Thus, the provided answers do not reflect the truth of
what the participant was experiencing, as he noted he could not even finish a single
television show without falling asleep, yet the responses would indicate a treatment’s
minimal impact on the participant’s activities of daily life. Another patient participant
noted falling asleep at meals.
The patient reported outcome measure was then designed so the typical EORTC or
PROMIS® item ‘lead in / prompt / question’ served as the answer (Figure 15). For
example, the radiation oncologists liked ‘taking a short walk (about one block)’ where
patient participants described being unable to complete a television show due to fatigue.
Item banks were reviewed for prompts capturing this feedback. Once selected, they were
reviewed by the thoracic radiation oncologists to determine if they provided enough
distinction and captured the symptoms that were concerning. Simple checkboxes for, “I am
taking a medication for this,” were also added to provide context and direction if
medications needed to be adjusted.
The tool was designed in a MS Word document and consisted of five symptom
prompts: nausea/vomiting, cough, chest pain, fatigue, and breathing. The tool was designed
pragmatically through the patient’s lens. For example, although the NCI considers nausea
and vomiting discrete adverse events, to a patient the end result of nausea is vomiting; thus,
vomiting is the most ‘severe’ of the nausea responses (Appendix M). Similarly, chest pain
can be caused by esophagitis, coughing, muscle strain, or even a sentinel event such as a
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Figure 16
Initial Design for Shared Decision Model/Communication Questionnaire (SDMCQ)

Note. Original design for the SDMCQ as implemented through the EHR. Each question
was answered using a drop down, with ‘no symptoms,’ as the last option.
pulmonary embolism. The prompt for chest pain provides the context (e.g., it feels like
burning, it feels tight) and enables the provider to further assess the symptom to assist in
the diagnosis. The tool was shared with Epic® EHR programmers who created a simple
questionnaire that could be assigned to patients on demand (Figure 16). Prior to release, the
tool was required to undergo regulatory and legal review.
Once cleared for use, the digital tool was installed within Epic® EHR and could be
pushed out through MyChart® (Epic® EHR Systems Corporation, Verona, WI) as well as
through the UIHC tablet, a digital pad with touch sensitivity. The UIHC tablet is wirelessly
connected to the EHR for direct patient information capture. MyChart® is an application
available via the internet as well as through applications for Android and Apple smart
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devices. MyChart® connects seamlessly with Epic® EHR and enables real-time access to
the electronic health record for patients.
The questionnaire responses then needed to be provided in an easy-to-interpret
print layout. After discussion with the radiation oncologists, a table format was selected
(Appendix M). This would be printed, provided to the radiation oncologist for the ontreatment visit, to serve as a collaborative decision-aid tool. The hybrid tool (electronic
questionnaire, printed tool) was implemented as the SDMCQ. The questions and answers
from the patient’s visit can be reviewed by the physician within Epic® EHR and by the
patient through MyChart® access.
4.2.4

Implementation: the PDSA’s DO Segment
The first SDMCQ was assigned the first week of June 2021. The first subject to

successfully completed the assigned SDMCQ on02 August 2021. In addition to the data
sources cited in Table 2, emergent source data for the implementation included field
notes from the researchers as well as communication artifacts (i.e., emails, text pages)
between the researcher, clinical staff, and stakeholders. These data sources supported
multiple observations during the first PDSA cycle. The two significant problem areas
identified during initial implementation were (1) assigning the SDMCQ and (2) providing
the tablet to the patient:
1. The department opted out, remember? The key stakeholder representing the front
desk (a supervisor) believed assigning a questionnaire and releasing a tablet to be
common foundational knowledge. The supervisor is also a senior administrator within
the hospital with significant experience in clinic management as well as the
scheduling front desk. However, when the workflow initiated, the front desk staff did
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not know either of these procedures (i.e., assigning a questionnaire, releasing a tablet)
because the department had opted out of questionnaire assignments. This resulted in a
crash course during a hectic Monday morning opening schedule to assign the first
SDMCQ. After the crisis was over, it was realized through reflection that because the
supervisor cross trains and serves on many committees (including the Epic® EHR
committee), the knowledge base differed from the staff’s.
2. Wait, there are TWO schedules? Epic® EHR enables clinical staff to leave
messages regarding a patient’s appointment in a comments field. For clinical staff,
this is readily apparent in Epic’s SCHEDULE, which is a conveniently located tab
labelled ‘schedule’. After three missed tablet distributions, the student researcher
learned the front desk staff uses only the Department Appointment Report (DAR).
This is significant because the DAR does not show the comments field — only the
notes field, so this is the field the front desk staff relied on. In contrast, clinical staff
only have access to modify the comments field through patient schedule, although it
shows both the comments field and the notes field. The front desk staff were unaware
of the comments made to them in the comment field (such as, ‘tablet needed’).
Humorously, as it was discussed amongst staff, the research nurses reflected that it
explained a few things – as they had noticed a problem getting front desk to act on
comments placed for research subjects over the past few years.
3. That doesn’t mean what you think it means. At the start of the PDSA cycle, an
adaptation was made to have the front desk both assign the SDMCQ as well as place
the prompt text for handing out a tablet at that OTV within the notes field. By
assigning an SDMCQ, a unique code is then assigned for the front desk staff to
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unlock the tablet and have it load all documents unique to that patient. It was
misunderstood by front desk staff that this code was equivalent to the SDMCQ being
assigned, not realizing that other departments could apply forms to the radiation
oncology clinical appointment as well. The supervisor re-educated the staff regarding
what the code meant.
4. Patients wanted a paper decision aid. Despite providing the samples to the
programmers and discussing the objective for the SDMCQ, the final product could
not be printed to represent the three timepoints requested by the radiation oncologist:
before treatment, visit before, current visit. The programmers were not certain how
this could be performed and, in the interim, the decision was made to manually create
the printout by monitoring patient completion of the SDMCQ.
5. You haven’t even had radiation yet. For both the fatigue and dyspnea prompts, a
response of, ‘I feel the same as before I started radiation therapy’ had been provided
as an option. A brief interim review suggested this was perhaps too easy – most
notably when patients answered that they felt the same as ‘before starting radiation
therapy’ at their initial consult appointment – which was, indeed, before radiation
therapy. By providing this answer, a true baseline and assessment of function prior to
radiation therapy is not available. The student researcher contacted the Epic®
programmer and substitute fields were implemented, so the pre-therapy baseline
SDMCQ truly reflected the symptoms the patients were experiencing.
4.2.5

Implementation: the PDSA’s STUDY Segment
Over the eight week cycle, the SDMCQ was requested 42 times for a total of 15

patients. Six of these patients were short-course radiation and did not continue with
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completing the SDMCQ. Of the remaining nine, five were currently receiving therapy,
three completed radiation, and one passed away from an unknown cause during the
course of therapy. The overall completion rate was 78% (32 completed of 41 assigned);
the majority of omitted SDMCQ were assigned to the short course radiation (2 completed
/ 6 assigned). For the long course subjects, two patients had SDMCQ omissions: one
patient due to an SDMCQ assignment error resulting in 4 missed questionnaires and the
second patient due to a scheduling failure from planning to the front desk resulting in a
single missed questionnaire. Thus, 30 out of 35 SDMCQ scheduled for long-course
radiation treatment were completed.
An end-of-cycle-1 meeting was held with the key stakeholders one week after the
completion of the first subject who completed baseline and the entire course of radiation.
After reviewing the Plan-Do-Study-Act cycle and its iterative nature, seven observations
were discussed utilizing a program theory logic chain model (i.e. if…then…). The outcomes
model was selected from the Kellogg Foundation’s development guide. It utilizes a basic
strategy employing a simple rationale: if this were to occur then the outcome(s) would
occur. As designed, the model is stepwise over time and identifies resources, activities,
outputs, outcomes, and/or impacts (W. K. Kellogg Foundation, 2004).The discussion and
model yielded four critical outcomes to be implemented in the next PDSA cycle (Table 7).
The radiation oncologists expressed concerns that completion of the SDMCQ by the
patients was lengthening the OTVs. Time expended to complete the SDMCQ was
requested for cases to date.
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Table 7
Observations Made During SDMCQ PDSA Cycle 1
If…(observation)
a lung cancer consult is placed
1.§ SDMCQ/tablet needs assigned

2.§

3.
4.§

7.

the SDMCQ/tablet needs assigned
clarify the appropriate lung cancer patients

clarification is needed

all patients with treatment consult are assigned

SDMCQ is needed at OTV

the physician marks it on the imaging form

the imaging form is marked

CT tech copies text into MOSAIQ EHR

the text is in MOSAIQ EHR

therapist marks SDMCQ on scheduling sheet

SDMCQ is on scheduling sheet

front desk schedules SDMCQ/tablet at OTVs

the tablet is not distributed

the SDMCQ will not be collected

a patient has a special
complaint

5.§ a patient leaves before review
6.

Then…(logic outcome)

the SDMCQ will not be assigned/collected
the SDMCQ is not reviewed

SDMCQ and physical exam

the physician will ensure the notes address the

(OTV) notes don’t align

discrepancy for clarity and resolution.

a 30 day follow-up is scheduled

SDMCQ will not be assigned/collected

§ denotes critical outcome impacting the next cycle.
4.2.6

Implementation: the PDSA’s ACT Segment
The decision was made to adapt the implementation strategy and initiate a second

PDSA cycle. Both radiation oncologists believed the information to be valuable, with one
stating their routine questions have changed as a result of the SDMCQ and the second
explaining the excitement as research is demonstrating the underlying value for patients,
emphasizing that if it is at no cost to the department, the benefit to the patient should be
underscored. The stakeholders decided to maintain a structured implementation and
mapping strategy to enable future adoption of the decision/communication aid into other
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clinics, with the breast cancer clinic, head and neck cancer clinic, and brain cancer clinic
identified as potential targets. There were four action items from the first PDSA cycle:
1. Scheduling the SDMCQ at a consult. For the first PDSA cycle, the potential cases
were identified by the student researcher and the front desk was notified to assign the
SDMCQ/tablet. With the first cycle complete, it was decided to adapt the
implementation to address the treatment consult visits. Front desk staff cannot
identify patients with lung cancer who may be considered for long course radiation
therapy, as this is determined by physicians after consult. The radiation oncologists
agreed regardless of prescribed radiation, the SDMCQ had meaningful information
for all patients with lung cancer and, as such, should be scheduled for any lung cancer
treatment consult.
2. Scheduling workflow outlined. During the first PDSA cycle, if a patient was
prescribed long course radiation therapy, the radiation oncologist or student
researcher noted in radiation oncology’s MOSAIQ EHR the patient required SDMCQ
assigned at OTV. The radiation therapists would then notify the front desk at the time
of OTV scheduling. This was considered a weak point and consistency was required.
Points of discussion included a pre-filled prompt as well as text for the CT-techs to
copy from a form into the MOSAIQ EHR notes. The final workflow to implement
was for the radiation oncologist to ‘uncheck’ a box in the imaging request form if a
patient with lung cancer was to receive only short course radiation therapy. If the box
was checked, the CT-techs could copy text from the imaging request form and paste it
into MOSAIQ EHR. This then would notify the therapists to have the SDMCQ/Tablet
scheduled at OTV. This was a significant change to workflow for the clinic.
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3. Omitting the SDMCQ for special complaints. Patients undergoing radiation often
have special complaints, which necessitate a review by a radiation oncologist. It was
discussed if these complaints should have SDMCQ assigned. Administration pointed
out there is not a code to the Epic® EHR visit to identify that level of encounter. The
radiation oncologists stated that many special complaints are without acute medical
need, such as requests for medication refills or parking placards. After discussion, the
determination was made not to assign the SDMCQ to special complaints.
4. What to do if the patient leaves early. Planning for the first PDSA cycle focused
heavily on recent oversight determinations that physicians were required to review
patient reported outcome measures and attest to that review. This hampered some
SDMCQ assignments, as a licensed provider is required to attest to review. To
provide attestation, the radiation oncologists must physically see the patient (or defer
that physical visit to another provider). If patients do not have an SDMCQ scheduled
for consult, or if it was omitted in error, the radiation verification (i.e., dry run) visit
was ideal to obtain a baseline SDMCQ. The problem was a physician visit for
attestation is not required that day. During the study review, the radiation oncologists
stated they were comfortable if a patient was inadvertently discharged without their
oncologist seeing the SDMCQ answers. Feedback from oversight was technically the
OTV and was not considered an independent outpatient clinic visit and was thus not
subject to attestation requirements. Despite this feedback, both radiation oncologists
in the meeting believed it to be a best practice to review in contemporaneously, using
a paper printout, as the decision aid was designed to be used.
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4.3

Quantitative Results of the Implementation
The Shared Decision Making/Communication Questionnaire (SDMCQ) went live

in Epic® EHR the first week of June 2021. It was assigned to any patient that was
receiving, or suspected to receive, long course radiation for the treatment of their lung
cancer. The first patient received a baseline SDMCQ during the third week of June 2021.
The SDMCQ was applied on the patient’s first day of treatment. Data were collected
through the calendar week the patient completed the course of radiation – approximately
eight weeks and captured 4 patients.
4.3.1

Case Demographics
During the first implementation cycle, SDMCQ was requested for 15 patients who

were being consulted for radiation treatment for lung cancer. Demographics are provided
for the nine patients prescribed long course radiation therapy and for all 15 patients
assigned an SDMCQ (in parentheses) (Table 8). In addition to age, gender, race, ethnicity,
and insurance status, histology of the lung malignancy is provided as is staging. The TNM
staging provides information on the size and extent of the tumor (T), the number and
distance of regional lymph nodes (N), and if distant metastasis is present (M). Prognostic
staging utilizes the TNM staging with the context of the tumor type and histology.

176
Table 8
Characteristics of Patients Assigned at Least One SDMCQ
Characteristic

n =9 (15)

Tumor category

Characteristic

n =9 (15)

Female

3 (6)

Tx

1 (1)

White

9 (15)

T1c

0 (3)

Non-Hispanic

9 (15)

T1

4 (5)

Age (years)

T2

1 (2)

50 – 59

0 (1)

T3

1 (2)

60 – 69

0 (1)

T4

2 (2)

70 – 79

7 (8)
2 (5)

N0

1 (6)

80 – 89
†
KPS

N1

1 (1)

80

2 (5)

N2

6 (7)

70

7 (8)

N3

1 (1)

60

0 (1)

50

0 (1)

Node category

Metastasis
M0

9 (15)

Insurer

Prognostic Stage
IA

0 (1)

Medicaid

3 (3)

IB

0 (2)

Medicare

4 (9)

IIIA

2 (2)

Private

0 (0)

IIIB

3 (4)

VAMC

2 (3)

IV

0 (2)

limited stage

4 (4)

Histology
adenocarcinoma

2 (5)

poorly differentiated non-small cell carcinoma

0 (0)

small cell lung cancer

4 (4)

squamous cell carcinoma

3 (5)

unknown

0 (1)

†
Karnofsky Performance Status is a subjective assessment in units of 10, with 100

having no signs/symptoms of disease, 50 being house-bound, and 0 denoting death.
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4.3.2

Control Demographics
For comparison, data were mined from 20 patients who had undergone long-course

radiation therapy: patient participants from the qualitative strand and an available registry
for chart-review research. Sample size was larger due to the anticipated sample size of the
SDMCQ cohort. Demographics are provided (Table 9).
Table 9
Characteristics of Patients within the Control Cohort
Characteristic
Tumor category

Characteristic
20

Node category

Characteristic
20

Prognostic Stage

20

T1a

2

N0

4

IA3

1

T1b

1

N1

0

IIB

1

T1c

3

N2

8

IIIA

5

T2a

1

N3

8

IIIB

3

T2

2

M category

IIIC

3

T3

3

M0

18

IVA

2

T4
†
KPS

8

M1

2

Limited stage

5

Female

12

60

1

White

18

70

2

African

80

12

90

5

Insurer

20

American
Non-Hispanic

Age (years)

2
20

50 – 59

4

60 – 69

11

70 – 79

4

80 – 89

1

Histology

Medicaid

2

Medicare

13

adenocarcinoma

6

poorly differentiated carcinoma

1

Private

4

poorly differentiated non-small cell carcinoma

2

VAMC

1

small cell lung cancer

6

squamous cell carcinoma

5

†
Karnofsky Performance Status is a subjective assessment in units of 10, with 100

having no signs/symptoms of disease, 50 being house-bound, and 0 denoting death.
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4.3.3

Expended Visit Times
The primary objective is to create the collaborative decision-aid tool and to also

implement it within the radiation oncology clinic. To assess potential disruption or
delays, expended time for OTVs was calculated. Epic® EHR provides a patient’s check-in
time, the rooming time (i.e., time the patient is taken to the examination room), waiting
for physician (i.e., the time the medical assistant/nurse is completed and out of the room),
the times the resident enters and exits the exam room (if a resident is assigned), the times
the radiation oncologist enters and exits the exam room, and the time the patient is
discharged from clinic. Unfortunately, these times are manually obtained based on
reporting, such as the medical assistant marking the resident’s entry into the room or the
radiation oncologist marking their exit from the exam room. The two values consistently
collected are check-in and discharge.
The radiation oncologists expressed the most interest in the time from check-in to
when they entered the exam room, as this would indicate the SDMCQ was delaying the
clinical workflow. This was calculated by subtracting the check-in time from the
physician-out time or, if this was unavailable, the discharge time (Table 10).
A second measure of OTV time is the time spent by the radiation oncologist in the
exam room. This was calculated based on available values using the waiting for physician
time subtracted from physician out time. Values were calculated for controls as well as
for patients assigned the SDMCQ. The number of visits is provided that were used for the
calculations (Table 11).
The final measure was the time expended to complete the SDMCQ. This is
provided and is a unique value to only the clinical implementation project.
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Table 10
Average Time Expended for a Radiation Oncology On-Treatment Visit
SDMCQ (n)†

Control (n) †

Clinic check-in to physician out

31 (35)

29 (119)

Clinic check-in to physician out or discharge time

31 (43)

30 (134)

Waiting for physician to physician out

17 (25)

17 (87)

5’55”* (36)

—

SDMCQ completion time

† Value is measured in average minutes per OTV; n represents the number
of OTV with the specified criteria used to calculate the average
* Calculated at 5 minutes 55 seconds for average completion time.
Of the 32 SDMCQ assigned during OTV, 27 had a referenced patient rooming time.
Comparing the SDMCQ completion time to the patient rooming time, two-thirds were
completed before the patient was taken back to an exam room (18 / 27). Of the remaining
nine, three were not completed prior to the physician completing the visit (3 / 27). Two of
these visits with SDMCQ delays were patients participating in a clinical trial (and were
with clinical trial staff) and the third was an inpatient who required complicated care.
4.3.4

Emergent Visits
Three types of emergent visits were captured: unplanned visits to an outpatient

clinic (i.e., physician visit during routine office hours), an emergency room visit, and
inpatient admission (Table 10). Of those subjects included in analysis, only four had
completed their radiation course. Reasons for emergency room visits included bleeding,
nausea, and chest pain. Reasons for admissions included chest pain, sepsis/sepsis-like
syndrome, chest pain, and hypoglycemia.
Per the Centers for Medicare and Medicaid, emergency room visits for nausea,
pain, and febrile neutropenia are considered to be services that could be addressed in an
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outpatient setting, not requiring emergency room visits. Emergency room ‘only’ visits for
the control cohort were due to pain (n=3), dyspnea (n=1), rectal bleeding (n=2), nausea
(n=1), and a central venous access device clot (n=1). Using the CMS criteria, four of these
visits (57%) could have been avoided. Of the four patients who had the SDMCQ applied,
one had an emergency visit for pain control; this also would meet the CMS criteria as a
potentially avoidable visit. The average cost for emergency room visit per patient was
$1,976 for the patients who had completed SDMCQ and $1,363 for the control cohort.
Although this likely reflects the small sample size rather than a difference between the
cohorts, it emphasizes the fiscal cost of events deemed by CMS to be preventable.
Table 11
Characteristics of Patients Assigned at Least One SDMCQ
SDMCQ (n=4)

Control (n=20)

Visits, unplanned outpatient clinics†

1

11

Visits, Emergency Room

2

13

Estimated costs

$ 7, 903

$ 24, 525

Average cost / patient

$ 1, 976

$ 1, 363

Admissions from ER

1

6

Inpatient admissions

2

14

7

55

3.5

3.9

Estimated costs

$ 41, 210

$ 322, 411

Average cost / patient

$ 10, 303

$ 17, 912

Total days
Days / admission

†

Non-routine medical oncology, radiation oncology, or surgical oncology visits or

referrals to other outpatient clinics as per the oncology service. Services/clinics as part
of an emergency room visit or inpatient admission were not included.
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4.3.5

Concomitant Medications
For the control population, 199 prescriptions were written during the course of

radiation. This averages to slightly over 1 ½ prescriptions per week per patient when
assuming the standard 6 week course of radiation for lung cancer (Table 12). Of these,
radiation oncologists wrote 45 prescriptions, roughly 1 prescription every 3 weeks for a
patient. Comparatively, patients assigned the SMDQ had 1.29 prescription per patient per
week with radiation oncologists averaging 1 prescription every other week per patient.
Weekly clinical visits are scheduled with both the medical oncologist to
determine tolerance to chemotherapy and radiation oncologist to determine tolerance to
radiation. However, prior to each radiation treatment, the radiation therapist will ask if
the patient is experiencing pain or if there are any other problems or concerns that need to
be addressed. If an issue is raised, the radiation therapist notifies the treating radiation
oncologist’s clinical nurse or the radiation oncologist. Given the visit ratio (six in
radiation oncology, one in medical oncology), it would be expected medications would
be prescribed principally in radiation oncology. However, the data do not support this
supposition as radiation oncologists were responsible for only 22% of the prescriptions
written for the control cohort.
For the control population, opioids were the most common prescription by the
radiation oncologists during the course of therapy, accounting for 35% of the opioid
prescriptions, ranging from tramadol (0.1 morphine equivalent dose) to Fentanyl (2.4
morphine equivalent dose) (Table 12). Although limited by the small sample size, patients
assigned the SDMCQ had only one opioid prescription written and it was not by a radiation
oncologist. Interestingly, all of the bolus sodium chloride 0.9% intravenous infusions were
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administered by radiation oncologists, even though medical oncology typically maintains
infusion therapy. Despite their use as a treatment for esophagitis, radiation oncologists did
not prescribe proton pump inhibitors (e.g., omeprazole, pantoprazole, lansoprazole) for the
control population but did for patients completing the SDMCQ. Although twenty-one
antimicrobial/antifungal prescriptions were written during the radiation therapy courses for
the control population; only one was written by a radiation oncologist (nystatin for
candidiasis) and none were written for the SDMCQ patients.
Table 12
Concomitant Medications Prescribed During Radiation Course
SDMCQ (4)

Control (20)

RAD

ALL

RAD

ALL

12

31

45

199

Per patient

3

7.75

2.25

9.95

Per week

2

5.17

7.5

33.17

0.5

1.29

0.38

1.66

0

1

11

30

Vicodin

0

1

4

8

oxycodone

0

0

1

7

0

0

3

3

MS Contin

0

0

0

3

tramadol

0

0

2

3

promethazine-codeine

Prescriptions–All
Total

Per patient per week
Opioids
®

fentanyl
®

0

0

1

2

®

Dilaudid

0

0

0

1

morphine

0

0

0

1

Percocet®

0

0

0

1

Carafate

2

3

7

8

NaCl 0.9% 500 mL bolus

4

4

7

7

lidocaine viscous solution

2

2

5

10
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SDMCQ (4)

Control (20)

RAD

ALL

RAD

ALL

lidocaine-prilocaine cream

2

1

4

6

pantoprazole

1

1

0

5

Tylenol®

0

0

2

2

albuterol

0

0

1

3

alteplase

0

0

1

1

benzonatate

0

1

1

1

magic mouthwash

0

0

1

1

meloxicam

0

0

1

1

nystatin

0

0

1

3

ondansetron

0

3

1

17

Silvadene®

0

0

1

1

4.3.6

Adverse Events
The radiation oncology on-treatment visit notes as well as nursing notes were

coded for adverse events using the CTCAE v4.03. The OTV notes captured 292 adverse
events for the control cohort (n=20) and 26 for the four patients who had the SDMCQ
applied through the first PDSA cycle (Table 13). The most common adverse events
identified in the control cohort were fatigue (12%), odynophagia (11.6%), dysphagia
(6.5%) and esophagitis (5.8%). The control group had an average of approximately 14.6
adverse events documented per patient. For the limited SDMCQ sample size, the most
common adverse event was esophagitis (11.5%) followed by odynophagia (7.7%) and
throat pain (7.7%). Patients with the SDMCQ applied had an average of 6.5 adverse
events documented in the OTV.
The most common symptoms and treatment emergent adverse events described by
patients in the qualitative strand were fatigue, dyspnea, nausea & vomiting, dysphagia,
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pain, dermatitis radiation, and esophagitis. These symptoms contributed to the design of
the tool; however, this is not consistent with the OTV documentation. Although fatigue is
the most commonly coded for the control cohort, it is not present in the SDMCQ cohort –
despite the four patients coding for fatigue nine times in the SDMCQ. Nausea &
vomiting was documented approximately 4% of the time in the control cohort and not at
all in the SDMCQ. However, antiemetics / antinausea medication use was marked six
times by the SDMCQ patients and a lack of appetite to nausea four times. It is reasonable
to consider the radiation oncologist did not further capture the nausea or fatigue, as the
SDMCQ answers are imported directly into the OTV note by the radiation oncologist.
However, a lack of independent assessment or comment from the radiation oncologist
within the OTV note suggests an agreement or validation by the radiation oncologist of
the symptoms and their severity.
On-treatment visit notes for both the control cohort and the patients who had
completed the SDMCQ were reviewed (SDMCQ = 22; control = 131). Of the 153 notes
reviewed and coded, the most common physical assessment performed by the radiation
oncologists was for skin (n=148), general appearance (e.g. ‘looks ok,’ ‘in no apparent
distress’; n=87), and breathing (e.g., ‘breathing comfortably on room air’; n=41).
Surprisingly given the patient population’s disease under treatment, a respiratory
examination was completed in only 11.1% of the OTVs.
4.3.7

Shared Decision Making Questionnaire (SDMCQ) Responses
The SDMCQ was applied beginning the first week of June 2021, targeting patients

prescribed long-course radiation therapy for treatment of their lung cancer. All patients had
the SDMCQ applied, regardless of how far along they were in their radiation treatment.
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During the first implementation cycle, 20 questionnaires were completed across four
patients; responses are provided in Appendix N. A brief summary is provided in Table 13.
Fatigue (n=9) and cough (n = 14) were the most common endorsed symptoms
(Table 13), although use of a cough medicine was only acknowledged three times.
Interestingly, these were the symptoms most frequently not captured within the OTV.
The least common symptom was dyspnea, which was acknowledged only 3 times by a
patient and documented once within an OTV. When there was agreement between the
SDMCQ responses and the OTV documentation, it was primarily due to an absence of
symptoms rather than an alignment between the patient and provider.
Table 13
SDMCQ Answers Compared to OTV Documented Adverse Events (AEs)
Documentation Source
Symptom / Adverse Event

SDMCQ

OTV notes

Patient 50
Nausea

1

0

Cough

2

0

Pain

2

0

Fatigue

3

0

Breathing

0

0

Nausea

2

0

Cough

4

1

Pain

3

2

Fatigue

4

0

Breathing

3

1

Patient-51
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Documentation Source
Symptom / Adverse Event

SDMCQ

OTV notes

Patient-52
Nausea

0

0

Cough

1

1

Pain

1

1

Fatigue

1

0

Breathing

0

0

Nausea

0

0

Cough

6

0

Pain

0

0

Fatigue

1

0

Breathing

0

0

Patient-53

Reviewing OTVs for the four patient participants, documentation addresses some
of these discrepancies. For example, patient 53 marked on the SDMCQ that “I may cough
but it doesn't bother me.” The radiation oncologist further documented in the OTV note
of the same date, “…reports an occasional cough…did have a small amount of
hemoptysis yesterday.” The hemoptysis was not reported in the SDMCQ despite a
prompt for, “I am coughing stuff up (snot, sputum, blood).” Similarly, patient 52
answered on the SDMCQ that they were not experiencing chest pain (which also queues
for pain with eating or swallowing), but upon evaluation by the radiation oncologist, the
following is noted, “Has some gastric reflux over the weekend (esophagitis grade 2) that
occurred with the water; improved with sulcrafate [sic] and pantoprazole.”
Esophagitis/gastric reflux should have triggered the SDMCQ response, “My chest hurts,
but only when I try to eat.” This highlights misalignment that is captured in the SDMCQ
response versus the OTV note. It is unknown if this was reconciled in a collaborative
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discussion between the radiation oncologist and the patient, if the patient was educated
about chest pain and symptoms, or if the discrepancy was simply allowed to exist. None
of the OTV reviewed had explicit documentation that differences between the physical
exam and SDMCQ were discussed or a determination of which assessment was
considered final or ‘true’.
4.3.8

Radiation Therapy Compliance
The MOSAIQ® EHR is a ‘verify and treat’ system for radiation oncology,

capturing the dose administered from each radiation beam, the end time of that beam, and
if there are any errors or overrides that have occurred during delivery. Recorded within
the system directly from the linear accelerator, doses, times, and dates are not subject to
human errors, such as transcriptions or omissions. All patients received their prescribed
total dose of radiation and the fractionation strategy (i.e., dose per radiation fraction,
number of fractions per day) remained unchanged (Table 14). Breaks are marked as “B”
in MOSAIQ® whereas a no-show/cancellation (e.g., weather, patient preference) are
Table 14
Radiation Oncology Treatment Compliance
SDMCQ (4)

Control (20)

Prescribed dose completed per patient (average %)

100

100

Treatment breaks per patient (average)

0.75

0.4

0–3

0–3

0.375

0.65

0 - 1.5

0-5

Range
Total break days per patient (average in days)
Range (days)

marked as an “X” by the attending radiation therapists. This enables number of treatment
breaks to be distinguished from a patient’s failure to show for treatment. Unfortunately,
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reasons for radiation breaks are not routinely documented by medical staff in Epic® EHR
or MOSAIQ®. Documented reasons for breaks included infection, anemia requiring blood
transfusion, general malaise, chest pain requiring emergent evaluation, and treatment
emergent altered mental status.
4.3.9

Chemotherapy Compliance
Chemotherapy is also a function of dose over elapsed days. In addition to tumor

histology and stage, considerations for prescription include age, body mass, body surface
area, renal function, and bone marrow function. National guidelines for lung cancer
include multiple therapeutic regimens, including weekly regimens, an every 21-day
regimen, and an every 28-day regimen. To evaluate efficacy across these varied
regimens, a relative dose intensity (RDI) calculation is employed (Chapter 3). This
calculation evaluates how much of a prescribed drug was administered against the ideal
and the number of elapsed days for the treatment against the ideal. Literature indicates
the RDI must be ≥ 85 for efficacious chemotherapeutic treatment. Chemotherapeutic
regimens prescribed as well as the calculated RDI are provided for both the control and
patients assigned the SDMCQ (Table 15). The details provided do not account for
provider-determined modifications to the regimen, such as adjusting for actual creatinine
or using ideal vs. actual body weight.
In total, the 20 control patients experienced 14 breaks in totally 26 weeks. The
most common reason for holds was inadequate blood cell counts (n=10), including
decreased neutrophils, platelets, or generalized pancytopenia. Esophagitis (n=2), febrile
neutropenia (n=1), sepsis (n=1) and anaphylaxis (n=1) also contributed to holds as did the
patient declining further chemotherapy (n=3). Two control patients had their
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chemotherapy regimen changed: one patient was switched from cisplatin / etoposide to
carboplatin / etoposide due to acute kidney injury and another switched form carboplatin
/ paclitaxel to carboplatin / Abraxane® due to paclitaxel-associated anaphylaxis.
Table 15
Chemotherapy Details and Treatment Compliance
SDMCQ (4)

Control (20)

Initial prescribed cytotoxic regimen (count)
cisplatin / etoposide†

1

2

carboplatin / vinorelbine

0

1

carboplatin / paclitaxel

3

12

carboplatin / etoposide

0

4

cisplatin / pemetrexed

0

1

7 calendar days (weekly)

3

13

21 calendar days

1

7

91.9

80.8

70.5 – 100

41.1 - 100

1

10

Average holds / patient

0.5

0.7

Average weeks / patient

0.5

1.3

1

1.9

⁕

Cycle length

Relative Dose Intensity
Average
Range
Number < 85
Holds (i.e., chemotherapy omitted for 7 days)

Average weeks / hold

Although sample size is small, patients who had the SDMCQ applied had a higher
level of chemotherapy compliance, with only one of the four having a calculated relative
dose intensity of less than 85. The reason for the hold contributing to the low RDI was a
localized infection requiring multiple courses of antibiotics. Incidentally, this same
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infection triggered an emergency room visit; presumably, this could have been addressed
by an outpatient visit.
4.3.10 Summary and Key Points
Initial findings suggest the collaborative decision aid tool does not add time to the
on-treatment visit, with the average completion time of the SDMCQ averaging just over
six minutes and the OTV averaging 30 minutes for visits utilizing SDMCQ whereas
control visits average 29 minutes. The initial implementation of the SDMCQ and the
collaborative decision aid tool, as well as review of the on-treatment notes highlights that
these documents do not align well with the adverse events recalled by patients and
radiation oncologists. The on-treatment visit physical exam principally notes skin and
OTV notes document fatigue, odynophagia, dysphagia, esophagitis, cough, and dermatitis
radiation as the treatment emergent events most frequently documented. Odynophagia,
dysphagia, and esophagitis are the common sources of pain for patients undergoing
radiation therapy for lung cancer and are well-established sequelae. However, roughly
50% of the patients presented to the ER for potentially preventable events as determined
by CMS. Lastly, 50% of the control patients did not achieve the relative dose intensity
literature has associated with improved treatment outcomes, with some of the holds due
to esophagitis and patient declining further treatment. This provides an area of
improvement for shared decision making and collaborative communication to help reduce
the side effects of treatment and increase treatment compliance.
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4.4

Mixed Methods Results
This exploratory sequential study sought to answer the question:
How does the impact of the collaborative decision-aid tool inform
recommendations for future designs and implementation ?

by designing a collaborative decision aid tool for patients undergoing radiation for lung
cancer, implementing it within an academic radiation oncology center, assessing its
impact, and then integrating these results. Considerations and integrations are provided
(Table 16) with emphasis on barriers, facilitators, practice considerations, stakeholders,
and insights from the literature.
4.4.1

Adverse Event Comparisons
The three most common adverse events as identified through the semi-structured

interviews with patient participants, the literature, the on-treatment visit notes, and the
SDMCQ were compared (Table 16). This mixed analysis explores adverse events that
were recalled during the patient interviews versus adverse events that were
contemporaneously reported (transcript vs. SDMCQ), the adverse events physicians
document compared to their concerns or the patient’s SDMCQ responses, and the patient
educational materials citing the top side effects of combined chemotherapy and radiation
for lung cancer. All adverse events listed in the transcripts and on-treatment notes are on
the SDMCQ except dysphagia; however, odynophagia, heartburn, and esophagitis are
grouped with chest pain. It is unclear if patients are identifying ‘chest pain’ with the
esophageal pain. Further use of the SDMCQ is necessary before considering an
adjustment to align with CMS’ potentially avoidable adverse events that could trigger
emergency room visits.
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Table 16
Top Three Adverse Events as Identified From Interview Transcripts, On-Treatment Visit
Notes, Patient-Education Material, and Centers for Medicare & Medicaid Services.
Adverse Event
Source

1

2

3

Patient transcripts

Fatigue

N / V⁕

Dyspnea

Radiation oncologist transcripts

Weight

Breathing

Esophagitis

OTV notes – controls

Fatigue

Odynophagia

Dysphagia

OTV notes – cases

Esophagitis

Heartburn

Odynophagia

Fatigue

Cough

Chest pain

Odynophagia

Fatigue

Erythema

Fatigue

Pain

SDMCQ responses
Patient education material

†

CMS potentially avoidable
†

N / V⁕

Patient education material provided by The American Society for Radiation

Oncology (ASTRO) (2020)

⁕N / V: nausea & vomiting
4.4.2

Time Expended During On-Treatment Visit and Adverse Events
Literature identifies time expended for patient reported outcome measure

implementation as well as shared decision making to be a significant barrier. A
contributing factor to shared decision making is the complex nature of patients with
multiple comorbidities. The mixed analysis explored if time expended for an ontreatment visit was impacted by the number of adverse events as recorded by the ontreatment visit notes (Table 17). The SDMCQ is not included in the analysis, only
adverse events recorded by the radiation oncologist in their on-treatment visit note.
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Table 17
On-Treatment Visit Time and SDMCQ Completion Time Compared to Number of
Adverse Events
On-Treatment Visit
Adverse Events
count

mean ± s.d.

Time† (mean ± s.d.)

Control cohort, overall n=20

301

15 ± 7

30 ± 15

SDMCQ cohort, overall n=4

31

8 ± 4.3

30 ± 16

48

8±2

24 ± 10

10 < AEs ≤ 20

151

15.1± 3.1

32 ± 15

> 20 AEs

102

25.5± 5.4

36 ± 17

≤ 30 minutes / OTV

121

12± 6.2

25 ± 10

> 30 minutes / OTV

180

19 ± 7

36 ± 16

≤ 10 AEs

17

5.7 ± 1.2

24 ± 10

10 < AEs ≤ 20

14

N/A

47 ± 18

≤ 30 minutes / OTV

17

5.7 ± 1.2

24 ± 10

> 30 minutes / OTV

14

N/A

47 ± 18

Control cohort
≤ 10 AEs

SDMCQ cohort

†

Measured in minutes

4.4.3

Unscheduled Visits and Adverse Events Comparison
The Centers for Medicare and Medicaid identified seven causes for emergency

room visits as potentially avoidable: nausea, vomiting, diarrhea, dehydration, anemia,
febrile neutropenia, and pain. Thus, emergency room visits and diagnoses were compared
against the number of recorded adverse events in OTV notes as well as in the interview
transcriptions (Table 18). The table reveals that the CMS adverse events have been
captured in OTV notes and also in the diagnosis for the emergency room visit
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(i.e., nausea, pain, anemia). These adverse events are manageable by radiation oncologists
and, as such, should be reviewed against the likelihood of a need for urgent care.
Table 18
Frequency of CMS’ Potentially Preventable Adverse Events as Captured Through
Transcriptions, On-treatment Visit Notes, and Emergency Room Visits
Data Source†
Adverse Event

Interviews

Nausea

‡

`C

S

C

S

14

7

0

1

0

Vomiting

8

4

0

0

0

Diarrhea

3

5

1

0

0

Dehydration

2

1

0

0

0

Anemia

0

3

0

2

0

Febrile neutropenia

0

2

1

0

1

§

9

4

1

Pain
†

ER‡

OTV

Potentially preventable

14

⁕

69

Interviews: those completed during qualitative strand; OTV: On-Treatment Visit;
ER: Emergency Room; C: control cohort; S: SDMCQ cohort
Includes ER-to-admission visits

⁕ Includes esophagitis, odynophagia, throat pain, and unspecified pain
§

Includes abdominal pain, chest pain, back pain, hip pain, esophagitis, odynophagia,
and throat pain.

4.4.4

Adverse Events and Concomitant Medications
Adverse events identified by radiation oncologists can drive prescriptions for

concomitant medications, including opioid prescriptions as well as antimicrobials and
antifungals. The collaborative decision-aid tool could heighten awareness to adverse
events, initiate earlier medical interventions, reduce emergency room visits and possibly
reduce admissions. Adverse events and the associated concomitant medications
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Figure 17
Incidence of Adverse Events Contrasted to Prescriptions Written by Radiation
Oncologists During Long Course Radiation Therapy for Lung Cancer

Adverse Events (count)

70
60
50
40
30
20
10
0

prescriptions
Control

SDMCQ

Prescriptions (count)

20
18
16
14
12
10
8
6
4
2
0

80

adverse events
Control
SDMCQ

Note. Prescriptions are those written by radiation oncologist during the long-course
radiation therapy treatment.
prescribed in an outpatient basis were explored against the control cohort and patients
who had the SDMCQ applied (SDMCQ cohort) (Figure 17). Due to the limited sample
size of the SDMCQ, correlations and inferences cannot be drawn. The graph does not
reflect drug compliance or the number of refills provided for each prescription.
4.4.5

Compliance and Adverse Events
Adverse events can create delays or dose reductions in chemotherapy and radiation

therapy, reduce the overall efficacy of therapy and resulting in decreased survival. Adverse
events were abstracted from on-treatment visit notes, quantified, and plotted against the
relative dose intensity administered during the chemo-radiation therapy (Figure 18).
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Figure 18
Relative Dose Intensity for Chemotherapy compared to the Total of Adverse Events
35
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Note. Adverse events reported as total documented in on-treatment notes. Each data point
represents a single patient.
4.4.6

Format of the Collaborative Decision-Aid and Adverse Events
The collaborative decision-aid tool was formatted to review the most common or

problematic adverse events, whether they are related to treatment, symptoms of the
cancer, or other underlying comorbidities. Three sources of information were utilized
when considering format and adverse event inclusion: interview transcriptions (patients
and radiation oncologists), literature regarding format, and the three selected sample
patient reported outcome measure surveys (PROMIS®, PRO-CTCAE™, QLQ-C30)
(Table 19). The recall period was a concern for patients and context/granularity was
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positive, as was a written record and paper tool. The format needed to adapt for patients
who were slow readers.
Table 19
Format Consideration using Adverse Event Prompts for the Collaborative Decision-Aid
Tool as Identified by Interviews, Literature, and Current Patient Reported Outcome
Measure Tools
Formatting for Time
The seven-day recollection window confused patients when reviewing
sample PROM questions. The radiation oncologists did not find a strict
QUAL

window meaningful – instead wanting to know what had happened since
the last radiation oncologist visit. Codes: timeframe – negative, question
timeframe, timeframe-interruption, timeframe – important, and SDM:
usefulness.
90.9% of the commonly used instruments in oncology utilize a seven

QUANT

day recall period. The Symptom Distress Scale does not have a defined
recall period.
Because radiation is not delivered on holidays or weekends, and the
number of outpatient physicians’ visits the patients, a strict window does
not meet needs pragmatically. Patients are concerned they must omit

MIXED

problems that were of significance to them whereas radiation oncologists
expressed wanting to know current concerns rather than resolved events
from a week prior. The format of the questionnaire was adapted to
reflect the milestone of “last radiation oncology doctor visit.”
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Table 19 (cont’d)
Format Consideration using Adverse Event Prompts for the Collaborative Decision-Aid
Tool as Identified by Interviews, Literature, and Current Patient Reported Outcome
Measure Tools

Formatting for Severity
Patients described adverse events as being more severe than they had a
QUAL

frame of reference for, particularly heartburn and fatigue. The severity
of the events was such that patients no longer had routine daily
activities. Codes: no normal, new normal, granularity, and no frustration.
Quantizing the on-treatment visit notes revealed the most commonly
documented adverse events to be fatigue (49%), odynophagia (43%),
cough (26%), esophagitis (24%), and dysphagia (24%). The current

QUANT

instruments queue for severity without context: PRO-CTCAE™ has
‘very severe,’ for the maximum score (i.e. four points), where PROMIS®
has ‘much difficulty,’ for the maximum (3 points), and QLQ-C30 has
‘very much’ (four points).
Without context for severity, a patient may prematurely provide the
maximum quantitative score when they have not yet reached the most
difficult part of their cancer treatment. This was echoed by radiation
oncologists, who were aware a patient’s only sphere of reference is their
personal experience, compared to the medical training of the physician.

MIXED

For this reason, numeric scales were not considered helpful by
physicians, as there is no true gold standard for the severity scales.
Providing a contextual answer (rather than a numeric one) serves two
purposes: providing commonly understood benchmarks as well as
preparing patients for the severity of the side effects they will
experience.
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Table 19 (cont’d)
Format Consideration using Adverse Event Prompts for the Collaborative Decision-Aid
Tool as Identified by Interviews, Literature, and Current Patient Reported Outcome
Measure Tools
Formatting for Function
Interviews revealed patients valued their physicians’ medical knowledge
as well as preferred academic knowledge compared to publicly available
QUAL

information. Identified barriers included feeling as being the only one to
receive the information, a need for a gatekeeper, and taking the time to
read during the hecticness of a clinic visit. Codes: slow reader, reading,
academic information, written record, intelligence, and health literacy.
A participant who identified as a slow reader took 52 seconds to read a
PRO-CTCAE™ question for fatigue, one minute and 37 seconds

QUANT

answering three PROMIS questions for fatigue, and one minute and 41
seconds to answer four QLQ-C30 questions regarding fatigue. This
extrapolates to just over 12 and a half minutes for this participant to
complete the QLQ-C30.
Literature recommends a questionnaire be no more than 20 minutes time
investment at baseline and then 10 to 15 minutes for subsequent
assessments. As suggested by observation during the qualitative
interviews, a self-described slow readers who are medically literate can

MIXED

take up to 32 seconds per question prompt, restricting the number of
questions to as few as 28 questions. With caregiver constraints due to the
pandemic, as well as tight staffing requirements within the clinic, at this
time the more reasonable solution is to create a short, pragmatic, and
focused collaborative decision-aid tool that will addresses clinical needs
rather than focusing on maintaining validation.
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4.4.7

Format and Unscheduled Visits
The format of the instrument encompasses the format of the questionnaire (i.e.

SDMCQ) on the MyChart® application or tablet and also its printout which is considered
the collaborative decision-aid tool). Paper was requested by patients to minimize on
repeated communication due to their dyspnea and also to provide the same discrete
information across providers (codes usefulness, paper: positive, paper: graphics, repeated
communication, and trend over time). As stated by patient participant 26, “[Paper] would
be helpful for me because they could have referenced this stuff. Some doctors take good
notes and other doctors don’t. This could have been a reference for all the other doctors
this would be helpful.”
However, a paper printout is a significant barrier to using the tool for an
unscheduled visit: someone having to log in to Epic®, print off the collaborative decision
aid tool, provide it to the radiation oncologist, and all without slowing down a very active
clinic for a patient who does not have a scheduled appointment. Additional
considerations from the implementation committee were who would identify the patient
needed a questionnaire, when would it be completed (waiting room or exam room), and
how would the radiation oncologist be notified. Typical on-treatment visits are scheduled
in 15 minute slots with providers only allowed two to three exam rooms to run their
clinic. This does not seem to be an issue until reviewing the expended time per OTV:
an average of 30 minutes per visit with a standard deviation of 15 minutes. If a radiation
oncologist has only two exam rooms and is expected to see four patients, the time within
the exam room cannot be more than 30 minutes. An addition of a unscheduled visit or a
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‘special complaint,’ staffed by the attending nurse clinician or resident can have
significant ramifications that impact the day’s entire clinical workflow.
Paper format for the tool was considered a priority for routine on-treatment visits
but was not deemed key for an unscheduled medical visit. Hybrid models, such as the
SDMCQ only or having a smart-text for the physicians to use to query directly, can be
reviewed as uptake increases.
4.4.8

Adverse Events and Implementation of the Collaborative Decision-Aid Tool
The collaborative decision-aid tool was formatted in Microsoft Word to fit on a

single sheet of paper focusing on five symptoms identified as troublesome or medically
important (i.e. nausea/vomiting, fatigue, dyspnea, cough, chest pain). Weight was also
included from the day’s vital signs. Additionally, a mockup of the desired printed output
was created. This was provided to the Epic® software group to implement the
questionnaire’s build and required four months for implementation. This was due to
regulatory and compliance confirmation in addition to the foundational programming.
Additional formatting conditions became apparently: swipe from page to page or scroll,
check-boxes or press-buttons, choose only one vs. choose all that apply, and selecting the
order of the responses. There was not a test environment for the SDMCQ so it was unable
to be seen by the researchers.
Once initiated, the SDMCQ responses were reviewed weekly for issues, and one
became readily apparent. Radiation oncologists had requested a way to know if a patient
felt the same as prior to receiving radiation. To address this, both the fatigue and
dyspneal prompts included, “I feel the same as before I started radiation therapy.”
The thought was patients would understand this should be selected only after beginning
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radiation therapy – however, for the first four patients to have the baseline assessed (i.e.,
0 fractions or fraction 1), the prompt for dyspneal was answered I feel the same as before
I started radiation therapy despite it being a baseline assessment. For this reason, this
answer was removed and contextual detail provided.
Patient participants had positive responses with MyChart® and were computer
literate (codes: proactive, single-line access, new information, MyChart: yes, safety net,
and gatekeeper). This is significant because the SDMCQ can also be accessed through
MyChart® up to one week prior to the completion date; the specific window for completion
(i.e., 1 day prior, 2 days prior) is set when the SDMCQ is assigned. Ideally, the SDMCQ
should be completed when an outpatient visit is scheduled due to a welfare concern for the
patient if they complete a question indicating a need for immediate medical intervention.
The minimum completion window possible in Epic® is one day; thus, it is possible a patient
couple complete the questionnaire the night before. That has not yet happened.
When reviewing the adverse events noted by the radiation oncologists and
comparing them to the on-treatment notes, there was a discrepancy. Focusing on the
adverse events of interest to the Centers for Medicare and Medicaid Services, nausea was
reported by three times but not mentioned by the physician and pain was captured only
50% of the time (Table 14). Fatigue was not captured by the physicians but was reported
by patients nine times, including the most severe metric I have not been able to watch a
TV show without falling asleep. This aligns with the literature which indicates installation
of the instrument is only part of the process and that active implementation of subjective,
assessment, and plan must be primed and maintained to increase shared decision making
and having the patient’s voice heard.
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4.4.9

Implementation and Expended Time
A concern expressed both in the literature and throughout the work was the

impact on the clinic as a function of expended time. The average on-treatment visit times
are provided in Table 10. Taking this a step further, the time spent by the physician with
the patient was compared to how long the patient was present in the clinic (Figure 19).
Times are estimates from workflow times logged into Epic®. Time spent with patient by
physician was calculated by subtracting the “physician out,” time from “waiting for
Figure 19
Estimated Time Spent by Radiation Oncologist with Patient During On-Treatment Visit
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Note. Represented on-treatment visits are those when the collaborative decision-aid tool
was utilized. Data represent 18 on-treatment visits that had both the time spent with
physician as well as time spent from check in to when the physician left the exam room.
Dashed line represents average time for time spent by physician in room for the control
cohort (17 minutes). Solid line represents control cohort average time from check-in (29
minutes). Average times for SDMCQ visits are 14.5 minutes with the physician and 28.5
minutes from check-in to physician exit.
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physician.” Time spent until physician exit was calculated by subtracting “waiting for
physician,” from “check in time.” Using the SDMCQ cohort, data were pulled for visits
where both the ‘time spent by the physician,’ and ‘time from check in to physician exit,’
were available. This display explores the impact of the SDMCQ on time spent with
physician and time spent in clinic, as best can be estimated from Epic®. Due to limited
sample sizes, an inference cannot be made but a trend is not observed.
4.4.10 Implementation and Unscheduled Visits
Implementation of the collaborative decision-aid tool should help reduce the
number of after-hours urgent care visits or emergency room visits if uptake is maintained.
Two problems with unscheduled visits could be addressed with the SDMCQ and the
resultant decision-aid tool and are analyzed briefly using a mixed strategy (Table 20, next
page).
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Table 20
Implementing Unplanned Outpatient Visits into the Collaborative Decision-Aid Workflow
Continuing the Continuity of Care
Patients liked feeling as part of the team but expressed frustrations and
doubt when providers failed to communicate between each other or
provided them conflicting information. Radiation oncologists note the
key to providing quality care for a patient is as much about the patient’s
personality as it is about the practice of medicine. The collaborative
QUAL

decision-aid tool was considered key to provide consistent information
across multiple providers, including on-call and emergency room staff
(codes: barriers to communication, repeated efforts to contact, medicine
by committee, information traffic, and familiarity with provider). Codes:
team, familiarity with provider, provider-to-patient communication, and
characteristics and context.
Radiation oncology is one of three oncology outpatient services caring
for patients with lung cancer. A review of the baseline cohort suggests

QUANT

that on average, patients with lung cancer have 44 notes written during
the radiation treatment; of these, only 36% are from radiation oncology
(~ 15.5 notes / patient).
In addition to these notes directly in Epic®, UIHC participates in
CareEverywhere® and scans in any outside medical records into the
‘Media’ tab as a PDF. This, coupled with the UIHC policy not
mandating notes to be finalizing for 10 business days, leads to a delay in
information and a loss of signal regarding key events. Patients sought to

MIXED

resolve this issue by having a paper communication-aid tool. Radiation
oncologists would like to see the patient reported outcome measures as a
centralized screen or report that they can review, similar to the Epic®
snapshot screen. Patient reported outcome measures as a trend over time
will assist in decreasing a knowledge gap to medical staff unfamiliar
with the patient. A centralized location would be best for these metrics.
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Table 20 (cont’d)
Implementing Unplanned Outpatient Visits into the Collaborative Decision-Aid Workflow
Toxicities Over Time and Iowa Stoicism
Patients acknowledged they were not as honest as they should have
been, contributing to emergency room visits and unplanned outpatient
visits. Radiation oncologists – particularly those who had practiced
QUAL

outside of Iowa – termed this the Iowa Stoicism, possibly associated
with the agrarian culture with over 90% of the state’s land dedicated to
farming. Patients described this as “toughing it out,” and interestingly
families also did not take action. Codes: treatment, self-reliance, selfcare, choice, symptoms, and trust in provider
Toxicity over Time (ToxT) is an adverse event evaluation method that is
unique to treatments where the patient is evaluated daily or is willing to
self-report in a daily log. The concept is the number of days a patient
experiences not only the adverse event but also the severity level for

QUANT

those days. Thus, ToxT provides insight not only into the maximum
severity of an event experienced, but also how long the patient can
expect to experience the adverse event and if is expected to get worse
and – if so – when. Converting the text answers to severity grades (i.e.
quantizing the data) provides a bridge to radiation oncologists, who are
trained in the NCI’s severity scoring system.
Failing to promptly report adverse events not only jeopardizes a
patient’s health, it also negatively impacts future patients as they will not
know what to expect regarding treatment and its side effects. With the

MIXED

ever-increasing focus on the patient’s voice, it is not simply a function of
listening, but a function of encouraging patients to speak. Consistent
with the literature, ‘toughing it out’ and stoicism remind us patients may
not want to be labelled as difficult and may seek to please providers
rather than be open about their problems and concerns.
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CHAPTER 5

5
5.1

DISCUSSION
Introduction
This primary objective of this research was to explore the creation and initial

implementation of a collaborative decision-aid tool by addressing the following
questions:
1. How do the stakeholders, practice considerations, and evidence base inform the ideal
design and implementation of a collaborative decision-aid tool?
2. What is the impact of the collaborative decision-aid on the medical management of
patients actively undergoing radiation treatment for lung cancer?
3. How does the impact of the collaborative decision-aid tool inform recommendations
for future designs and implementation ?
These questions will be addressed through synthesis of qualitative, quantitative,
and mixed results as well as from the literature base. The contribution to the knowledge
base is implementation of a hybrid collaborative decision-aid utilizing a pragmatic
quality improve process. Literature searches suggest a clinical implementation process is
novel for a collaborative decision-aid utilizing patient reported outcome measures; the
current literature base has evaluated applying and evaluating decision aids through the
traditional clinical trial methodology, assigning dedicated research staff and research
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procedures to a clinical process. Regimented research interventions provide internal
validity but may be negatively impacting generalizability and fidelity. Implementing the
collaborative decision-aid tool as a clinical initiative enables real world findings–not only
for outcomes of interest but also for future implementation strategies.
5.2
5.2.1

Major Findings of the Dissertation
Ideal Design and Implementation
Shared decision making as well as the use of patient reported outcomes within

oncology lags behind other medical disciplines. Initial work in oncology research utilized
instruments focused on symptoms and their impact on quality-of-life, such as the EORTC
QLQ-C30 (Aaronson et al., 1993). Although validated, there was a knowledge gap
between interpretation of the results and clinical applicability; these scores were also not
used to support drug research by the U.S. FDA (Boyce & Browne, 2013; Snyder et al.,
2017). In 2008, initial research was funded by the National Cancer Institute to symptoms
during chemotherapy using patient self-reporting (National Institutes of Health, 2021).
This was the seed of development for NCI’s current PRO-CTCAE™ instrument, which is
considered the patient version of the Common Terminology Criteria for Adverse Events
(CTCAE), which provides matrices for physicians to harmonize adverse event terms as
well as their severity (Cancer Therapy Evaluation Program (CTEP), 2017). The PROCTCAE™, which is freely available for download, has been validated for use in multiple
languages and has been used to explore the patient’s assessment of events compared to
healthcare providers (Atkinson, Hay, et al., 2018; Atkinson, Reeve, et al., 2018;
Badalucco & Reed, 2011; Basch et al., 2012; Basch et al., 2015; Basch, Pugh, et al.,
2017; Basch et al., 2014; Bennett, Dueck, et al., 2016; Bennett, Reeve, et al., 2016;
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Bruner et al., 2011; Dueck et al., 2015; Falchook et al., 2016; Gilbert et al., 2015; Hay et
al., 2014; Kim et al., 2018; Kluetz et al., 2016; Kluetz, Kanapuru, et al., 2018; Mendoza
et al., 2017; National cancer Institute (NCI), 2016d; Wood et al., 2015). It is enticing to
consider a tool that has a patient component and a provider component, yielding insight
into the assessments of treatment emergent adverse events.
5.2.1.1 Initial Design
Disappointingly, sample questions from the PRO-CTCAE™ were ranked lowest
by patient participants when considering questions for the collaborative decision-aid tool.
Patients like context and details, neither of which was provided by PRO-CTCAE™. In
reflection, this highlighted a gap between the PRO-CTCAE™ and the physician’s version
CTCAE. The CTCAE has qualifying descriptors, such as moderate fatigue being a
fatigue not relieved by rest or that interferes with instrumental activities of daily life.
However, the PRO-CTCAE™ does not provide this clarification (Chapter 1, Figure 3), as
it prompts only for mild, moderate, severe, or very severe without any guiding context.
Although two radiation oncologists preferred the simplicity and directness of the PROCTCAE™, the remaining four did not like it. The prompts, open to interpretation by each
patient, requires the physician to “know” the patient or be familiar with their personality,
causing problems for new consults or secondary providers (e.g., covering physicians,
emergency room physicians, hospitalists). Radiation oncologists also disliked numeric
rating scales for the same reason. The importance of the need to know a patient’s
personality was heightened with the emergence of the pandemic, which ended the
UIHC’s long standing tradition of allowing all caregivers and family to attend each visit.
Patients were now alone and radiation oncologists quickly realized the extent that they
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relied on other individuals as secondary sources of information. The new normal requires
radiation oncologists to hone their interpersonal communication skills and has created a
desire to utilize additional information sources available to them to offset the absence of
secondary informants. To address these concerns, the tool utilized standard quality-of-life
prompts as the responses to questions (Chapter 4, section 4.2.3).
With the design of the tool sketched, the question turned to what symptoms were
of concern to the patient or radiation oncologist. The initial goal was to create decisionaid instruments that would be individualized for each patient, addressing their unique
concerns or complaints. However, during interviews patients were not able to voice
concerns they had during initial diagnosis and treatment – other than survival. The
average age of the interviewees was 67, members of a generation who are doctor-trusting
and tend to be less autonomous (Kahana et al., 2018; Wrede-Sach et al., 2013). Without
individual guidance, the decision was made to use the symptoms commonly mentioned
during patient-participant interviews and noted as concerning to radiation oncologists. In
future years, this may need to be revisited as the younger generations mature and
experience lung cancer. These younger, technically-savvy generations may continue to be
self-advocates and autonomous (Kilbride & Joffe, 2018). If so, these future generations
may be able to describe their concerns and the symptoms they wish to monitor.
Lastly, despite the population being older, the patient participants all endorsed use
of technology and had favorable opinions of its use in healthcare. This was somewhat
surprising given the average age and the deference to the radiation oncologists as a key
source of information. The patients requested a paper printout as the collaborative
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decision-aid as a source of harmonized information between providers as well as to take
home as a reference document for caregivers and themselves.
5.2.1.2 Implementation
The paper print-out request served as a focus for implementation within the
department and was the first step in shared decision-making between the radiation
oncologist and the patients. The radiation oncologists’ clinics were hectic, typically
overscheduled, and the physicians were concerned about slowing the clinic down. This is
consistent with the literature, which lists time per clinic visit as a common barrier to SDM
(Martin et al., 2019; Paladino et al., 2019). Use of a paper printout that could only be
printed after the patient’s arrival for that day’s clinical visit would unavoidably alter
clinical flow. The first challenge of the radiation oncologists’ commitment to their patients
occurred when planning the tool’s implementation began at the first committee meeting.
The departmental administrator expressed confusion as to why a patient would
want paper when they themselves had just completed the questionnaire. One of the
radiation oncologists was confused as to why anyone would want paper when electronic
is easier. Yet both of these concerns were resolved with the “give them a pickle,”
customer service philosophy taught within the department, wherein it is better to provide
a pickle at no cost than to lose the customer’s business (Farrell, n.d.). This customer
focused training was required within the department and is honed in monthly meetings.
Similarly, changes in workflow management are not new to the department – for
example, in 2005, the department became the first truly paperless radiation oncology
clinic in the nation. These two examples highlight the culture of the department, which
significantly impacted the collaborative decision-aid tool’s implementation by reinforcing
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a “can-do,” attitude as well as the need to put patients first. Rather than the discomfort
adapting to a new shift in workflow would cause, the implementation committee focused
on the potential benefit to patients’ outcomes.
As a result of this culture, and despite a delay in an Epic® generated printed report,
the radiation oncologists stated they were willing to print out the tool themselves, if
required, to meet the patients’ request. With this decision, the printed report was prioritized
and a manual report and workflow created. This example illustrates the significant impact
of culture and practice considerations on implementation. The healthcare culture, described
as a culture of “do, do, do,” by Reed and colleagues (2016) is a barrier to thoughtful
implementation. Healthcare’s pervasive pressures of resolving issues quickly and not
engaging in review or reflection, can lead to the initiative not being performed as originally
intended or designed (Reed & Card, 2016).
In addition to the department’s culture serving as a strong implementation
facilitator, the academic setting also served as a facilitator. In the academic culture of
publish or perish, the radiation oncologists were keenly aware future publications would
require patient reported outcome measures. The radiation oncologists identified routine
collection of PROM as an investiture for stronger chart review research and better
academic success. Additionally, as physician researchers translating bench to bedside,
they were also aware of FDA’s requirement that clinical trials (including investigatorinitiated clinical trials) include patient reported outcome measures in the trial design
(U.S. Food and Drug Administration (FDA), 2020a, 2020d). As professors serve as the
superiors in the American academic paradigm, if a new resource is identified by faculty
as necessary for continued academic prowess, support staff accommodate the request.
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Key Points. Patients and radiation oncologists wanted an easily understandable decisionaid that provided contextual details. Strong facilitators were (1) the department’s culture
(2) the department actively engages when faced with a paradigm shift, and (3) PROM
data were deemed significant by both FDA and NIH. As an academic medical center,
PROM data are an important currency for publications to support tenure as well as
research funding research funding. The most significant barrier is found throughout the
literature and was repeated by radiation oncologists: do not slow down clinic. This did not
prevent implementation but did expended clinical visit time as a critical metric to
maintain uptake. Identified local barriers included the downtime for designing a software
build as well as approval through hospital regulatory / legal and not being able to test the
software before it was put into production. A mild barrier was encountered with faculty
and staff confusing patient satisfaction scores and PROM; however, this did not
negatively impact implementation planning.
Despite planning, there were difficulties during implementation (Chapter 4). The
initial implementation design focused on three pivot points: assigning the questionnaire
(i.e., SDMCQ), distributing the tablet, and printing the decision-aid tool. Assigning the
questionnaire was a three-step process requiring the radiation oncologist to notify the
imaging specialist who then notified the front desk/scheduling. The radiation therapist on
the committee volunteered to train all of the radiation therapists about this new process
and workflow and completed it the next day at their team meeting. The front desk was
informed about the new process via an email workflow distribution; due to the gap
between the email and initiation, this was forgotten and resulted in poor start-up and
frustration (Chapter 4). Unlike radiation therapists, who have a group lunch break for an

214
hour, the front desk must be staffed at all times, removing any chance for a harmonized
group training. A refresher email should have been distributed when the decision-aid tool
was initiated. The third process – printing the tool – was managed by the student
researcher as a bridge until the Epic® build is completed. This requires monitoring check
in times, questionnaire answers, and then paging the radiation oncologist to notify of the
printed tool. Similarly, this is supported by the department with the end-goal of improved
patient outcomes and benefit to the clinic (e.g., reduced add-on visits, reduced resource
usage). This departmental culture and investment are seen as a significant facilitator to
implementation which is most likely not realized at other academic institutions
5.2.2

Impact on Medical Management
The goal of the collaborative decision-aid is to have a positive impact on the

patient, hopefully both in quality-of-life as well as in medical outcomes. From an
operational standpoint, attention turns to resource use and costs for services. Management
in an outpatient clinic is preferable to an emergency room visit not only for cost
considerations but for an immunocompromised patient’s exposure to hospital acquired
pathogens. Of interest, CMS has identified treatment emergent adverse events considered
to be potentially avoidable; this list includes nausea, vomiting, diarrhea, dehydration, and
pain (Centers for Medicare & Medicaid Services, 2021). Of these, nausea/vomiting and
pain were identified by patients, radiation oncologists, on-treatment documentation, and
patient educational materials as common side effects of therapy for lung cancer. These
symptoms are manageable in an outpatient radiation oncology clinic and provide a target
metric that can be compared to state and federal claims data through CMS claims.
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Although this work is too premature to begin to draw conclusions (Chapter 4), CMS claims
data provides a metric for future review as well as information specific to the region.
Of interest to the radiation oncologists was time expended per on-treatment visit
to determine what impact the decision aid tool had on their time in clinic and patient
throughput. Despite the small sample size, this was easier to assess because of the
number of clinic visits completed by each patient. When reviewing these data, it takes
less than 6 minutes for a patient to complete the questionnaire and the clinic visit time
(from check-in to physician exit) are comparable. A trend is apparent of having the
patient starting the questionnaire but then taken back to have vital signs assessed and
taken to the clinic exam room while the questionnaire is incomplete. This could
contribute to an artificial elevation of questionnaire completion times.
Although the radiation oncologists were focused on questionnaire completion
times delaying clinic, a review of the data indicated it was the workflow of the
questionnaire causing delays. Factors contributing to delays included failing to distribute
the tablet timely, patients taken to the exam room while the questionnaire was
incomplete, and staff declining to participate in the tablet distribution. This underscores
the need to increase buy-in and planning for implementation but also stresses the need to
refrain from conclusions regarding the cause of a concern. When the completion times
and patterns of time (i.e., check in time, completion time, rooming time) were shared
with the radiation oncologists, their attention turned from the tool delaying their clinic to
staff needing further training and alignment.
An incidental yet significant finding was identifying that physicians will not
request corrections or revisions to a colleague’s note. This possibility was not revealed in
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the literature review and was unanticipated. If a radiation oncologist is covering for a
treating radiation oncologist’s absence and a mistake is made in the physical exam, the
assessment, or the plan, physicians would prefer to call the patient directly to discuss or
request a return visit as evidenced by this interchange:
Query: If you had concerns about the notes at all would you have addressed them
at all?
Physician: No…calling a note out with a colleague is not done.
Query: Is it fair to say that a faculty member may be willing to allow a gap in a
documented clinical note rather than…
Physician: …cause conflict? Yes.
Query: So there could be gaps in documentation that could lead to patient
frustration…because this is not addressed.
Physician: Yes.
This discussion aligned with patient participant 26 who had stated, “Some doctors take
good notes and other doctors don’t. This could have been a reference for all the other
doctors this would be helpful.” Three other physicians concurred with the statement of
not asking for note revisions or corrections, describing that it was akin to a breach of
etiquette that could result in hard feelings, difficult clinics, and perhaps even impacting
livelihood if it results in fewer referrals. Physicians providing coverage for absences rely
on notes to be complete and accurate; when covering for an unfamiliar patient, these
notes can serve as lifelines. In absence of robust notes, radiation oncologists would seek
out resident physicians or the nurse clinician to provide background on the patient.
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This finding provided a previously unconsidered opportunity for the collaborative
decision-aid tool to further impact medical management: an ability to provide accurate
information directly from the patient (i.e., SDMCQ) and for the treating radiation
oncologist to provide direct medical information to the patient on the collaborative
decision aid tool. As a paper tool, the patient can then retain it to review for direction on
what to watch for, instructions on what to do for an adverse event, and who to contact,
including names and clinics. Unfortunately, because errors in notes are not routinely
identified and, most likely, resultant harm is not catalogued it is difficult to compare the
impact of the collaborative decision aid on adverse events stemming from outpatient visit
errata. It is hoped that by reducing frustration the quality-of-life for patients would be
improved and the continuity of care between providers would also be better served.
5.2.3

Recommendations for Future Tool Designs and Further Implementation
In contrast to the literature presented in Chapter 2, which provided insight into the

patients’ descriptions of intolerable side effects and the risk-to-benefit ratios of treatment
(Rocque et al., 2019), this work also explored the perspectives of the radiation
oncologists. Both patients and physicians identified lack of detail as a significant
concern; context would provide a translation between provider and patient regarding the
adverse event’s severity and if it is impact on their daily life. This translation serves as
the first step to shared decision making because when physicians assume their goals are
the same as the patient’s, shared decision making fails (Beers et al., 2017; Herrmann et
al., 2018). Thus, translating the severity of a treatment emergent event and its impact on
the patient’s activities, becomes critical when considering future tool design.
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As tested, the tool is a hybrid, employing an electronic strategy to collect the data
(i.e., questionnaire, SDMCQ); whereas, a printed paper serves as the ‘true’ collaborative
decision-aid tool. The format of the collaborative decision-aid tool is basic and mirrors
the questionnaire (Appendix M) but also reports the baseline and prior visit responses.
Work by Bennett et al. (2016) suggests the majority of patients prefer tablet completion
over paper (59% vs. 23%). The work of Basch and others explored the use of a tabletonly system and did not describe utilizing the patient reported outcome measures as a
function of shared decision making, even though they were shared with clinicians as
medical information (Basch, Deal, et al., 2016; Basch, Pugh, et al., 2017). It is reasonable
that the current hybrid format could become outdated for future patient generations. To
address this proactively, a future tool design could query patient’s preference for
information distribution (i.e. paper vs. electronic through MyChart® or similar).
Recall disparities are endemic in healthcare and radiation oncology is no
exception (Chen et al., 2021; Gabrijel et al., 2008; Lee et al., 2018; Linford et al., 2020;
Temel et al., 2011). A proposed solution in the literature is to have caregivers/family
present for discussions; however, the current pandemic has removed that capability for
most healthcare clinics (Linford et al., 2020; Smith et al., 2017). Additionally, the
solution assumes the family member or caregiver can be present for visits regarding a
chronic healthcare condition, such as cancer. The collaborative decision-aid tool not only
provides an opportunity for patients to share direct information with their family and
caregivers but also treatment, side effects, and outcomes to be reinforced through
iterative review. Findings from the patient interviews are consistent with Smith et al.
(2017), who found patients were ill-prepared for the severity of the side effects they
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experienced while undergoing radiation therapy. Additionally, the adverse events
documented in the OTV notes, the SDMCQ responses, and adverse event codes from the
patient participant interviews do not align (Chapter 4). This suggests adverse event trends
change over time and, as a result, the tool may be need adjustment. This could be done
based on review of prior SDMCQ responses or an adaptive design could be created. This
would enable a patient to independently report an adverse event that is unexpectedly
serious or distressing.
The collaborative decision aid tool can also minimize both patient and provider
distress by providing an opportunity for clear documentation. Both patients and radiation
oncologists commented on problems with documentation, contributing to stress and
continuity problems during treatment. This is consistent with literature which has
identified errors in radiation oncology documentation which has contributed to treatment
errors (Blakaj et al., 2017; Schechter et al., 2020). Currently, the questionnaire results are
imported into the radiation oncologist’s note using an Epic® smart text strategy.
Inadvertently, this is contributing to documentation confusion, as the patient’s reported
outcome measures may be markedly different than on exam. A best practice would be for
the provider to clarify in the notes, at minimum, what the ground truth is. When discussed
with providers, this was seen as additional time expenditure. Thus, a future tool design
would be to enable a mechanism to provide comments to the questionnaire answers by
the provider with minimal intervention.
Additional considerations include:
•

Look for outliers. Time per question is available by report and questions
presenting as outliers – either by time or the number of reviews – should be
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considered for redesign. Redesign could be a visual layout, an order layout, or a
response needing to be changed. This requires time for reflection and review,
which is not typical in healthcare (Reed & Card, 2016)
•

Mix it up. The collaborative decision-aid tool can be adapted by replacing the
responses with prompts capturing the appropriate context from established patient
reported outcome instruments . The tool is not intended to be validated at this time
– a site could also use a verbatim description if it aligns with a population’s culture.

•

Different cultures, different problems. Research demonstrates problems occur
at varying frequencies and severity based on race, ethnicity, and culture. Versions
of the tool could be designed using a community participatory approach to
identify unique situations and culturally sensitive context.

•

It works better when shared. Currently, the SDMCQ is tied to the on-treatment
visit to which it is assigned and requires access to the specific encounter to view
the responses. Although the radiation oncologist imports the results into their ontreatment visit note, this also requires other physicians to be aware the tool exists
and where to find it. The PROM is not beneficial only to radiation oncologists but
to any physician treating the patient. For this reason, a key modification would be
to centralize the tool and the responses within Epic® EHR for tool awareness and
ease of access.

5.2.3.1 Recommendations for Implementation
Considerations for tool design should be done in concert with a renewed
implementation cycle . Detailed implementation procedures have been discussed
previously (Chapter 4). The Plan-Do-Study-Act (PDSA) model worked well for the tool’s
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implementation with its iterative nature enabling a focus on initial priorities, evaluation,
adjustment, and then initiation of another implementation cycle to amend the workflow
or to expand the implementation (The W. Edwards Deming Institute, 2021). The
detractor to the PDSA is well described in an article by Reed and colleagues (2017), who
caution the simplicity of the PDSA leads to poor implementation outcomes if it is not
combined with other models and frameworks. For this work, the PDSA was combined
with the Ottawa Model of Research Use, which was selected in part due to its grounding
in research (due to the clinic being an academic research clinic) as well as the cues it
provides for planning, studying, and acting (Graham & Logan, 2004). However, there are
multiple models and frameworks that could be used to augment PDSA dependent upon
the implementation needs (Chapter 2, section 2.4). For example, implementing patient
reported outcome measures for improved communication could use the framework by
Golden et al. (20187) whereas focusing on improved patient management could utilize
Santana and Feeney (2014). End-users focusing on a clinical trial to align with FDA’s
objectives should utilize the framework of van der Wees et al. (2019), which emphasizes
the FDA’s priorities of defining the objective, select the appropriate patient reported
outcome and its measure, and identify the metric to be used as an indicator of quality. As
a project matures and the PDSA cycle goes under additional cycles, additional
frameworks or models should be considered for the next cycle.
Despite the use of the guiding framework and models, there were oversights for
implementation that should be considered for future projects and similar tools:
•

Stakeholder = the worker. Stakeholders in the meeting were the supervisors of
the individuals who would the work rather than the staff themselves. This
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decision was guided by the logic that the supervisors had the authority to change
workflows and authorize training. At implementation, it was identified that
supervisors had a broader knowledge base, contributing to the failure to identify a
knowledge gap (i.e., tablet assignment, SDMCQ assignment). Future
implementation should include representatives of the workers engaged in the
workflow as well as their supervisor.
•

Upgrades affect us all. Epic® EHR underwent an upgrade concurrently with the
SDMCQ initiation. Training provided on accessing the SDMCQ answers and how
to print them was negated as the upgrade version removed those pathways. This
was a reminder that, in the scheme of electronic health records, an end-user
designed questionnaire is not on the list of checks and balances when upgrades
are performed. If possible, implementation cycles should have access to a test
version of the upgrade with the SDMCQ/questionnaire installed. If this is not
possible, resources should be dedicated the following business day to evaluate the
workflows and identify potential solutions to new functional challenges. This
issue should be addressed proactively by the committee to clarify this
contemporaneous solution as unique compared to those problems that arise as a
function of the implementation.

•

What! It was finished…when? There is not a mechanism in Epic® EHR to
automatically notify the physicians when the SDMCQ is completed. The
completion is the milestone to trigger review by the radiation oncologist, collect
the printed document, and enter the exam room for the outpatient visit. The
solution employed by the site was a manual intervention and monitoring

223
completion. This is an implementation barrier that must be thoughtfully reviewed
and addressed prior to the first implementation cycle.
•

Perfection will not be achieved. The simplicity of the PDSA cycle is its iterative
use to slowly ramp up implementation. This translates to the initial
implementation cycle not addressing all issues identified at start-up as well as
those identified during the DO and STUDY segments. A project manager should be
identified for the STUDY segment to memorialize problems, one-offs, and
questions for the end-of-cycle ACT segment meeting. Attempting to solve the
problems during the STUDY segment leads to a failure of an interdisciplinary
committee to address the issue as a team and ultimately weakens the
implementation. A recommended strategy to avoid the instinct to fix in the
moment is for the committee and the implementation project manager to accept
problems are not only expected but needed to fully assess implementation and
customize it to the site.

•

SDMCQ on demand, please. Currently, patients can contact the care team
through MyChart® but responses to MyChart® messages can be delayed and
should not be used for time critical concerns. Radiation therapy provides a unique
opportunity as a patient undergoing radiation therapy is seen daily. Prior to the
day’s radiation therapy, if a patient is feeling marginally unwell or has a medical
concern, the patient could request a tablet with an SDMCQ to provide the
healthcare provider a review of the complaint through the patient’s lens and also
document an emergent issue.
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•

Share the rationale. Buy-in and investiture is critical for tool success. Much of
the literature emphasizes physician buy-in, but the critical step in implementation
was the front desk staff assigning the SDMCQ and distributing the tablet. This
added work to an already hectic clinic day and, due to the ‘new’ nature, led to
errors during the first cycle. Rather than adopting a punitive response, all involved
should be educated as to why the PROMs are so important for patients and what
literature demonstrates to date. When the rationale is provided (i.e., for patient
benefit), staff understood the necessity for the workflow change and that they
were – in their part – contributing to better care for the patient.

•

Are we there yet? Human tendency is to have success and a sense of completion.
Implementation and uptake require maintenance and review, removing a formal
sense of completion for the project. To maintain investiture and buy-in, small
milestones should be identified for celebration as well as a feedback loop to the
committee and stakeholders of findings to date. Although this will use data from
the STUDY and ACT segments of the implementation cycle, the focus should be on
team building and celebrating achievements, a respite from the work.

5.3

Study Limitations
This work as conducted does have limitations. The predominant factors

contributing to study limitation are it is not intended to be a source for objective
measures, the sample/population homogeneity, the SARS-CoV-2 pandemic, and the
midwestern culture. Minor limitations include the unique culture of the study site, studysite clinical workflow, the use of Epic® EHR, and the predominantly Medicare/Medicaid
insurer status.
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5.3.1

Measurement in Patient Reported Outcome Measures
The collaborative decision-aid tool was designed as an impetus to communication

regarding adverse events between the radiation oncologist and their patient. The goal was
to obtain information about the experienced events, allow the radiation oncologist to
review, and then for a purposeful communication to occur about managing the events and
what to expect next. For this reason, the description of the toxicity had to easily correlate
to the experienced adverse event. By transitioning away from a severity concern and to a
pragmatic description, there is no longer an ordinal ranking established. Some descriptors
may be the same in severity (i.e., the intervention required) but require different
interventions or education. For this reason, the decision-aid tool has multiple “equitable”
options and does not make an attempt to rank them based on severity. In summary, the
tool is not used to quantitatively measure a patient’s reported outcome but to inform their
radiation oncologist how the patient is assessing the adverse event at that point in time.
5.3.2

Sample and Population Homogeneity
This work took place at University of Iowa Hospitals and Clinics within Iowa City,

Iowa, a city of just over 75,000 individuals. Per census data, the population is 78% white
and 75% white, non-Hispanic or Latino. (United States Census, 2019). Approximately 8%
of Iowa City’s residents identify as black or African American, 7% Asian, and 5.8%
Hispanic or Latino. The same data indicate over 90% of the state’s population identify as
white, 85% do not identify as Hispanic, 4% identify as black or African American, and
2.7% identify as Asian – the remaining races are represented at less than 1% (United States
Census, 2019). Approximately eight percent of the state’s population speaks a language
other than English at home (United States Census, 2019). The predominant religion is
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Christianity (77% of adults) with Protestants being the dominant denomination (58%) (Pew
Research Center, 2021). Non-Christian faiths comprise 1% of the population with Muslim
being the dominant non-Christian faith (Pew Research Center, 2021). The UIHC’s
coverage map includes the state of Iowa in its entirety as well as border counties in the
neighboring states, primarily Illinois and Missouri.
This homogeneity limits generalizability of the tool . Application to other races,
ethnicities and religious cultures should be considered during implementation. Impact of
sample and population homogeneity is minimized on measures of impact if an
implementing site uses its own historical data as its control.
5.3.3

SARS-CoV-2 Pandemic
The impact of the pandemic in oncologic care and its research is indeterminate

but certain to be significant. The primary pandemic control measures contributed to a
foundational communication change: prohibiting caregivers at appointments,
telemedicine in lieu of physical follow-up visits, social distancing, use of a mask and
face-shield, and minimizing paper transfer. This resulted in immediate changes in
communication strategy, from being unable to see a person smile in solidarity or provide
a comforting touch on the shoulder to having to rely on a single source for information
about a patient’s treatment tolerance, health, and welfare. Additional context was the
emotional burden of additional pandemic precautions, the stress of a life-threatening virus
which did not have a prevention or cure during the study, and having to quarantine from
family to protect them from spread. All of this contributes to an atypical communication
pattern that may be reflected in the results of the work.
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Implementation is not impacted by the pandemic in so far as the PDSA model
enables adaptation to the continually shifting landscape of the pandemic. When
reviewing measures of impact, such as time spent per OTV and cost of unplanned ER
visits, pandemic conditions should be considered, especially if attempting any
correlational assessments.
5.3.4

Midwest & Iowa Nice
The term Iowa Nice became prevalent during the 2012 presidential caucuses as a

result of video produced in response to the commercial media’s coverage of the state
(Iowa Filmmakers, 2012). The video, which quickly went viral, highlighted aspects of
Iowa that seem often contradictory. The term Iowa Nice is used to describe the stoicism
of the average Iowan, who tends to care for their family and themselves but will not
impose upon others. This self-reliant attitude may stem from the isolationist lifestyle of
farming; however, it extends beyond livelihood as well as across religion, race, and
locale. It is a unifying characteristic within the state and a ‘tell’ to identify someone wo is
not an Iowa native.
This Iowa Nice culture created one of the tool’s communication needs: breaking
down a wall of self-reliance, decreasing the stoicism, and giving patients permission to
complain. This creates a limitation when generalizing to other communities or cultures.
without this inherent trait (e.g., stoicism, isolationism, self-reliance). The communication
goal will need to be reviewed prior to implementing this collaborative decision-aid tool
outside of Iowa (i.e., increasing communication, clarifying communication, harmonizing
information provided).
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Similarly, the metrics of decreasing emergency room visit were based on
information from the qualitative strand that patients would unknowingly allow adverse
events to increase in severity by attempting to ‘tough it out,’ ultimately resulting in an
after-hours ER visit. For areas where the ER visits are triggered due to knowledge gaps
or resource availability, ER visit as a measure of medical impact may not be
appropriate. Lastly, many larger metropolitan areas have after-hours clinics tailored to
the needs to oncology patients; this is unavailable in Iowa. The presence of such a
clinic would also shift measurement of medical impact. Thus, this should be evaluated
at the PLAN stage of implementation.
5.3.5

Other Limitations
Additional limitations the unique culture of the radiation oncology clinic where

the work was performed (e.g., pickle philosophy), the clinic’s routine workflow, the use
of Epic® as the electronic health record system, and the predominant Medicare population
(which can also be used as an estimate of socioeconomic resources). These are not
considered prohibitive but should be carefully considered when tailoring the tool to
another radiation oncology clinic. Lastly, the tool was not reviewed by patients for their
thoughts and feedback prior to implementation.
5.4

Recommendations and Directions for Translational Research
Shared decision making has been identified as beneficial to patients since 1972

with work from Veatch. Despite the known benefits of improved quality-of-life,
treatment adherence, and reduced psychological distress, SDM has not routinely been
adopted within oncology. To add to this, with the 21st Century Cures Act PROMs have
not only been thrust into the arena of clinical research but were also deemed a valid
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measure of outcome by the United States regulatory establishment – a measure just as
important to oncology as objective disease measurements or hematologic counts (U.S.
Food and Drug Administration (FDA), 2020a). This is a stark change from prior
expectations and, as a result, the oncologic world is ill-prepared. The logic is
straightforward: if a drug or device is FDA approved to improve quality-of-life, how does
an oncologist discuss this in a cogent manner with their patient? This highlights a
disconnect between the existing literature and what is occurring in practice. Thus, this
work targeted the T3 chasm as defined by Drolet and Lorenzi in 2011 to move patient
reported outcome measures and shared decision making beyond a controlled research
paradigm and to a routine clinic.
This novel work addresses the first step in crossing the chasm: how to
implement patient reported outcome measures in a radiation oncology clinic. It provides
an implementation map for a collaborative decision aid tool into a radiation clinic
through a clinical implementation strategy, rather than employing a clinical research
pipeline paradigm. This implementation map (Figure 20) thus provides real-world
strategies to install a collaborative decision-aid tool. Based upon the literature review
(Chapter 2), this is unique information that can further standard use of patient reported
outcome measures and collaborative decision-aid tools into routine clinics, rather than
targeting the research enterprise.
5.4.1

Translating the Collaborative Decision-Aid Tool
The resultant collaborative decision-aid instrument has unique characteristics:

compared to validated tools currently in use, such as QLQ-C30, the PRO-CTCAE™,
FACT-L, and PROMIS (Basch et al., 2005; Haraldstad et al., 2019; Minasian et al., 2007)

230
Figure 20
Proposed Implementation Map for Collaborative Decision-Aid Tool

Note. Adapted from the NIRN framework (Bertram et al., 2015), the OMRU model
(Graham & Logan, 2004), and the PDSA cycle (Langley et al., 2009).
the tool does not use a numeric scale for quantitative assessment nor is there is not a
defined recall window. The tool is adaptable based on the symptoms of interest and the
desired context for severity. By removing the numeric scales, the ability to quantify
subjective responses was severed, anchoring the tool to the clinic and emphasizing its
designed to stimulate communication between provider and patient.
In creating the tool, it was decided not to focus or pursue validity (i.e., the
instrument measures what is intended to be measured), reliability (i.e., consistency of
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measurement across a population) or acceptability (i.e., the ease of use) (Jerosch-Herold,
2005; Streiner, 2003; Streiner et al., 2015). It is recognized that these measures are
important for the simple reason that if used to assess a patient’s health or recovery there
should be confidence in knowing the measures reflect a true change in health. However,
for the purposes of this study, the tool was intended to simply initiate conversation about
concerning adverse events to increase shared decision making.
By reducing emphasis on validation and focusing on the patient and clinic, the
tool gained real-world applicability. Rather than being a static instrument, the tool serves
as a functional scaffold, for clinicians to substitute the symptoms of interest and to
incorporate the context from any of the existing PRO instruments. The layout of the
collaborative decision-aid tool would remain unchanged, providing trends over time for
the monitored symptoms. This provides an extremely adaptable tool to meet the needs of
multiple clinics, increasing the likelihood of its use across the T3 chasm.
5.4.2

Implementation of the Collaborative Decision-Aid Tool
This work used the NIRN framework, the OMRU model, and the PDSA model to

guide implementation (Figure 2). Despite the proactive plan, there were missteps during
the cycle 1 of the implementation (Chapter 4). Based on this experience, and the resulting
logic chain, an implementation map based on the PDSA cycle and OMRU is provided for
implementation of PROM measures in a radiation oncology clinic (Figure 20). The map
identifies specific considerations that were required when implementing the decision-aid
tool. Priorities for implementation should be identification of how the questionnaire will
be added to the electronic health record and the workflow for that installation, who will
touch or interact with the questionnaire and the resulting decision-aid tool, and who will
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be the project manager or owner of the implementation. The implementation map, as
designed, is generalizable to any clinic utilizing an EHR. A clinic seeking to utilize the
map will have investments for implementation:
•

Walk through. The clinic considering implementation should walk through the
process, stepwise and slowly, using a logic chain model. This can be done as a
meeting or as an actual walk through the clinic. The logic chain (if/then) should
be edited contemporaneously with feedback from attendees. The work path
should identify stakeholders at the basic foundational level to not only provide
key information but also serve as champions at implementation.

•

Project management. A project manager / coach should be assigned. In addition
to funneling information to the appropriate staff, this person should memorialize
issues and obtain metrics for review.

•

Consider patient representation. Depending upon the metric selected, patient
representation or community participation may be beneficial. Patients
experiencing the disease under study and treatment should contribute to
identifying outcome measures of significance. This should be strongly considered
when tailoring a tool to specific populations within the community.

•

EHR requirements. Dependent upon the organizational structure, the clinic may
be required to support the EHR build financially. If this is not feasible, the
implementation team should consider shifting from an EHR-focused tablet to a
paper form and how that would affect the workflow.

•

Team environment. The project manager and implementation champion (the
person who is requesting the tool be adopted) should provide a team environment
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that is a psychological safe space. Additionally, the end goal should be clearly
identified as well as team roles and expectations.
•

Day 1 contact. If using an EHR, the clinic will need to identify a contact person
when the first implementation cycle begins, to address any emergent EHR or
programming issues.

•

Staffing. A clinic considering implementation will need to provide adequate
staffing with protected time for the staff. The amount of hours and staff is
dependent upon the stakeholders and path identified in the clinic. Staffing will be
required to memorialize issues and questions as well as to educate regarding the
importance of the tool and its outcomes.
Adopting this implementation map should aid in crossing the T3 chasm, resulting

in a greater chance at clinical adoption. To share the information map, information will
first be distributed to radiation oncology clinics as well as community oncology clinics
within Iowa. Information dissemination will occur through two primary means: the
statewide radiation oncology annual meeting (ISTRO) and through a newsletter
distributed to former students, staff, and faculty of the UIHC Department of Radiation
Oncology. This first roll-out will focus on similar geographical and cultural locales. The
second distribution will be through traditional academic pathways but will include the
nursing journals in addition to academic publications. The third distribution will occur
contemporaneously with the second and will focus on information distribution through
the Oncology Nursing Society. It is hoped by targeting patient champions, such as
oncology certified nurses, implementation and adoption will snowball within the state
and – hopefully – beyond.
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This research crosses the T3 chasm to partially address the knowledge gap in
current literature that shared decision making and patient reported outcome measures are
not being routinely used in radiation oncology clinics. Knowledge gained from this
research should increase shared decision making and improve the patient experience
through the implementation of a collaborative decision-aid tool. Lastly, this tool has been
created and implemented such that it should be usable by other clinics within the
Midwest and, with adaptation through a robust PLAN segment of PDSA cycle utilizing the
NIRN framework and OMRU model, it is hoped the decision-aid tool can be used outside
the midwestern locale.
5.5

Next Steps in Research
Research of PROM and SDM within oncology crosses decades without realized

implementation in the clinic or community. To gain forward momentum, research must
continue pragmatically, either through quality improvement designs or consent-waived
comparative effectiveness research. Both PROM and SDM are research areas that benefit
from community participatory research, both at the community level but also at the more
focused disease level. Next steps in this vein of research must include:
•

Identify the downstream impact. Outcomes of interest include inpatient
admissions, emergency room visits, scheduled outpatient visits, emergent
outpatient visits, concomitant medication and opioid prescribing patterns,
treatment compliance, and healthcare costs. It is unknown how these outcomes
will shift: for example, increasing emergent outpatient visits may appear to be
negative but not if the trade-off is decreased emergency room visits. Thus, a next
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step is to not only estimate impact but also assess if it is potentially positive,
negative, or neutral.
•

Remix. The initial PDSA did not include patient advocates or representatives.
Similarly, patient participants did not review the instrument designed from their
input. A subsequent mixed methods study to (1) obtain direct feedback from the
representative patient population as well as clinical staff through focus groups, (2)
complete semi-structured interviews from patient participants who completed the
instrument during therapy, (3) invite patients to have their on-treatment visits
recorded to assess shared decision making, and (4) compare the outcomes of
interest with historical data.

•

Tool quantization. As designed, the tool focuses on increasing communication
through patient reported outcomes. To employ the tool for an investigatorinitiated clinical trial, an investigator may wish to quantize the data similar to the
Common Terminology Criteria for Adverse Events (CTCAE), which quantizes
subjective assessments to ordinal categories. This enables statistical evaluation
(e.g., Wilcoxon Signed Ranks Test, Spearman Correlation, Mann-Whitney U
test). This is likely to increase adoption due to the familiarity of oncology with the
CTCAE as well as quantitative clinical trial data.

•

Psychometric analysis. This study could also be broadened to include
psychometric analysis (i.e. validity, reliability, responsiveness) to further examine
its role in assessing and reporting adverse events. Validity demonstrates the tool is
measuring what it is designed to be measure. Reliability demonstrates the tool
provides consistent responses within groups being examined. Responsiveness is
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the tool’s sensitivity to change. These should be examined within groups (e.g.,
same location, same patient base) and across groups (e.g., different tumor sites,
different practice types, different locations). Determining the tool’s validity,
reliability and responsiveness will support generalizability and increase uptake.
•

Clinician adoption. The tool was implemented pragmatically but within one
patient base focused on one treatment. The tool should be expanded for use for
adoption across patients within a clinician’s practice. Within the practice, for the
purpose of increasing communication and shared decision making, psychometric
analysis is not a top priority and the tool can be tailored to the clinician’s practice.

•

Facility adoption. The tool can be expanded so patient results are incorporated
into sister oncology clinics (e.g., medical, surgical, radiation) as well as emergent
and inpatient care for their use. This expands the tool’s purpose from increasing
communication and shared decision making to also use PROM as a key healthcare
measure. With this framing, at minimum the facility should consider the shift in
targeted use but, ideally, should consider psychometric analysis. In addition to
utilizing the implementation map, this would require assessing readiness for
change, harmonized goals across the clinics, and identifying the primary clinic
that would champion the tool.

•

Interfacility adoption. A reasonable use of the tool would be to increase
communication and shared decision making between cancer centers and then
determining the impact the tool has on downstream measures. Similar to
individual clinician adoption, this may not require validity, reliability, and
responsiveness assessments as the goal is to increase discussion and not determine
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measures reliable across sites. However, if the tool is also to be expanded to
utilize PROM as a healthcare measure, psychometric assessments are essential to
the tool’s use. Variables to explore include tumor type, oncologic practice (e.g.,
medical oncology, surgical oncology, gynecologic oncology, radiation oncology),
treatment location (i.e., physiologic area of the body to be treated), and cultural
considerations of the different locations. When assessing for use between centers,
further exploration could be undertaken to reduce the size of the individual query
response, identify barriers to response understanding, and the need to
individualize responses by culture, treatment center, and/or tumor type. This will
increase generalizability of the tool.
•

Provide the translational feedback. Due to the failure of both PROM and SDM
to be implemented in routine clinical care, both bench science and drug/device
development have been starved of the patient perspective. The instrument will not
provide quantitative data; instead, it will provides more meaningful, rich detail
about how the patients experience experimental treatments. This informs current
and future research about the tolerability of treatments and real-world impact on
patients’ side effects, activities of daily living and quality of life. To move
forward with introducing the instrument into clinical research, an initial
psychometric analysis would be required for the tool.

5.6

Final Reflections and Conclusion
Radiation oncologists have a critical role for a patient undergoing combined

therapy for treatment of lung cancer. Radiation oncologists have a tremendous amount of
knowledge to share with their patients so the treatments are tailored to their needs and to
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prevent emergency room visits or inpatient admissions. Although literature reports
radiation oncologists are not participating in shared decision making OTVs (Fromme et
al., 2016; Golden et al., 2016; Golden et al., 2017), this work suggests patients are not
sharing their symptoms and side effects with their radiation oncologists. Interviewing
patients with lung cancer identified the patients’ tendency to not want to burden others by
reporting side effects. This stoicism masks problems and contributes to emergent
healthcare needs and expenditures as well as exposing the patient to additional risk
through community acquired infections. Thus, this work created a collaborative decisionaid tool informed by both patients with lung cancer and radiation oncologists at a
midwestern cancer center. The resultant tool is a hybrid that is both electronic (the
questionnaire, SDMCQ) and paper (the collaborative tool). Digitally, the patient’s
responses can be easily imported into a clinic note; other providers, such as emergency
room providers, can review the radiation oncologist’s note to read the patient’s responses
directly. In paper format, the instrument serves as a springboard, providing the radiation
oncologist information to discuss with the patient and a medium to write down additional
notes or instructions. The patient can take home the information to their caregivers or
family but also provide it to other caregivers to minimize verbal communication (due to
dyspnea) and provide continuity in documentation. This becomes more significant as an
incidental finding during the interviews was that errors in notes remain unchallenged
between physicians, resulting in the medical record having poor and/or inconsistent
documentation regarding a patient’s care.
After developing the collaborative decision-aid tool, the decision was made to
implement it pragmatically through a clinical initiative, rather than utilizing the tool in a
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controlled clinical research method. This provided insights into barriers and facilitators
but also broke down the steps necessary to begin the implementation process. The
resultant implementation map provides a pathway for community clinics to install the
tool without dedicated research personnel. Both the collaborative decision-aid tool and
the implementation map should serve as a keystone in increasing SDM and PROM
utilization in clinical radiation oncology practice, making their use routine and increasing
the known potential benefits to the patient community.
This work is considered novel because neither decision aid tools or patient
reported outcome instruments have been described in the peer reviewed literature as
being implemented directly in the clinic, rather than a research trial. This work creates a
foundation to (1) tailor a collaborative decision-aid tool to the unique needs of a
community or culture, (2) eliminate ambiguity of an adverse event’s impact on a patient
and their daily lives, (3) improve shared decision making through discussion about
adverse events during weekly on-treatment visits, (4) provide a secondary information
source for providers when caregivers and/or family cannot be present, and (5) implement
this adaptable tool into a community radiation oncology clinic. The next step in
furthering this work is to continue the tool’s implementation within the target clinic and
determine effect size for emergency room visits and expenditures. Through its pragmatic
installation, as well as its focus on the patient and provider needs, this instrument has the
potential to truly place the patient in patient-focused drug development and patientcentered medicine.
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APPENDIX A: SARS-COV-2 IMPACT
This work was designed to be completed in two parts: the qualitative strand and
the quantitative strand. Both strands were significantly impacted by the ongoing SARSCoV-2 pandemic, which mandated changes to both human subjects research procedures
as well as clinical modifications to minimize risk to staff and patients (The University of
Iowa Human Subjects Office, 2020; The University of Iowa Office for the Vice President
for Research, 2020).
The qualitative strand and the control for the quantitative strand were opened for
accrual 03 May 2019 with the first consent obtained in July of 2019. Beginning in March
2020, human subjects research at University of Iowa and University of Iowa Health Care,
was restricted to only essential, life-sparing research which was justified – and approved
– by the University of Iowa Human Subjects Office (HSO, 2020; OVPR, 2020).
During this time, University of Iowa Health Care was faced with an impossible
reality: protective equipment shortages, a lack of effective testing methods, and the
absence of an effective treatment for a potentially lethal disease. For this reason, the
difficult decision was made that no one could patients to their appointments in an attempt
to stop community spread and minimize risk to all (e.g., family, friends, caregivers).
Patients could be dropped off at only two approved hospital entrances and the driver
could wait in a nearby parking lot. Similarly, volunteers, students, and hospital escorts
were also prohibited entry into University of Iowa Health Care, stranding infirm patients
who were dropped off at one of two the approved entrances but needed to get to their
oncology clinic three buildings away. Without escorts and volunteers, physicians and
allied healthcare staff returned to treating the patient and not the disease. For example,
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attending physicians wheeled patients to their waiting car, nurses sat with patients in the
cafeteria so they could eat, and providers talked to their patients, acknowledging that the
doctor’s appointment may be the only interaction the patient had. To add to the strain,
staff were assigned overtime hours to screen incoming patients, faculty, and staff for
COVID-19 symptoms at the designated entry points.
With so little prevention or treatment possible, potential sources of contamination
(e.g., exam table paper, pamphlets, paper towels, pens) were obsessively stripped from
exam rooms. Staff were no longer allowed to walk down the hall side-by-side. Only two
individuals were allowed in an elevator at once. The use of communal clinical
workrooms was minimized. Residents no longer gave report to their attending physicians
in person but over the phone using screen share technology to review key information
and imaging. Routine cancers treatments (e.g., pulmonology, chemotherapy, standard
radiation) were referred to local clinics away from UIHC, which was considered similar
to ground zero for the pandemic.
On 16 June 2020, the University of Iowa Human Subjects Office and the Office
for the Vice President of Research agreed to allow research to resume provided there
were no ‘research only’ visits and the departmental chair approved the restart. On 18 June
2020, after discussion with the site’s nurse manager, administrator, and attending
physicians, the departmental chair deemed it appropriate to continue with interviews as
long as they were on an established on-treatment clinic visit, as follow-up visits were
now performed through telemedicine. Additionally, the clinic’s workroom as well as
workflow was irrevocably altered: communication occurred via phone, rooms were
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evaluated for maximum occupancy using social distancing, and staff were assigned nontraditional work roles.
In November 2020, Iowa saw a secondary peak of SARS-CoV-2; as a result,
human subjects research was again immediately placed on hold. This was to
accommodate the foreseen burden: to accommodate the burden, outpatient floors were
modified to house additional critical care and required the appropriate healthcare staff to
maintain them. Faculty and staff were reassigned to these floors; licensed research staff
were then reassigned to address these vacancies (HSO, 2020). As of December 2020,
human subjects studies were restarted but the workflows and healthcare processes at
UIHC remained altered due to the pandemic. The long-term impact of SARS-CoV-2 on
healthcare, its workflow, and clinical research remain unknown but are likely to be
widespread and long-lasting.
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APPENDIX B: HUMAN SUBJECTS DETERMINATION FOR INSTRUMENT
IMPLEMENTATION
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APPENDIX C:
SAMPLE PATIENT PARTICIPANT INTERVIEW QUESTIONS
Lead in: Before we begin, I want to remind you that your participation is
voluntary. You can stop participating in this study without any impact in your healthcare.
If you choose to continue, you can choose to skip any question you would like or even
choose to answer none at all. (pause). Is it okay to continue?
- if no, thank the participant for their time and ask if they would like to end study
participation.
- if yes, “Thank you, I am going to be begin the recording.”

A1.

Thinking about your radiation treatment, what do you think was important for
your radiation doctor to know about how you were feeling?

A2.

I’m interested in how patients being treated with radiation describe their
symptoms to their radiation oncology doctor. Please describe a time when you
had difficulty describing a symptom to your radiation doctor?

A3.

Thinking about that time, what do you think could have made it easier to help
your radiation doctor understand?

A4.

Think about your radiation treatments and your visits with your radiation doctor
during that time. Think about how you felt, how much time the visits took, and
what you were worried about or what you were experiencing. If you could create a
paper or report to share what you were worried about, what would that look like?

A5.

During your radiation treatment for your lung cancer, how would you prefer to
communicate your symptoms and concerns to your radiation doctor?
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APPENDIX D:
SAMPLE RADIATION ONCOLOGIST INTERVIEW QUESTIONS
[TREATING RADONC, LUNG CANCER FOCUS]
B1.

What are the common medical concerns for patients undergoing definitive
chemotherapy and radiation therapy for lung cancer?

B2.

What information do you need to know to manage the on-treatment visits?

B3.

What information do you find difficult to obtain from patients or information that
varies from provider to provider?

B4.

What format do you prefer information conveyed (graphics, tables, etc.)

B5.

A decision-aid tool is often a report, paper, or other prompt that helps patients
understand the decision that needs to be made, to help empower the patient. If
RADONC were to design a decision-aid tool to help patients describe their
adverse events, how do you envision that tool?

B6.

If patients were to complete patient-reported outcome questions, and this
information was available for review in Epic® EHR, where would you like to see
it? Where do you believe it is most accessible?

B7.

What process or workflow do you have after your patient has been seen by a
covering RADONC?

B8.

What is the most common cause for add-on visits or special complaints in the
lung cancer patient base?
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APPENDIX E:
SAMPLE RADIATION ONCOLOGIST INTERVIEW QUESTIONS [COVERING]

Note: Small group interview structure
D1.

You have been identified as radiation oncologists who cover for a treating
radiation oncologist for a lung cancer patient. What is your average workflow to
prepare for that on-treatment visit?

D2.

A decision-aid tool is often a report, paper, or other prompt that helps patients
understand the decision that needs to be made, to help empower the patient. If
RADONC were to design a decision-aid tool to help patients describe their
adverse events, how do you envision that tool?

D3.

If patients were to complete patient-reported outcome questions, and this
information was available for review in Epic® EHR, where would you like to see
it? Where do you believe it is most accessible?

D4.

What do you consider to be the most concerning or difficult AEs for lung cancer
patients?
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APPENDIX F:
SAMPLE RADIATION ONCOLOGIST INTERVIEW QUESTIONS
(TREATING RADONC, NON-LUNG CANCER FOCUS)
C1.

You specialize in primary tumors other than lung, but you treated (name of
patient) for lung cancer. How does the lung cancer patient base compare to the
patients you normally treat?

C2.

What type of communication problems do you have with lung cancer patients
compared to your routine patients?

C3.

What do you consider to be the most concerning lung cancer symptoms, or
treatment AEs, that can lead to problems?

C4.

What do you find the most difficult about managing or treating lung cancer
patients?

C5.

A decision-aid tool is often a report, paper, or other prompt that helps patients
understand the decision that needs to be made, to help empower the patient. If
RADONC were to design a decision-aid tool to help patients describe their
adverse events, how do you envision that tool?

C6.

If patients were to complete patient-reported outcome questions, and this
information was available for review in Epic® EHR, where would you like to see
it? Where do you believe it is most accessible?

C7.

What process or workflow do you have after your patient has been seen by a
covering RADONC?

C8.

What is the most common cause for add-on visits or special complaints in the
lung cancer patient base?
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APPENDIX G: LINKAGES AND RELATIONSHIPS FOR COMMUNIATION
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The shared decision-making tool could address the patient-identified communication barriers of
having to repeat information across multiple providers as well as reduce the feeling of isolation
while undergoing radiation therapy.
•
•

•
•

I don’t have an idea of who to call because I don’t recognize the physician on the pill bottle.
That’s a lot of things they asked me. Not in a form like this. They did it verbal. This would
be helpful for me because they could have referenced this stuff. Some doctors take good
notes and other doctors don’t. This could have been a reference for all the other doctors
this would be helpful. I did a lot of that repeat, repeat. And by the end, I’m tired.
[Y]ou can just hand it to them and they could go over it with you. You could just answer it
without going through everything over again.
If there was anything frustrating it didn’t have anything to do with them, you know, it was
a matter that no one can be with you and you know, so, you’re sort of responsible to
remember all the stuff to take home and to talk about it.

Analytic Memos
There are a total of 12 direct links to communication; of these, 4 are codes, 5 are categories,
and 3 are upper level categories (i.e. conceptual categories, ATLAS.ti ‘nodes’).

Codes
Approval is directly associated with communication with a generalized symmetric relationship
– approval for communication was coded in comments from participants such as, “He did really
well with that,” as well as, “All I can say is… he pretty much nailed on the head what was gonna
happen to me.”
Choice is identified as part of communication, from communication method (e.g. reading vs.
verbal) but also regarding type of chemotherapy as well as clinical trial participation.
Isolation is secondary to the current COVID-19 pandemic and negatively impacts
communication. In the abstract, isolation could also extend directly to the code single-source
of information and inversely to gatekeeper and team. This is based on participant comment
such as, “[B]y the time I walked from the truck … to where I needed to be… I thought my leg was
gonna fall off. It was so swollen,” and “I was wondering on potassium cause the doctor said one
day the potassium was low so I asked him.”
Information root. This code represents an abstract concept arising from participants’
responses when queried what they believed was important for their radiation oncologist to
know. The question was geared to explore lifestyle goals and/or maintain abilities. Instead,
participants responded that it was what they needed to hear and not that they had information
to share with the radiation oncologist. This extends beyond a lack of foundational knowledge,
mixing with paternalism and perhaps a low prioritization of normal in the face of a lifethreatening disease.

Categories
Barriers to communication is a category that negatively impacts communication. Participants
describe barriers such as failure to respond (I called up here one time, on a Friday morning, and
they didn’t get back to me til Tuesday.) as well as failure to prioritize communication with the
patient (Cause I kept calling back to Minnesota…“Well your doctor isn’t here today.” “Oh…your
doctor – she went on vacation.”). Barriers identified were person-to-person barriers;
participants did not note a problem with technology. Interestingly, participants were aware of
MyChart, approved of MyChart, would muse that they should have used MyChart, and then
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would become irritated with other patients who did not use MyChart and complained (wherein
MyChart would have presumably solved the issue). There was never a negative mention of
MyChart per se; just a failure to use it when they knew they should have.
Factors affecting communication. The code information root as well as health literacy are two
factors that affect communication; however, three other unique codes were also identified as
factors: “didn’t know,” “medicine by committee,” and “team.” Depending on the presence in
statements made by the participant, communication was team-oriented and patient-centered
(“we,” “our,”) or was isolative, with the participant receiving treatment from a committee
(“medicine by committee,” “they”). Participants would switch between “they,” and “we,” in
interviews; this was not investigated for further significance. It’s an interesting flip/flop that
may mean nothing.
Emotional reactions. This category aggregates verbal responses that extend beyond the words
and into the tone or emotion behind the statement and thus influences communication.
Examples include the code comradery (So then when he lifted my pant leg and said,
“SWOLLEN!?”), feeling lucky (So, knock on wood I guess I’m one of the weirdos that didn’t get
anything), and not concerned (It wasn’t something I was freaking out about). Emotional
reactions provide insight into the participant’s lived experience through their treatment, a
glimmer into the humanity of their responses to healthcare communications and their mindset.
Characteristics & context. If emotional reactions category provides a framing to the
psychological or social reactions, characteristics and context category provides framing to the
setting and context of the communication. This category also influences communication
depending upon the situation. Characteristics such as verbal communication, active listening,
and direct information were appreciated by participants as was accuracy of information
provided. Two quotations that capture this with relationship to communication are “It was
down to earth, he made me understand. He’s very good at that, I think.” and “So they fed me
the information. I… I’m not sure I would of known what to ask at that point.” Both quotes have
a nurturing context (down to earth, fed me) in an educational context (…made me understand).
None of the participants declined to know their prognosis and all stated they were interested
in longevity despite side effects. Prognosis & diagnosis were not considered difficult
conversations, other than being described as a bit overwhelming.
Information traffic. This category centers on the patient/provider dyad and is the combination
of the codes provider to patient communication, patient to provider communication, and
information sharing. Patient to provider is unilateral, with discussion points ranging from
discussion of diagnosis (I would do the research and write down a question, like my particular
diagnosis…”) to seeking reassurance (“If it was something that spooked me or something, I
could call and talk to someone on the team.”). Provider to patient is also unilateral, but as retold
by the participant; primary areas were diagnosis, treatment, and control of adverse events.
Information exchange is the mutual sharing of information between patient and provider;
perhaps the strongest quote for this code is “I’m used to what they tell me and how they act
and how I act back to them. The exchange of information.” Although the literature suggests
some patients still prefer paternalism and – as such – in pursuit of true patient autonomy,
participants’ expressing paternalism also expressed that it was their responsibility to share
information with their provider (“[K]eep her in touch with how I was feeling and what was going
with my body and stuff…stay in touch, basically be honest with, you know, what’s going on with
how I’m feeling and all that stuff. I think that’s pretty important.”) This provides insight that
paternalism and shared decision making may not be oppositional as some of the peer-reviewed
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literature suggests and that a simplistic SDM tool can still be used for patients who prefer a
paternalistic relationship with their provider(s).

Upper Level Categories / Conceptual Categories
HEALTH LITERACY. This upper level category captures not only medical literacy but also
individual concepts/factors that impact an individual’s use of medical information. For
example, commitment, proactive, comparison, printed education documents, and reading.
Health literacy as a concept is best captured in two oppositional quotes:
– “Then I was like, ‘Okay, after 5 days, it’s time to give.’ …So, I called. And the nurse was, she
was really sympathetic about it but then at the end, she’s like ‘You are either up here today
or you are in Fairfield, one or the other. You have no options.’ And she goes, ‘You should
have called me the first day, not now.’ I said, ‘I realize this.’”
– “I was having a hard time breathing so I went in to see the doctors so I figured it was
probably COPD. Took a chest x-ray… and said it was, uh, a mass…and that was in December.
FINALLY (emphasis) got it sent out to Nevada… in February – beginning of March. It took
‘em a while to get stuff sent out there. By the time they found out what it was and that it
was cancer and stuff, and since it was one that grows fast, it probably went from stage two
to four because the doctors were just so slow.”
SYMPTOMS. An adverse event is defined by FDA as an untoward medical event that occurs
during the contact of a clinical trial; this is then extended to an event that occurs during routine
clinical care. There is a subtle nuance for this study that patient-reported symptoms are those
that the patient reported but have not been confirmed by physical exam. Additionally,
anticipated events are those side effects a provider noted were possible but may not have
been realized. Concerning symptoms are those that necessitated urgent intervention,
emergency care, or intensive care. Symptoms can also be present at baseline, consistent with
the underlying disease or another comorbidity. SYMPTOMS serves as a critical category for the
research question, as it is partnered to COMMUNICATION to create the shared decision making
tool. Special interest was taken in the symptoms that were most commonly commented on by
participants (fatigue, dyspnea, nausea, vomiting) as well as those that appeared to significantly
interrupt their daily life (fatigue, edema, cognitive impairment). It is interesting to note that
participants consistently noted prompting about symptoms across providers. This provides an
opportunity for the SDM tool to capture this information consistently.
SDM IMPLEMENTATION. This upper level category focuses on the science and strategy behind
implementation of the shared decision making tool. How the SDM tool will interact with all the
categories is unclear, but the goal is that the SDM will positively impact communication
through information sharing. How SDM implementation interacts with communication (if at
all) will further be explored in the quantitative strand of this study.

Representative Codebook
Arranged alphabetically, definitions are provided for the codes shown in the COMMUNICATION
depiction above. Categories are listed in bold with upper level categories in UPPERCASE. In
general, a code is the most basic concept or construct present in an interview transcript. A
category reflects a grouping or pool of constructs with a common idea. An upper-level category
reflects the largest amalgamation of information, a pool or sea comprised of rivers of thought.
Categories can serve as codes as well, dependent upon the concept/construct.
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Code
accuracy
active listener
all-at-once
approval
Barriers to
communication
blame chemo
caregiver
Characteristics &
context
choice
COMMUNICATION
communication
expectation
comradery
COVID-19

didn't know

direct
disbelief
doubt
Emotional reaction
Factors affecting
communication
failing to
communicate
failure to provide
necessary tools

Comment
Information provided to the patient aligned with the lived experience.
Information is provided by a healthcare provider and not by an alternate
source (i.e., website).
Physician engages in active listening: eye contact, acknowledging what is
said, or acting on information provided.
Information strategy; direct transfer of information at a single timepoint.
Not piecemeal.
to speak or think favorably of; pronounce or consider agreeable or good;
judge favorably
Category encompassing events, situations, or factors that impede
communication between patient and provider.
Reaction, explanation, or coping mechanism that blames chemotherapy
for the event, reaction, or symptom
A person who provides support to the patient during treatment.
Category encompassing characteristics & situational context of
communication.
Ability to choose or option to choose. May be patient, caregiver, or
provider.
Upper level category representing the totality of medical experience,
foreknowledge, academic information as well as commercial information
sources.
Expectations regarding communication whether it is patient, caregiver,
or provider.
Attribute of communication and/or interaction; playful, friendly, and
warm.
Disease caused by SARS-CoV-2; this can refer to the frank disease or
pandemic precautions due to COVID-19
Lack of background knowledge (medical, health), context, or electing to
deprioritize in the face of other decisions or information requirements.
Often associated with 'information root,' which is the nebulous concept
around the goals of treatment and defining the patient's desired new
normal.
Direct communication strategy and/or methods; using direct language
mental rejection of something as untrue
Calls into question if it is real or true
Category encompassing a response elicited to a prompt, situation, or
stimulus that conveys more than the spoken words.
Category encompassing things that impact communication negatively or
positively. Not to be confused with characteristics & context, which are
properties and/or traits.
Failure of a patient, caregiver, or provider to actively communicate
regarding an adverse event or concern.
Failure to provide the patient or caregiver the tools needed for self-care,
concomitant care, and/or supportive management.
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Code
failure to respond
failure to use
available tools
familiarity with
provider
fear
feeling lucky
fun
HEALTH LITERACY
honesty
information root
information sharing
Information traffic
isolation
medicine by
committee
new information
not concerned
open ended
overwhelmed
patient repeated
communication
patient to provider
communication
physical contact
pragmatic
prioritizing
prognosis
provider cares

Comment
Failure by the patient, caregiver, or provider to respond to
communication requests (e.g., email, phone, on-call).
failure to use available tools to reduce burden (e.g., MyChart).
Knowing the name and/or clinic of the provider.
unpleasant emotion associated with anxiety, sense of foreboding or
danger.
Patient reaction / emotion that they are fortunate with their outcomes
and that this outcome is mostly likely related to chance.
Enjoyment, happy experience or sensation
Upper level category; defined by Institute of Medicine as the degree to
which individuals have the capacity to obtain, process, and understand
basic health information and services needed to make appropriate health
decisions.
Truthfulness, being open regarding treatment, outcome, side effects.
The recognition that the information is not available to the patient or
provider and they cannot act due to the lack of information. The
information root is missing.
Information sharing (back and forth) between at least two parties:
provider, patient, caregiver.
Category encompassing verbal signals or messages for communication
Frank or subjective separation from caregiver, family, or other providers.
Negative connotation regarding the use of multiple providers in
providing a single treatment.
New medical information regarding treatment or side effect.
Patient and/or caregiver was not concerned regarding treatment or side
effects.
Communication format enabling descriptive or qualitative responses.
inundated with information and / or the intensity of the situation.
Patient or caregiver must repeat the same comment, information, or
symptoms to a provider or provider(s) within a reasonable timeframe
(same clinic day, same visit, same phone triage).
Communication initiated by the patient to the provider, as per the
patient. This is a one-way conversation; for quotes where both parties
discuss (i.e. patient is responding to provider, or provider then responds
to patient) consider 'information sharing."
Physical contact between provider and patient that is occurring outside
a physical exam or medical assessment.
Real-world and free of jargon.
Prioritization of symptoms or adverse events in communication.
Expected trajectory and outcome of therapy.
Verbal communication, physical interaction, or other indication that the
provider cares personally for the patient as a person, beyond medical
obligation.
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Code
provider personality
provider prompting
provider support
provider to patient
communication
provider to provider
communication
reaction
repeated efforts to
contact
safety net
SDM
IMPLEMENTATION
stress
surprise
sympathy
SYMPTOMS

team

understanding
verbal
communication
winning

Comment
The personality of the provider and its impact in communication
Provider's prompting for further information and/or communication
Providers providing support on a personal level, beyond the
stereotypical patient/provider relationship.
Communication centered around, or from, the provider to the patient as per patient. This is a one-way conversation; for quotes where both
parties discuss (i.e. patient is responding to provider, or provider then
responds to patient) consider 'information sharing."
Communication between the providers, as per patient.
The reaction to news, a circumstance, or event. Non-verbal or contextual
communication.
Repeated efforts are made by the patient, caregiver, or provider to reach
the other.
Something, or someone, that is reassuring to the patient.
Upper level category representing pool of information regarding
implementation of a shared decision-making tool for patients diagnosed
with lung cancer undergoing radiation therapy at a Midwestern
academic hospital.
Bodily or mental tension
Unexpected news or situation.
An affinity, association, or relationship between persons or things
wherein whatever affects one similarly affects the other
Upper level category representing pooled information regarding
symptoms, side effects, and adverse events.
Positive connotation regarding the multiple providers involved in the
treatment and care of patient. This is the opposite of medicine by
committee code. One of the facets of TEAM is if the subject describes
decisions as "we," rather than "they," and/or describes a seamless
interchangeability with the providers.
Caring and/or compassionate
Verbal communication
Completion of goal to a satisfactory outcome
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APPENDIX H: LINKAGES AND RELATIONSHIPS FOR HEALTH LITERACY
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Health Literacy directly impacts Communication, SDM format, and SDM implementation but also
has a secondary relationship to Treatment and Symptoms through Communication. Thus, the
shared decision-making tool is dependent upon Health Literacy and may impact the tool’s
implementation and/or usefulness.
•
•
•
•

And the doctor would know, but I wouldn’t know.
You know, I mean, just… you know I’m…I’m never had cancer before.
I didn’t ask a lot of questions because I didn’t know what to ask.
Well, you know, over the years you always hear when you’re unhealthy that… well the
white blood cells that are fighting off infection and stuff and that goes low during chemo
and radiation and I figured I would ask.

Analytic Memos
In total, only thirty-three codes and categories are linked to health literacy; this is the smallest
set of links for any of the upper level categories. However, of these there are 17 direct links to
health literacy, which is more than Symptoms or Communications (which Health Literacy feeds
to). Of the 17 links, 8 are source links (i.e. originating from Health Literacy) and 9 are target
links (i.e. moving to Health Literacy). Of these links, of these, 26 are categories with 13 being
upper level categories (i.e. conceptual categories, ATLAS.ti ‘nodes’). These 17 are described
below.

Codes
Academic information has a direct and positive impact on health literacy. Academic
information is medical information obtained by participants outside of clinical visits, from
verified academic secondary sources (“…there is the Mayo Clinic site and the University of Iowa
site you can research. So, there are good sites out there, just stay away from WebMD.”).
Information obtained / provided between patient & providers in the clinical setting is not
tagged as Academic Information because this is captured through routine communications. Of
the two quotations tagged with academic information, the second reflects academic
information intention / SDM when discussing the SDM tool: “You mean for [the doctor] to just
… while s/he is looking over my stuff… to take some notes and then give me those notes?” This
is a weak code, having only two quotations, and can easily be confused with the robust
academic medical information provided/shared in weekly on-treatment visits with radiation
oncologists. However, the lack of associated quotations could be informative. Two participants
noted using the internet for information (with only one specifically stating to look for academic
sites) and preferred not to use computers. This is – ultimately – beyond the scope of the study.
Choice is identified as part of communication as well as part of SDM implementation. It is
directly impacted by Health Literacy. Logic suggests a direct relationship, as health literacy
increases, choice should then begin to align with the patient’s goal (which may be different
than the physicians’ and/or caregivers). A common thread through choice is provider held
information such that choice is limited:
– They really … they say this is what you need to do. And that was about it, so. I could’a
refused it except…I had two options there, I think, you know.
– He explained then more than the immunotherapy at that time about whether to have it or
not have it in general. It wasn’t a matter of a menu of many choices – it was more like, ‘This
is what it is about.’
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– So, we got the 50 or the 60 percent... ((pause)) I don’t know. But all these side effect things?
I didn’t care. I didn’t care, really.
As with informed consent in research participation, a patient’s lack of knowledge regarding
options and side effects negatively impacts autonomy. The impact of poor health literacy,
coupled with the power dynamic between provider and patient, could impair consent to
treatment as well as the patient’s active participation in treatment and treatment decision.
Prior literature indicates there are patients may prefer a paternalistic relationship with their
provider(s); this should be an active choice rather than an assumption or fall into a standard
operating procedure. Although the shared decision making tool would be utilized during active
radiation therapy, initiation of the shared decision making tool would occur at treatment
planning. The discussion regarding concerning side effects related to chemotherapy/radiation
therapy that should be tracked on the shared decision making tool may spark awareness by
the provider regarding health literacy level. This may, in turn, remedy some literacy deficits.
Commitment in the context of health literacy demonstrates the participant’s efforts to increase
their health literacy. This is evident in participant’s actions that occur beyond standard
patient/provider interaction. For example, reading & re-reading a packet of information after
treatment, or even struggling to read as the participant prefers verbal information. All
participants described a commitment to improving their health literacy, whether reading,
communicating with the team, researching information at home, and organizing information
provided to them to disseminate to their caregivers. Logically, commitment is most likely driven
by diagnosis and prognosis – however, this association was not explicitly made by the
participants during the interviews. Participants endorsed using an SDM tool to further guide
their research regarding their side effects and treatment. For this reason, commitment is
considered to have a positive influence on health literacy.
Comparison. Three participants compared their adverse events to symptoms/illnesses they
were familiar with (e.g., gastroesophageal reflux disease, dyspnea, fatigue, chemotherapy
effects). Only one participant compared their treatment experience to the connotatively
common side effects of cancer treatment. Except for that comparison, the participant
descriptions regarding expectation of how the side effects would feel compared to what the
participant experienced (“[I had reflux] sometimes but not like that. It was pretty nasty.”)
suggests patient reported outcome measures should be framed by patients undergoing
antineoplastic treatment to capture the nuanced differences and/or severity experienced.
Expectancy is an outlier code which represents the anticipated, yet unknown, results of
treatment. There is only one quotation linked to the code (“They actually said a survival rate
of 50%. And … and… 60... maybe 60… I thought I didn’t like those numbers. I thought I had a
bigger number.”) Although the same numbers occur in other transcripts, the reflection back to
self is absent. Like academic information, expectancy may require being merged into another
code. The quotation provides insight that expectancy provides a bridging concept between
prognosis and health literacy. Health literacy influences (positive or negative) expectancy
whereas and prognosis is influenced by expectancy (positive or negative). Although an
argument could be made that prognosis spurs interest in medical literacy resulting in an impact
in health literacy and ultimately the shared decision making tool – this was not voiced by
participants (and is thus not captured on the nodal map) and seems a convoluted logical path.
Goal is a code that conceptualizes the desired end result. Goal has a nuanced difference from
expectancy, whereas expectancy captures the ‘given,’ or ‘expected,’ end results the concept
of goal reflects the end result the patient must work for, earn, or achieve. This is reflected not
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only in treatment outcomes (“I know my goal … I know my goal was that I wasn’t give up and I
was gonna fight through whatever I had to go through, so, you know – whatever it be this and
I get sick from it or whatever I’m gonna deal with it.”) but also as a rationale for the disease
(“The way I looked at it. God put me on here. He gave me this challenge. I have to climb this
mountain.”). Health literacy influences goal(s) (“…we wanted to treat it aggressively and this
was the way to do it. So, I guess I wasn’t really interested in learning any other treatments.”)
but a direct connection from goal to health literacy was not voiced during the interviews.
Information root. This code represents an abstract concept arising from participants’
responses when queried what they believed was important for their radiation oncologist to
know. The question was geared to explore lifestyle goals and/or maintain abilities. Instead,
participants responded that it was what they needed to hear and not that they had information
to share with the radiation oncologist. This extends beyond a lack of foundational knowledge,
mixing with paternalism and perhaps a low prioritization of normal in the face of a lifethreatening disease. It is presumed information root and health literacy likely have an inverse
relationship; poor health literacy increases the information root as an abstract concept (e.g.,
not knowing what to know, not knowing what to ask). It is unclear if a stronger health literacy
foundation decreases the information root and, if so, would it have a positive impact on
identifying goals for patient reported outcome measurements on the shared decision-making
tool?
Medical literacy provides insight into a participant’s ability to apply layperson’s medical
knowledge to general events (“I can’t eat hamburger. I will throw it up… I think it is because it
is so fatty.”), their current cancer therapy (“I have other issues with my liver tumors on my liver
that can be treated. Autoim…autoimmune therapy.”) as well as familiarity with the medical
regime (“I broke my leg, on crutches for 5 years, 20 some procedures. So, I know about the
student teaching hospital part of it. And they would come in 4 or 5 physicians and residents and
stuff and they would talk to you in third person. Because it was a learning opportunity.”)
Medical literacy represents a relationship between medical experience, foreknowledge, and
shared information sources (e.g., internet, TV commercials). Medical literacy directly
influences health literacy in a relationship that is influenced by the patient’s evaluation of the
medical information source as well as their experience.
Patient to provider communication is directly influenced, positively and negatively, by health
literacy. Using the IOM definition, health literacy includes the (in)ability of a patient to
communicate effectively with their provider. Barriers to communication can include not
knowing who to contact (“I’m not sure I have [a primary medical oncologist], it changes.
Whoever’s on call… whoever’s working that day…”) as well as simple issues in trust (“I took
some medicine and I had a horrendous diarrhea and it wasn’t supposed to affect it the opposite
way. I think he didn’t believe me … and it was really bad.”) In reviewing patient-to-provider
communication, it becomes apparent the communication patterns between patient, provider,
and health literacy are unidirectional, representing a triad and not contributing to a bilateral
information sharing. Health literacy directly influences patient-to-provider communication in
a unilateral flow.
Provider to patient communication directly influences health literacy. The healthcare providers
(e.g., physicians, nurses, radiation therapists, respiratory therapists) provide medical
information directly to the patient and, if available, the caregivers. The goal of provider to
patient communication is to transfer knowledge to the patient and increase their health
literacy (“It was down to earth, he made me understand. He’s very good at that, I think. He lets
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you know what’s going on.”) as well as instruct so that it is clear when further services are
needed (“But there were many times where uh … one of those nurses would say to me, ‘If you
have any problems with this, that or this, vomiting or whatever, and you think it is unusual, do
not hesitate to call these numbers.’”). Again, this is a unilateral flow of information from the
provider(s) to the patient and not a mutual information exchange.
Printed education materials are provided to patients through routine nursing practice at UIHC.
Participants described reading them, including the participant who described himself as a slow
reader (“In fact, I have my sister do most of it.”). This provides insight into the patients’
willingness to read information for self-education.
Proactive is codified for one participant regarding her engagement in the healthcare process;
consider merging with “self-reliance.”
Reading introduces the only barrier to the health literacy nodal map: slow reader. Reading
directly influences health literacy, SDM implementation, and format of the SDM tool. The
barrier reminds to keep the SDM tool with the appropriate readability but also short to reduce
burden for a patient with slow reading skills. Logically, illiteracy also becomes a barrier to
reading, although not identified during interviews. During implementation, workflow will need
to be considered for slow readers as well as illiterate patients.

Categories
Factors affecting communication. The code information root as well as health literacy are two
factors that affect communication; however, three other unique codes were also identified as
factors: “didn’t know,” “medicine by committee,” and “team.” Depending on the presence in
statements made by the participant, communication was team-oriented and patient-centered
(“we,” “our,”) or was isolative, with the participant receiving treatment from a committee
(“medicine by committee,” “they”). Participants would switch between “they,” and “we,” in
interviews; this was not investigated for further significance. It’s an interesting flip/flop that
may mean nothing.

Upper Level Categories / Conceptual Categories
COMMUNICATION. This upper level category and health literacy mutually influence each other.
Communication & Health literacy are captured in two oppositional quotes:
– “Then I was like, ‘Okay, after 5 days, it’s time to give.’ …So, I called. And the nurse was, she
was really sympathetic about it but then at the end, she’s like ‘You are either up here today
or you are in Fairfield, one or the other. You have no options.’ And she goes, ‘You should
have called me the first day, not now.’ I said, ‘I realize this.’”
– “I was having a hard time breathing so I went in to see the doctors so I figured it was
probably COPD. Took a chest x-ray… and said it was, uh, a mass…and that was in December.
FINALLY (emphasis) got it sent out to Nevada… in February – beginning of March. It took
‘em a while to get stuff sent out there. By the time they found out what it was and that it
was cancer and stuff, and since it was one that grows fast, it probably went from stage two
to four because the doctors were just so slow.”
SDM FORMAT. This upper level category focuses on the format and presentation of the shared
decision making tool. In addition to being linked to SDM Implementation, both reading and
health literacy also influence SDM format unilaterally (from Health Literacy / reading to
FORMAT).
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SDM IMPLEMENTATION. This upper level category focuses on the science and strategy behind
implementation of the shared decision making tool. How the SDM tool will interact with all the
upper level categories is unclear. It is unlikely that SDM implementation will impact or influence
health literacy. There are no plans to measure health literacy during SDM implementation.

Representative Codebook
Arranged alphabetically, definitions are provided for the codes shown in the HEALTH LITERACY
depiction above. Categories are listed in bold with upper level categories in UPPERCASE. In
general, a code is the most basic concept or construct present in an interview transcript. A
category reflects a grouping or pool of constructs with a common idea. An upper-level category
reflects the largest amalgamation of information, a pool or sea comprised of rivers of thought.
Categories can serve as codes as well, dependent upon the concept/construct.
Code
academic
information
accomplishment
choice
commitment
COMMUNICATION
comparison
coping

doing better
expectancy
Factors affecting
communication
foreknowledge
Format of SDM
tool / SDM
FORMAT
goal
HEALTH LITERACY

hope

Comment
Medical information obtained from an accredited academic institution
(e.g. Mayo, UIOWA, MSKCC).
Synonymous with completion or achievement.
Ability to choose or option to choose. May be patient, caregiver, or
provider.
Resolved to do something; expended energy or effort to complete.
Upper level category representing the totality of medical experience,
foreknowledge, academic information as well as commercial information
sources.
Patient-specific attribution.
Synonymous with "cope with." Deal with and attempt to overcome
problems and difficulties. Primarily patient construct; could be used with
caregiver as appropriate.
Subjective assessment that frank symptoms of disease or treatment
emergent adverse events are improving or have improved. This
assessment can be made by patient, caregiver, or provider.
Anticipation of results or outcome
Category encompassing things that impact communication negatively or
positively. Not to be confused with characteristics & context, which are
properties and/or traits.
A patient's or caregiver's familiarity with cancer, the healthcare system, or
medicine in general.
Upper level category representing pool of information regarding the
format, design, and graphical layout of the shared decision making tool
Synonymous with aim; the desired end-result treatment.
Upper level category; defined by Institute of Medicine as the degree to
which individuals have the capacity to obtain, process, and understand
basic health information and services needed to make appropriate health
decisions.
To want something to happen or be true
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Code
information root
inspiration
Internet search
medical experience
medical literacy
new normal
patient abilities

Patient reported
outcome

Patient to provider
communication
printed education
documents
proactive
prognosis
provider to patient
communication
reading
SDM
IMPLEMENTATION
self-reliance
slow reader
TV commercials

Comment
The recognition that the information is not available to the patient or
provider and they cannot act due to the lack of information. The
information root is missing.
An influence or action that is used to keep momentum, positivity, or faith.
Using the internet as a source of information about the cancer, treatment,
or side effects.
Patient's medical experience prior to receiving radiation therapy.
Ability to obtain, read, understand, and use healthcare information in
order to make appropriate health decisions and follow instructions for
treatment.
A lifestyle, activity level, or physical issue (taste, cough) that is not
consistent with life prior to the disease or treatment.
The physical, emotional, or social abilities of a patient. These are typically
queried in quality of life assessments as well physical examinations. Should
not be confused for Activities of Daily Life which are those specific
activities that are assessed for adverse event severity and criteria.
Category and code. An outcome (disease outcome, treatment outcome)
as reported frankly by the patient. This may include an adverse event if
the event aligns with a final outcome (e.g. weight gain, hair loss) rather
than a treatment emergent event. Often, this is in summary or retrospect
and in the framing of a response to therapy; can also include a lack of
response to therapy.
Category and code. Communication initiated by the patient to the
provider, as per the patient. This is a one-way conversation; for quotes
where both parties discuss (i.e. patient is responding to provider, or
provider then responds to patient) consider 'information sharing."
Education materials in printed format provided to the patient and/or their
caregiver.
Self-actuation or care; patient putting self-first to ensure best treatment,
best outcomes.
Expected trajectory and outcome of therapy.
Communication centered around, or from, the provider to the patient - as
per patient. This is a one-way conversation; for quotes where both parties
discuss (i.e. patient is responding to provider, or provider then responds
to patient) consider 'information sharing.’
Information that was conveyed by reading and/or the preference to read.
Upper level category representing pool of information regarding
implementation of a shared decision-making tool for patients diagnosed
with lung cancer undergoing radiation therapy at a Midwestern academic
hospital.
Patient relying on self through treatment and post-treatment
Having a slow reading speed, limiting reading functionality
Information about cancer treatments obtained from television
commercials
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APPENDIX I: LINKAGES AND RELATIONSHIPS FOR SYMPTOMS
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The most commonly patient-identified symptoms are fatigue, nausea, vomiting, dyspnea and
malaise, all of which are subjective, variable by patient, and negatively impact activities of daily
life and all of which can be more consistently quantified utilizing a shared-decision making tool.
– It’s awful. You’re more tired then... this normal tired you’re supposed to be experiencing.
And…you can’t eat, and you know, you don’t want to do anything but lay on the couch or
your bed.
– Well, I…. I wake up most of the time and I’m still tired.
– So, when you poke 7 pills one day, 7 the next day. So that was 14 pills dumped down in me
and then try to drink enough water to dilute them…and I just couldn’t do it and then I got
sick and I couldn’t take my regular pills. I would put ‘em in my mouth. I’d drink water. They
would come right back up…I’d just … I’d give up at a point.
– Since I don’t have any usual or daily activities …or anything to do… it really doesn’t interfere
with anything. All I do is watch TV.
– The burn on my back… it didn’t show up until I went home. And the nausea too. Everything
was delayed until I was done with it.

Analytic Memos
In total, seventy-three codes and categories are linked to symptoms. However, there are only
16 direct links to symptoms of which 5 are source links (i.e. originating from symptoms) and 11
are target links (i.e. moving to symptoms). Of these links, of these, 7 are codes, 5 are categories,
and 4 are upper level categories (i.e. conceptual categories, ATLAS.ti ‘nodes’). These 16 are
described below.

Codes
Burden is a direct result of symptoms represented by a unilateral relationship. Burden was
identified explicitly only once (“…(caregiver) … asking if it is okay if they come and pick it up
now and those types of things.”) but is also implied in quotes such as “In fact, I have my sister
do most of it,” as well as, “Some of the side effects kinda scare me from what they say. But my
husband’s like, ‘and it is if. IF IF IF.’” Burden encompasses not simply physical support from
family, friends, and caregivers, but also pthe psychological and social support. Burden remains
intangible but continually present, most likely impacted by COVID-19 (perhaps heightened),
and reminds of the possibility of an unreliable patient narrator, as the patient may attempt to
minimize symptoms in order to reduce burden.
Patient abilities are the participant’s insights into their functions: “Can I actually do this? Am I
able to?” as well as “Cause they would take me longer. Um, to do that type of stuff. Where you
do one thing, and you have to sit and rest.” Patient abilities also refers to the participant’s
abilities to complete the sample questions provided (“I can answer any of these. I would
think.”).
Provider-to-patient question is a code capturing provider prompts to further assess adverse
events as well as encourage discussion between provider and patient. Four of the six
participants commented on provider questions, from “What can I do to make your day better?”
to “Are you having any pain?” as well as “Anything else you want to talk to me about?”. Prompts
are identified through participant recall. Provider prompts were described as similar to quality
of life questions provided as samples to participants (“That’s a lot of things they asked me. Not
in a form like this. They did it verbal.”)
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Recall. This code is the action of a participant remembering details regarding diagnosis,
treatment, and decision making. Recall, as a whole, was inconsistent, with deficits in memory
regarding key points in the cancer journey (i.e., treatment options, decisions). Lapse or
inconsistent recall could be a function of stress or chemotherapy.
Self-care is a code that reflects the participant’s care for self (i.e., physical, social, psychological
spiritual, emotional). Self-care was described by five of the participants, with supportive quotes
including the physical (“I talked to them about getting the flu shot since I wasn’t sure.”), social
(“[my brother and sister-in-law] just wanna take me out for dinner with them. I forget the place
she said.”) and psychological (“But I already told them I need a break. You gotta give me some
time off.”). However, quotations supporting explicit emotional self-care or spiritual self-care
were not identified. Although emotional could be seen as part of the psychological health
system, spiritualism in the context of self-care was not identified in any transcript. This could
be due to the medical setting of the interview as well as the limited scope of the questions.
Uncertainty. This code captures the concept of the unknown from the participant’s
perspective. As expected, it was identified regarding treatment outcomes (“Not knowing if its
gonna work if you’re doing all this for no reason.”) but also regarding the severity of the
treatment-emergent adverse events that were experienced:
– And I slept a lot! And I still sleep a lot! I sit here, and think, when am I going to get my
energy back? Because I could still sleep a 12-hour day in a heartbeat.
– And part of that is because I’m old or because …. I mean, you slow down. How much of it
is THAT or how much of it is… you know, like I had all this other happen and now I’m not
gonna be 100%. I don’t know.
– I kept wondering – when is this gonna hit me?
This was somewhat unexpected as participants were seen daily throughout their course of
radiation therapy by a variety of medical professionals (e.g., radiation therapists, nurses,
radiation oncologists). This should have provided substantial opportunity to address
uncertainty and provide reassurance. A potential strength of the SDM tool would be to provide
a trend over time for adverse events of interest, which could provide reassurance for individual
patients as well as provide key foundational information for treatment and recovery as a whole.
Variability by patient. Five of the six participants acknowledged the individuality of patients
undergoing therapy and that each would have unique experiences. The majority of the quotes
were variations of a common statement regarding “everybody’s different,” but one quote
stood apart from the rest: “Listening to the patients… the patients know their bodies. They know
what is going on inside their bodies and what isn’t. And that, to me, is one of the first things a
doctor needs to listen.” This quote ties the patient and provider together through
communication and individuality. Ostensibly, the shared decision-making tool addresses this
individuality by allowing the patient to identify the signs/symptoms of concern, addressing the
concerns unique to each individual.

Categories
Activities of daily life. This category captures codes that align with activities of daily life as listed
in the Common Terminology Criteria for Adverse Events (CTCAE). Eating and walking were the
commonly identified. ADLs were not specifically queried during the interviews. Although a
category, activities of daily life was a proscribed category created to gauge the impact of
symptoms and other factors on ADL.
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Anticipated events. Anticipated events are those recalled by the participant as side effects or
symptoms that were to be expected during the course of therapy. Some were explicitly
mentioned (e.g., alopecia, nausea, vomiting) but it also includes broader concepts:
– I knew what was coming, their explanation of what was gonna happen to me was very
precise and helpful
– They had explained the series of chemo and at what point I would not start feeling well or
I could start looking for signs of not feeling well this way or that way or the other way
– I took some medicine and I had a horrendous diarrhea and it wasn’t supposed to affect it
the opposite way.
Recalled anticipated events are significant because they provide insight into what information
made a lasting impression, resulting in retention. Of note, weight loss was not an anticipated
event recalled by participants despite being described as both an anticipated and significant
treatment emergent adverse event.
Factors & context. This category captures codes that either impact symptoms (factors) or
provide detail regarding the event (context). This includes sudden onset (“One minute – you
can be just…fine…doing what you’re doing. And then all of a sudden, it’s just like….your body is
just dropped to nothing.”), delayed events (“My symptoms from the radiation didn’t really show
up until it was all over with.”), intensive care (“I spent the night in intensive care because my
oxygen level wasn’t high enough for me to go home.”), persistent symptoms (“They gave it to
me in the E.R. It didn’t make my symptoms go away.”), as well as not concerned (“He did a very
good job listening to me and my concerns. I really didn’t have any.”).
Patient reported outcome. Slightly different than a patient reported symptom, a patient
reported outcome is a result in the opinion of the participant. This can be a treatment outcome
(“…But that was the day that the tumors had shrunk down completely. Hardly just spots.”), a
symptomatic outcome (“I really did not have any problems with my radiation. I mean everything
went so smoothly with that. It went so smoothly.” “I didn’t lose my hair.”), as well as an overall
assessment of the treatment journey (“And I’m better than I was, I’m doing better than I was.”).
Some patient reported outcomes overlap with symptoms; the primary dividing line is having it
be an outcome or consequence of treatment rather than a concurrent event.
Patient reported symptom. The largest category, this group of codes is comprised of adverse
events/symptoms as reported by the participants. This category includes baseline symptoms
(“…I could tell every week I was getting worse. Ended up having almost about a liter of fluid
behind my lung.”), treatment emergent events (“…my throat started getting worse 2 to 3
weekends ago… yesterday’s meal was quite harsh trying to swallow that one.”), adverse events
due to concurrent events (“I got sick in the bathroom and the nurse took me to the E.R. I spent
8 hours there and they said, ‘We’re gonna take your gallbladder out.’”) as well as generalized
adverse events (“I’ve, uh, just been dealing with mainly the side effects from chemotherapy are
mainly what messed with me.”). This category provides the customary rich and thick detail of
the patients’ experiences during the treatment journey. This becomes key to the shared
decision-making tool to provide the context required to increase pragmatism and patient-level
understanding. For example, one participant noted, “Unbelievable amount of sleep… watching
a movie… I don’t think I’ve seen four shows in the last week from beginning to end.” This is not
reflected well in the only PRO-CTCAE question for fatigue (In the last 7 days, what was the
SEVERITY of your FATIGUE, TIREDNESS OR LACK OF ENERGY at its WORST? None, Mild,
Moderate, Severe, or Very severe) but PROMIS item bank has the question How often were
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you too tired to watch television? Thus, this pivots question selection away from the NCI’s
developed PRO-CTCAE and toward the more granular questions that align with a patient’s daily
experience while undergoing treatment.

Upper Level Categories / Conceptual Categories
COMMUNICATION. Shared decision making is an intersection of SYMPTOMS and
COMMUNICATION; the interaction between the two upper level categories is a bilateral
association. Of interest, patients conveyed understanding that communication regarding side
effects / symptoms was critical for their care. One participant likened this communication to a
safety net (“…you’re coming every day for radiation, and that was also sort of a safety net.
Because if you didn’t feel good from one day to the next, you knew you were coming back. And
you could ask somebody the question…”). Another admitted they failed to communicate as they
should have and that led to emergency care (“And if you got problems and you need help, you
as the patient have to ask because they don’t know. And if you don’t ask, like I don’t sometimes,
they’re not gonna know that there’s a problem.”). Participants had a favorable view of MyChart
and were critical of individuals who failed to use it (“Those are things out there for people to
use to reduce the time. But if they don’t use them, they need to stand in line.”) “Toughed it out,”
is the code within symptoms that confounds communication and shared decision making,
representing a concept of self-reliance that becomes detrimental to the patient. This was
described by three participants:
– They kept saying a lot of this stuff was gonna happen but it never happened until I got
home. And then I said, “Well, it’s happening now.” It happened like they described it. I just
felt it and got over it.
– I should have [called the doctor] when I got sick on the pills (laughs boisterously). I just
thought, ‘You know, I have a really bad stomach anyways.’
– I sorta limped along
This concept is most likely influenced by the concepts of burden and self-reliance. It is apparent
from the interviews (50%) that the toughed it out concept was as strong, or stronger, than the
knowledge a patient must communicate with a provider. Instituting a shared decision-making
tool to identify and quantify adverse events of special significance provides normalcy and
expectation, shifting symptoms from a compliant to a rote process. With this pivot, reviewing
and communicating regarding symptoms is acknowledged as anticipated, acceptable
assessment to succeed in therapy. Thus, the SDM tool may tilt communication patterns away
from toughing it out back to information sharing.
TREATMENT. Treatment refers to the antineoplastic therapy and not for adverse events or
symptoms. Treatment is directly associated with symptoms logically as well as through
description by the patient participants. In practice, symptoms associated to treatment are
termed treatment emergent events; for the purposes of this research, treatment associated
are the patient-recalled ‘anticipated events,’ which were collected through direct query during
the interviews. Anticipated events represent a small fraction of the symptoms described by
participants but are of interest for the shared decision-making tool, as they suggest treatment
would need to be modified and/or paused if the symptoms are too severe. Again, it is also
interesting what anticipated events were recalled by participants compared to which side
effects providers consider to be the most important or concerning.
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SDM IMPLEMENTATION. This upper level category focuses on the science and strategy behind
implementation of the shared decision-making tool. How the SDM tool will interact with all the
upper level categories is unclear, but the goal is that the SDM will positively impact
communication through information sharing. Implementation of the SDM will impact
documentation of symptoms / side effects; if implemented as designed, it should provide
consistent documentation, using standardized definitions of severity and harmonized terms.
SDM FORMAT. This upper level category focuses on the graphical design of the SDM tool,
including the presentation of data. Symptoms provide the key information for the SDM tool,
with six symptoms / goals collected on the tool (3 from the patient, 3 from the provider). In
addition to the symptoms, participants identified granularity as important, commenting that
PRO-CTCAE was too general as well as timeframe. For example, participants questioned how
to categorize the framing of “the past seven days,” – did it include weekends or holidays? Most
interestingly, despite the favored viewpoint of MyChart, participants preferred to have paper
to hold and take with them from provider to provider:
– You can just hand it to them and they could go over it with you.
– This would be helpful for me because they could have referenced this stuff. Some doctors
take good notes and other doctors don’t. This could have been a reference for all the other
doctors this would be helpful.
– That way if I’m home, and I had a piece of paper, and all of a sudden I hit that side effect I
could say, ‘Oh, this and…. Hmmm, call in!’

Representative Codebook
Arranged alphabetically, definitions are provided for the codes shown in the SYMPTOMS
depiction above. Categories are listed in bold with upper level categories in UPPERCASE. In
general, a code is the most basic concept or construct present in an interview transcript. A
category reflects a grouping or pool of constructs with a common idea. An upper-level category
reflects the largest amalgamation of information, a pool or sea comprised of rivers of thought.
Categories can serve as codes as well, dependent upon the concept/construct.
Code
acceptance
accomplishment
Activities of daily
life
alopecia
anorexia
anticipated events
arthralgia
baseline symptoms

Comment
Accepting the situation, information, or occurrence; no longer attempting
to change the situation.
Synonymous with completion or achievement.
Category and code. Activities performed daily by the patient. This can
include Instrumental ADL (e.g. preparing meals, shopping for groceries or
clothes, using the telephone, managing money) as well as self-care ADL
(e.g., bathing, dressing and undressing, feeding self, using the toilet, taking
medications)
Defined in CTCAE 4.03. Hair loss.
Defined in CTCAE 4.03. Loss of appetite.
Adverse events or side effects that were expected to occur in the opinion
of the patient, caregiver, or provider.
Joint pain; MedDRA term
Symptoms that are present prior to the initiation of treatment; consistent
with underlying disease, age, and/or other.
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Code
burden
burning
caregiver identified
medical need
chemotherapy
reaction
chest pain
cognitive
disturbance
commitment
COMMUNICATION
communication
expectation
concerning
symptom
constipation
coping

cough
dehydration
dermatitis
radiation
diarrhea
dysphagia
dyspnea
dyspnea PROMIS
edema - limb
esophagitis
Factors & context
fatigue
fever

Comment
The subjective opinion or feeling that the patient is causing extra work,
effort, or cost to family and caregivers.
CTCAE, other: subjective sensation similar to being scalded by hot water
or injured by a hot surface.
A need (physical, psychological, social, emotional) identified not by the
patient but by a caregiver.
An adverse event directly attributed to chemotherapy by the patient,
caregiver, or provider.
Defined by CTCAE 4.03: discomfort in the chest; may or may not be related
to a cardiac issue
A disorder characterized by a conspicuous change in cognitive function.
Resolved to do something; expended energy or effort to complete.
Upper level category representing the totality of medical experience,
foreknowledge, academic information as well as commercial information
sources.
Expectations regarding communication whether it is patient, caregiver, or
provider.
An adverse event that is concerning to the patient, caregiver, or provider
and most likely requires notification or intervention.
Defined in CTCAE 4.03: use of laxatives or nutritional intervention to
stimulate bowels.
Synonymous with "cope with." Deal with and attempt to overcome
problems and difficulties. Primarily patient construct; could be used with
caregiver as appropriate.
Defined in CTCAE 4.03: A disorder characterized by sudden, often
repetitive, spasmodic contraction of the thoracic cavity, resulting in
violent release of air from the lungs and usually accompanied by a
distinctive sound.
Defined in CTCAE 4.03: excess loss of water from body.
Defined in CTCAE 4.03: cutaneous inflammatory reaction occuring as a
result of exposure to biologically effective levels of ionizing radiation.
Defined in CTCAE 4.03: an increase of at least 4 stools per day over
baseline.
Defined in CTCAE 4.03: difficulty in swallowing.
Defined in CTCAE 4.03: shortness of breath
Dyspnea questions using PROMIS question bank
Defined in CTCAE 4.03: swelling due to excessive fluid accumulation in the
upper or lower extremities.
Defined in CTCAE 4.03: inflammation of the esophageal wall
Category encompassing things and situational context that impact
symptoms positively or negatively.
Defined in CTCAE 4.03: state of generalized weakness with a pronounced
inability to summon sufficient energy to accomplish daily activities.
Defined in CTCAE 4.03: body temperature of at least 38°C
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Code
Format of SDM
tool / SDM
FORMAT
gagging
gastroesophageal
reflux disease
generalized
adverse reaction
hypokalemia
hypoxia
lifestyle activity
lifestyle food
lung infection
malaise
memory
impairment
mucositis oral
nausea
new normal
obstruction
odynophagia
out of town
pain
patient abilities

Patient reported
outcome

Patient reported
symptom
prior normal

Comment
Upper level category representing pool of information regarding the
format, design, and graphical layout of the shared decision making tool
adverse event associated with the sensation of choking when swallowing
or eating.
synonymous with acid reflux and GERD. Occurs when stomach acid
frequently flows back into the tube connecting your mouth and stomach
(esophagus).
A side effect or adverse event that is non-specific but attributed to a
treatment, drug, or device.
Defined in CTCAE 4.03: a potassium level below the lower limit of normal.
Defined in CTCAE 4.03: an oxygen saturation of less than 88% with
exertion and/or indication for supplementation
Patient's lifestyle; may be pre-treatment, during treatment, or posttreatment
Eating habits pre-treatment, post-treatment, and during treatment
Defined in CTCAE 4.03: active infection of the lung, connotatively
consistent with pneumonia
Generally unwell; synonymous will ill feeling, unwell, and / or felt ill.
Inability to remember; may or may not be related to chemotherapy.
Frank adverse event to capture oral sores within the mouth often
associated with antineoplastic therapy. MedDRA term.
Defined in CTCAE 4.03: queasy sensation with or without urge to vomit
A lifestyle, activity level, or physical issue (taste, cough) that is not
consistent with life prior to the disease or treatment.
Subjective obstruction due to tumor
pain with swallowing
Patient lived outside of town where treatment center was located.
marked discomfort
The physical, emotional, or social abilities of a patient. These are typically
queried in quality of life assessments as well physical examinations. Should
not be confused for Activities of Daily Life which are those specific
activities that are assessed for adverse event severity and criteria.
Category and code. An outcome (disease outcome, treatment outcome)
as reported frankly by the patient. This may include an adverse event if
the event aligns with a final outcome (e.g. weight gain, hair loss) rather
than a treatment emergent event. Often, this is in summary or retrospect
and in the framing of a response to therapy; can also include a lack of
response to therapy.
Category and code. Patient's reported symptom that may or may not be
endorsed by the physical exam or provider. Typically, treatment or disease
related and is an unwanted side effect.
The lifestyle, activities, or physicality (taste, strength, for example) that
existed prior to the cancer or treatment
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Code
prolonged effort
provider to patient
question
radiation related
symptoms
recall
relationship
routine illness
SDM
IMPLEMENTATION

self-care
self-reliance
SYMPTOMS
throat pain
thromboembolic
event - superficial
treatment /
TREATMENT
uncertainty
variability by
patient
verbal
communication
vomiting
weight gain
weight loss
white blood cell
decreased
working through

Comment
An increased amount of time, effort, or both to accomplish an activity as
compared prior to disease and/or treatment.
Questions directed to the patient from the provider, as per patient
Adverse events known to be related to radiation therapy.
The patient's ability to recall - or strategy to recall - information. This is
different than memory impairment or cognitive disturbance, which are
adverse events/symptoms.
Social or romantic relationship
An illness that is deemed common and not considered associated to
cancer, the pandemic, or side effects of treatment - for example, the
common cold.
Upper level category representing pool of information regarding
implementation of a shared decision making tool for patients diagnosed
with lung cancer undergoing radiation therapy at a Midwestern academic
hospital.
Patient taking care of self during treatment and after. Includes proactive
treatment to reduce symptoms, side effects, or stress as well as care to
maintain or improve the domains of health: physical, psychological, social,
emotional, spiritual.
Patient relying on self through treatment and post-treatment
Upper level category representing pooled information regarding
symptoms, side effects, and adverse events.
sore throat
Defined in CTCAE 4.03: blood clot not requiring emergent intervention
Upper level category and code. Medical treatment, including surgery,
radiation therapy, chemotherapy, nutritional support, and emergency
care for the lung cancer.
Uncertainty regarding treatment outcomes, side effects, or the future.
Individuality of patients impacting treatment, diagnosis, and shared
decision making.
Verbal communication
Defined in CTCAE 4.03: emesis occurring at least once in a 24 hour period
weight gain of more than 5% from onset of treatment or disease.
Loss of at least 5% during the treatment.
Defined in CTCAE 4.03: white blood cell decreased to less than the lower
limit of normal.
Maintaining an outside job or career during treatment
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APPENDIX J: LINKAGES AND RELATIONSHIPS FOR TREATMENT
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Treatment is linked to the patient experience, and thus shared decision making, through
symptoms and patient reported outcomes. This reminds us that the impact of shared decision
making on treatment is secondary and influenced by the lens of patient reported outcome
measures (symptoms, treatment outcomes). This aligns with the research question, which seeks
to identify the collaborative decision-aid tool regarding side effects and symptoms (not
treatment).
– So, they immediately jumped on you know, “We need the medicine for this and that. You
need to do this and that.” It’s not like they ignore you when you say there’s something
wrong. They check it out.
– They suggested Lubriderm, which is what I put on it. And that took care of … they’re like,
“We’re gonna dry your skin out.”
– They had me on 3 different pills of medication to help with the nausea so I never noticed
it.
– They were gonna get me in right away to find out what the infection was. So, they were
gonna schedule me for some procedure the next day…Okay, fine. And then they called
back: “We can’t do that procedure because you have to have a COVID test.”

Analytic Memos
In total, forty-six codes and categories are linked to treatment. However, there are only 13
direct links to treatment of which 5 are source links (i.e. originating from treatment) and 8 are
target links (i.e. moving to treatment). Of these links, of these, 7 are codes, 1 is a category, and
1 is an upper level category. These 13 are described below.

Codes
Choice is key to patient autonomy for treatment. In the interviews, choice was touched upon
regarding treatment for symptoms but was not explicitly recalled for treatment of the tumor.
Logically, as well as legally, autonomy and choice are critical for any treatment decision, most
notably for the therapy for the tumor. A common sentiment expressed by most participants
was that they were sure there had been a discussion regarding antineoplastic treatment but
they could not remember it. Only one participant had the opinion there was no choice for
primary treatment (“[T]hey say this is what you need to do. And that was about it.”). Most
subjects described being offered choices for treatment for side effects/symptoms; this is
notable as it is the focus of this research and the target of the shared decision making tool.
Examples include:
– The tums, like I said, and they were available to give me something else if that didn’t work
but that worked fine.
– The nurse was, she was really sympathetic about it, but then at the end she’s like “You are
either up here today or you are in Fairfield. One or the other. You have no options.”
– One of those nurses would say to me, If you have any problems with this, that or this,
vomiting or whatever, and you think it is unusual, do not hesitate to call these numbers.
And actually, when I, you know and we were early on and I got that infection we DID call
the number because it’s like, “Oh my gosh my temperature’s over 101.5°F.”
It is interesting that participants discussed treatments for symptoms / symptom management
organically (i.e., without direct query) but did not recall discussions regarding their primary
antineoplastic treatment despite direct query. Patients were certain they had the discussion
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but could not recall direct information provided to them. Although this is interesting, the
absence of recall regarding primary therapeutic decision is out of scope of the research
question. It is also interesting, and supportive of the research question, that patients recalled
the choices provided to them regarding symptom management. This suggests a sense of
control the patients have in these treatment decisions as well as being part of the treatment
team. This supports an environment that is ready for implementation of a shared decision
making tool, as both providers and patients are comfortable with patient-directed choice to
manage side effects of treatment and symptoms of disease.
Clinical Trial. Of the patients interviewed, one was considered for a clinical trial and two others
were treated on a clinical trial. These three patients were comfortable and well versed in
aspects of the clinical trial, including the required staging to enter into a clinical trial (“[F]or this
study they staged me as a III…They changed the staging criteria for me to go into their study.”),
the investigational drug being withheld due to adverse events (“I couldn’t have my [study drug]
that day because my temperature was too high.”), the significance of a placebo control and its
impact on their treatment (“But the placebo is a pretty strong thing there, you know?”) and the
ability to stop research treatment at any time (“Same with this [points to study infusion]. Said I
could stop at any time if I wanted.”). Although – again – the key rationale or discussion for
consenting to trial participation is absent, this recall of key legal elements of consent suggests
the clinical trials team is providing effective and continual informed consent for these patient
participants. Mirroring this strategy when implementing the shared decision making tool could
lead to an earlier determination of the impact (if any) of the SDM on outcomes of interest.
Delay in seeking treatment is a concept that negatively impacts treatment as it represents an
acknowledged (deliberate) delay in seeking treatment for the cancer (“That Friday of… of our
last day of school I went to the doctor at that point. And uh that’s when they said they thought
it was bronchitis and that’s how they treated me for it. Um, and then, you know … I didn’t get
better…”) or adverse events (“So I finally called and then got yelled at by them. (laughs). Not
really yelled at…but, I should have called them the very first day.”). This code is only present
twice but represents a strong concept of denial as well as intertwining with the code of
Toughed It Out, which is similar but not synonymous. The shared decision making tool may be
able to address this barrier by (1) providing an objective assessment to guide the patient /
caregiver when to call in as well as (2) preventing escalation of symptoms through proactive
identification.
Doing better is a patient assessment that compares change over time for a symptom, side
effect, or generalized health. It is associated with treatment and creates the bridge between
goal and treatment. This highlights a concept for consideration of the shared decision making
tool: changes in symptoms over time, not simply for prevention of a serious adverse event but
also to provide progress toward a goal. “You don’t realize how bad you were until…you’re a
little bit better. And you realize how…how difficult it was.”
Expedient treatment is a property of treatment and it positively affects patient approval, which
then influences communication. This creates a bridge and indirect relationship between
treatment and communication. This is summarized best in the quotation “Things went quickly
for me. And I appreciate that.” This is related with the code immediate response, which
addresses a similar yet slightly different concept. This code focuses on the patient’s treatment.
Immediate response is a part of treatment and the result of a concerning symptom. Logically,
a concerning symptom is identified by the treating physician or allied healthcare team; for the
purposes of this project, a concerning symptom was one which the patient was instructed to

323
call in for should it occur (“If it was something that spooked me or something, I could call and
talk to someone on the team.”). This code captures the healthcare provider’s immediate
response to assess or address a symptom or initiate treatment: “He goes, uh, ‘I’m gonna have
you run down to do this scan.’ The girl put me in the wheelchair and it was right close to five
and they wanted to get me there before 5. She like literally ran pushing me in this cart.”
Although this code creates a link between concerning symptoms and treatment, it does not
otherwise appear with the other upper level categories.
Prognosis influences treatment but otherwise does not appear to provide significant
interaction for shared decision making tool, as it resides in the foundation of diagnosis and
prognosis, which then feeds into treatment. Logically, one could argue that prognosis is
influenced by compliance with treatment, self-care, and symptoms; however, this was not a
connection described by the patients.
Self-care is associated with treatment but is also associated with symptoms as well as being a
part of activities of daily life; patient abilities is a code that is responsible for self-care. None of
these codes tie back to communication except through symptoms. This again emphasizes the
need to recognize the relationship between communication and symptoms to address
appropriate treatment, which addresses the research question for shared decision making
(“What he suggested and I followed his guidance which was spot on and very good.”)
Toughed it out is a part of coping and associated with self-reliance, self-care, and treatment;
most notably, it is a cause of emergency care. Toughed it out is the concept of a patient
knowing they should address a symptom or side effect with their healthcare provider but
instead choosing to shoulder through and suffer through the effects, rather than address them
and/or ask for help. Not surprisingly, this resulted in emergency care for patients endorsing
this behavior. The rationale or reason for this action is unknown; patients describing this
behavior also acknowledged that they should not have engaged in it and should have sought
attention earlier. (“And she goes, ‘You should have called me the first day, not now.’ I said, ‘I
realize this.’”). Logically, toughed it out could be though to serve as a nexus between
symptoms, communication, and treatment – a negative concept that could entangle all three.
This was not described by patients other than choosing to tolerate their symptoms rather than
acknowledge their severity (or, perhaps, not believing they were severe enough to
acknowledge). With this framing, the shared decision making took could impact both toughed
it out and treatment, as it provides a rote mechanism to describe the impact of treatment and
the symptoms of disease – allowing evaluation and discussion without the judgement of
‘severity,’ or the connotation of, ‘complaining,’ or being ‘needy.’ In this framing, the SDM tool
could be an equalizer, creating a psychological safe space to openly discuss what the patient is
experiencing so the patient does not feel judged or demanding.
Treatment non-compliance is a barrier negatively impacting treatment as well as negatively
impacting patient to provider communication. Only two patients described non-compliance,
one regarding not calling in severe nausea/vomiting after not being able to take the prescribed
antiemetics and the second not picking up a prescription to address a side effect. This is similar
to toughed it out with the exception that it captures not taking a medication as prescribed. For
adverse events of concern (nausea, vomiting, esophagitis), it may be reasonable the SDM tool
also have a checkbox to assess if patients have been taking medication to address the symptom
(simply yes/no). This will enable a provider to assess if further intervention is needed and/or
communication.
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Trust in provider positively impacts treatment but also positively impacts information sharing;
the codes intelligence, provider held knowledge, direct, and provider personality also positively
impact trust in provider. Lastly, provider-to-provider communication influences trust in
provider as does the code/concept team. This creates a relatively complex association for trust
in provider when extending to treatment, which is the only upper level category it connects to
directly. Thus, to positively impact treatment, the trust in provider must be impacted. To do
this, we must increase provider held knowledge and, preferably, that should be provided
directly to the patient. The shared decision making tool should increase direct transfer from
patient to provider, increasing provider held knowledge which should then impact treatment.

Categories
Patient reported outcome. Slightly different than a patient reported symptom, a patient
reported outcome is a result in the opinion of the participant. This can be a treatment outcome
(“…But that was the day that the tumors had shrunk down completely. Hardly just spots.”), a
symptomatic outcome (“I really did not have any problems with my radiation. I mean everything
went so smoothly with that. It went so smoothly.” “I didn’t lose my hair.”), as well as an overall
assessment of the treatment journey (“And I’m better than I was, I’m doing better than I was.”).
Some patient reported outcomes overlap with symptoms; the primary dividing line is having it
be an outcome or consequence of treatment rather than a concurrent event.

Upper Level Categories / Conceptual Categories
SYMPTOMS. An adverse event is defined by FDA as an untoward medical event that occurs
during the contact of a clinical trial; this is then extended to an event that occurs during routine
clinical care. There is a subtle nuance for this study that patient-reported symptoms are those
that the patient reported but have not been confirmed by physical exam. Additionally,
anticipated events are those side effects a provider noted were possible but may not have
been realized. Concerning symptoms are those that necessitated urgent intervention,
emergency care, or intensive care. Symptoms can also be present at baseline, consistent with
the underlying disease or another comorbidity. Symptoms serves as a critical upper level
category for the research question, as it is partnered to communication to create the shared
decision making tool. Special interest was taken in the symptoms that were most commonly
commented on by participants (fatigue, dyspnea, nausea, vomiting) as well as those that
appeared to significantly interrupt their daily life (fatigue, edema, cognitive impairment). It is
interesting to note participants consistently noted prompting about symptoms across
providers. This provides an opportunity for the SDM tool to capture this information
consistently. Symptoms is the only upper level category connected directly to treatment; thus,
in order to impact treatment, the shared decision making tool must impact symptoms.

Representative Codebook
Arranged alphabetically, definitions are provided for the codes shown in the TREATMENT
depiction above. Categories are listed in bold with upper level categories in UPPERCASE. In
general, a code is the most basic concept or construct present in an interview transcript. A
category reflects a grouping or pool of constructs with a common idea. An upper-level category
reflects the largest amalgamation of information, a pool or sea comprised of rivers of thought.
Categories can serve as codes as well, dependent upon the concept/construct.
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Code
academic medicine
Activities of daily life

approval
characteristics &
context
choice
clinical trial
COMMUNICATION

concerning symptom
coping
COVID-19
delay in seeking
treatment
direct
doing better
emergency care
examination
expectancy
expedient treatment
goal
HEALTH LITERACY

immediate response
information sharing
intelligence

Comment
Medical care provided through the educational apprenticeship
method (e.g. student, resident, fellow).
Category and code. Activities performed daily by the patient. This
can include Instrumental ADL (e.g. preparing meals, shopping for
groceries or clothes, using the telephone, managing money) as well
as self-care ADL (e.g., bathing, dressing and undressing, feeding
self, using the toilet, taking medications).
to speak or think favorably of; pronounce or consider agreeable or
good; judge favorably
Category encompassing characteristics & situational context of
communication.
Ability to choose or option to choose. May be patient, caregiver, or
provider.
A therapeutic option involving an investigational medical product or
device. Aligns to the NIH definition.
Upper level category representing the totality of medical
experience, foreknowledge, academic information as well as
commercial information sources.
An adverse event that is concerning to the patient, caregiver, or
provider and most likely requires notification or intervention.
Synonymous with "cope with." Deal with and attempt to overcome
problems and difficulties. Primarily patient construct; could be used
with caregiver as appropriate.
Disease caused by SARS-CoV-2; this can refer to the frank disease or
pandemic precautions due to COVID-19.
Patient delays seeking care despite indications it was medically
necessary.
Direct communication strategy and/or methods; using direct
language.
Subjective assessment that frank symptoms of disease or treatment
emergent adverse events are improving or have improved. This
assessment can be made by patient, caregiver, or provider.
Requiring emergency care, may be at a local facility or at
emergency room.
Physical exam by provider for medical evaluation or determination.
anticipation of results or outcome.
Treating quickly but not due to an emergent need.
Synonymous with aim; the desired end-result treatment
Upper level category ; defined by Institute of Medicine as the
degree to which individuals have the capacity to obtain, process,
and understand basic health information and services needed to
make appropriate health decisions.
Patient, caregiver, or provider responded immediately.
Information sharing (back and forth) between at least two parties:
provider, patient, caregiver.
Smart; having high mental acuity.
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Code
isolation
medicine by committee
multiple providers
new information
patient abilities

Patient reported
outcome

patient to provider
communication
persistent symptom
prognosis
provider held
knowledge
provider held power
provider personality
provider to provider
communication
recall
SDM IMPLEMENTATION

SDM: treatment matrix
self-care

Comment
Frank or subjective separation from caregiver, family, or other
providers.
Negative connotation regarding the use of multiple providers in
providing a single treatment.
Healthcare requiring multiple providers, whether they are within
the same clinic, the same center (e.g., Cancer Center, Pulmonary),
or institution.
New medical information regarding treatment or side effect.
The physical, emotional, or social abilities of a patient. These are
typically queried in quality of life assessments as well physical
examinations. Should not be confused for Activities of Daily Life
which are those specific activities that are assessed for adverse
event severity and criteria.
Category and code. An outcome (disease outcome, treatment
outcome) as reported frankly by the patient. This may include an
adverse event if the event aligns with a final outcome (e.g. weight
gain, hair loss) rather than a treatment emergent event. Often, this
is in summary or retrospect and in the framing of a response to
therapy; can also include a lack of response to therapy.
Communication initiated by the patient to the provider, as per the
patient. This is a one-way conversation; for quotes where both
parties discuss (i.e. patient is responding to provider, or provider
then responds to patient) consider 'information sharing."
Context and/or factor of adverse event. Symptom persists despite
treatment, self care, or intervention. May, or may not, increase in
severity from initial presentation.
Expected trajectory and outcome of therapy.
Information about the disease and/or treatment that the provider
holds and needs to share.
Power that the provider has over the treatment.
The personality of the provider and its impact in communication.
Communication between the providers, as per patient.
The patient's ability to recall - or strategy to recall - information.
This is different than memory impairment or cognitive disturbance,
which are adverse events/symptoms.
Upper level category representing pool of information regarding
implementation of a shared decision-making tool for patients
diagnosed with lung cancer undergoing radiation therapy at a
Midwestern academic hospital.
Regarding the SDM treatment matrix (the table of outcomes and
adverse events.
Patient taking care of self during treatment and after. Includes
proactive treatment to reduce symptoms, side effects, or stress as
well as care to maintain or improve the domains of health: physical,
psychological, social, emotional, spiritual.
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Code
self-reliance
SYMPTOMS

Comment
Patient relying on self through treatment and post-treatment.
Upper level category representing pooled information regarding
symptoms, side effects, and adverse events.
team
Positive connotation regarding the multiple providers involved in
the treatment and care of patient. This is the opposite of medicine
by committee code. One of the facets of TEAM is if the subject
describes decisions as "we," rather than "they," and/or describes a
seamless interchangeability with the providers.
toughed it out
The patient forcing themselves to experience an adverse event until
its natural resolution; often, declining to seek support or help.
treatment / TREATMENT Code and Upper level category . Medical treatment, including
surgery, radiation therapy, chemotherapy, nutritional support, and
emergency care.
treatment
patients failing to comply with treatment or supportive care as
noncompliance
prescribed by their provider.
trust in provider
Trusting in the providers for treatment, diagnosis, prognosis, and
managing care.
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Patients described a useful shared decision making tool as one that is paper-based, providing
detail regarding side-effects and symptoms, with a time-frame that addresses weekends and
holidays as well as provides information for providers across multiple clinics. Patient interviews
identify a need for the tool to be simple to address slow reading skills, modifiable to address poor
health literacy, and provide direct instructions to address concerning symptoms.
– You don’t want to ask too many questions.
– [The PRO-CTCAE] is too general!
– I don’t have any usual or daily activities…so… it really doesn’t interfere with anything. All I
do is watch TV.
– This would be helpful for me because they could have referenced this stuff. Some doctors
take good notes and other doctors don’t. This could have been a reference for all the other
doctors this would be helpful.
– [I]f I’m home, and I had a piece of paper, and all of a sudden I hit that side effect I could
say, “Oh, this and…. Hmmm, call in!”
– [The PRO-CTCAE] are pretty wide open…I mean, [the questions] could go back to prior to
you being ill. While you were being sick. So, if you were a patient and you really wouldn’t
know what you were answering. I know in the last 7 days… but what about prior, right now
I’m not, but back then I did.

Analytic Memos
In total, fifty-one codes and categories are linked to SDM Format. Of these 21 are direct links
to SDM Format, of which 2 are source links (i.e., originating from SDM Format) and 19 are
target links (i.e., moving to SDM Format). Of these links, of these, 15 are codes, 3 are
categories, and 3 upper level categories. These 21 are described below.
Compared to the other analyses [treatment, symptoms, communication, health literacy], these
codes are more spartan and far more functional. There is little interpretation and more
directness regarding what should be present, per the patient, to make this functional.

Codes
Context – positive is a code that captures a positive patient reaction to the context of sample
questions provided for review: “’I have trouble starting…’ yeah, it kind of explains what you are
looking for.”
Details is a code that identifies a patient’s positive reaction to the details in a question. “Yeah,
yeah, it gets a little more…a little more in depth, you know, about what you’re able to do.”
EORTC fatigue is a code that indicates a patient’s comment, or preference, regarding the
EORTC fatigue question items. “I would have been too tired to do household chores.”
Granularity; synonymous with details. Details should be merged into granularity.
Information sharing was mentioned by patients as influencing the format of the shared
decision making tool. Examples include “You mean for [the doctor] to just…take some notes
and then give me those notes?” and “Well, I guess a lot of it depends on… what do YOU want
to know?”
Paper: graphics identify areas of transcripts where patients described using a graphic image to
depict information. This was used once only and in the context of prognosis, which is beyond
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the scope of this SDM tool: “The 40 / 60 thing. There you got your circle and there your pie
chart. Not that I need help with 40 / 60 but there are some people who...you know.”
Paper: neutral captures neutral or apathetic feedback regarding the SDM tool as proposed as
a paper chart. This was captured for one subject: “Query: For example, this would be a prompt
to talk about things that the doctor is concerned about. Would this have helped if he had a
chart? Response: Yeah, probably.”
Paper: positive captures positive feedback or positive reactions regarding the SDM tool as
proposed as a paper chart. Responses from patients include suggestions for use (“That would
work. Then you can just hand it to them and they could go over it with you. You could just
answer it without going through everything over again. That’d work.”) as well as simple
emotional responses (“Query: If he had a chart of side effects and what you did for it – would
that be helpful? Response: Oh yeah!”)
Questionnaire review is not a code, per se, but a tag regarding a detailed review / comparison
of the questionnaires. This review provides rich and thick detail about the thought process
behind answering the questions:
– “Since I don’t have any usual or daily activities…or anything to do…it really doesn’t interfere
with anything. All I do is watch TV.” [regarding PRO-CTCAE question: how much did
FATIGUE, TIREDNESS, OR LACK OF ENERGY INTERFERE with your usual or daily activities?]
– “Can’t say I was frustrated doing things that I wanted to do, cause there really wasn’t to
do. I don’t have a gal or anything here with me, so…that would have made a difference!”
[regarding PROMIS question: I was frustrated by being to too tired to do the things I wanted
to do.]
This thoughtful detail provides a logical rationale for answering the patient reported outcome
measures in a manner that is contradictory to the question’s intent. For example, the
participant answered “not at all,” for the PRO-CTCAE question regarding fatigue – the context
and framing is wrong. Depending upon the patient’s interpretation (if I did have usual activities
– would it have interfered?) the answer will be consistent with intent. It is reasonable the
question is answered in the opposite of its intention – that the patient answers “not at all,”
with regard to fatigue because the fatigue has eliminated usual/daily activities in the prior
weeks (and the question is only querying the past 7 days). Fundamentally -what are usual or
daily activities when a cancer patient is undergoing aggressive multimodality therapy? The
reference is off. As one of the patients stated there is no ‘normal.’
Reading captures instances when patients describe reading for the purposes of their selfeducation or cancer treatment. Two patients described reading packets of printed information
from their radiation oncologist. Reading is also associated with academic information, printed
education documents, information sharing and slow reader. Reading is a core concept for the
SDM tool from the patient’s perspective (“I got a lot of paperwork too. And, you know, the
MyChart thing… there would be explanations or the test results anyway on there that you could
read.”) as well as from a logical perspective which supports reading as a foundational
requirement for a text-based shared decision making tool.
SDM: treatment matrix was originally a table of options and morphed into a matrix with choice.
Should be reviewed and possible removed as a code. Non-contributory.
Slow reader is a barrier to reading and influences the format of the SDM tool. For the patient
who acknowledged he was a slow reader, it took 56 seconds to read and internalize the PRO-
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CTCAE questions (n=2) for fatigue. This highlights two aspects of the SDM for slow readers: text
should be kept to a minimum and the text should be consistent from week to week.
Specific is a code that intertwines with context and framing. When reviewing questions, not
only did patients like details/granularity but specificity that reflects their current activities,
lifestyle, or situation. This is highlighted in questionnaire review, which identifies the impact
the lack of aligned specificity can have on capturing patient reported outcome measures.
Timeframe – negative is a code that directly influences the SDM format but also contributes to
the category Question Timeframe. This code captures aspects of the timeframe (e.g., in the
past week, in the past 7 days) of the PROM queries. Because of the potential for negative
impact on the PROM query, it is linked directly to SDM format as well as the category (“I know
in the last 7 days… but what about prior, right now I’m not, but back then I did.”).
Written record is a single instance capturing information that the provider holds, verbally
provides to the patient, and would be beneficial to have written for the patient: “So actually just
writing it down rather than just in his head? Because he comes in and he’s …got it. And I’m sure
it’s written down somewhere.” Facets of this information could be captured in the SDM tool.

Categories
Activities of daily life. This category captures codes that align with activities of daily life as listed
in the Common Terminology Criteria for Adverse Events (CTCAE). Eating and walking were the
commonly identified. ADLs were not specifically queried during the interviews. Although a
category, activities of daily life was a proscribed category created to gauge the impact of
symptoms and other factors on ADL. Activities of daily life can be queried on the SDM tool,
similarly to symptoms, if these are of priority to provider or patient.
PRO-CTCAE is a category marking conversation regarding the PRO-CTCAE, the NCI’s patient
reported outcomes measure. In general, feedback regarding the PRO-CTCAE was that the
questions were too broad. When asked which question style was preferred, none of the
patients selected the PRO-CTCAE question samples for fatigue or dyspnea. (“[PRO-CTCAE],
which would be the most vague. You’re just asking me very much in general how my fatigue
was…. Period.”)
Question timeframe. This collects information regarding the timeframe prompts for patient
reported outcome measures. The codes timeframe-important, timeframe-negative, and
timeframe-interruption pool into this category, influencing SDM format as well as SDM usefulness.

Upper Level Categories / Conceptual Categories
SYMPTOMS. An adverse event is defined by FDA as an untoward medical event that occurs
during the contact of a clinical trial; this is then extended to an event that occurs during routine
clinical care. There is a subtle nuance for this study that patient-reported symptoms are those
that the patient reported but have not been confirmed by physical exam. Additionally,
anticipated events are those side effects a provider noted were possible but may not have
been realized. Concerning symptoms are those that necessitated urgent intervention,
emergency care, or intensive care. Symptoms can also be present at baseline, consistent with
the underlying disease or another comorbidity. Symptoms serves as a critical upper level
category for the research question, as it is partnered to communication to create the shared
decision making tool. Special interest was taken in the symptoms that were most commonly
commented on by participants (fatigue, dyspnea, nausea, vomiting) as well as those that
appeared to significantly interrupt their daily life (fatigue, edema, cognitive impairment). It is
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interesting to note participants consistently noted prompting about symptoms across
providers. This provides an opportunity for the SDM tool to capture this information
consistently. Symptoms is the only upper level category connected directly to treatment; thus,
in order to impact treatment, the shared decision making tool must impact symptoms.
SDM IMPLEMENTATION. This upper level category focuses on the science and strategy behind
implementation of the shared decision-making tool. How the SDM tool will interact with all the
upper level categories is unclear, but the goal is that the SDM will positively impact
communication through information sharing. Implementation of the SDM will impact
documentation of symptoms / side effects; if implemented as designed, it should provide
consistent documentation, using standardized definitions of severity and harmonized terms.
HEALTH LITERACY. This upper level category captures not only medical literacy but also
individual concepts/factors that impact an individual’s use of medical information. For
example, commitment, proactive, comparison, printed education documents, and reading. The
SDM tool format should accommodate varying levels of health literacy to enable
generalizability as well as implementation.

Representative Codebook
Arranged alphabetically, definitions are provided for the codes shown in the SDM FORMAT
depiction above. Categories are listed in bold with upper level categories in UPPERCASE. In
general, a code is the most basic concept or construct present in an interview transcript. A
category reflects a grouping or pool of constructs with a common idea. An upper-level category
reflects the largest amalgamation of information, a pool or sea comprised of rivers of thought.
Categories can serve as codes as well, dependent upon the concept/construct.
Code

Comment

academic information

Medical information obtained from an accredited
academic institution (e.g. Mayo, UIOWA, MSKCC).

accomplishment

Synonymous with completion or achievement.

activities of daily life

Activities performed daily by the patient. This can
include Instrumental ADL (e.g. preparing meals,
shopping for groceries or clothes, using the telephone,
managing money) as well as self-care ADL (e.g., bathing,
dressing and undressing, feeding self, using the toilet,
taking medications).

burden

The subjective opinion or feeling that the patient is
causing extra work, effort, or cost to family and
caregivers.

choice

Ability to choose or option to choose. May be patient,
caregiver, or provider.

context - positive

Positive reaction or feedback to sample item bank
questions (PROCTCAE, PROMIS, EORTC) when discussing
the SDM tool.
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Code

Comment

details

Granularity of questions when discussing the SDM tool.

dyspnea PROMIS

Dyspnea questions using PROMIS question bank.

EORTC fatigue

Fatigue questions using EORTC question bank.

Upper level category representing pool of information
Format of SDM tool / SDM FORMAT regarding the format, design, and graphical layout of the
shared decision making tool
granularity

Detailed context.

HEALTH LITERACY

Upper level category ; defined by Institute of Medicine
as the degree to which individuals have the capacity to
obtain, process, and understand basic health
information and services needed to make appropriate
health decisions.

information sharing

Information sharing (back and forth) between at least
two parties: provider, patient, caregiver.

Information traffic

Category encompassing verbal signals or messages for
communication.

intelligence

Smart; mental acuity.

lifestyle activity

Patient's lifestyle; may be pre-treatment, during
treatment, or post-treatment.

lifestyle food

Eating habits pre-treatment, post-treatment, and during
treatment.

no frustration

frustration was not present with the encounter.

no normal

Activity, lifestyle, or physical symptoms are changing
such that a new baseline or expectation cannot be met.
Nothing is predictable.

no questions

Patient and/or caregiver did not have questions or
concerns regarding the disease, treatment, or outcomes.

out of town

Patient lived outside of town where treatment center
was located.

paper: graphics

Positive feedback regarding the use of graphics (pie
charts, circles) in the SDM tool.

paper: neutral

Neutral feedback regarding the use of paper SDM tool.
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Code

Comment

paper: positive

Positive feedback regarding the use of paper SDM tool.

patient abilities

The physical, emotional, or social abilities of a patient.
These are typically queried in quality of life assessments
as well physical examinations. Should not be confused
for Activities of Daily Life which are those specific
activities that are assessed for adverse event severity
and criteria.

printed education documents

Education materials in printed format provided to the
patient and/or their caregiver.

prior normal

The lifestyle, activities, or physicality (taste, strength, for
example) that existed prior to the cancer or treatment.

PRO-CTCAE

Category and code. Feedback regarding the PRO-CTCAE
fatigue and dyspnea questions.

PROCTCAE fatigue

Fatigue questions using PROCTCAE question bank.

provider held knowledge

Information about the disease and/or treatment that
the provider holds and needs to share.

Question timeframe

Category capturing thoughts and concepts regarding the
timeframe for questions soliciting patient reported
outcome measures [PRO-CTCAE, PROMIS, EORTC]

questionnaire review

A section of transcript with detailed review by a subject
on how he would answer the questions from the 3
different QoL groups.

reading

Information that was conveyed by reading and/or the
preference to read.

recall

The patient's ability to recall - or strategy to recall information. This is different than memory impairment
or cognitive disturbance, which are adverse
events/symptoms.

relationship

Social or romantic relationship.

SDM IMPLEMENTATION

Upper level category representing pool of information
regarding implementation of a shared decision-making
tool for patients diagnosed with lung cancer undergoing
radiation therapy at a Midwestern academic hospital.
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Code

Comment

SDM: treatment matrix

Regarding the SDM treatment matrix (the table of
outcomes and adverse events.

SDM: usefulness

Whether the SDM tool is useful.

self-care

Patient taking care of self during treatment and after.
Includes proactive treatment to reduce symptoms, side
effects, or stress as well as care to maintain or improve
the domains of health: physical, psychological, social,
emotional, spiritual.

slow reader

Having a slow reading speed, limiting reading
functionality

specific

granularity associated with questions, shared decision
making prompts, and evaluations.

SYMPTOMS

Upper level category representing pooled information
regarding symptoms, side effects, and adverse events.

timeframe - important

The timing / framing of the timing is important in the
SDM tool.

timeframe - interruption

Interruptions for holidays and weekends - or treatment
breaks - need to be addressed in the framing for the
question.

timeframe - negative

Problems regarding the timeframe; negative aspects
that need to be considered.

trend over time

pattern of change in symptom, side effect, adverse
event over time. Context / property of SDM tool.

trust in provider

Trusting in the providers for treatment, diagnosis,
prognosis, and managing care.

uncertainty

Uncertainty regarding treatment outcomes, side effects,
or the future.

vague

Related to SDM tool and item questions. Nonspecific or
nongranular questions

working through

Maintaining an outside job or career during treatment

written record

Written record of anticipated outcomes, side effects due
to lung cancer therapy.
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Patients described implementation of an SDM tool as multi-disciplinary, enabling consistent
sharing regarding of patient-reported side-effects and symptoms. If effectively implemented, the
SDM tool could support the gatekeeper function, serving as a single source of information to the
multidisciplinary committee as well as a resource for the patient to know when to escalate
situations and who to contact during holidays and weekends.
– This would be helpful for me because they could have referenced this stuff. Some doctors
take good notes and other doctors don’t. This could have been a reference for all the other
doctors this would be helpful.
– Then you can just hand it to them and they could go over it with you…without going
through everything over again.
– Maybe you just want to know from week to week whether it’s getting better. It was REALLY
BAD and oh, now it’s not quite so bad, and you know so you can see the trend that it’s
getting better and better.
– We need somebody that has direct input into the committee who knows what’s going on.
Like a gatekeeper. One person I talk to and they direct me.
– You’re coming every day for radiation, and that was also sort of a safety net. Because if you
didn’t feel good from one day to the next, you knew you were coming back and you could
ask somebody the question.

Analytic Memos
In total, 54 codes and categories are linked to SDM Implementation. Of these 18 are direct
links to SDM Implementation, of which 6 are source links (i.e., originating from SDM
Implementation) and 12 are target links (i.e., moving to SDM Implementation). These links
consist of 14 codes and 4 upper level categories. These are described below.
Compared to the other analyses [treatment, symptoms, communication, health literacy], these
codes are more spartan and far more functional. There is little interpretation and more
directness regarding what should be present, per the patient, to make this functional.

Codes
Choice is one of the key ethical tenets in medicine and defines patient autonomy. Choice was
not directly linked by patients to SDM implementation but is considered, logically, to be a
property of shared decision making. Curiously, patients could not recall treatment options
and/or rationale for choosing their cancer treatment but could recall being given options to
treat side effects (“[T]hey were available to give me something else if that didn’t work but that
worked fine.”)
Gatekeeper captures the concept that a single person serves as the communication conduit.
Patients alluded to SDM implementation serving this function by providing after hours
instructions as well as serving as the common information source across clinic visits:
– That way if I’m home, and I had a piece of paper, and all of a sudden I hit that side effect I
could say, “Oh, this and…. Hmmm, call in!” or “drink some milk!” or “get some ice cream.”
– Some doctors take good notes and other doctors don’t. This could have been a reference
for all the other doctors this would be helpful.
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Information root is a complex concept that has a broader information deficit than “I don’t
know.” The information root encompasses not even knowing what to ask, what to research, or
where to begin. Information root also includes – somewhat - a lack of self. This is because none
of the responses to the question “What did you think was important for your radiation
oncologist to know?” were based in self and instead reflected on an information gap. Logically,
this significantly impacts the shared decision making tool. If a patient cannot identify their goals
or the minimum quality of life they would like to maintain during therapy, this hobbles a
patient-centered patient reported outcome measure paradigm. Thus, implementation needs
to incorporate a strategy to cross the information root, to tease out the patient’s preferred
patient reported outcome measures.
Information sharing occurs when there is a back and forth between a healthcare provider and
the patient. The presumption at study design was that the SDM tool would increase
information sharing, based on the peer-reviewed literature. Thus, this relationship in the
diagram reflects that posited by peer-reviewed literature [Cochrane Database of Systematic
Reviews. 2011. PMID: 21975733 ]
MyChart: yes has a positive impact on the SDM tool implementation as per patient comments.
Patients commented positively on MyChart and its immediate access and link to providers.
Although patients indicated they wanted the SDM tool itself to be provided in paper, positive
association with MyChart indicates the questions can be submitted to the patient through the
MyChart portal, creating a smooth implementation workflow:
– You sign up for MyChart, it’s there. You get home you forgot something you can look at it.
– So when I got to Fairfield they already knew what was going on because of the MyCharts
and everything was transferred back to them…
– And, you know, the MyChart thing… there would be explanations or the test results anyway
on there that you could read.
New normal is a patient described concept that their life and lifestyle – as they knew it – had
ended. This captured – primarily – their lack of physical ability and how it impacted their life,
but also tangentially their lack of knowledge about their healthcare condition as well as its
treatment and, lastly, the unknown of if they would get better. Ultimately, it captures the fact
that they don’t know if they can ever ‘go back,’ to how they were prior. This intertwines with
SDM implementation as the ‘new normal’ is so new, it may be difficult to identify goals during
treatment.
– [B]ut that’s just something I do now…
– It’s been a life changing experience, I’ll tell you that much. And there’s times when I can
see why folks do give up and they fail with it. Because the stress that comes with it.
Sometimes I can go most of the day and not have a problem. Then there are days that 3 or 4
o’clock I’m done.
Patient to provider communication captures communication initiated by the patient to the
provider. It is a one-sided communication. For the SDM implementation tool, patients provided
comments that can impact its implementation for communicating to the provider:
– If it was something that spooked me or something, I could call and talk to someone on the
team.
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– I would do the research and write down a question, like, my particular diagnosis, and the
staging, is what I wrote down
– And if you got problems and you need help, you as the patient have to ask because they
don’t know. And if you don’t ask, like I don’t sometimes, they’re not gonna know that
there’s a problem. So the biggest thing is the patient has to be upfront with the doctor
also. It’s true though, if you’re not upfront with the doctor, they don’t know how to take
care of it. And they assume you’re okay.
For this reason, a text prompt has been added to the SDM tool to enable patients to ask
questions or comment on a problem not directly queued in the pre-built SDM tool.
Proactive for patient is the code that captures the physician acting on the patient’s behalf,
proactively, but from the patient’s point of view. This is represented as a property of the SDM
implementation through patient feedback as part of the plan for the patient:
– [M]aking sure that I was not having any pain.
– What he suggested and I followed his guidance which was spot on and very good.
– And then those two worked together making a plan for what was best for me.
Questionnaire review is a code identifying a thoughtful review of the sample questions
provided for the shared decision making tool. It is something that should be reviewed when
implementing the SDM tool:
– [regarding PRO-CTCAE fatigue]: Since I don’t have any usual or daily activities …or anything to
do… it really doesn’t interfere with anything. All I do is watch t.v. (chuckles).
– [regarding PROMIS fatigue Q1] I would have been too tired to do household chores…
– [regarding PROMIS fatigue Q3] Can’t say I was frustrated doing things that I wanted to do,
cause there really wasn’t to do. I don’t have a gal or anything here with me, so… that would
have made a difference!
– [regarding EORTC fatigue Q1] Yeah, I definitely have problems carrying uh… heavy things.
Walking ain’t bad but as soon as a I start using more muscles and then my legs … makes it
harder to breathe. (4 sec pause) …
– [regarding EORTC fatigue Q2] …only went on one semi-long walk.
– [regarding EORTC fatigue Q3] Short walk is no problem. I usually take the stairs when I go out
of the hotel. I took them once when I went up…but it’s just as much energy as it is to walk
down to the elevator and back as it is to go down the stairs.
– [regarding EORTC fatigue Q4] Yeah, I’m pretty much in… laying down most of the day these
last couple of weeks
– [regarding EORTC fatigue Q5] And I don’t need help with the eating, dressing, washing.
This questionnaire review provides insight into how patients read the questions and apply
them to their daily actions – but it also provides a critical look at how “the new normal,”
impacts the answers to those questions. Here, the patient was removed from his home and
living at a hotel (due to COVID, Hope Lodge was closed) and away from friends and family. As
he stated, he didn’t have anything to do – so PROMIS Q3 does not apply and neither does the
PRO-CTCAE question regarding fatigue. The review also points to a binary response: walking
up stairs only once. Taking a long walk only once. This goes against the standard patient
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reported outcome measure tools, changing it from a gradient to a binary response. This also
impacts SDM tool implementation.
Reading codes to the amount of reading a patient is expected to engage in, did engage in, or
completed. What was striking was the amount of reading – and returning to the information
provided – that patients described:
– Little one [packet], about 10 pages or so. Listed it all and everything.
– I like the explanation the way he explained it to me is good, but then when I get home… I
would pull that out and re-read it.
– They actually provided stuff like this about the symptoms. I could review it at home and if
something else come up – I could pull that out and look through it.
Safety net is described by patients as the comfort from daily radiation treatments (i.e.,
interaction with someone on the healthcare team). This is critical for implementation of the
SDM tool and, eventually, generalizability – as the tool will be designed for a therapy that is
rooted in daily treatments, not the prolonged schedule of chemotherapy treatment (one visit
every 2 to 4 weeks).
– Because if you didn’t feel good from one day to the next, you knew you were coming back.
And you could ask somebody the question…
Single-line access codes to gatekeeper; no other single line access was identified by patients
(i.e., group email, group phone call). Other single line access could be provided (MyChart,
receptionist, email) but this was not discussed or identified by patients. Patients identified a
single person as the gatekeeper, as the “go to.”
Slow reader to a patient’s ability to read and/or the impact of reading on the patient’s intake
and processing of information. One subject openly commented on being a slow written
processor, having information read to him rather than reading himself. This is a reminder the
tool must be implemented to accommodate all reading strengths.
Verbal communication codes for verbal communication as a strategy for information sharing
by the provider / healthcare team to the patient. This reminds us that the implementation must
still have a verbal communication component, not simply relying on paper.
– Well, in the morning when I come in… mostly talking with Heather & Megan and they are
pretty informative.
– I think verbal plus the research part like this would be helpful, you know.
– I like the explanation the way he explained it to me is good, but then when I get home… I
would pull that out and re-read it.

Categories
None.

Upper Level Categories / Conceptual Categories
COMMUNICATION. Shared decision making is an intersection of SYMPTOMS and
COMMUNICATION; the interaction between the two upper level categories is a bilateral
association. Of interest, patients conveyed understanding that communication regarding side
effects / symptoms was critical for their care. One participant likened this communication to a
safety net (“…you’re coming every day for radiation, and that was also sort of a safety net.
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Because if you didn’t feel good from one day to the next, you knew you were coming back. And
you could ask somebody the question…”). Another admitted they failed to communicate as they
should have and that led to emergency care (“And if you got problems and you need help, you
as the patient have to ask because they don’t know. And if you don’t ask, like I don’t sometimes,
they’re not gonna know that there’s a problem.”). Participants had a favorable view of MyChart
and were critical of individuals who failed to use it (“Those are things out there for people to
use to reduce the time. But if they don’t use them, they need to stand in line.”) “Toughed it out,”
is the code within symptoms that confounds communication and shared decision making,
representing a concept of self-reliance that becomes detrimental to the patient. This was
described by three participants:
– They kept saying a lot of this stuff was gonna happen but it never happened until I got
home. And then I said, “Well, it’s happening now.” It happened like they described it. I just
felt it and got over it.
– I should have [called the doctor] when I got sick on the pills (laughs boisterously). I just
thought, ‘You know, I have a really bad stomach anyways.’
– I sorta limped along
This concept is most likely influenced by the concepts of burden and self-reliance. It is apparent
from the interviews (50%) that the toughed it out concept was as strong, or stronger, than the
knowledge a patient must communicate with a provider. Instituting a shared decision-making
tool to identify and quantify adverse events of special significance provides normalcy and
expectation, shifting symptoms from a compliant to a rote process. With this pivot, reviewing
and communicating regarding symptoms is acknowledged as anticipated, acceptable
assessment to succeed in therapy. Thus, the SDM tool may tilt communication patterns away
from toughing it out back to information sharing.
SDM FORMAT. This upper level category focuses on the graphical design of the SDM tool,
including the presentation of data. Symptoms provide the key information for the SDM tool,
with six symptoms / goals collected on the tool (3 from the patient, 3 from the provider). In
addition to the symptoms, participants identified granularity as important, commenting that
PRO-CTCAE was too general as well as timeframe. For example, participants questioned how
to categorize the framing of “the past seven days,” – did it include weekends or holidays? Most
interestingly, despite the favored viewpoint of MyChart, participants preferred to have paper
to hold and take with them from provider to provider:
– You can just hand it to them and they could go over it with you.
– This would be helpful for me because they could have referenced this stuff. Some doctors
take good notes and other doctors don’t. This could have been a reference for all the other
doctors this would be helpful.
– That way if I’m home, and I had a piece of paper, and all of a sudden I hit that side effect I
could say, ‘Oh, this and…. Hmmm, call in!’
HEALTH LITERACY. This upper level category captures not only medical literacy but also
individual concepts/factors that impact an individual’s use of medical information. For
example, commitment, proactive, comparison, printed education documents, and reading. The
SDM tool format should accommodate varying levels of health literacy to enable
generalizability as well as implementation.
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SYMPTOMS. An adverse event is defined by FDA as an untoward medical event that occurs
during the contact of a clinical trial; this is then extended to an event that occurs during routine
clinical care. There is a subtle nuance for this study that patient-reported symptoms are those
that the patient reported but have not been confirmed by physical exam. Additionally,
anticipated events are those side effects a provider noted were possible but may not have
been realized. Concerning symptoms are those that necessitated urgent intervention,
emergency care, or intensive care. Symptoms can also be present at baseline, consistent with
the underlying disease or another comorbidity. Symptoms serves as a critical upper level
category for the research question, as it is partnered to communication to create the shared
decision making tool. Special interest was taken in the symptoms that were most commonly
commented on by participants (fatigue, dyspnea, nausea, vomiting) as well as those that
appeared to significantly interrupt their daily life (fatigue, edema, cognitive impairment). It is
interesting to note participants consistently noted prompting about symptoms across
providers. This provides an opportunity for the SDM tool to capture this information
consistently. Symptoms is the only upper level category connected directly to treatment; thus,
in order to impact treatment, the shared decision making tool must impact symptoms.

Representative Codebook
Arranged alphabetically, definitions are provided for the codes shown in the SDM
IMPLEMENTATION depiction above. Categories are listed in bold with upper level categories in
UPPERCASE. In general, a code is the most basic concept or construct present in an interview
transcript. A category reflects a grouping or pool of constructs with a common idea. An upperlevel category reflects the largest amalgamation of information, a pool or sea comprised of
rivers of thought. Categories can serve as codes as well, dependent upon the
concept/construct.
Code
academic information
caregiver
characteristics & context
choice
COMMUNICATION
comparison
COVID-19

didn't know

Comment
Medical information obtained from an accredited
academic institution (e.g. Mayo, UIOWA, MSKCC).
A person who provides support to the patient during
treatment.
Category encompassing characteristics & situational
context of communication.
Ability to choose or option to choose. May be patient,
caregiver, or provider.
Upper level category representing the totality of
medical experience, foreknowledge, academic
information as well as commercial information sources.
Patient-specific attribution
Disease caused by SARS-CoV-2; this can refer to the
frank disease or pandemic precautions due to COVID-19
Lack of background knowledge (medical, health),
context, or electing to deprioritize in the face of other
decisions or information requirements. Often associated
with 'information root,' which is the nebulous concept
around the goals of treatment and defining the patient's
desired new normal.
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Code

Comment
Category encompassing things that impact
communication negatively or positively. Not to be
Factors affecting communication
confused with characteristics & context, which are
properties and/or traits.
familiarity with provider
Knowing the name and/or clinic of the provider.
unpleasant emotion associated with anxiety, sense of
fear
foreboding or danger.
A patient's or caregiver's familiarity with cancer, the
foreknowledge
healthcare system, or medicine in general.
Upper level category representing pool of information
Format of SDM tool / SDM FORMAT regarding the format, design, and graphical layout of the
shared decision making tool
Individual who provides a single line of information
gatekeeper
between patient, caregiver, and providers.
Upper level category ; defined by Institute of Medicine
as the degree to which individuals have the capacity to
obtain, process, and understand basic health
HEALTH LITERACY
information and services needed to make appropriate
health decisions
The recognition that the information is not available to
information root
the patient or provider and they cannot act due to the
lack of information. The information root is missing.
Information sharing (back and forth) between at least
information sharing
two parties: provider, patient, caregiver.
Category encompassing verbal signals or messages for
Information traffic
communication.
Frank or subjective separation from caregiver, family, or
isolation
other providers.
Negative connotation regarding the use of multiple
medicine by committee
providers in providing a single treatment.
Healthcare provided through multiple clinics; this is
different than multidisciplinary clinic which is one
multiple clinic
physical clinic with multiple providers. This construct is
multiple physical locations.
Healthcare requiring multiple providers, whether they
multiple providers
are within the same clinic, the same center (e.g., Cancer
Center, Pulmonary), or institution.
Agreed to use MyChart (electronic EHR portal system),
MyChart: yes
used, or has positive connotations with MyChart.
New medical information regarding treatment or side
new information
effect.
A lifestyle, activity level, or physical issue (taste, cough)
new normal
that is not consistent with life prior to the disease or
treatment.
Patient and/or caregiver did not have questions or
no questions
concerns regarding the disease, treatment, or outcomes.
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Code

patient abilities

patient to provider communication

printed education documents
proactive
proactive for patient
provider cares
provider held knowledge
provider held power
provider prompting
provider support

provider to patient communication

questionnaire review
reading
recall
safety net
SDM IMPLEMENTATION

Comment
The physical, emotional, or social abilities of a patient.
These are typically queried in quality of life assessments
as well physical examinations. Should not be confused
for Activities of Daily Life which are those specific
activities that are assessed for adverse event severity
and criteria.
Communication initiated by the patient to the provider,
as per the patient. This is a one-way conversation; for
quotes where both parties discuss (i.e. patient is
responding to provider, or provider then responds to
patient) consider 'information sharing."
Education materials in printed format provided to the
patient and/or their caregiver.
Self-actuation or care; patient putting self first to ensure
best treatment, best outcomes.
Provider construct to put patient first to receive the best
care or outcomes.
Verbal communication, physical interaction, or other
indication that the provider cares personally for the
patient as a person, beyond medical obligation.
Information about the disease and/or treatment that
the provider holds and needs to share.
Power that the provider has over the treatment.
Provider's prompting for further information and/or
communication.
Providers providing support on a personal level, beyond
the stereotypcial patient/provider relationship.
Communication centered around, or from, the provider
to the patient - as per patient. This is a one-way
conversation; for quotes where both parties discuss (i.e.
patient is responding to provider, or provider then
responds to patient) consider 'information sharing."
A section of transcript with detailed review by a subject
on how he would answer the questions from the 3
different QoL groups.
Information that was conveyed by reading and/or the
preference to read.
The patient's ability to recall - or strategy to recall information. This is different than memory impairment
or cognitive disturbance, which are adverse
events/symptoms.
something, or someone, that is reassuring to the patient
Upper level category representing pool of information
regarding implementation of a shared decision-making
tool for patients diagnosed with lung cancer undergoing
radiation therapy at a Midwestern academic hospital.
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Code
SDM: treatment matrix
SDM: usefulness
single source
single-line access
slow reader
stress
SYMPTOMS

team

treatment / TREATMENT
treatment noncompliance
trust in provider
verbal communication

Comment
Regarding the SDM treatment matrix (the table of
outcomes and adverse events.
Whether the SDM tool is useful
Construct that only one person is hearing the verbally
communicated information.
single line of communication or access to providers
Having a slow reading speed, limiting reading
functionality
bodily or mental tension
Upper level category representing pooled information
regarding symptoms, side effects, and adverse events.
Positive connotation regarding the multiple providers
involved in the treatment and care of patient. This is the
opposite of medicine by committee code. One of the
facets of TEAM is if the subject describes decisions as
"we," rather than "they," and/or describes a seamless
interchangeability with the providers.
Upper level category and code representing medical
treatment, including surgery, radiation therapy,
chemotherapy, nutritional support, and emergency care.
patients failing to comply with treatment or supportive
care as prescribed by their provider
Trusting in the providers for treatment, diagnosis,
prognosis, and managing care.
Verbal communication
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APPENDIX M: SDMCQ QUESTIONS AND COLLABORATIVE DECISION AID
Nausea (feeling like you could vomit or be sick to your stomach)
Since the last time I saw a radiation doctor:








I have vomited (thrown up).
I have nausea but haven’t vomited.
I have not had nausea or vomited but I’m not that hungry.
I have not had nausea or vomited but I’m not eating.
I can’t be around food – the smell or looking at it.
I have not had nausea or vomited.
[separate checkbox – not drop down] I am using medicine for nausea

Cough
Since the last time I saw a radiation doctor:







I am coughing stuff up (snot, sputum, blood).
I cough when I try to talk or breathe deeply.
I get lightheaded when I cough.
I may cough but it doesn’t bother me.
I have not coughed.
[separate checkbox – not drop down] I am using cough medicine

Chest pain
Since the last time I saw a radiation doctor:






My chest hurts – it feels like burning.
My chest hurts – it feels tight and/or hurts when I breathe.
My chest hurts, but only when I try to eat.
My chest hasn’t been hurting.
[separate checkbox – not drop down] I am using medicine for chest pain

Fatigue
Since the last time I saw a radiation doctor:






I have not been able to watch a TV show without falling asleep.
I am okay sitting but needed a wheelchair to get to my appointments.
I walk only to my appointments from the car/taxi/valet.
I went for a short walk (about a block).
I’m as active as I was before I started radiation therapy.

Breathing
Since the last time I saw a radiation doctor:








I can’t walk 10 steps without stopping to catch my breath.
I can’t walk to my appointments without stopping to catch my breath.
I use a wheelchair because I become so short of breath.
I feel lightheaded when I try to walk or when I stand up.
I feel the same as before I started radiation therapy.
[separate checkbox – not drop down] I am using oxygen
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Collaborative Decision Aid Tool - Example
Question

Baseline (June 7,
2021)

July 5, 2021

Today

Nausea
(feeling like you
could vomit or be
sick to your
stomach):

I have not had nausea
or vomited

I have not had nausea
or vomited but I'm not
that hungry.

I can’t be around
food – the smell or
looking at it.

I am using medicine
for nausea

Yes

Yes

Yes

Cough:

I have not coughed.

I am coughing stuff up
(snot, sputum, blood)

I may cough but it
doesn’t bother me

I am using cough
medicine:

No

Yes

Yes

Chest pain:

My chest hasn’t been
hurting

My chest hurts – it
feels tight and/or hurts
when I breathe

My chest hurts,
but only when I try
to eat

I am using medicine
for chest pain:

No

Yes

Yes

Fatigue:

I am okay sitting but
needed a wheelchair
to get to my
appointments.

I am okay sitting but
needed a wheelchair
to get to my
appointments.

I have not been
able to watch a TV
show without
falling asleep

Breathing:

I can’t walk to my
appointments without
stopping to catch my
breath.

I can’t walk to my
appointments without
stopping to catch my
breath.

I can’t walk 10
steps without
stopping to catch
my breath.

I am using oxygen:

No

No

No

Weight:

78 kg

74.8 kg (96% baseline)

71.73 (92%
baseline)

Question:

None

None

Do I need oxygen
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APPENDIX N: SDMCQ RESPONSES DURING FIRST IMPLEMENTATION CYCLE

Symptom Descriptor
Nausea

Cough

Pain

I have not had nausea or vomited but I'm not that hungry

Breathing

3

I have not had nausea or vomited

17

I may cough but it doesn't bother me.

11

I get lightheaded when I cough

1

I cough when I try to talk or breathe deeply

1

I am coughing stuff up (snot, sputum, blood)

1

I have not coughed.

6

My chest hurts, but only when I try to eat.

4

My chest hurts, it feels tight and/or hurts when I breathe

1

My chest hasn't been hurting.
Fatigue

Count

15

I am okay sitting but needed a wheelchair to get to my appointments

2

I have not been able to watch a TV show without falling asleep

1

I walk only to my appointments from the car/taxi/valet

3

I went for a short walk (about a block)

3

I'm as active as I was before I started radiation therapy.

11

I feel lightheaded when I try to walk or when I stand up.

3

I feel the same as before I started radiation therapy.

17

